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Abstract	
The	rise	of	antibiotic	resistance	and	the	decline	in	antibiotic	discovery	have	been	well	
publicised.	 These	 issues,	 in	 combination	 with	 a	 growing	 global	 reliance	 upon	
antibiotics	 for	 everyday	 modern	 life,	 urgently	 require	 the	 discovery	 of	 novel	
antibacterial	drugs.	
Endolysins	 are	 one	 potential	 candidate	 to	 support,	 or	 replace,	 conventional	
antibiotics.	 Endolysins	 are	 lytic	 enzymes	 produced	 by	 bacteriophage	 in	 natura	 to	
enable	the	release	of	viral	progeny	from	inside	the	host	bacterium.	When	applied	
exogenously,	endolysins	can	lyse	Gram-positive	bacteria,	and	thus	could	be	used	as	
a	novel	antibacterial	for	this	group	of	pathogens.	
Biologically	active	endolysins	have	been	successfully	expressed	as	recombinants	 in	
the	chloroplast	of	the	green	alga,	Chlamydomonas	reinhardtii.	C.	reinhardtii,	and	in	
particular	 the	 chloroplast,	 has	 several	 features	 as	 a	 cell	 factory	which	make	 it	 an	
attractive	alternative	to	the	traditional	recombinant	protein	production	platforms.	C.	
reinhardtii	 is	free	of	endotoxins,	can	be	cultivated	at	low	cost	in	photobioreactors,	
has	GRAS	status,	and	is	genetically	tractable.	
This	 study	 initially	 focuses	 upon	 improving	 the	 accumulation	 and	 activity	 of	 one	
endolysin,	Cpl-1,	targeting	Streptococcus	pneumoniae.	Recombinant	Cpl-1	has	been	
shown	 previously	 in	 the	 Purton	 lab	 to	 accumulate	 to	 moderate	 levels	 in	 the	 C.	
reinhardtii	 chloroplast.	Here	we	present	 two	 transgenic	 lines	of	C.	 reinhardtii	 that	
appear	 to	 accumulate	 recombinant	 Cpl-1	 to	 higher	 levels	 –	 one	 through	 the	
incorporation	 of	 multiple	 expression	 cassettes,	 and	 one	 through	 codon	 pair	
optimization.	 To	 improve	 the	 activity	 of	 Cpl-1	 as	 an	 enzyme,	 Cpl-1	 binding	 site	
mutagenesis,	Cpl-1	dimerization,	and	the	production	of	a	potentially	synergistic	holin	
protein	were	all	attempted.	
Finally,	an	endolysin	against	Clostridium	difficile,	CD27L,	was	successfully	produced	
in	the	C.	reinhardtii	chloroplast	and	shown	to	be	active	in	vitro.	Another	endolysin,	
this	time	targeting	Propionibacterium	acnes,	 failed	to	express	 in	C.	reinhardtii,	but	
was	expressed	in	E.	coli,	albeit	without	obvious	lytic	activity.		
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Abbreviations	
aadA	 	 	 aminoglycoside-3’’-adenyl-transferase	gene	
Amp	 	 	 ampicillin	
AMPS		 	 	 ammonium	persulphate		
BHI	 	 	 brain	heart	infusion	
BME	 	 	 β-mercaptoethanol	
bp	 	 	 base	pairs	
BSA	 	 	 bovine	serum	albumin	
CBD	 	 	 cell	binding	domain	
CD	 	 	 catalytic	domain	
CES	 	 	 control	by	epistasis	of	synthesis	
CFU	 	 	 colony	forming	unit	
CPK	 	 	 Corey,	Pauling,	Koltun		
CTB	 	 	 cholera	toxin	B	
DNA		 	 	 deoxyribonucleic	acid		
dNTP		 	 	 2’deoxynucleoside	5’-triphosphate		
EDTA		 	 	 ethylenediaminetetraacetic	acid	(disodium	salt)		
e.	g.		 	 	 exempli	gratia	=	for	example	
ELISA	 	 	 enzyme-linked	immunosorbent	assay	
g	 	 	 gram	
GC	 	 	 guanine	and	cytosine	
GFP	 	 	 green	fluorescent	protein	
GOI	 	 	 gene	of	interest	
HA	 	 	 hemagglutinin	
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His	 	 	 histidine	
HSM	 	 	 high	salt	minimal	medium	
IPTG	 	 	 Isopropyl	β-D-1-thiogalactopyranoside	
kb	 	 	 kilo	base	pairs	
kDa	 	 	 kilo	Dalton	
LB	 	 	 luria-bertani	medium	
mg	 	 	 milligram	
min	 	 	 minute	
ml	 	 	 millilitre	
mM	 	 	 milimolar	
mRNA			 	 messenger	ribonucleic	acid		
mt	 	 	 mating-type	
NCBI		 	 	 National	Centre	for	Biotechnology	Information		
OD		 	 	 optical	density		
ORF		 	 	 open	reading	frame		
PCR		 	 	 polymerase	chain	reaction		
PDB	 	 	 protein	data	bank	
PEG		 	 	 polyethylene	glycol		
PG	 	 	 peptidoglycan	
PMF	 	 	 proton	motive	force	
PSI	 	 	 photosystem	I	
PSII	 	 	 photosystem	II	
psi	 	 	 pounds	per	square	inch	
RCSB	 	 	 Research	Collaboratory	for	Structural	Bioinformatics	
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RNA		 	 	 ribonucleic	acid		
rRNA		 	 	 ribosomal	ribonucleic	acid		
SD	 	 	 Shine-Dalgarno	consensus	sequence	
SDS		 	 	 sodium	dodecyl	sulphate		
SDS-PAGE		 	 sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis		
STGG	 	 	 skimmed	milk	tryptone	glycerol	glucose	medium	
Strep	 	 	 streptavidin	 	 	
TAP	 	 	 tris	acetate	phosphate	medium	
TBS	 	 	 tris	buffered	saline	
TBS-T	 	 	 tris	buffered	saline	–	tween	20	
TCP	 	 	 total	cell	protein	
TEMED		 	 N,	N,	N’,	N’-tetramethylethylenediamine		
tris		 	 	 tris	(hydroxymethyl)	aminomethane		
TRA	 	 	 turbidity	reduction	assay	
tRNA		 	 	 transfer	ribonucleic	acid		
TSP		 	 	 total	soluble	protein		
TSY	 	 	 trypticase	soy	yeast	extract	medium	
UTR		 	 	 untranslated	region		
v/v		 	 	 volume	for	volume		
w/v		 	 	 weight	for	volume		
WGS	 	 	 whole	genome	sequencing	
WHO	 	 	 World	Health	Organisation	
WT		 	 	 wild	type	
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Chapter	1 Introduction	
1.1 A	new	generation	of	antibiotics	
1.1.1 Why	are	antibiotics	so	important?	
1.1.1.1 History	
Sir	Alexander	Fleming	(1881-1955)	is	best	known	for	his	discovery	of	benzylpenicillin	
(Penicillin	G)	in	1928,	an	observation	that	shaped	the	modern	world	and	opened	up	
huge	vistas	of	modern	medical	and	surgical	 techniques	 that	have	become	routine	
across	 the	 globe.	 After	 the	 initial	 discovery	 of	 penicillin	 by	 Fleming	 at	 St	 Mary’s	
Hospital	 in	 London,	 it	 took	 a	 further	 16	 years	 of	 refinement,	 optimization	 and	
collaboration	between	industry	and	academia	before	penicillin	could	be	produced	in	
sufficient	volumes	 to	 treat	humans	 (Zaffiri	et	al.	2012).	 In	contrast	 to	 the	popular	
story	of	Fleming	stumbling	across	penicillin	on	his	return	from	holiday,	the	scaling	up	
of	production	was	no	mean	feat.	After	12	years	of	promoting	penicillin	and	searching	
for	solutions	to	the	purification	and	stability	issues	penicillin	faced,	Fleming	had	all	
but	given	up	on	his	discovery	(Aminov	2010).	However,	due	to	the	pressures	of	the	
second	world	war,	the	work	was	continued,	though	still	it	did	not	come	easy:	as	John	
L.	Smith	of	Pfizer	said	at	the	time,	“The	mould	is	as	temperamental	as	an	opera	singer,	
the	yields	are	low,	the	isolation	is	difficult,	the	extraction	is	murder,	the	purification	
invites	disaster,	and	 the	assay	 is	unsatisfactory.”	 (Werth	2014).	By	1945	however,	
mass	production	and	distribution	of	penicillin	had	been	achieved	–	the	world’s	first	
commercially	available	antibiotic.	The	chemical	structure	of	Penicillin	G	and	its	mode	
of	action	as	displayed	in	Figure	1.1.	
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Figure	Removed	
	
Figure	1.1	The	small	molecule	benzylpenicillin	(Penicillin	G),	known	as	a	β-lactam	due	to	the	
presence	of	a	β-lactam	ring	in	its	molecular	structure	(Drugbank	2017).	As	with	most	β-lactam	
antibiotics,	 benzylpenicillin	 functions	 through	disrupting	 cell	wall	 biosynthesis	 in	bacteria.	
The	 image	 on	 the	 right	 shows	 benzylpenicilin	 inhibiting	 formation	 of	 crosslinks	 in	 the	
bacterial	 peptidoglycan	 cell	 wall.	 Normally	 transpeptidases	 (also	 called	 penicilin-binding	
proteins)	 bind	 to	 D-alanyl-D-alanine	 pentapeptide	 of	 the	 peptidoglycan	 monomers	 and	
catalyse	 cross-linking	 via	 a	 peptide	 bridge.	 However,	 penicillin	 resembles	 the	 D-alanyl-D-
alanine	pentapeptide	and	blocks	the	active	site	of	the	transpeptidases,	preventing	monomer	
polymerisation.	The	lack	of	cross-linking	weakens	the	cell	wall,	causing	osmotic	lysis.	Image	
reproduced	from	Kaiser	(2011).	
Penicillin	G	was	the	first	of	more	than	20	distinct	antibiotic	classes	to	be	discovered	
from	the	1940s	to	the	1960s,	in	what	is	now	recognised	as	a	golden	era	of	antibiotic	
discovery	 (Arias	 and	Murray	 2015).	 These	 small	molecules	were	 all	 isolated	 from	
bacteria	 and	 fungi	 for	 their	 ability	 to	 block	 key	 enzymatic	 steps	 in	 bacteria,	 and	
presumably	serve	to	give	microorganisms	a	competitive	advantage	in	environmental	
niches	(Lewis	2013).	However,	there	are	also	theories	that	these	small	molecules	act	
as	cell-cell	communication	systems	at	low	concentrations,	given	their	vast	diversity	
and	their	ability	to	modulate	cell	transcripts	(Davies	2006).	Regardless	of	their	natural	
role,	these	identified	 	antibiotics	 targeted	 several	 different	 aspects	 of	 bacterial	
machinery	essential	for	cell	maintenance	and	reproduction,	an	illustration	of	which	
is	presented	 in	Figure	1.2.	The	 incredible	efficacy	of	antibiotics,	 their	rapid	rate	of	
discovery	and	their	ability	to	cure	previously	deadly	infections	in	a	matter	of	days	led	
to	them	being	hailed	as	a	“magic	bullet”	(Sengupta	et	al.	2013).	They	were	not	only	
valuable	as	cures	to	bacterial	infections,	but	in	prevention	too,	thus	opening	up	vast	
avenues	for	medicine	and	industry	which	will	be	further	explored	in	the	next	section.	
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Figure	Removed	
	
Figure	1.2	The	various	modes	of	action	of	different	antibiotic	classes	to	kill	bacteria.	It	should	
be	 noted	 that	 many	 classes	 share	 the	 same	 targets,	 for	 example	 cell-wall	 synthesis	 is	
inhibited	by	five	separate	classes	of	antibiotics.	Reproduced	from	Lewis	(2013).	
1.1.1.2 Applications	
The	most	obvious	application	for	antibiotics	is	in	treating	bacterial	infections.	When	
penicillin	was	 first	mass	 produced,	World	War	 II	was	 still	 raging	 and	 stocks	were	
earmarked	for	soldiers	on	the	front	line,	suffering	from	staphylococcal,	streptococcal,	
and	pneumococcal	wound	infections	(Mailer	and	Mason	2001).	While	infections	of	
minor	cuts	and	injuries	can	still	warrant	antibiotics	on	occasion,	better	knowledge	of	
hygiene,	vaccinations,	and	after-care	have	reduced	this	market.	
Prophylactic	 antibiotics	 on	 the	 other	 hand	 are	 still	 of	 immense	 importance	 and	
enable	a	whole	suite	of	surgeries	and	chemotherapies	which	many	take	for	granted.	
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All	invasive	surgeries,	from	organ	transplants	to	dental	work,	are	accompanied	with	
a	prophylactic	course	of	antibiotics.	Immunosuppressing	chemotherapies	for	cancer	
treatments	rely	on	antibiotics	to	stop	bacterial	infections	while	the	body’s	immune	
system	is	out	of	action	(O’Neill	et	al.	2015).	In	short,	access	to	antibiotics	underpins	
vast	numbers	of	surgeries	and	medical	techniques	used	in	modern	medicine.	
One	of	the	most	controversial	uses	of	antibiotics	is	as	growth	promoters	in	livestock.	
This	 stems	 from	 the	 discovery	 that	 sub-therapeutic	 levels	 of	 antibiotic	 cause	
increased	growth.	The	mechanism	for	this	remains	unclear,	but	the	most	likely	theory	
seems	 to	 be	 that	 growth	 is	 more	 efficient	 without	 gut	 bacteria	 competing	 for	
nutrients	(Gaskins	et	al.	2002).	Not	only	do	low	levels	of	antibiotics	improve	growth	
rates,	 but	 also	 conception	 rates	 and	 feed	 conversion	 ratios,	 altogether	 having	 a	
pronounced	impact	upon	global	meat	production	(Hao	et	al.	2014).	
Veterinary	medicine	 is	 another	 large	 consumer	of	 antibiotics,	 enabling	 farmers	 to	
rear	animals	in	closer	proximity	to	one	another	such	as	in	barns	where	previously	a	
build-up	of	potentially	infectious	bacteria	would	prevent	high	animal	densities	and	
continuous	farming.	Economically,	this	has	been	advantageous	–	increasing	farming	
efficiencies	and	lowering	food	prices.	The	same	is	true	of	fish	farming:	the	growth	of	
aquaculture	 to	 industrial	 scales	 has	 been	 almost	wholly	 reliant	 upon	prophylactic	
antibiotic	use,	enabling	the	high	density	farming	of	fish	to	meet	the	growing	global	
demand	(Cabello	2006).	
The	 remarkable	 reliance	 that	 the	 modern	 world	 has	 built	 upon	 antibiotic	
consumption	 leads	 us	 to	 worry	 about	 what	 would	 happen	 if	 they	 ceased	 to	 be	
effective.	We	have	mentioned	briefly	just	a	few	of	the	huge	industries	that	use,	and	
over-use,	antibiotics.	As	we	will	see	in	the	following	section,	antibiotics	are	a	finite	
resource	due	to	the	emergence	of	resistant	bacteria	and	 if	 these	 industries	are	to	
continue	to	grow,	then	new	antibiotics	must	be	sought.		
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1.1.2 Why	do	we	need	new	antibiotics?	
1.1.2.1 Resistance	
The	World	Health	Organisation	(WHO)	defines	antibiotic	resistance	as	a	change	which	
occurs	to	bacteria	when	exposed	to	antibiotics,	resulting	in	the	antibiotic	becoming	
ineffective	 and	 the	 persistence	 of	 the	 infection	 (WHO	 2016).	 This	 definition	 is	
valuable	at	a	therapeutic	level,	but	this	section	will	give	an	overview	of	how	antibiotic	
resistance	functions	a	molecular	level.	
The	five	mechanisms	of	antibiotic	action	illustrated	in	Figure	1.2	represent	the	entire	
variability	 within	 our	 antibiotic	 arsenal.	 Given	 how	 important	 antibiotics	 are	 to	
modern	society,	this	is	an	alarmingly	small	number	of	bacterial	targets	to	rely	upon,	
given	that	there	are	known	to	be	approximately	200	conserved	essential	bacterial	
proteins	(Lewis	2013).	Resistance	to	each	of	these	targets	has	arisen	quickly	as	each	
new	drug	has	been	used	on	a	large	scale,	with	resistance	to	more	recent	antibiotics	
such	as	Levofloxacin	(a	second	generation	fluoroquinolone)	being	reported	in	1996,	
the	 same	 year	 as	 it	 was	 introduced	 (Ventola	 2015).	 It	 is	 therefore	 important	 to	
understand	 how	 resistance	 is	 acquired	 both	 at	 the	 molecular	 level,	 so	 that	 new	
therapies	and	drug	combinations	can	be	produced,	and	at	the	population	level,	so	
that	preventative	measures	and	procedures	can	be	implemented.		
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Figure	1.3	The	six	major	antibiotic	resistance	mechanisms.	Resistance	mechanisms	are	not	
necessarily	specific	 to	a	certain	class	of	antibiotics,	with	many	antibiotics	being	subject	to	
multiple	resistance	mechanisms.	Some	therapies	target	the	resistance	mechanism	in	order	
to	restore	antibiotic	efficacy,	for	example	the	application	of	β-lactamase	inhibitors	alongside	
β-lactam	antibiotics.	Reproduced	from	Lewis	(2013).	
Resistance	arises	due	to	the	high	selective	pressure	that	antibiotics	put	upon	bacterial	
populations.	Each	mode	of	resistance	to	each	of	the	five	sites	of	antibacterial	action	
is	illustrated	in	Figure	1.3.	For	example,	penicillin	is	a	β-lactam,	a	class	of	antibiotics	
that	 inhibit	 cell	 wall	 synthesis	 in	 bacteria.	 β-lactams	 bind	 to	 penicillin-binding	
proteins	(PBPs),	which	are	responsible	for	bacterial	cell	wall	cross-linking,	and	inhibit	
their	action.	The	resulting	inability	of	the	bacteria	to	correctly	form	a	cell	wall	leads	
to	autolysis	(Fernandes	et	al.	2013).	Several	methods	of	resistance	have	developed	
towards	 β-lactams.	 Firstly,	 target	 modification:	 modification	 of	 PBPs	 to	 exhibit	 a	
much	lower	affinity	to	penicillin.	Second	is	the	production	of	β-lactamases,	enzymes	
which	degrade	or	modify	β-lactams,	and	thirdly	are	changes	to	permeability	in	the	
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cell	wall	to	β-lactams,	which	can	either	block	entry	or	actively	remove	the	β-lactams	
via	 efflux	 proteins	 (Fernandes	 et	 al.	 2013).	 In	 this	 single	 example	 three	 different	
resistance	mechanisms	exist	for	a	single	antibiotic,	highlighting	the	remarkable	ability	
of	bacteria	to	evolve	under	antibiotic	induced	selective	pressure	and	underlining	the	
real	potential	for	some	antibiotics	to	become	obsolete.	
It	is	reasonable	to	ask	how	antibiotic	resistance	evolves	and	spreads	so	rapidly.	Two	
categories	 for	 resistance	 can	 be	 formed:	 endogenous	 resistance	 and	 exogenous	
resistance.	 Endogenous	 resistance	 refers	 to	 resistance	 arising	 within	 the	 bacteria	
itself	 i.e.	 by	mutation	and	 selection.	 Exogenous	 resistance	 involves	 the	passing	of	
resistance	 genes	 between	 different	 bacterial	 species	 via	 horizontal	 gene	 transfer	
(Silver	2011),	each	of	which	is	explored	below.	
Endogenous	resistance	is	often	genetically	recessive	as	it	tends	to	result	in	a	loss	of	
function,	 for	 example	 reduced	 permeability	 to	 antibiotics,	 which	 have	 other	
(negative)	consequences	for	normal	cell	operation.	If	antibiotic	selection	is	continued	
for	a	long	time,	then	secondary	mutations	may	eventually	evolve	to	compensate	for	
loss	of	function.	However,	generally	these	mutations	will	eventually	be	lost	after	the	
removal	of	selective	pressure.	
Exogenously	 acquired	 resistance	 on	 the	 other	 hand	 generally	 involves	 a	 gain	 of	
function	and	is	therefore	more	stable,	for	example	the	ability	to	synthesize	antibiotic-
degrading	enzymes.	Apart	from	a	slight	metabolic	burden,	these	gains	of	function	are	
not	 generally	 detrimental	 to	 the	 bacterium.	 Exogenous	 resistance	 is	 therefore	 of	
most	concern	clinically,	as	resistance	persists	after	antibiotic	treatment	has	finished	
(Silver	and	Bostian	1993).		
The	many	uses	of	antibiotics	described	in	1.1.1.2	provide	perfect	opportunities	for	
resistance	 to	 be	 selected.	 For	 example,	 the	 lack	 of	 distinction	 between	 “human	
antibiotics”	 and	 “veterinary	 antibiotics”	 has	 dangerous	 implications	 for	 emerging	
resistance	via	horizontal	gene	transfer.	Furthermore,	the	manner	in	which	antibiotics	
are	generally	delivered	to	livestock,	such	as	in	their	food	or	water,	can	lead	to	sub-
inhibitory	 concentrations	 of	 antibiotic	 which	 provides	 an	 ideal	 environment	 for	
resistance	selection	(Meek	et	al.	2015).		
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1.1.2.2 Antibiotic	development	
During	the	golden	era	of	antibiotic	discovery,	a	range	of	broad-spectrum	antibiotics	
were	quickly	 identified,	patented	and	scaled	 to	production,	but	 today	 these	same	
chemicals	still	form	the	basis	of	our	antibiotic	arsenal.	From	the	mid-1960s	onwards,	
only	six	new,	approved,	antibiotic	classes	have	been	discovered,	and	none	since	the	
discovery	of	daptomycin	in	1986.		
	
Figure	1.4	The	“Golden	Era”	of	antibiotic	discovery	produced	the	basis	for	all	of	the	antibiotics	
upon	which	we	still	 rely	 today.	Modifications	and	synthetic	variants	of	 these	classes	have	
extended	the	life	of	many	of	these	drugs,	but	a	lack	of	truly	novel	antibiotics	persists.	Very	
recently	new	bacterial	culturing	techniques	have	raised	hopes	of	new	antibiotic	classes	being	
discovered	and	approved	(e.g.	teixobactin),	and	are	discussed	later	in	this	section	(Ling	et	al.	
2015).	Image	reproduced	from	Silver	(2011).	
This	alarming	drop-off	 in	antibiotic	discovery	 is	due	to	several	 factors.	 In	the	early	
days	of	antibiotic	research,	discovery	was	largely	through	empirical	screening	–	this	
amounted	 to	 testing	 of	 various	 microorganism	 extracts	 for	 bacterial	 growth	
inhibition,	 requiring	 little	 understanding	 of	 their	 action.	 This	 method	 worked	
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extremely	well	in	the	1940s,	50s	and	60s,	but	soon	these	“low	hanging	fruits”	had	all	
been	 discovered.	 These	 methods	 soon	 led	 to	 replication	 of	 discovery;	 common	
antibiotics	 were	 being	 repeatedly	 discovered,	 thus	 reducing	 the	 efficiency	 of	 the	
discovery	system.	The	method	deployed	shifted	towards	target-directed	screens	and	
eventually	 big	 pharma	 companies	 reallocated	 resources	 to	 more	 lucrative	
therapeutics	(Livermore	2011;	Silver	2011).	Economically,	the	antibiotic	market	has	
been	 somewhat	 a	 victim	 of	 its	 own	 success:	 with	many	 competing	 drugs	 on	 the	
market,	 the	 price	 pharmaceutical	 companies	 can	 charge	 per	 prescription	 of	
antibiotics	is	much	lower	than	that	of	many	other	drugs	(Bax	1997).	
However,	 the	 news	 is	 not	 all	 bad.	 Although	 no	 (or	 few)	 new	 classes	 have	 been	
discovered	 since	 the	 1980s,	 there	 have	 been	 improvements	 within	 the	 existing	
classes.	While	such	modifications	do	increase	the	efficacy	of	these	antibiotics	for	a	
limited	 period	 of	 time,	 the	 fundamental	 resistance	 mechanisms	 still	 exist	 and	
resistance	often	quickly	re-emerges	(Payne	et	al.	2007).	Other	tactics	have	involved	
blocking	the	resistance	mechanisms,	such	as	through	use	of	β-lactamase	inhibitors	
(Walsh	and	Wencewicz	2014),	and	delivering	these	in	combination	with	existing	β-
lactam	 antibiotics.	 But	 none	 of	 these	 techniques	 broaden	 the	 limited	 number	 of	
targets	that	our	antibiotic	arsenal	currently	possesses	and	have	been	incremental	in	
nature.		
New	 strategies	 to	 specifically	 target	 virulence	 factors,	 thus	 applying	 less	 selective	
pressure	and	with	resistance	being	at	the	cost	of	virulence,	present	neat	alternative	
targets	for	antibiotics,	but	remain	a	long	way	from	the	clinic	(Clatworthy	et	al.	2007).	
Combinations	of	antibiotics	are	now	the	norm,	and	can	achieve	synergistic	effects.	In	
some	cases,	resistance	to	one	antibiotic	may	increase	susceptibility	to	another	–	for	
example	 colistin	 acts	 as	 a	 highly	 synergistic	 combination	 with	 several	 other	
antibiotics,	by	improving	the	permeability	of	the	bacterial	outer	membrane	in	Gram	
negative	bacteria	(Tängdén	et	al.	2014).	
One	of	 the	greatest	 restraints	 to	 the	“Golden	Era”	of	antibiotic	discovery	was	 the	
limited	number	of	microbes	that	could	be	grown	in	the	laboratory,	and	then	tested	
for	 antimicrobial	 properties.	 In	 fact,	 it	 is	 estimated	 that	 99%	 of	 bacteria	 are	
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“uncultured”	and	thus	untapped.	The	development	of	new	techniques	for	culturing	
soil	microbes	in	situ	enables	the	products	of	these	microorganisms	to	be	studied	for	
the	 first	 time.	 This	 technology	 has	 already	 produced	 a	 new	 antibiotic	 candidate	
teixobactin	which	binds	lipid	II	and	III,	the	respective	precursors	of	peptidoglycan	and	
cell	wall	teichoic	acid,	and	thus	inhibits	cell	wall	synthesis	(Ling	et	al.	2015).	
It	is	clear	that,	despite	recent	innovations,	the	dearth	of	recent	antibiotic	discovery	
combined	with	the	rise	of	antibiotic	resistance	is	a	worrying	state	of	affairs	for	our	
modern	way	of	life.	Better	control	of	current	antibiotic	usage	may	slow	the	rate	of	
resistance	occurrence,	but	new	antibiotics	are	desperately	needed	to	compete	in	our	
evolutionary	arms	race	against	bacteria.	
1.1.3 What	alternatives	to	antibiotics	currently	exist?	
The	arms	race	against	bacteria	will	never	end,	and	even	when	new	antibiotics	with	
new	targets	are	discovered,	resistance	will	eventually	arise.	It	is	therefore	vital	that	a	
robust	pipeline	for	antibiotic	production	is	in	place,	and	given	the	lack	in	discovery	of	
conventional	antibiotics	over	the	past	50	years,	 it	makes	sense	to	look	to	plug	the	
gaps	 with	 alternative	 antimicrobials.	 With	 the	 advancement	 of	 knowledge	 and	
technology	in	these	novel	antibiotic	fields,	it	is	likely	that	eventually	one,	or	many,	of	
these	“alternative	antibiotics”	will	become	the	new	“conventional	antibiotics”.		
1.1.3.1 Non-lethal	treatments	
While	not	strictly	“antibiotics”,	non-bactericidal	therapies	deserve	a	brief	mention	in	
this	 literature	 review	 as	 they	 provide	 an	 alternative	 treatment	 to	 traditional	
antibiotics.	They	also	open	up	a	different	way	of	thinking	about	bacterial	infections,	
namely	that	damage	to	host	organisms	when	suffering	from	bacterial	infection	can	
be	caused	as	much	by	host	response	as	by	microbial	factors	(Pirofski	and	Casadevall	
2008).	 Efforts	 to	 prevent	 the	 host	 response,	 through	 tactics	 such	 as	 anti-
inflammatory	monoclonal	antibodies	can	potentially	minimise	host	damage	while	the	
body’s	immune	system	fights	the	infection.	
Other	methods	involve	hindering	the	activity	of	the	bacteria	through	competition	for	
resources,	 either	 by	 the	 introduction	 of	 other	 bacteria	 (probiotics)	 or	 the	
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sequestration	 of	 host	 nutrients	 (Spellberg	 2014).	 Furthermore,	 bacterial	 toxin	
inhibitors	and	biofilm	inhibitors	which	do	not	directly	harm	the	bacteria,	but	reduce	
their	pathogenicity	offer	a	promising	alternative	path.	A	major	advantage	of	these,	
along	with	host-response	modulation,	 is	 that	 they	do	not	apply	 the	 same	 level	of	
selective	 pressure	 on	 the	 bacteria	 in	 question	 to	 evolve	 resistance	 as	 traditional	
bactericidal	measures	(Cheng	et	al.	2014).	
1.1.3.2 Predatory	bacteria	
Some	bacteria,	such	as	Bdellovibrio,	Peredibacter	and	Vampirococcus,	prey	on	other	
bacteria	 and	 therefore	 may	 offer	 a	 mechanism	 for	 active	 control	 of	 bacterial	
infections.	These	bacteria	go	one	step	 further	 than	commensal	 ‘probiotics’,	which	
generally	 compete	 for	 nutrients	 and	 resources	 thus	 reducing	 the	 scope	 for	
opportunistic	 pathogenic	 bacterial	 colonisation,	 by	 entering	 host	 bacteria	 and	
causing	 cell	 lysis	 (Dwidar	 et	 al.	 2012).	 Predatory	 bacteria,	 widely	 known	 as	
Bdellovibrio-and-like-organisms	 (BALOs),	 have	 demonstrated	 killing	 of	 pathogenic	
bacteria	in	vitro	(Van	Essche	et	al.	2011),	and	recent	in	vivo	studies	show	a	reduction	
in	bacterial	burden	of	Klebsiella	pneumoniae	in	rat	lungs	(Shatzkes	et	al.	2016).		
An	interesting	strength	of	BALOs	is	their	ability	to	prey	upon	Gram-negative	bacteria,	
which	are	a	major	source	of	global	disease.	The	outer-membrane	of	Gram-negative	
bacteria	 presents	 a	 barrier	which	 several	major	 antibiotics	 (e.g.	 vancomycin)	 and	
antibiotic-alternatives	(e.g.	endolysins)	struggle	to	penetrate	(Miller	2016).	Another	
advantage	is	that	prey	resistance	is	extremely	rare,	with	only	one	case	so	far	reported	
(Varon	1979),	suggesting	a	derived	therapy	could	be	effective	for	a	substantial	period	
of	time.	
However,	 safety	 concerns	 around	 inoculating	 humans	 with	 bacteria	 must	 be	
addressed.	 A	 potentially	 toxic	 response	 to	 the	 lipopolysaccharides	 in	 the	 Gram-
negative	 outer-membrane	 of	 BALOs	 is	 yet	 to	 be	 solved.	 Furthermore,	 predatory	
bacteria	are	unable	to	eradicate	all	their	prey,	even	when	applied	in	very	high	ratios	
(Sockett	and	Lambert	2004),	and	are	also	strictly	aerobic	thus	limiting	their	potential	
for	 internal	human	application.	They	may	however	 find	a	place	 in	 therapies	when	
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used	together	with,	for	example,	β-lactams	to	which	they	are	tolerant	(Dwidar	et	al.	
2012).	
1.1.3.3 Antimicrobial	peptides	and	bacteriocins	
Antimicrobial	peptides	(AMPs)	are	small	peptides	(10-50	amino	acids)	that	form	part	
of	the	innate	immune	system,	and	are	found	in	all	classes	of	life.	AMPs	have	been	
shown	 to	 act	 independently	 as	 antimicrobials,	 but	 also	 to	 have	 wide	 ranging	
immunomodulatory	 functions	 in	 mammals,	 including	 altering	 gene	 expression,	
promoting	wound	 healing	 and	modulating	 dendritic	 cell	 response	 (Bowdish	 et	 al.	
2005;	Fernebro	2011).	Furthermore,	AMPs	can	display	activity	against	viruses	and	
fungi	too,	thus	earning	the	use	of	the	word	“antimicrobial”,	rather	than	 its	subset	
“antibiotic”.	AMPs	also	have	activity	against	biofilms,	which	can	harbour	bacteria	in	
chronic	diseases	 and	are	 therefore	an	 interesting	 route	of	 research.	 The	mode	of	
action	of	AMPs	 is	 still	unclear,	although	 it	 is	believed	that	 they	cause	cell	 lysis	via	
permeation	of	the	cytoplasmic	membrane	(Chung	and	Khanum	2017).	
However,	the	high	toxicity	of	AMPs	to	mammalian	cells	and	their	poor	stability	have	
led	to	poor	results	in	clinical	trials.	This	has	guided	research	into	the	modification	of	
AMPs,	 to	 produce	 Structurally	 Nanoengineered	 Antimicrobial	 Peptide	 Polymers	
(SNAPPs),	which	are	more	stable	and	display	greater	levels	of	antimicrobial	activity	
(Lam	et	al.	2016).	While	as	yet	unproven	clinically,	SNAPPs	have	been	shown	to	be	
particularly	active	against	Gram-negative	bacteria	and	show	promising	synergy	with	
conventional	antibiotics.	
Antimicrobial	peptides	 from	prokaryotes	are	known	as	 “bacteriocins”	and	 tend	 to	
have	a	narrower	activity	 spectrum.	Bacteriocins	have	been	used	 for	 some	 time	 in	
food	preservatives	–	for	example	nisin	is	used	to	treat	cheese,	meat	and	vegetables	
to	 improve	 shelf	 life	 (Yang	 et	 al.	 2014).	While	 effective	 as	 inhibitors	 of	microbial	
colonisation,	 the	 instability	 and	 potency	 of	 bacteriocins	 has	 to	 date	 limited	 their	
potential	as	therapeutics.		
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1.1.3.4 Bacteriophage	
Bacteriophage,	or	“phage”,	are	the	subset	of	viruses	than	infect	bacteria.	They	are	
believed	to	be	the	most	numerous	biological	entities	on	the	planet,	outnumbering	
bacteria	10-to-1	and	displaying	huge	variability	(Oliveira	et	al.	2013).	Phage-therapy,	
which	involves	using	phage	to	combat	bacterial	infections,	has	been	investigated	as	
a	potential	antibiotic	since	the	early	1900s	but	interest	in	the	field	declined	across	
much	 of	 the	 globe	 after	 the	 discovery	 of	 penicillin.	 However,	 phage	 therapy	
continued	to	be	practiced	 in	 the	USSR	due	to	 their	 limited	access	 to	conventional	
antibiotics,	and	even	today	the	Eliava	 Institute	 in	Georgia	still	 treats	patients	with	
phage	therapy	(Fernebro	2011).	
Phage	 therapy	makes	use	of	 the	 lytic	 cycle	of	 live	bacteriophage	 to	 lyse	 infecting	
bacteria.	The	lytic	cycle,	illustrated	in	Figure	1.5,	involves	specific	attachment	of	the	
bacteriophage	to	the	host	bacterial	cell	wall,	injection	of	viral	DNA	into	the	host	cell,	
and	recruitment	of	the	host	protein	synthesis	machinery	to	produce	bacteriophage	
progeny.	After	sufficient	bacteriophage	progeny	synthesis,	host	cell	lysis	is	initiated	
by	the	combined	effects	of	holin	and	endolysin	proteins,	thus	killing	the	host	cell	and	
releasing	the	phage	progeny	into	the	environment	(Reindel	and	Fiore	2017).		
	
Figure	 1.5	 The	 bacteriophage	 lytic	 cycle.	 Phage	 specifically	 bind	 to	 their	 target	 bacterial	
species	 and	 inject	 viral	 DNA.	 The	 host	 cell	 protein	 synthesis	 machinery	 produces	 phage	
progeny,	then	holins	to	form	a	pore	in	the	cell	membrane	and	finally	endolysins	to	hydrolyse	
the	peptidoglycan	layer.	Reproduced	from	Feiner	et	al.	(2015).	
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Since	the	rise	of	antibiotic	resistance	and	the	decline	 in	new	antibiotic	discoveries	
however,	interest	in	phage	therapy	has	been	renewed.	In	2006	phage	treatment	of	
cooked	meats	was	approved	by	the	FDA	to	prevent	post-processing	contamination	
with	 Listeria	monocytogenes	 (Fernebro	 2011).	However,	 no	 FDA	 approval	 has	 yet	
been	made	for	human	therapies,	although	a	recent	“emergency	investigational	new	
drug	application”	was	 approved	 for	 the	 treatment	of	 a	patient	 in	 San	Diego,	USA	
suffering	 from	 a	 multi-drug	 resistance	 bacterial	 infection,	 which	 resulted	 in	 the	
successful	treatment	of	that	patient	(LaFee	and	Buschman	2017).	
The	high	specificity	of	bacteriophage	results	in	a	narrow-spectrum	of	activity.	This	is	
excellent	news	 for	 the	protection	of	 commensal	 flora	 in	 the	gut	 for	example,	but	
relies	on	 rapid	and	effective	diagnosis	 techniques	which	are	not	 readily	 available.	
Furthermore,	occurrence	of	resistance	to	phage	is	high,	and	poor	data	exist	on	the	
efficacy	 of	 treatment	 and	 their	 safety	 profile	 (Fernebro	 2011).	 However,	 if	 these	
obstacles	 can	 be	 overcome,	 then	 the	 sheer	 number,	 diversity	 and	 availability	 of	
bacteriophage	make	them	a	very	attractive	source	of	novel	antibiotics.	
1.1.3.5 Bacteriophage	endolysins	
Many	of	the	hurdles	faced	by	bacteriophage	therapy	can	be	overcome	by	the	use	of	
their	 endolysins.	 These	 are	 the	 lytic	 enzymes	 which	 degrade	 the	 host	 bacterial	
peptidoglycan	cell	wall	during	cell	lysis.	The	use	of	these	proteins	as	novel	antibiotics	
holds	 great	 promise	 and	 is	 the	 focus	 of	 this	 thesis.	 Endolysins	 are	 introduced	 in	
greater	detail	in	section	1.2.	
1.2 An	overview	of	bacteriophage	endolysins	
1.2.1 The	biological	role	of	bacteriophage	endolysins	
1.2.1.1 Background	
Peptidoglycan	hydrolase	 is	 a	 generic	name	given	 to	 an	enzyme	 that	 catalyses	 the	
hydrolysis	of	 the	bacterial	peptidoglycan	cell	wall.	Peptidoglycan	hydrolases	come	
from	many	different	 sources,	with	different	 functions:	autolysins	are	produced	by	
bacteria	to	remodel	their	cell	wall	or	cause	apoptosis;	exolysins	are	a	weapon	used	
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by	 bacteria	 to	 attack	 competing	 bacteria	 of	 another	 species;	 lysozymes	 can	 be	
produced	 by	 eukaryotes	 as	 part	 of	 their	 innate	 immune	 response;	 tail-associated	
lysins	 enable	 bacteriophage	 to	 inject	 their	 DNA	 into	 a	 new	 host	 bacterial	 cell;	
endolysins	are	peptidoglycan	hydrolases,	also	of	viral	origin,	that	lyse	the	bacterial	
host	cell	wall	from	within	at	the	end	of	the	lytic	cycle.		
Upon	 injection	of	bacteriophage	DNA	into	the	host	bacterium,	bacteriophage	viral	
progeny	are	synthesized	and	assembled	by	the	host	machinery.	Two	other	proteins	
are	also	produced,	which	act	in	synchrony	to	optimize	the	timing	of	host	bacterium	
lysis.	One	is	the	holin,	which	oligomerises	in	the	inner	membrane	to	form	a	pore.	The	
other	is	an	endolysin	which	is	able	to	access	the	host	peptidoglycan	cell	wall,	via	the	
pore	formed	by	the	holins,	degrading	the	cell	wall	and	causing	cell	lysis.	
1.2.1.2 Structure	
Endolysins	are	generally	encoded	by	a	single	gene	and	two	distinct	categories	exist:	
those	 from	Gram-positive	 infecting	bacteriophage,	and	 those	 from	Gram-negative	
infecting	bacteriophage.	Endolysins	targeting	Gram-positive	bacteria	have	a	modular	
structure	 and	 are	highly	 species	 specific.	 Their	modular	 structure	 consists	 of	 a	N-
terminal	catalytic	domain	and	a	C-terminal	cell	wall	binding	domain	(CBD),	generally	
connected	by	a	flexible	acidic	linker	(Figure	1.6).	The	majority	of	endolysin	specificity	
is	 conferred	by	 the	cell	wall	binding	domain,	although	 in	 some	cases	 the	catalytic	
domain	 has	 been	 shown	 to	 bestow	 specificity	 via	 recognition	 of	 the	 enzymatic	
substrate	(Mayer	et	al.	2011).	Removal	of	the	CBD	in	some	instances	can	improve	the	
activity	and	spectrum	of	an	endolysin,	but	 in	other	cases	the	CBD	appears	to	be	a	
requirement	for	activity,	perhaps	by	achieving	the	correct	orientation	of	the	catalytic	
domain	to	the	substrate.	
	
Figure	1.6	The	canonical	modular	structure	of	a	Gram-positive	endolysin.	The	cell	wall	binding	
domain	 (CBD)	 is	 responsible	 for	 conferring	 specificity	 to	 the	 enzyme	 and	modification	 or	
removal	of	the	CBD	has	sometimes	resulted	in	improved	activity	of	the	truncated	endolysin	
(Cheng	and	Fischetti	2007).	
Cell	wall	binding	
domainCatalytic	Domain
Acidic	
linkerN C
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Gram-negative	 endolysins	 on	 the	 other	 hand	 tend	 to	 be	 smaller	 with	 a	 globular	
structure,	and	lack	the	high	binding	affinity	and	specificity	for	the	cell	wall.	The	reason	
for	 this	 is	 believed	 to	 be	 that,	 while	 it	 may	 be	 advantageous	 for	 Gram-positive	
targeting	endolysins	to	bind	tightly	to	the	peptidoglycan	cell	wall	in	order	to	prevent	
them	 from	 lysing	 surrounding	 bacteria	 which	might	 be	 future	 hosts	 for	 the	 viral	
progeny,	 the	 surrounding	 Gram-negative	 bacteria	 are	 protected	 by	 their	 outer	
membrane	so	no	such	restraint	is	required	(Loessner	et	al.	2002).	
These	descriptions	are	of	course	simplifications,	and	there	are	many	exceptions	that	
prove	the	rule.	For	example	several	staphylococcal	endolysins	have	two	N-terminal	
catalytic	 domains,	 the	 streptococcal	 λSA2	 endolysin	 has	 a	 central	 CBD	 with	 two	
flanking	catalytic	domains	at	each	terminal,	and	PlyC,	another	streptococcal	lysin	and	
one	of	the	most	active	endolysins	tested	to	date,	is	encoded	by	two	separate	genes	
forming	a	multimeric	lysin	(Schmelcher	et	al.	2012).	
A	few	three-dimensional	crystal	structures	of	endolysins	have	been	solved	to	date,	
but	formation	of	crystals	has	proved	difficult	partially	due	to	the	flexible	acidic	linker	
between	the	domains.	However,	T4	lysozyme	(Sagermann	and	Matthews	2002),	T7	
amidase	(Cheng	et	al.	1994),	PSA	endolysin	(Korndörfer	et	al.	2006),	Cpl-1	(Hermoso	
et	al.	2003),	CTP1L	(Dunne	et	al.	2016)	and	parts	of	CD27L	(Dunne	et	al.	2014)	have	
all	been	elucidated.	The	crystal	structure	of	Cpl-1	will	be	discussed	in	greater	detail	
in	4.3.1.	
1.2.1.3 Mechanism	of	action	
Endolysins	display	huge	variation	in	their	mechanism	of	action.	While	they	all	attack	
the	peptidoglycan,	there	have	been	endolysins	identified	which	target	almost	every	
bond	within	the	peptidoglycan	network.	These	can	be	broadly	split	into	glycosidases	
which	hydrolyse	the	aminosugar	linkages,	and	amidases/peptidases	which	attack	the	
cross-linking	peptide	stems	and	interpeptide	bridges	(Loessner	2005).	
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Figure	1.7	The	peptidoglycan	from	Streptococcal	cell	wall	(A3α).	Hexagons	represent	sugars	
and	ovals	are	amino	acids.	Red	arrows	indicate	sites	of	action	for	glycosidases	(A:	N-acetyl-
β-D-muramidase;	B:	 N-acetyl-β-D-glucosaminidase).	 Green	 arrows	 indicate	 endopeptidase	
targets	 (C:	 D-glutamyl-L-lysine	 endopeptidase;	 D:	 D-alanoyl-L-alanine	 endopeptidase).	
Modified	from	Schmelcher	et	al.	(2012).	
CBD	 domains	 are	 present	 in	 Gram-positive	 targeting	 endolysins,	 and	 recruit	 the	
catalytic	domain	to	the	peptidoglycan	cell	wall.	The	CBD	is	largely	responsible	for	the	
specificity	observed	in	endolysins	and	is	able	to	recognize	and	bind	(non-covalently)	
a	range	of	 ligands	 in	the	cell	wall.	These	 ligands	can	either	be	a	direct	part	of	 the	
peptidoglycan,	or	they	can	be	other	components	of	the	cell	wall.	An	example	of	the	
first	is	the	LysM	domain,	one	of	the	most	common	conserved	binding	modules,	which	
binds	 the	 GlcNAc	 residues	 in	 the	 peptidoglycan.	 Meanwhile,	 the	 SH3b	 domain	
present	in	the	Cpl-1	endolysin	binds	choline	moieties	in	cell-wall	associated	teichoic	
acids	of	Streptococcus	pneumoniae.	The	specificity	conferred	to	endolysins	by	their	
CBD	can	range	from	an	entire	bacterial	genus,	down	to	serovar	or	strain	and	often	
the	binding	is	exceptionally	tight	–	in	the	pico-	to	nano-molar	range	(Loessner	et	al.	
2002;	Briers	et	al.	2009).	
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Figure	Removed	
1.2.2 The	therapeutic	potential	of	endolysins	and	“exolysis”	
1.2.2.1 Theory	and	history	
Gram-positive	 bacteria,	 which	 have	 no	 outer	 membrane,	 are	 also	 susceptible	 to	
endolysins	 applied	 exogenously	 as	 the	 endolysin	 can	 directly	 access	 the	
peptidoglycan	 cell	 wall.	 The	 osmotic	 pressure	 inside	 the	 bacterial	 cell	 (20-50	
atmospheres)	 then	 causes	 cell	 lysis.	 This	 sensitivity	 enables	 endolysins	 to	 be	
exploited	as	novel	antibacterial	agents,	with	a	range	of	advantages	over	conventional	
antibiotics.	
Gram-negative	bacteria	on	the	other	hand	have	a	protective	outer	membrane	(Figure	
1.8)	 which	 prevents	 the	 endolysins	 from	 accessing	 the	 peptidoglycan	 layer	 when	
applied	exogenously.	However,	recent	advancements	have	opened	up	the	field	for	
endolysin	 therapy	 against	 Gram-negative	 bacterial	 infections.	 The	 addition	 of	 a	
polycationic	 peptide,	 able	 to	 cross	 the	 lipopolysaccharide	 outer-membrane,	 to	 a	
globular	 Gram-negative	 endolysin	 has	 yielded	 exciting	 results,	 and	 the	 chimeric	
proteins	have	been	named	Artilysins®	(Briers	et	al.	2014).	However,	Gram-positive	
targeting	endolysins	are	the	focus	of	this	thesis.	
	
Figure	 1.8	 The	 cell	wall	 structural	 differences	 between	Gram-positive	 and	Gram-negative	
bacteria.	 The	 noticeable	 differences	 are	 the	 thicker	 peptidoglycan	 cell	 wall	 in	 the	 Gram-
postive	bacteria,	and	the	presence	of	an	outer	membrane	in	Gram-negative	bacteria.	In	both	
instances	 the	 cytoplasm	 is	 at	 the	bottom	of	 the	diagram.	Reproduced	 from	 (Brown	et	al.	
2015).	
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The	 first	 in	 vivo	 demonstration	 of	 endolysin	 activity	 was	 performed	 by	 Vincent	
Fischetti’s	 group	 at	 Rockefeller	 University	 in	 2001.	 The	 group	 used	 an	 endolysin	
prophylactically	to	prevent	a	Streptococcal	infection	in	the	mouse	pharynx,	showing	
that	after	a	single	treatment	no	streptococcal	bacteria	remained	in	the	oral	pharynx	
while	leaving	the	indigenous	oral	flora	unaffected	(Nelson	et	al.	2001).	Since	then	the	
field	has	grown	significantly,	with	one	commercially	available	endolysin	therapeutic	
and	several	more	in	the	pipeline	as	will	be	discussed	in	the	following	section.	
1.2.2.2 Current	therapeutic	uses	
The	Dutch	company	Micreos	produced	the	first	endolysin-based	therapy	to	receive	
FDA	approval.	The	product,	named	Staphefekt	and	marketed	under	the	brand	name	
GladSkin,	 has	 been	 approved	 for	 topical	 treatment	 of	 Staphylococcus	 aureus	 on	
unbroken	 skin,	 treating	 diseases	 such	 as	 acne,	 rosacea,	 eczema	 and	 furunculosis	
(Micreos).		
Another	notable	company	in	the	therapeutic	endolysin	field	is	ContraFect.	ContraFect	
are	also	developing	an	endolysin	therapy	against	Staphylococcus	aureus	named	CF-
301,	which	is	in	phase	II	clinical	trials	and	has	been	granted	Fast	Track	Designation	by	
the	FDA	having	previously	been	put	on	clinical	hold	due	to	concerns	over	trial	design	
(Parmley	 2014).	Notably,	 ContraFect	 are	 focusing	upon	endolysin	 purity,	with	 the	
intention	of	treating	bacteraemia	systemically.	ContraFect	also	have	a	Gram-negative	
endolysin	at	discovery	stage	(ContraFect).	
To	the	author’s	knowledge,	these	are	the	only	two	endolysin-based	therapeutics	in	
clinical	 trials.	 However,	 there	 are	 other	 companies	 such	 as	 Lysando,	 who	 have	
licenced	Artilysins®,	with	new	products	in	sight.	
Both	Micreos	and	ContraFect	use	E.	coli	as	their	endolysin	production	platform,	and	
ContraFect	 in	particular	have	focussed	on	engineering	their	endolysin	to	be	highly	
expressed,	 soluble	 and	 readily	 purified	when	 produced	 in	 E.	 coli	 (Parmley	 2014).	
While	 this	 appears	 to	 have	 been	 a	 suitable	 approach	 for	 producing	 endolysins	
targeting	Gram-positive	bacteria,	it	is	unclear	whether	these	companies	will	seek	to	
use	 an	 alternative	 expression	 platform	 for	 producing	 endolysins	 targeting	 Gram-
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negative	bacteria.	Some	Gram-negative	targeting	endolysins	have	been	shown	to	be	
highly	 toxic	 to	E.	 coli,	 such	as	SPN9CC	 (Lim	et	al.	 2014),	 and	 therefore	potentially	
render	E.	coli	an	inefficient	production	platform.	
1.2.2.3 Advantages	of	endolysins	over	conventional	antibiotics	
Endolysins	 hold	 great	 promise	 as	 novel	 antibiotics	 and	 they	 have	 numerous	
advantages	over	conventional	antibiotics.	
Firstly,	endolysins	kill	bacteria	at	a	significantly	faster	rate	than	that	of	conventional	
antibiotics.	Indeed,	purified	lysins	in	nanogram	quantities	have	been	shown	to	reduce	
107	Streptococcus	pyogenes	by	more	than	6	logs	in	only	a	matter	of	seconds	(Fischetti	
2008).	In	vivo	models	have	shown	that	the	endolysin	ClyS	achieves	a	3	log	reduction	
of	bacteria	in	30	minutes,	while	daptomycin	takes	6	hours	and	vancomycin	>24	hours	
to	 achieve	 similar	 levels	 of	 killing	 (Pastagia	 et	 al.	 2013).	Generally,	 endolysins	 act	
much	 faster	 than	conventional	antibiotics,	which	 for	blood	 infections	 in	particular	
such	as	sepsis	and	bacteraemia,	could	be	lifesaving.	
The	 specificity	 of	 endolysins	 presents	 an	 enormous	 advantage	 over	 conventional	
antibiotics	if	the	infecting	bacteria	has	been	diagnosed.	The	advantages	are	two-fold:	
firstly,	 a	 specific	antibiotic	will	not	disrupt	 the	body’s	 indigenous	 “good”	bacteria,	
while	killing	the	pathogen.	This	minimises	the	opportunity	for	secondary	infections	
such	 as	 Clostridium	 difficile	 infection	 and	 yeast	 infections	 which	 are	 common	
complications	 after	 a	 course	 of	 broad-spectrum	 antibiotics	 (U.S.	 Department	 of	
Health	and	Human	Services	2013).	Secondly,	as	the	vast	majority	of	bacteria	in	the	
body	or	environment	are	unaffected	by	the	endolysin,	no	selective	pressure	is	applied	
to	 them.	 This	 is	 in	 contrast	 to	 broad-spectrum	 antibiotics,	 which	 put	 a	 selective	
pressure	for	resistance	upon	all	bacterial	species	in	the	environment,	thus	increasing	
the	chances	of	resistance	emerging.	High	specificity	is	also	a	limitation	of	endolysins	
however,	as	will	be	discussed	in	section	1.2.2.4.	
One	of	the	greatest	problems	that	conventional	antibiotics	face	is	their	limited	ability	
to	kill	persister	cells	in	biofilms.	Biofilms	can	form	in	various	locations	–	from	the	gut	
lining,	 to	 water	 treatment	 plant	 equipment.	 Bacterial	 cells	 in	 biofilms	 are	 in	 a	
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dormant	 state,	 designed	 to	 withstand	 harsh	 environments	 and	 therefore	 do	 not	
undergo	replication.	Due	to	the	mechanism	of	action	of	conventional	antibiotics,	such	
as	disrupting	cell	wall	formation,	these	biofilm-dwelling	bacteria	are	unaffected	by	
them.	After	treatment	with	antibiotics,	the	unaffected	biofilm	cells	are	then	able	to	
recolonise	the	environment.	Endolysins	on	the	other	hand	actively	lyse	bacterial	cell	
walls,	 regardless	 of	 the	 state	 of	 the	 cell	 and	 have	 been	 shown	 to	 be	 extremely	
effective	against	biofilms	(Gutiérrez	et	al.	2014).	
One	of	the	greatest	and	most	often	quoted	advantages	of	endolysins	is	that,	so	far,	
bacterial	 resistance	 to	 them	 has	 been	 unreported,	 despite	 efforts	 to	 produce	 it	
(Loeffler	 et	 al.	 2001).	 It	 is	 believed	 that	 several	 factors	 contribute	 to	 endolysin-
resistance	being	a	rare	event.	Firstly,	the	natural	evolution	of	endolysins	has	led	to	
the	adoption	of	highly	conserved	 targets	 in	 the	peptidoglycan	cell	wall,	which	are	
essential	for	bacterial	viability	(Fischetti	2008).	Secondly,	the	exogenous	application	
and	action	of	endolysins	avoids	many	of	the	resistance	mechanisms	observed	against	
conventional	 antibiotics	 (efflux	 pumps	 and	 deactivating	 enzymes).	 Finally,	 with	
regards	to	real	life	applications,	the	specificity	of	endolysins	means	that	no	selective	
pressure	is	being	applied	to	non-target	bacteria.		
It	is	inevitable	that	one	day,	if	endolysins	become	widely	used,	then	some	resistance	
will	 eventually	 be	 observed.	 In	 the	 case	 of	 conventional	 antibiotics,	 as	 we	 have	
discussed,	 discovering	new	antibiotics	 requires	 serendipity	 and	a	huge	amount	of	
time,	and	has	recently	proven	very	difficult.	In	contrast,	given	the	diversity	and	size	
of	the	bacteriophage	population,	there	is	a	huge	store	of	endolysins	to	tap	when	the	
need	arises.	
Water	pollution	by	conventional	antibiotics	is	a	growing	concern.	When	antibiotics	
are	not	fully	metabolised	by	the	body,	the	high	stability	of	some	antibiotics	can	lead	
them	 to	 remain	 active	 throughout	 the	 sewerage	 system	 and,	 eventually,	
watercourses	 too.	 These	 low	 levels	 of	 antibiotics	 in	 the	 environment	 create	 ideal	
conditions	 for	resistance	emergence,	and	 indeed	antibiotic	 resistant	bacteria	have	
been	detected	in	British	watercourses	for	some	time	(Hughes	and	Meynell	1974).	The	
proteinaceous	endolysins	on	the	other	hand	are	relatively	unstable,	with	a	half-life	
		 36	
of	about	20	minutes	in	the	body,	so	are	unlikely	to	survive	into	other	environments,	
and	given	their	specificity	and	lack	of	resistance,	are	a	considerably	lower	risk.	
Finally,	though	not	a	true	advantage	over	conventional	antibiotics,	 is	the	ability	of	
endolysins	 to	 act	 synergistically	 with	 antibiotics	 to	 reduce	 antibiotic	 usage	 and	
improve	therapeutic	efficacy.	For	example,	the	endolysin	ClyS	has	been	shown	to	act	
synergistically	with	oxacillin	to	kill	MRSA	 in	vivo.	As	oxacillin	is	a	cell	wall	synthesis	
inhibitor,	and	causes	cell	lysis	by	the	resulting	upregulation	of	autolysins,	it	is	believed	
that	ClyS	further	exacerbates	the	degradation	of	the	cell	wall,	thus	promoting	even	
more	bacterial	 autolysin	 activity	 (Daniel	 et	 al.	 2010).	 Such	 synergistic	 effects	may	
enable	 discontinued	 antibiotics	 to	 be	 reinstated	when	 used	with	 endolysins,	 and	
reduce	overall	antibiotic	intake	or	course	length.	
1.2.2.4 Limitations	
The	bacteria	posing	 the	greatest	 threat	 to	mankind	have	been	given	 the	acronym	
ESKAPE	 by	 the	 Infections	 Diseases	 Society	 of	 America,	 standing	 for	 Enterococcus	
faecium,	 Staphylococcus	 aureus,	 Klebsiella	 pneumoniae,	 Acinetobacter	 baumanni,	
Pseudomonas	aeruginosa,	and	Enterobacter	species	(Rice	2008).	Of	these,	the	final	
four	 are	 all	 Gram-negative.	 Conventional	 antibiotics	 currently	 in	 clinical	 trials	 are	
skewed	towards	Gram-positive	activity.	One	limitation	of	endolysins	is	their	inability	
to	cause	Gram-negative	lysis	due	to	their	inability	to	penetrate	the	outer	membrane.	
However,	as	mentioned	earlier,	Artilysins®	have	made	some	progress	towards	being	
able	 to	 tackle	Gram-negative	 infections,	 and	 for	 topical	 applications	 EDTA	 can	 be	
used	to	permeablise	the	Gram-negative	outer	membrane	(Briers	and	Lavigne	2015). 
There	are	two	factors	to	be	considered	in	terms	of	immune	response	to	application	
of	endolysins.	The	first	 is	to	the	endolysin	 itself:	endolysins	are	a	protein	and	thus	
may	trigger	an	immune	response	including	antibody	generation,	potentially	limiting	
future	use	of	that	endolysin.	An	attempt	to	reduce	the	postulated	immune	response	
to	Cpl-1	was	made	by	PEGylation	of	the	protein,	a	well-known	method	of	minimising	
immune	 response	 and	 increasing	 half-life,	 but	 this	 completely	 inhibited	 the	 lytic	
activity	of	the	endolysin	(Resch	et	al.	2011b).	However,	it	has	been	observed	in	vivo	
that	although	antibodies	are	 indeed	raised	against	the	Cpl-1	endolysin	 in	mice,	on	
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reapplication	no	adverse	effects	were	observed	and	activity	was	only	slightly	slowed	
(Jado	et	al.	2003).	It	is	postulated	that	the	endolysin	activity	is	much	faster	than	the	
host’s	 antibody	 mediated	 secondary	 immune	 response,	 and	 is	 thus	 largely	
unaffected.		
The	second	immune	response	of	concern	is	to	the	large	volume	of	bacterial	cell	debris	
rapidly	 released	 by	 endolysin	 activity.	 Two	 studies	 have	 been	 undertaken	 to	
investigate	 this	 issue,	 with	 varying	 results:	 the	 first	 study	 found	 that	 the	 Cpl-1	
endolysin	produced	an	accentuated	cytokine	response	when	compared	to	the	same	
treatment	using	vancomycin	(Entenza	et	al.	2005);	the	latter	study	observed	no	major	
difference	 in	cytokine	production	between	Cpl-1	and	amoxicillin	(Witzenrath	et	al.	
2009).	This	discrepancy	is	thought	to	be	an	issue	of	endolysin	dosing:	when	a	high	
dose	 is	 given,	 then	 the	 bacterial	 cell	wall	 is	 fragmented	 thus	 producing	 a	 greater	
response,	compared	to	a	low	dose	which	merely	punctures	the	bacterial	cells	with	
minimal	fragmentation	(Fischetti	2008).	
Bioavailability	 of	 endolysins	 is	 a	 concern	 given	 their	 large	 size	 compared	 to	
conventional	 antibiotics.	 In	 particular,	 intracellular	 bacterial	 infections	 such	 as	
chlamydia	and	tuberculosis	are	particularly	hard	to	access,	and	present	a	challenge	
even	for	conventional	antibiotics.	However,	a	recent	demonstration	that	PlyC	is	able	
to	 enter	 human	 throat	 cells	 and	 kill	 internalized	 S.	 pyogenes	 demonstrates	 the	
diverse	abilities	of	the	endolysins	(Shen	et	al.	2016).	In	this	instance	it	appears	that	a	
specific	component	of	the	throat	cell	membrane,	a	phosphatidylserine,	grants	access	
to	the	PlyC	endolysin	–	however	it	 is	also	noted	in	the	study	that	other	endolysins	
could	not	be	expected	to	function	in	this	way.	This	finding	does	however	raise	the	
prospect	that	even	intracellular	bacteria	may	eventually	be	treated	with	endolysins.	
The	only	endolysin	currently	on	the	market,	Staphefekt,	is	designed	for	topical	use	
and	 is	delivered	either	as	a	cream	or	a	gel	 (Micreos).	 It	 is	unclear	how	ContraFect	
intend	to	deliver	 their	endolysin	drug,	however	their	studies	and	discussions	have	
mostly	focussed	around	intranasal	and	aerosol	delivery	methods	(Doehn	et	al.	2013;	
Loeffler	et	al.	2003).	Oral	delivery	of	endolysins	will	be	harder,	as	the	proteinaceous	
nature	of	endolysins	means	that	they	are	susceptible	to	digestion	and	denaturing	in	
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the	stomach,	and	would	need	to	be	encapsulated	to	ensure	release	into	the	intestine	
for	example.		
The	 final	 limitation	of	endolysins,	which	was	contrastingly	presented	earlier	as	an	
advantage,	 is	 their	specificity.	The	narrow-spectrum	of	target	bacteria	killed	by	an	
endolysin	presents	a	challenge	for	clinicians	in	that	the	infection	must	be	accurately	
diagnosed	before	an	endolysin	treatment	can	be	prescribed.	This	diagnosis	is	not	yet	
easily	possible,	but	the	potential	to	create	endolysin	“cocktails”,	which	target	all	the	
most	common	bacteria	associated	with	a	certain	disease,	may	work	around	this.	
To	 conclude,	 although	 various	 challenges	 have	been	 laid	 in	 the	path	of	 endolysin	
research,	none	has	yet	presented	a	serious	flaw	to	the	technology	as	a	therapeutic,	
and	techniques	are	emerging	to	solve	the	majority	of	issues.	
1.2.3 Other	applications	
The	 remarkable	 ability	 of	 endolysins	 to	 identify	 and	 strongly	 bind	 highly	 specific	
bacterial	targets	has	produced	interest	in	fields	other	than	direct	therapeutics.	
For	example,	work	by	the	Loessner	group	at	ETH,	Zurich	has	used	endolysins	to	create	
rapid	 diagnostic	 tools	 for	 food	 safety.	 Their	 technology	 uses	 electrochemical	
impedance	 spectroscopy	 (EIS)	 to	 rapidly	detect	Listeria	 cells	 binding	 to	endolysin-
derived	CBDs	immobilized	on	a	gold	screen	printed	electrode.	This	enables	extremely	
rapid,	 accurate,	 and	 sensitive	 detection	 of	 contaminating	 Listeria	 cells	 in	 food	
products	(Tolba	et	al.	2012).		
Nelson’s	 group	 at	 the	University	 of	Maryland	 have	 designed	 two	 novel	 endolysin	
based	platforms,	designed	to	aid	the	body’s	natural	immune	system.	The	first	is	the	
generation	 of	 Infection	 Site	 Targeted	 Antitoxin	 antibodies	 (ISTAbs),	 which	 are	
endolysin	CBDs	fused	to	specific	antitoxin	neutralizing	monoclonal	antibodies.	The	
CBD	targets	the	antibody	to	the	pathogen	cell	wall,	where	it	sequesters	the	released	
toxins,	 thus	 reducing	 the	 toxin	 load	 and	 furthermore,	 functionally	 opsonises	 the	
bacterium	 for	 opsonophagocytic	 killing	 by	 the	 host	 immune	 system.	 The	 second	
approach,	named	Infection	Site	Targeted	universal	Bridging	Antigen	(ISTuBA),	fuses	
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CBDs	 to	 antigens	 for	 which	 most	 people	 have	 existing	 immunity	 (e.g.	 childhood	
vaccine	targets).	This	anchors	the	antigen	to	the	pathogen	cell	wall,	and	directs	the	
existing	immunity	towards	the	new	pathogen	(Nelson	2016).	
Other	applications	include	endolysin	based	disinfectants,	which	have	been	shown	to	
be	 1,000x	more	 active	 than	 virkon-S	 against	 Streptococcus	 equi	 over	 30	minutes	
(Hoopes	et	al.	2009).	Food	biopreservation	and	biofilm	elimination	have	also	been	
shown	to	be	successful	applications	of	endolysins	(Ajuebor	et	al.	2016).	
1.3 Producing	recombinant	therapeutic	proteins	
The	successful	administration	of	therapeutic	 insulin	to	a	severely	diabetic	14-year-
old	boy	 in	1922	marked	the	first	use	of	a	protein	as	a	pharmaceutical	 (Joshi	et	al.	
2007).	 Since	 then,	 the	 ability	 to	 produce	 proteins	 recombinantly	 in	 a	 number	 of	
biological	 platforms	 has	 led	 to	 lower	 costs	 of	 production	 and	 the	 rise	 of	 protein	
therapies.	In	1977	Somatostatin,	a	very	small	inhibitor	peptide,	was	the	first	human	
recombinant	protein	to	be	produced	in	Escherichia	coli,	by	Genentech	Inc	(Brooker	
2010).	 Other	 platforms	 have	 since	 been	 developed	 to	 meet	 the	 various	 protein	
requirements,	 such	 as	 producing	 larger	 proteins,	 glycosylation	 patterns,	 and	
disulphide	 bonds.	 Here	 we	 provide	 a	 very	 brief	 overview	 of	 some	 of	 the	 most	
common	expression	platforms	used	today.	
1.3.1 Common	expression	platforms	
E.	coli,	as	already	mentioned,	was	the	first	recombinant	protein	expression	platform	
and	remains	widely	used.	Due	to	many	years	of	research	and	development	resulting	
in	 an	 excellent	 understanding	 of	 E.	 coli	 genetics,	 genetic	 engineering	 of	 E.	 coli	 is	
cheap,	easy	and	extremely	fast.	High	yields	of	recombinant	proteins	can	be	readily	
achieved	and	many	genetic	tools,	such	as	inducible	expression	systems	and	protein	
secretion,	enable	its	precise	manipulation.	However,	the	system	is	not	well	suited	to	
producing	large	proteins	(over	50	kDa).	Furthermore,	the	proteins	can	form	inactive	
inclusion	 bodies,	 E.	 coli	 does	 not	 naturally	 glycosylate	 proteins,	 and	 endotoxin	
contamination	requires	expensive	down-stream	purification	procedures	(Gupta	and	
Shukla	2015).	
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Chinese	Hamster	Ovary	(CHO)	cells	are	probably	the	most	commonly	used	expression	
platform	 for	 current	 therapeutic	 proteins,	 in	 particular	 for	 the	 production	 of	
antibodies	 (Dumont	 et	 al.	 2015).	 As	 a	mammalian	 system,	 CHO	 cells	 are	 able	 to	
produce	 large	 proteins	 (over	 100	 kDa)	 and	 glycosylate	 and	 fold	 them	 correctly	 -	
although	 they	 do	 produce	 some	 post-translational	 modifications	 that	 are	 not	
expressed	 in	 humans,	 and	 subsequently	 against	 which	 humans	 have	 antibodies	
(Dumont	et	al.	2015).	On	the	whole,	CHO	cells	are	used	to	produce	larger	and	more	
complex	biologics	than	other	systems.	Their	drawbacks	 include	potential	DNA	and	
viral	contamination,	very	high	costs	of	production	and	lower	yields	than	some	other	
systems	(Demain	and	Vaishnav	2011).		
Yeast,	as	a	single	cellular	eukaryote,	shares	some	of	the	advantages	of	a	microbial	
platform,	 such	 as	 cheap	 growth	media	 and	 high	 yields,	 as	 well	 as	 advantages	 of	
mammalians	 cells,	 such	 as	 protein	 glycosylation	 and	 disulphide	 bond	 formation.	
Yeast	 therefore	 presents	 a	 very	 attractive	 platform	 for	 recombinant	 protein	
expression,	although	a	 few	 issues	prevent	 it	 from	being	using	 for	all	proteins.	For	
example,	yeast’s	high-mannose	 type	N-glycosylation	pattern	can	 lead	 to	a	 shorter	
protein	 half-life	 and	 reduced	 therapeutic	 efficacy,	 and	 its	 lack	 of	 necessary	
chaperones	can	often	result	in	poor	protein	folding	(Nielsen	2013).		
Plant-based	platforms	have	lagged	behind	others	over	the	past	decades,	despite	the	
numerous	advantages	they	hold	as	a	recombinant	protein	production	platform.	Plant	
cells	are	able	to	fold	complex	proteins	and	perform	post-translational	modifications	
including	 glycosylation.	 Either	 whole	 plants	 or	 plant	 cell	 cultures	 can	 be	 used	 as	
expression	 platforms.	 Both	 are	 devoid	 of	 the	 endotoxins	 and	 potential	 viral	
contamination	 of	 other	 platforms,	 but	 otherwise	 have	 different	 advantages	 and	
pitfalls.	Whole	plants,	such	as	tobacco	(Nicotiana	tabacum)	are	highly	scalable,	and	
cost	effective	at	scale.	Transient	gene	expression	in	leaf	tissue	of	whole	plants	can	be	
achieved	very	rapidly	and	has	been	used	to	successfully	produce	ZMapp,	 the	only	
successful	drug	produced	to	treat	Ebola	viral	 infection	in	humans,	as	well	as	being	
regularly	used	for	producing	influenza	vaccines	(Yao	et	al.	2015).	However,	several	
issues	 have	 limited	whole	 plant	 use	 to	 date,	 including	 the	 relatively	 long	 time	 to	
produce	 stable	 transgenic	 plants	 desired	 for	 long-term	 production,	 variable	
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expression	 levels,	and	 issues	of	biocontainment	at	 large	scale	 (Park	and	Wi	2016).	
Plant	cell	cultures	offer	solutions	to	many	of	these	issues,	such	precise	monitoring	
and	control	of	growth	conditions,	 consistent	 cell	 yields	and	biocontainment	when	
grown	in	bioreactors.	Several	plant	cell	lines	are	used	routinely,	such	as	those	derived	
from	N.	 tabacum,	 as	well	 as	 those	 from	edible	 crops	 including	 rice	 (Oriza	 sativa),	
carrot	(Daucus	carota)	and	tomato	(Lycopersicon	esculentum)	(Xu	and	Zhang	2014),	
and	 in	 2012	 taliglucerase	 alfa,	 the	 first	 plant-made	 pharmaceutical	 approved	 for	
human	use,	was	made	in	a	carrot	cell	line	to	treat	Gaucher’s	disease	(Grabowski	et	
al.	2014).		
Like	 plant	 cell	 cultures,	 microalgae	 offer	 many	 similar	 advantages	 over	 other	
platforms	 and	 higher	 plants,	 but	 have	 additional	 advantages	 too.	Microalgae	 are	
photosynthetic	 (unlike	carrot	cell	 cultures	 for	example),	enabling	 the	potential	 for	
using	 cheaper,	 less	 complex	 media	 that	 is	 less	 susceptible	 to	 contamination.	
Microalgae	also	generally	grow	faster	than	plant	cell	cultures	and	are	more	robust	in	
terms	of	resisting	stresses	from	pH	changes	and	shear	stress	(Sun	and	Linden	1999).	
Finally,	the	generation	of	new	transplastomic	lines	is	faster	in	microalgae	(2-3	weeks)	
than	plant	cell	cultures	(4-5	weeks)	(Govea-Alonso	et	al.	2017).	
1.3.2 Microalgae	as	expression	platforms	
1.3.2.1 What	are	microalgae?	
The	 term	 microalgae	 can	 generally	 refer	 to	 any	 unicellular	 organism	 capable	 of	
oxygenic	 photosynthesis,	 both	 eukaryotic	 (e.g.	 green	 algae)	 and	 prokaryotic	 (e.g.	
cyanobacteria)	(Walker	et	al.	2005).	Microalgae	are	therefore	an	extremely	diverse	
group	of	organisms	and	can	be	found	in	both	fresh	and	salt	water	environments,	as	
well	as	terrestrially.	Figure	1.9	illustrates	the	level	of	diversity	observed	within	the	
microalgae.	
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Figure	1.9	A	selection	of	images	displaying	the	diversity	of	microalgae.	(A)	Meridion	circulare	
(B)	 Merismopedia	 elegans	 (C)	 Acutodesmus	 acuminatus	 (D)	 Microcystis	 novacekii	 (E)	
Arthrospira	 jenneri	 (F)	 Dissodinium	 pseudolunula	 (G)	 Zygnema	 circumcarinatum	 (H)	
Actinocyclus	 normanii	 (I)	Pediastrum	duplex	 (J)	Klebsormidium	dissectum	 (K)	Diploneis	 (L)	
Chlamydomonas	 reinhardtii.	 A-F	 from	 http://nordicmicroalgae.org/.	 G-K	 from	
http://www.algaterra.org/.	L	from	http://protist.i.hosei.ac.jp/.	Images	not	to	scale.		
Microalgae	such	as	Arthrospira	(Spirulina)	and	Aphanizomenon	have	been	used	as	a	
source	of	food	for	thousands	of	years	(Spolaore	et	al.	2006),	but	only	in	the	last	50	
years	have	microalgae	been	subject	to	commercial	cultivation.	The	first	company	to	
produce	 Chlorella	 sorokiniana	 on	 a	 commercial	 scale	 was	 Taiwan	 Chlorella	
Manufacturing	Ltd,	which	was	founded	in	1964	and	still	produces	Chlorella	today,	to	
be	sold	as	dietary	supplement	(Spolaore	et	al.	2006).	While	Spirulina	and	Chlorella	
remain	popular	health-food	products,	the	ability	of	microalgae	to	act	as	“sunlight-
driven	 cell	 factories”	 (Chisti	 2008)	 for	 producing	 high	 value	 products	 has	 spurred	
research	in	the	field	towards	harnessing	the	full	potential	of	these	diverse	organisms.	
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1.3.2.2 The	history	of	microalgae	as	an	expression	platform	
Microalgae,	and	in	particular	the	green	alga	Chlamydomonas	reinhardtii,	have	been	
used	 as	 a	 model	 organism	 for	 many	 years	 for	 the	 investigation	 of	 the	 genetic	
mechanisms	behind	cellular	processes	(Harris	2009).	Microalgae	gained	prominence	
as	 a	 recombinant	 protein	 production	 platform	 with	 their	 potential	 to	 produce	
biofuels	without	 affecting	 food	 production	 -	 as	 a	 photosynthetic	 organism	 it	was	
postulated	that	algae	could	be	grown	in	areas	unsuitable	for	crop	production,	thus	
producing	 biomass	 from	 cheap	 substrates	 on	 unused	 land.	 However,	 despite	 the	
successful	 production	 of	 biodiesel	 in	 microalgae,	 the	 economics	 of	 this	 strategy	
currently	fail	to	compete	with	that	of	fossil-fuels	(Scranton	et	al.	2015).		
Despite	the	current	shortcomings	of	microalgae	for	the	production	of	biodiesel,	the	
platform	still	holds	promise	for	high-value	proteins	and	has	several	advantages	over	
higher-plants.	 Microalgae	 have	 the	 ability,	 like	 higher	 plants,	 to	 synthesize	 and	
correctly	fold	human	antibodies,	and	many	are	Generally	Regarded	As	Safe	(GRAS).	
But	in	addition	to	these	attributes,	microalgae	can	be	grown	in	closed	containment	
photobioreactors,	removing	the	risk	of	gene	flow	into	the	environment	via	pollen;	
genetically	 engineered	 strains	 can	 be	 produced	 in	 a	matter	 of	weeks	 rather	 than	
sometimes	years	for	higher-plants;	and	scale	up	from	bench	to	production	scale	is	
straightforward	 (Franklin	 and	 Mayfield	 2004).	 Microalgae	 therefore	 present	 an	
extremely	attractive	platform	for	recombinant	protein	expression.		
Several	species	of	microalgae	have	to	date	been	genetically	transformed,	including	
C.	 reinhardtii,	Haematococcus	 pluvialis,	 Chlorella	 and	 diatoms	 (Spicer	 and	 Purton	
2016).	 H.	 pluvialis	 is	 a	 natural	 producer	 of	 astaxanthin,	 a	 carotenoid	 with	 high	
economic	 and	 health-related	 value,	 and	 it	 has	 been	 successfully	 genetically	
engineered	 to	 produce	 higher	 levels	 of	 astaxanthin	 (Steinbrenner	 and	 Sandmann	
2006).	The	green	alga	Chlorella	vulgaris	is	a	source	of	several	products	believed	to	be	
beneficial	 as	 health	 supplements,	 including	 high-quality	 proteins,	 fatty	 acids,	 and	
essential	amino	acids,	and	a	method	of	agrobacterium-mediated	transformation	has	
been	established	(Cha	et	al.	2012).		
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However,	while	various	species	of	microalgae	have	been	genetically	modified,	 the	
species	with	 the	most	 advanced	 genetic	 toolkit	 is	C.	 reinhardtii.	C.	 reinhardtii	 has	
been	 shown	 to	 express	 multiple	 recombinant	 proteins	 using	 a	 variety	 of	
transformation	 methods,	 and	 in	 all	 three	 genomes	 (nuclear,	 mitochondrial	 and	
chloroplast)	(Scaife	et	al.	2015).	The	potential	of	C.	reinhardtii	will	be	explored	further	
in	the	following	section.	
1.3.3 Chlamydomonas	reinhardtii	as	an	expression	platform	
1.3.3.1 An	introduction	to	Chlamydomonas	reinhardtii		
Chlamydomonas	 reinhardtii	 is	 a	 unicellular	 green	 alga	 found	 widely	 in	 soil	 and	
freshwater	and	belongs	to	the	Chlorophyta	division	of	green	algae.	Figure	1.10	shows	
a	schematic	of	a	C.	reinhardtii	cell	as	well	as	a	scanning	electron	microscopy	image,	
highlighting	the	main	morphological	features	of	the	cell.	It	is	approximately	10	μm	in	
diameter	 and	 has	 two	 flagella	 enabling	 phototaxis,	 and	 a	 large	 chloroplast	 filling	
approximately	 70%	 of	 the	 cell	 volume	 (Harris	 2009).	 C.	 reinhardtii	 can	 grow	
phototrophically	or,	in	the	presence	of	acetate,	mixotrophically	or	heterotrophically.	
All	three	genomes	have	been	sequenced	(Vahrenholz	et	al.	1993;	Maul	et	al.	2002;	
Merchant	et	al.	2010),	and	a	simple	(and	controllable)	sexual	cycle	exists	 in	which	
nuclear	genes	are	inherited	according	to	Mendelian	rules,	chloroplast	genes	inherited	
uniparentally	from	the	mating-type	(mt)	plus	parent,	and	mitochondrial	genes	from	
the	mt	minus	parent.	Furthermore,	the	haploid	nature	of	the	nuclear	genome	and	
the	 fact	 that	many	 nuclear	 genes	 are	 single	 copy	 (rather	 than	members	 of	 gene	
families)	 makes	 the	 recovery	 and	 classical	 genetic	 analysis	 of	 mutants	 very	
straightforward.	This	has	led	to	C.	reinhardtii	being	refered	to	as	the	“photosynthetic	
yeast”	 (Rochaix	1995).	Given	 these	attributes	and	 the	 fact	 that	 it	 is	 relatively	 fast	
growing	(5	-	8	hour	doubling	time,	depending	on	nutrient,	CO2	and	light	availability	
(Hosler	et	al.	1989)),	 it	has	been	an	attractive	model	 for	 studying	photosynthesis,	
circadian	rhythms,	mating	and	other	processes	for	many	years	(Harris	2009).		
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Figure	1.10	(A)	The	Chlamydomonas	reinhardtii	cell	represented	as	a	schematic	diagram	with	
labelled	physiological	 features	 (Shi	2013).	 (B)	A	Scanning	Electron	Microscopy	 image	of	C.	
reinhardtii	clearly	showing	the	main	morphologies	of	the	cell	including	the	two	flagella	(Smith	
et	al.	1996).	
1.3.3.2 Genetic	engineering	of	Chlamydomonas	reinhardtii	
C.	reinhardtii	is	the	most	genetically	well	studied	of	the	microalgae,	and	methods	to	
transform	 the	 nuclear,	 chloroplast	 and	 mitochondrial	 genomes	 have	 all	 been	
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developed.	The	sexual	cycle	can	be	precisely	controlled,	enabling	genetic	crosses	to	
be	carried	out	and	introduced	traits	to	be	combined	(Grossman	et	al.	2003).		
The	 nuclear	 genome	 can	 be	 transformed	 using	 a	 number	 of	 methods	 including	
electroporation	and	particle	bombardment	 to	 randomly	 incorporate	DNA	 into	 the	
genome	(Jinkerson	and	Jonikas	2015).	Antibiotic	markers	and	rescuing	of	nutritional	
auxotrophs	have	been	successful	methods	for	nuclear	transformation	selection,	but	
positional	effects	lead	to	a	spectrum	of	gene	expression	levels	(Rochaix	1995).	The	
nuclear	genome	is	very	GC	rich	(64%),	and	codon	optimization	has	been	shown	to	
play	an	 important	 role	 in	 gene	expression	 levels,	 improving	GFP	expression	 levels	
approximately	 5-fold	 (Fuhrmann	 et	 al.	 1999).	 However,	 gene	 silencing	 and	 low	
protein	 yields	 have	 been	 problematic	 for	 C.	 reinhardtii	 nuclear	 transformants,	
although	recent	work,	such	as	that	by	Barahimipour	et	al.	(2016)	demonstrating	high	
yields	 of	 HIV	 antigen	 P24,	 show	 that	 these	 issues	 are	 being	 gradually	 overcome.	
Furthermore,	 Lauersen	 et	 al.	 (2015)	 have	 created	 the	 pOptimized	 vector	 system,	
which	 allows	 the	 rapid	 swapping	 of	 reporter	 genes,	 selectable	 markers	 and	
regulatory	 elements	 to	 speed	 up	 the	 optimisation	 of	 nuclear	 protein	 expression,	
while	Scranton	et	al.	(2016)	have	demonstrated	the	successful	identification	and	use	
of	synthetic	nuclear	promoters	to	improve	heterologous	nuclear	gene	expression.		
The	 chloroplast	 on	 the	 other	 hand	 offers	 a	 more	 attractive	 target	 for	 genetic	
modification.	 Very	 simple	 transformation	 processes	 exist,	 for	 example	 transient	
pores	 can	 be	 formed	 by	 vortexing	 cell	 wall-less	mutants	 with	 glass	 beads,	 which	
enables	DNA	entry	to	the	chloroplast	(Kindle	et	al.	1991;	Maliga	2014).	Homologous	
recombination	 then	 allows	 precise	 targeting	 of	 expression	 cassettes	 into	 the	
plastome,	 and	 generally	 results	 in	 greater	 protein	 accumulation	 than	 nuclear	
transformations	(Franklin	et	al.	2002).	Furthermore,	by	transforming	photosynthesis-
deficient	 mutants,	 antibiotic-free	 selection	 is	 possible	 by	 using	 the	 rescue	 of	
photosynthesis	 as	 a	 selection	 mechanism	 (Wannathong	 et	 al.	 2016).	 The	 precise	
method	 of	 transformation	 is	 described	 in	 more	 detail	 in	 2.3.13.	 Gene	 silencing,	
thought	to	be	a	defence	mechanism	against	viral	DNA	insertion	into	the	genome,	has	
not	been	observed	in	the	C.	reinhardtii	chloroplast.	However,	the	chloroplast	does	
not	glycosylate	proteins.	
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A	summary	of	the	strengths	and	limitations	of	the	C.	reinhardtii	chloroplast	compared	
to	the	nucleus	can	be	seen	in	Figure	1.11.	
	
Figure	 1.11	 The	 nucleus	 and	 chloroplast	 genomes	 represent	 the	 major	 locations	 for	
transgene	 insertion	 and	 recombinant	 protein	 synthesis	 in	 C.	 reinhardtii.	 While	 the	
mitochondrial	 genome	 has	 been	 transformed	 it	 is	 not	 commonly	 used	 for	 recombinant	
protein	production.	Reproduced	from	Rasala	&	Mayfield	(2015).	
1.3.3.3 The	suitability	of	the	C.	reinhardtii	chloroplast	for	endolysin	synthesis	
Over	one	billion	years	ago	an	endosymbiotic	event,	resulting	in	the	encapsulation	of	
a	photosynthetic	prokaryote	inside	a	nonphotosynthetic	eukaryotic	host,	is	believed	
to	have	been	the	genesis	of	the	chloroplast	organelle	(Purton	2007).	Since	then	the	
prokaryotic	genome	has	shed	much	of	its	unnecessary	genetic	material,	resulting	in	
a	 simplified	 circular	 plastome.	 The	 C.	 reinhardtii	 chloroplast,	 sequenced	 in	 2002	
(Maul	et	al.	2002),	contains	99	genes	and	has	a	low	GC	content	(34%),	in	contrast	to	
the	nuclear	genome.		
The	prokaryotic	beginnings	of	the	chloroplast	result	in	an	environment	well	suited	for	
the	 production	 of	 endolysins,	 which	 are	 naturally	 produced	 in	 bacteriophage-
infected	prokaryotes.	For	example,	the	chloroplast	appears	to	contain	proteases	that	
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are	direct	homologues	of	prokaryotic	proteases	(Adam	et	al.	2006).	This	is	expected	
to	lead	to	a	respectable	half-life	of	the	endolysins	inside	the	chloroplast,	as	they	are	
adapted	 to	 be	 relatively	 resistant	 to	 prokaryotic	 proteases.	 Furthermore,	 the	
chloroplast	is	non-glycosylating,	which	may	often	be	seen	as	a	disadvantage,	but	for	
the	production	of	endolysins,	and	other	prokaryotic	proteins,	is	beneficial	(Almaraz-
Delgado	et	al.	2014).	The	expression	of	endolysins	to	high	levels	in	E.	coli	has	been	
reported	 to	 have	 a	 detrimental	 effect	 upon	 bacterial	 cell	 growth,	 presumably	
because	of	low-level	activity	against	its	peptidoglycan	cell	wall	despite	the	specificity	
of	endolysins	and	lack	of	holin.	However,	plant	and	green	algal	chloroplasts	have	lost	
the	cell	wall	during	evolution,	and	extremely	high	levels	of	endolysin	accumulation	
(~70	%	TSP)	have	been	reported	 in	 the	chloroplast	of	Nicotiana	 (Oey	et	al.	2009).	
Therefore,	 the	 prokaryotic	 environment,	 lack	 of	 glycosylation,	 and	 lack	 of	
peptidoglycan	structures	makes	the	chloroplast	a	well	suited	platform	for	endolysin	
production	(Oey	et	al.	2009).	The	C.	reinhardtii	chloroplast	has	successfully	produced	
therapeutic	proteins	 in	the	past,	 including	endolysins,	a	summary	of	which	can	be	
seen	in	Table	1.1.	
C.	reinhardtii	has	been	designated	GRAS	status	and	there	is	speculation	in	the	field	
that	this	may	lead	to	reduced	downstream	processing	costs,	or	even	the	ability	to	use	
crude	extracts	of	recombinant	protein	therapeutically	(Almaraz-Delgado	et	al.	2014).	
In	 fact,	 the	 two	companies	closest	 to	 therapeutic	endolysin	production	have	both	
been	 hampered	 by	 issues	 of	 product	 purity	 and	 solubility	 with	 their	 bacterial	
production	 systems.	ContraFect,	 attempting	 to	produce	an	endolysin	 for	 systemic	
use,	have	so	far	failed	to	receive	FDA	approval,	while	Micreos	have	instead	opted	to	
produce	 an	 endolysin	 for	 topical	 use,	 with	 less	 regulation	 around	 product	 purity	
(Parmley	2014).	
To	 date,	 the	major	 limitation	 to	microalgae	 as	 a	 recombinant	 protein	 production	
platform	has	been	their	low	production	yields.	CHO	cells	are	capable	of	producing	4-
6	 g/L	 of	 recombinant	 protein	 (Wurm	 2004),	 yeasts	 9-12	 g/L,	 E.	 coli	 15-17	 g/L,	
transgenic	animals	(e.g.	goat	milk)	up	to	23	g/L,	and	fungal	expression	systems	have	
been	 reported	 to	 achieve	 35	 g/L	 (Demain	 and	 Vaishnav	 2011).	 These	 are	 clearly	
optimized	 yields,	 and	 differ	 depending	 on	 the	 protein	 in	 question.	 However,	 the	
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highest	 level	 of	 recombinant	 protein	 production	 in	C.	 reinhardtii	 is	 5%	 TSP	 under	
laboratory	conditions	(Manuell	et	al.	2007),	which	would	equate	to	approximately	8	
mg/L	culture	volume	when	scaled	to	pilot	scale	 (Gimpel	et	al.	2015).	As	 it	 is,	pilot	
scale	 production	 of	 recombinant	 bovine	 milk	 amyloid	 A	 (MAA)	 in	 C.	 reinhardtii	
achieved	 3.28	 mg/L	 (Gimpel	 et	 al.	 2015).	 It	 is	 clear	 from	 these	 data	 that	 the	 C.	
reinhardtii	 platform	has	 a	 long	way	 to	 go	before	 being	 able	 to	 compete	with	 the	
platforms	named	above.	However,	rate	of	development	can	be	fast:	between	1986	
and	2004	the	recombinant	protein	yield	of	CHO	cells	rose	from	50	mg/L	to	4.7	g/L	
(Wurm	2004).	This	vast	 improvement	was	achieved	through	a	variety	of	 improved	
techniques	 such	 as	 better	 selection	 strategies	 for	 high-productivity	 clones	 and	
identification	and	subsequent	targeting	to	transgenes	to	transcriptional	“hotspots”	
(Kim	et	al.	2012).		Furthermore,	different	platforms	have	different	protein	recovery	
rates,	for	example,	due	to	inclusion	bodies	in	E.	coli,	production	rates	may	be	high,	
but	 recovery	 rates	 and	 renaturation	 rates	 can	 be	 extremely	 low,	 leading	 to	 the	
possibility	 that	 another	 platform	 with	 a	 lower	 headline	 production	 rate	 is	 more	
suitable	(Datar	et	al.	1993).		
While	the	GRAS	status	of	many	microalgae	gives	hope	that	subsequent	purification	
of	protein	products	will	be	cheaper	and	less	necessary	in	comparison	to,	for	example,	
E.	coli,	there	are	other	limitations	to	their	use	as	a	protein	production	platform,	such	
as	the	presence	of	chlorophyll.	Chlorophyll	is	a	problematic	pigment	present	in	algal	
extracts	that	requires	further	purification,	although	this	can	be	performed	relatively	
cheaply	by	use	of	column	chromatography	with	activated	carbon	(Santillan-Jimenez	
et	al.	2016).
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RECOMBINANT	
Protein	 Function	 Use	 Reference	
HSV8-lsc	 Human	antibody	against	glycoprotein	D	from	Herpes	simplex	virus	 Therapeutic	 (Mayfield	et	al.	2003)	
CTB-VP1	 Protein	VP1	from	foot-and-mouth	disease	virus	fused	to	cholera	toxin	B	(CTB)	 Vaccine	 (Sun	et	al.	2003)	
hTRAIL Tumour	necrosis	factor-related	apoptosis-inducing	ligand	 Therapeutic	 (Yang	et	al.	2006)	
M-SAA	 Bovine	mammary-associated	serum	amyloid	 Therapeutic	 (Manuell	et	al.	2007)	
CSFV-E2 Swine fever virus structural protein E2 Vaccine (He et al. 2007) 
hGAD65	 Human	glutamic	acid	decarboxylase	 Diagnostics	 (Wang	et	al.	2008)	
VP28	 White	spot	syndrome	virus	protein	28	 Vaccine	 (Surzycki	et	al.	2009)	
CTB-D2	 D2	fibronectin-binding	domain	of	Staphylococcus	aureus	fused	to	CTB	 Vaccine	(oral)	 (Dreesen	et	al.	2010)	
VEGF	 Human	vascular	endothelial	growth	factor		 Therapeutic	 (Rasala	et	al.	2009)	
Pfs25	and	Pfs28	 Plasmodium	falciparum	surface	proteins	 Vaccine	(oral)	 (Gregory	et	al.	2012)	
αCD22PE40	 Antibody	against	DC22	surface	protein	from	B-cells	fused	to	two	domains	of	an	exotoxin	from	Pseudomonas	aeruginosa	 Immunotoxin	 (Tran	et	al.	2013)	
CtxB-Pfs25	 Plasmodium	falciparum	surface	protein	25	fused	to	CTB	 Vaccine	(oral)	 (Gregory	et	al.	2013)	
TPS4	 Bifunctional	diterpene	synthase,	for	therapeutic	terpenoid	synthesis	 Bioprocessing	 (Zedler	et	al.	2015)	
VHH	 Camelid	heavy	chain-only	antibodies	 Therapeutic	 (Markey	et	al.	2015)	
Ara	h	1	 Major	peanut	allergen	 Therapeutic	 (Gregory	et	al.	2016)	
Cpl-1	and	Pal	 Streptococcus	pneumoniae	targeting	endolysins	 Therapeutic	 (Stoffels	et	al.	2017)	
CD27L(1-179)	 Clostridium	difficile	targeting	endolysin	 Therapeutic	 This	study	
Table	1.1	A	selection	of	therapeutic	recombinant	proteins	successfully	produced	in	the	C.	reinhardtii	chloroplast.	Modified	and	updated	from	(Stoffels	2015),	
originally	adapted	from	(Specht	et	al.	2010)	and	(Almaraz-Delgado	et	al.	2014).
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Figure	Removed	
1.4 Targets/applications	
1.4.1 Streptococcus	pneumoniae	
Although	 S.	 pneumoniae	 is	 a	 common	 commensal	 bacterium	 found	 in	 the	
nasopharynx,	and	 is	usually	benign,	colonisation	and	 infection	can	cause	a	host	of	
diseases,	 including	 pneumonia,	 meningitis,	 febrile	 bacteraemia	 and	 otitis	 media	
(Bogaert	 et	 al.	 2004).	 Pneumococcal	 infection	 accounts	 for	 the	 death	 of	
approximately	1.2	million	people	every	year,	most	of	them	children	under	the	age	of	
five	(Obaro	and	Adegbola	2002).		
	
Figure	 1.12	 Scanning	 electron	 microscope	 image	 of	 an	 encapsulated	 strain	 (R6)	 of	 S.	
pneumoniae,	in	its	streptococcal	form	with	2	%	choline	(left)	and	diplococcal	form	without	
choline	(right).	Scale	bars	are	2	μm.	Image	reproduced	from	(Paik	et	al.	1999).	
S.	pneumoniae	is	a	mesophilic,	non-motile,	Gram-positive	bacterium	and	was	named	
after	 its	 role	 in	 pneumonia.	 It	 usually	 takes	 a	 diplococcal	 form	 but	 can	 form	
streptococci	in	liquid	medium.	Depending	upon	the	strain,	a	polysaccharide	capsule	
sometimes	encases	the	cell,	below	which	is	the	peptidoglycan	cell	wall.	Presence	of	
this	 capsule	 can	 increase	 virility	 of	 the	 strain	 and	 interferes	 with	 leukocyte	
phagocytosis	 (Hyams	et	 al.	 2010).	However,	 it	 has	been	 shown	 that	encapsulated	
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strains	are	no	more	or	less	susceptible	to	lysis	by	endolysins	than	un-encapsulated	
strains	(Loeffler	et	al.	2001).	
The	 peptidoglycan	 cell	 wall	 is	 approximately	 six	 layers	 thick	 and	 teichoic	 acid	 is	
attached	 to	 approximately	 every	 third	 N-acetylmuramic	 acid.	 Specifically	 to	 S.	
pneumoniae,	 both	 the	 teichoic	 acid	 and	 lipoteichoic	 acid	 (attached	 to	 the	 cell	
membrane	 via	 a	 lipid	 moiety)	 are	 decorated	 with	 phosphoryl-choline	 residues.	
Choline	 is	an	essential	 requirement	for	pneumococcal	activity,	being	the	 ligand	by	
which	 it	 attaches	 to	 human	 cells	 via	 the	 platelet-activating-factor	 receptor	 and	
choline-binding	protein,	CbpA	(Dworkin	and	Falkow	2006;	Gehre	et	al.	2008).	Choline	
is	also	the	ligand	by	which	the	S.	pneumoniae	autolysin,	LytA,	and	the	endolysin,	Cpl-
1,	bind	to	the	cell	wall.	
	
Figure	1.13	A	schematic	of	a	generic	peptidoglycan	cell	wall.	Some	strains	of	S.	pneumoniae	
also	 have	 an	 outer	 capsule,	 and	 both	 teichoic	 and	 lipoteichoic	 acids	 are	 decorated	 with	
choline.	Reproduced	from	Madigan	&	Martinko	(2006).	
While	 highly	 effective	 vaccines	 have	 been	 produced	 to	 protect	 humans	 from	 S.	
pneumoniae	infections,	their	success	has	been	limited	due	to	poor	coverage,	and	the	
threat	 of	 non-vaccine	 serotypes	 requires	 an	 active	 solution	 (Bogaert	 et	 al.	 2004).	
Studies	agree	that	prevention	of	nasopharyngeal	colonization	is	the	most	successful	
method	of	 averting	 infection,	however	 the	 rise	of	 antibiotic	 resistant	 strains	of	S.	
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pneumoniae,	in	particular	penicillin-resistant	S.	pneumoniae	(PRSP),	chloramphenicol	
resistance,	macrolide	 resistance,	 and	multiresistant	 strains	present	a	major	 global	
health	threat	(Appelbaum	1992;	Adam	2002;	Bogaert	et	al.	2004;	Stanek	et	al.	2011).	
The	presence	of	a	virulence-factor	target	(choline)	in	S.	pneumoniae,	and	the	rise	of	
multiresistant	 strains	 makes	 it	 an	 excellent	 candidate	 for	 endolysin	 treatment.	
Furthermore,	for	non-systemic	infections,	for	example	topical	applications	or	inhalers	
to	 reduce	nasopharyngeal	colonization,	 regulatory	 requirements	are	 less	 stringent	
thus	being	an	attractive	target	for	endolysin	proof-of-concept.		
1.4.2 Clostridium	difficile	
Clostridium	 difficile,	 which	 inhabits	 the	 gastrointestinal	 tract,	 was	 first	 isolated	 in	
1935	(Hall	and	O’Toole	1935)	and	has	had	its	whole	genome	sequenced	(Sebaihia	et	
al.	 2006).	 It	 is	 a	 Gram-positive	 anaerobe,	 has	 the	 ability	 to	 form	 spores,	 and	 has	
shown	itself	to	be	particularly	adept	at	resisting	antibiotics.	C.	difficile	infections	(CDI)	
generally	occur	nosocomially,	and	are	a	common	problem	after	antibiotic	treatment,	
causing	antibiotic-associated	diarrhoea	and	pseudomembranous	colitis.	
11	%	of	the	C.	difficile	genome	has	been	shown	to	consist	of	mobile	genetic	elements,	
including	 conjugative	 transposons	 and	 phage,	 conferring	 high	 mobility	 to	 the	
genome.	This	highly	mobile	genome	has	enabled	C.	difficile	to	survive	in	the	highly	
variable	gastrointestinal	tract	environment,	and	has	benefitted	from	a	niche	where	
opportunities	to	exchange	DNA	with	other	organisms	are	frequent.	It	is	believed	that	
many	of	the	antibiotic	resistance	genes	present	in	C.	difficile	are	encoded	by	these	
mobile	genetic	elements	(Sebaihia	et	al.	2006).	Resistance	and	multiresistance	has	
been	 reported	 to:	 metronidazole;	 vancomycin;	 clindamycin;	 erythromycin;	
tetracycline;	moxifloxacin;	rifampicin;	and	fusidic	acid,	via	a	number	of	mechanisms	
including	ribosomal	modification,	antibiotic	efflux	and	drug	inactivation	(Huang	et	al.	
2009).	 Furthermore,	 the	ability	of	C.	difficile	 to	 form	spores	when	 it	 comes	under	
environmental	stress	causes	huge	healthcare	issues.	The	resultant	spores	are	long-
lived	and	resistant	to	many	disinfectants	and	antibiotics,	making	them	a	source	of	
infection	in	many	hospital	environments	(Gerding	et	al.	2008).		
		 54	
Spore-formation,	 alongside	 huge	 potential	 for	 antibiotic	 resistance,	 frequently	
results	in	a	residual	population	of	C.	difficile	surviving	in	the	human	gut	after	a	course	
of	antibiotics.	This	population	is	then	able	to	rapidly	colonise	the	gut	due	to	lack	of	
competition	 from	natural	 gut	 flora,	and	 the	 result	 is	CDI.	 Further	 treatment	using	
antibiotics	 is	then	required	to	treat	the	recurrent	 infection	which	can	increase	the	
rate	of	future	recurrence.	Faecal	transplant	therapy,	a	method	of	repopulating	the	
gut	with	the	natural	microbiota	to	compete	with	C.	difficile	and	prevent	CDI,	as	well	
as	probiotics	have	been	used	relatively	successfully	to	combat	this	issue	(Allen	et	al.	
2014).	Endolysin	therapy	as	a	treatment	for	CDI	is	particularly	attractive	as	it	would	
not	disturb	the	natural	gut	flora	against	which	C.	difficile	is	usually	unable	to	compete,	
while	conventional	antibiotics	often	exacerbate	the	situation.		
1.4.3 Propionibacterium	acnes		
Propionibacterium	acnes	is	a	Gram-positive	bacilliform	and	forms	a	significant	part	of	
the	human	commensal	microbiome.	It	can	be	found	on	the	skin,	particularly	in	fatty	
acid	rich	areas	such	as	the	face	and	scalp,	as	well	as	on	internal	membranes	such	as	
the	large	intestine	and	urinary	tract	(Dessinioti	and	Katsambas	2017).	P.	acnes	is	best	
known	for	its	role	in	the	common	skin	affliction	acne	vulgaris,	but	is	also	associated	
with	 a	 wide	 range	 of	 inflammatory	 diseases	 and	 implant-associated	 infections	
(Portillo	et	al.	2013).	Acne	vulgaris	is	one	of	the	most	common	global	skin	diseases,	
affecting	45	million	people	in	the	USA	and	accounting	for	approximately	20	%	of	all	
dermatologist	 appointments	 (Bhatia	 et	 al.	 2004).	 Currently	 treatments	 include	
topical	 and	 systemic	 antibiotics,	 as	 well	 as	 chemical	 treatments	 such	 as	 benzyl	
peroxide.	 However,	 growing	 antibiotic	 resistance	 and	 the	 sometimes	 severe	 side	
effects	of	chemical	therapies	call	for	a	new	solution.		
Due	to	the	prevalence	and	unsightly	nature	of	acne	vulgaris,	P.	acnes	has	been	widely	
treated	 with	 antibiotics	 for	 many	 years,	 and	 cross-resistance	 to	 clindamycin	 and	
erythromycin	was	 first	 reported	 in	1979.	Since	then,	 resistance	to	oxytetracycline,	
doxycycline,	 and	minocycline	 have	 also	 been	 reported	world-wide	 (Dessinioti	 and	
Katsambas	2017).	While	 rarely	 life-threatening	 in	 the	 form	of	acne	vulgaris,	other	
less-common	P.	acnes	infections	benefit	from	resistance	commonly	acquired	when	
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treating	acne,	for	example,	implant-associated	infections	are	a	serious	threat	(Portillo	
et	al.	2013).	It	is	therefore	highly	desirable	to	reduce	the	selective	pressure	upon	P.	
acnes	during	the	treatment	of	acne.	
As	a	topical	infection	with	a	high	prevalence	of	antibiotic	resistance	and	large	afflicted	
population,	acne	vulgaris,	and	more	precisely	P.	acnes,	makes	a	suitable	target	for	
endolysin	therapy.	Furthermore,	the	targeted	killing	of	P.	acnes	in	the	affected	region	
is	preferable	to	elimination	of	the	bacterium	across	the	body,	as	P.	acnes	has	been	
demonstrated	to	be	a	nonspecific	immune	stimulant,	so	may	be	beneficial	at	some	
level,	although	precisely	how	this	mechanism	works	is	not	yet	understood	(Bhatia	et	
al.	2004).	
1.5 Summary,	aims	and	objectives	
The	 importance	of	antibiotics	 to	modern	society	cannot	be	overstated.	They	have	
wide	ranging	uses,	from	enabling	invasive	surgeries,	to	large	scale	food	production.	
For	the	past	70	years	we	have	become	increasingly	dependent	upon	them,	but	the	
efficacy	of	the	old	drugs	is	dwindling	and	new	drugs	are	becoming	harder	to	find.	
A	 number	 of	 potential	 alternative	 antibiotics	 exists,	 each	 with	 strengths	 and	
weaknesses.	From	reviewing	 the	 literature,	 it	has	become	evident	 that	our	 future	
antibiotic	 use	 will	 require	 a	 different	 strategy	 to	 that	 which	 we	 have	 become	
accustomed.	We	will	not	be	able	to	rely	on	a	handful	of	broad-spectrum	antibiotics,	
but	are	likely	to	require	a	variety	of	antimicrobial	products	to	best	suit	the	problem	
in	hand.	
One	of	 the	possible	 tools	against	bacteria	 that	we	will	be	able	 to	 call	upon	 is	 the	
bacteriophage	endolysins.	The	question	remains	of	how	to	produce	them	in	a	cost-
effective	and	safe	manner.	Recombinant	expression	in	the	C.	reinhardtii	chloroplast	
provides	 a	 potential	 solution	 to	 this	 problem:	 featuring	 GRAS	 status;	 lack	 of	
glycosylation;	 quick	 and	 precise	 genetic	 transformation;	 and	 ability	 to	 scale	 to	
production	rapidly.	However,	low	recombinant	protein	yields	have	so	far	held	back	
this	platform.	Three	pathogens,	S.	pneumoniae,	C.	difficile,	and	P.	acnes	have	been	
selected	as	suitable	targets	for	endolysin	therapy.	
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This	thesis	sets	out	to	address	the	issues	discussed	above,	with	the	aims	of	advancing	
both	the	use	of	the	C.	reinhardtii	chloroplast	as	a	recombinant	protein	platform,	and	
the	potential	for	endolysin	therapy,	using	the	following	objectives:	
1. To	 improve	 the	 level	 of	 recombinant	 endolysin	 accumulation	 in	 the	 C.	
reinhardtii	chloroplast.	
2. To	 improve	 the	 activity	 of	 endolysins	 produced	 in	 the	 C.	 reinhardtii	
chloroplast	against	S.	pneumoniae.	
3. To	demonstrate	the	synthesis	and	activity	of	two	endolysins	never	previously	
expressed	in	the	C.	reinhardtii	chloroplast.	
		 57	
Chapter	2 Materials	and	Methods	
2.1 Strains,	media,	culture	conditions	and	cell	density	quantification	
2.1.1 Chlamydomonas	reinhardtii	
2.1.1.1 Strains	
Strains	of	C.	reinhardtii	in	this	thesis	are	named	in	a	similar	manner	to	previous	work	
(Taunt	2013;	Stoffels	2015),	and	the	convention	is	illustrated	in	Figure	2.1.	
	
Figure	2.1	A	naming	convention	modified	from	Taunt	(2013)	and	in	line	with	previous	work	
by	 Stoffels	 (2015).	 This	 convention	 is	 used	 throughout	 this	 thesis,	 and	 any	 minor	
modifications	are	noted	in	the	following	sections.	
STRAIN DESCRIPTION REFERENCE 
TN72 A recipient strain based upon the cell 
wall-less strain cw15 (mt+). Partial 
deletion of psbH gene via aadA 
cassette insertion. PSII-deficient 
mutant. Spectinomycin resistant. 
Ninlayarn 
(2012) 
TN72_SR_Control TN72 transformed with pSRSapI 
expression vector, containing no GOI, 
psbH rescued. 
Young & 
Purton (2014) 
TN72_SR_cpl1_c-HA
The	cellular	
background
An	abbreviation	of	
the	expression	
vector	used.	
pSRSapI (SR),	
pASapI (A),	
pWUCA2	(WUCA)
The	expressed	
gene
Modifications	
and	mutations	
made	to	the	
expressed	gene
Epitope	tag
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TN72_ SR_cpl1-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1, psbH 
rescued. 
Taunt (2013) 
TN72_ SR_cpl1_CPO1-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with a 
single codon change, psbH rescued. 
This study 
TN72_ SR_cpl1_CPO2-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with a 
single codon change, psbH rescued. 
This study 
TN72_ SR_cpl1_W202A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202 mutated to an alanine, 
psbH rescued. 
This study 
TN72_ SR_cpl1_W209A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-209 mutated to an alanine, 
psbH rescued. 
This study 
TN72_ SR_cpl1_W230A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-230 mutated to an alanine, 
psbH rescued. 
This study 
TN72_ 
SR_cpl1_W202A_W209A-HA 
TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202 and -209 mutated to 
alanine residues, psbH rescued. 
This study 
TN72_ 
SR_cpl1_W223A_W230A-HA 
TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-223 and -230 mutated to 
alanine residues, psbH rescued. 
This study 
TN72_ 
SR_cpl1_W202A_W209A_-
W223A_W230A-HA 
TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202, -209, -223 and -230 
mutated to alanine residues, psbH 
rescued. 
This study 
TN72_ SR_cpl1_dimer-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
mutations to putatively enable 
dimerization, psbH rescued. 
This study 
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TN72_ A_cpl1_c-HA TN72 transformed with pASapI 
containing HA-tagged cpl1 encoded by 
a different DNA nucleotide sequence 
(cpl1_c), psbH rescued. 
This study 
TN72_SR_cpl1-HA_A_cpl1_c-
HA 
TN72 transformed with a plasmid 
containing both the HA-tagged cpl1 
under the psaA exon 1 promoter, and 
the HA-tagged cpl1_c under the atpA 
promoter, psbH rescued 
This study 
TN72_ SR_cpl1-StrepII TN72 transformed with pSRSapI 
containing StrepII-tagged cpl1, psbH 
rescued 
This study 
TN72_SR_cpl1-StrepII_A_cpl1-
HA 
TN72 transformed with a plasmid 
containing both the StrepII-tagged cpl1 
under the psaA exon 1 promoter, and 
the HA-tagged cpl1-c under the atpA 
promoter, psbH rescued 
This study 
TN72_SR_cd27l-HA TN72 transformed with pSRSapI 
containing HA-tagged cd27l, psbH 
rescued 
This study 
TN72_ SR_cd27l-StrepII TN72 transformed with pSRSapI 
containing StrepII-tagged cd27l, psbH 
rescued 
This study 
TN72_ WUCA2_Control TN72 transformed with pWUCA2 
expression vector, containing no GOI, 
psbH rescued. 
Young & 
Purton (2016) 
TN72_ WUCA2_cph1-HA TN72 transformed with pWUCA2 
containing HA-tagged cph1, psbH 
rescued 
This study 
TN72_A_gp20-HA TN72 transformed with pASapI 
containing HA-tagged gp20, psbH 
rescued 
Taunt (2013) 
TN72_ WUCA2_gp20N-HA TN72 transformed with pWUCA2 
containing N-terminal HA-tagged 
gp20, psbH rescued 
This study 
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2.1.1.2 Media	
2.1.1.2.1 Tris-acetate	phosphate	(TAP)	medium	
NH4Cl 0.4 g/L 
MgSO4•7H2O 0.1 g/L 
CaCl2•2H2O 0.05 g/L 
K2HPO4 0.108 g/L 
KH2PO4 0.056 g/L 
Tris 2.42 g/L 
Trace element stock solution  1 ml/L 
Glacial acetic acid - to pH 7.0 
Bacto agar (Optional) 2 g/L 
	
2.1.1.2.2 High	salt	medium	(HSM)		
NH4Cl 0.4 g/L 
MgSO4 • 7H2O 0.1 g/L 
CaCl2 • 2H2O 0.05 g/L 
K2HPO4 0.717 g/L 
KH2PO4 0.363 g/L 
Trace element stock solution  1 ml/L 
HCl - to pH 6.9 
Bacto agar (optional) 2 g/L 
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2.1.1.2.3 Trace	element	stock	solution	(Kropat	et	al.	2011)	
A	detailed	 recipe	 can	be	 found	 in	Kropat	et	al.	 (2011).	 In	brief	 seven	1000x	 stock	
solutions	 were	 prepared	 and	 then	 combined	 into	 a	 single	 solution.	 1	ml	 of	 each	
individual	stock	(7	ml	of	mixture)	was	added	to	each	litre	of	medium.	This	trace	recipe	
was	devised	to	support	a	cell	density	of	2	x107	cells/ml	(a	typical	stationary	phase	cell	
density),	with	Cu,	Fe,	Mn	and	Zn	ions	in	3-fold	excess	and	molybdate	in	2-fold	excess.		
STOCK SOLUTION CONCENTRATION 
IN STOCK 
COMPOSITION 
EDTA-Na2 25 mM Titrated to pH 8.0 with trace element 
grade KOH  
(NH4)6Mo7O24 28.5 µM  
Na2SeO3 0.1 mM  
Zn×EDTA 2.5 mM 2.5 mM ZnSO4 in 2.75 mM EDTA 
Mn×EDTA 6 mM 6 mM MnCl2 in 6 mM EDTA 
Fe×EDTA 20 mM 20 mM FeCl3 and 22 mM Na2CO3 in 22 
mM EDTA 
Cu×EDTA 2 mM 2 mM CuCl2 in 2 mM EDTA 
	
2.1.1.3 Culture	conditions	
Chlamydomonas	 reinhardtii	 was	 cultured	 by	 streaking	 the	 cells	 under	 aseptic	
conditions	using	a	sterile	toothpick	onto	plates	containing	TAP	supplemented	with	
2%	bacto	agar.	The	plates	were	then	incubated	at	20	°C	under	a	light	intensity	of	50	
μmol/m2/s.		
Liquid	starter	cultures	of	C.	reinhardtii	were	started	in	50	ml	flasks,	with	25	ml	liquid	
TAP	medium.	C.	reinhardtii	cells	were	scrapped	from	an	actively	growing	colony	from	
a	TAP	agar	plate	and	smeared	onto	the	inside	of	the	flask,	just	above	the	water-line.	
The	cells	were	then	resuspended	by	swirling	the	flask	to	avoid	clumping.	The	flasks	
were	 incubated	at	25°C,	120	 rpm	agitation,	24-hour	 illumination	at	50	μmol/m2/s	
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light	intensity,	to	mid-log	phase.	A	100-fold	dilution	was	then	performed	for	larger	
sub-cultures.		
2.1.1.4 Cell	density	quantification	
Cell	counting	was	performed	using	a	haemocytometer.	1	ml	sample	was	extracted	
from	a	flask	and	10	μl	tincture	of	iodine	(19.7	mM	iodine	in	95	%	(v/v)	ethanol)	was	
added	to	immobilise	the	cells.	The	number	of	cells	on	two	grids	was	then	counted	by	
eye	at	400x	magnification,	the	mean	taken,	and	multiplied	by	10,000	to	provide	an	
estimation	of	the	number	of	cells/ml	of	culture	volume.	
Alternatively,	the	optical	density	of	the	culture	was	measured	using	a	Unicam	UV/Vis	
Spectrometer	at	750	nm,	with	a	path-length	of	1	cm.	
2.1.1.5 Storage	
Inoculated	TAP	plates	were	stored	at	20°C,	under	dim	light	conditions	(5	μmol/m2/s)	
for	up	to	5	weeks	before	being	re-streaked	on	fresh	plates.	
Cryopreservation	of	C.	reinhardtii	strains	was	based	upon	a	protocol	from	Crutchfield	
et	al.	(1999).	C.	reinhardtii	strains	were	re-streaked	on	TAP	agar	plates	every	3	days	
for	a	week	to	ensure	active	growth	states.	The	cells	were	then	resuspended	in	10	ml	
TAP-Sorbitol	 (1	%),	with	 the	 sorbitol	 acting	 as	 an	 osmoprotector	 for	 the	 cell-wall	
deficient	strains,	to	a	concentration	of	approximately	107	cells/ml.	The	suspension	
was	gently	shaken	at	120	rpm	to	ensure	cell	dissociation	for	30	minutes,	and	then	
diluted	to	6	x106	cells/ml.	The	cell	suspension	was	then	gently	mixed	in	a	1:1	ratio	
with	TAP	containing	10	%	methanol,	under	low	light	conditions.	2	ml	aliquots	of	the	
final	cell	mixture	were	then	cooled	at	an	approximate	rate	of	-1	°C/min	to	-80	°C	for	
90	minutes,	before	being	stored	permanently	in	a	Dewar	containing	liquid	nitrogen.		
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2.1.2 Escherichia	coli	
2.1.2.1 Strains	
STRAIN DESCRIPTION REFERENCE 
DH5α fhuA2 Δ(argF-lacZ)U169 
phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
Hanahan (1983) 
DH5α_ProEX_cpl1_dimer-
HA-StrepII 
Carrying pProEX HTb 
containing HA-tagged cpl1 
with mutations to induce 
dimerization 
This study 
DH5α_ProEX_gp20-HA Carrying pProEX HTb 
containing gp20 tagged on 
the C-terminus with an HA 
tag 
This study 
	
2.1.2.2 Media	
2.1.2.2.1 Lysogenic	broth	(LB)	(Bertani	1951)	
Bacto-tryptone 10 g/L 
Yeast Extract 5 g/L 
Sodium chloride 10 g/L 
Bacto agar (optional) 15 g/L 
	
Where	 necessary,	 ampicillin	 was	 added	 to	 a	 final	 concentration	 of	 100	 μg/ml.	
Ampicillin	stocks	were	created	at	100	mg/ml	in	H2O	and	stored	in	aliquots	at	-20	°C.	
2.1.2.3 Culture	conditions	
E.	coli	was	cultured	either	on	solid	LB	agar	plates	at	37	°C,	or	in	liquid	LB	at	37	°C	with	
constant	shaking.		
		 64	
2.1.2.4 Storage	
25	%	(v/v)	glycerol	stocks	were	prepared	for	long	term	storage	of	E.	coli	by	mixing	
500	μl	of	stationary	phase	bacterial	culture	with	500	μl	50	%	(v/v)	sterile	glycerol.	The	
aliquots	were	then	snap	frozen	in	liquid	nitrogen	and	stored	at	–80	.	
2.1.3 Streptococcus	pneumoniae	
2.1.3.1 Strains	
STRAIN DESCRIPTION REFERENCE 
D39 Serotype 2, Mouse-passaged clinical 
isolate 
McDaniel et al. 
(1987) 
AL2 D39 LytA ̅ . Defined autolysin-
deficient lytA mutant of D39; Emr 
Berry et al. 
(1989) 
	
2.1.3.2 Media	
2.1.3.2.1 Trypticase	Soy	yeast	(TSY)	extract	medium	
Trypticase soy broth 30 g/L 
Yeast Extract 3 g/L 
2.1.3.2.2 Columbia	blood	agar	plates	(SIGMA)	
Agar 15 g/L 
Special nutrient substrate 23 g/L 
Sodium chloride 5 g/L 
Starch 1 g/L 
 
2.1.3.3 Culture	conditions	
S.	pneumoniae	were	cultured	in	liquid	culture	in	TSY	medium	at	35		in	an	anaerobic	
CO2	rich	environment,	using	an	anaerobic	 jar	 from	Oxoid	and	Oxoid	AGC	CO2	Gen	
Compact	gas	packs.	S.	pneumoniae	cultures	were	grown	for	16	h	in	Trypticase	Soy	
yeast	extract	medium,	sub-cultured	the	next	morning	and	grown	to	mid-log	phase.	
Inoculated	Columbia	blood	agar	plates	were	sealed	and	incubated	at	35°C	for	18	h.		
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2.1.3.4 	Cell	density	quantification	
Optical	density	was	measured	in	96-well	plates	using	a	FLUOstar	Omega	plate	reader	
(BMG	Labtech)	at	595	nm.	
Serial	dilution	followed	by	a	colony	forming	unit	assay	were	also	used	to	estimate	cell	
density.	
2.1.3.5 Storage	
Aliquots	of	bacterial	culture	were	snap	frozen	in	liquid	nitrogen	and	stored	at	–80	°C.	
2.1.4 Clostridium	difficile	
2.1.4.1 Strains	
STRAIN DESCRIPTION REFERENCE 
NCTC 11204 Isolated from human neonatal 
meconium 
(Hafiz and 
Oakley 1976) 
	
2.1.4.2 Media	
2.1.4.2.1 Robertsons	Cooked	Meat	Medium	(SGL,	Corby)	
Heart muscle 454.0 g/L 
Peptone 10.0 g/L 
`Lab-Lemco’ powder 10.0 g/L 
Sodium chloride 5.0 g/L 
Glucose 2.0 g/L 
pH 7.2 ± 0.2 @ 25°C    
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2.1.4.2.2 Liquid	Brain	Heart	Infusion	+	complements	(Mayer	et	al.	2008)		
Brain infusion solids 12.5 g/L 
Beef heart infusion solids 5.0 g/L 
Proteose peptone 10.0 g/L 
Glucose 2.0 g/L 
Sodium chloride 5.0 g/L 
Disodium phosphate 2.5 g/L 
pH 7.4 ± 0.2 @ 25°C    
Complements:   
Vitamin K 50 mg/L 
Hemin 5 mg/L 
Resaurin 1 mg/L 
L-cysteine 0.5 g/L 
 
 
   
2.1.4.3 Culture	conditions	
The	 C.	 difficile	 NCTC	 11204	 spore	 stock	 was	 stored	 in	 Robertson’s	 cooked	 meat	
medium	(SGL,	Corby).	The	stock	was	then	grown	in	25	ml	of	liquid	Brain	Heart	Infusion	
(BHI)	+	complements	(Mayer	et	al.	2008).	After	16	h	of	growth	at	37	°C,	200-500	μl	of	
C.	difficile	culture	was	used	to	inoculate	fresh	broth	and	grown	to	an	OD595nm	of	1-1.4	
(late	log	phase).	
2.1.5 Propionibacterium	acnes	
2.1.5.1 Strains	
STRAIN DESCRIPTION REFERENCE 
ATCC 6919 Type strain. Strain Designations: 
NCTC 737 [VPI 0389] 
From Laura 
Stoffels 
	
2.1.5.2 Media	
2.1.5.2.1 Liquid	Brain	Heart	Infusion	
See	2.1.4.2.2,	without	complements.	
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2.1.5.2.2 Columbia	blood	agar	plates	(SIGMA)	
See	2.1.3.2.2.	
2.1.5.3 Culture	conditions	
P.	acnes	was	grown	at	37	°C	for	4-5	days	in	liquid	heart	brain	infusion	or	on	blood	
agar	plates	in	an	anaerobic	CO2	rich	environment,	using	an	anaerobic	jar	from	Oxoid	
and	Oxoid	AGC	CO2	Gen	Compact	gas	packs.		
2.1.5.4 Storage	
Aliquots	of	bacterial	suspension	were	mixed	in	equal	volumes	with	50	%	(v/v)	sterile	
glycerol	and	snap	frozen	in	liquid	nitrogen	before	being	stored	at	–80	°C.		
2.2 Plasmids	
PLASMID DESCRIPTION REFERENCE 
pSRSapI Based on the pUC8 backbone, 
containing the endogenous psaA 
promoter and 5’ UTR, with the rbcL 
terminator and 3’ UTR. Includes 
flanking regions around the expression 
cassette for homologous recombination 
with the chloroplast genome, and a 
functional psbH gene 
Young and 
Purton (2014) 
pSRSapI_Control pSRSapI expression vector, containing 
no gene of interest 
Young & 
Purton (2015) 
pSRSapI _cpl1-HA pSRSapI containing HA-tagged cpl1 Taunt (2013) 
pSRSapI _cpl1_CPO1-HA pSRSapI containing HA-tagged cpl1 
with a single codon change 
This study 
pSRSapI _cpl1_CPO2-HA pSRSapI containing HA-tagged cpl1 
with a single codon change 
This study 
pSRSapI _cpl1_W202A-HA pSRSapI containing HA-tagged cpl1 
with tryptophan-202 mutated to an 
alanine 
This study 
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pSRSapI _cpl1_W209A-HA pSRSapI containing HA-tagged cpl1 
with tryptophan-209 mutated to an 
alanine 
This study 
pSRSapI _cpl1_W230A-HA pSRSapI containing HA-tagged cpl1 
with tryptophan-230 mutated to an 
alanine  
This study 
pSRSapI 
_cpl1_W202A_W209A-HA 
pSRSapI containing HA-tagged cpl1 
with tryptophan-202 and -209 mutated 
to alanines  
This study 
pSRSapI 
_cpl1_W223A_W230A-HA 
pSRSapI containing HA-tagged cpl1 
with tryptophan-223 and -230 mutated 
to alanines  
This study 
pSRSapI 
_cpl1_W202A_W209A_-
W223A_W230A-HA 
pSRSapI containing HA-tagged cpl1 
with tryptophan-202, -209, -223 and -
230 mutated to alanines  
This study 
pSRSapI _cpl1_dimer-HA pSRSapI containing HA-tagged cpl1 
with mutations to induce dimerization  
This study 
pASapI Based on the pUC8 backbone, 
containing the endogenous atpA 
promoter and 5’ UTR, with the rbcL 
terminator and 3’ UTR. Includes 
flanking regions around the expression 
cassette for homologous recombination 
with the chloroplast genome, and a 
functional psbH gene 
(Wannathong et 
al. 2016) 
pASapI_cpl1_c-HA pASapI containing HA-tagged cpl1 
with a different DNA nucleotide 
sequence (cpl1_c  
This study 
pSRSapI _cpl1-HA_A_cpl1_c-
HA 
pSRSapI containing both the HA-
tagged cpl1 under the psaA exon 1 
promoter, and the HA-tagged cpl1-c 
under the atpA promoter  
This study 
pSRSapI _cpl1-StrepII pSRSapI containing StrepII-tagged 
cpl1  
This study 
pSRSapI _cpl1-StrepII_A_cpl1-
HA 
pSRSapI containing both the StrepII-
tagged cpl1 under the psaA exon 1 
promoter, and the HA-tagged cpl1-c 
under the atpA promoter  
This study 
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pSRSapI _cd27l-HA pSRSapI containing HA-tagged cd27l  This study 
pSRSapI _cd27l-StrepII pSRSapI containing StrepII-tagged 
cd27l  
This study 
pWUCA2 Based upon pSRSapI, with the 
introduction of a sythetic trnWUCA gene 
Young & 
Purton (2015) 
pWUCA2_Control pWUCA2 expression vector, 
containing no GOI  
Young & 
Purton (2015) 
pWUCA2_cph1-HA pWUCA2 containing HA-tagged cph1  This study 
pWUCAC2_gp20N-HA pWUCA2 containing N-terminal HA-
tagged gp20  
This study 
pProEX HTb An expression vector confering 
Ampicilin resistance and under trc 
promoter 
Gift from J. 
Santini, 
Birkbeck 
College 
pProEX_cpl1_dimer-HA-StrepII pProEX HTb containing cpl1 with 
mutations to induce dimerization. 
Tagged on the C-terminus with an HA-
tag, followed by a StrepII tag 
This study 
pProEX_gp20-HA pProEX HTb containing gp20 tagged 
on the C-terminus with an HA tag 
This study 
	
2.3 Molecular	biology	
2.3.1 Buffers	
2.3.1.1 Sodium	phosphate	(Na-Pi)	buffer	
NaH2PO4 59.99 g/L 
Adjust pH to 7.4 with NaOH  
2.3.1.2 Tris-HCl	
Tris                                                    121.14 g/L 
Adjust pH to 8.0 (unless otherwise stated) with HCl 
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2.3.2 Gene	design	and	synthesis	
Gene	sequences	were	acquired	from	Genbank	(www.ncbi.nlm.nih.gov/genbank)	and	
verified	with	Blastn.	 The	 sequence	 for	 an	 epitope	 tag	was	 added	before	 the	 stop	
codon,	unless	otherwise	indicated.		
EPITOPE TAG AMINO ACID 
SEQUENCE 
NUCLEOTIDE SEQUENCE 
HA tag YPYDVPDYA 
 
5' TAC CCA TAC GAT GTT CCA 
GAT TAC GCT 3' 
StrepII tag WSHPQFEK 5’ TGG TCT CAC CCA CAA TTC 
GAA AAA 3’ 
His tag HHHHHH 5’ CAT CAC CAT CAC CAT CAC 
3’ 
	
A	SapI	and	a	SphI	restriction	site	were	 included	at	the	5’	and	3’	ends	of	the	gene,	
respectively,	for	subsequent	cloning	unless	otherwise	indicated.	The	sequences	were	
then	codon	optimised	using	Codon	Usage	Optimizer	Beta	0.92	(Kong	2013)	software	
developed	specifically	for	C.	reinhardtii	chloroplast	genes	in	the	Purton	lab	by	Khai	
Kong.	Genes	were	then	synthesised	by	Integrated	DNA	Technologies.	
2.3.3 Polymerase	chain	reaction	(PCR)	
DNA	amplification,	when	carried	out	 in	vitro,	was	performed	using	the	Polymerase	
Chain	Reaction	(PCR).	The	reaction	was	generally	carried	out	in	50	μl	volumes,	and	
using	the	Fermentas	Phusion	polymerase.	Mix:		
5x HF Buffer 10 µl 
Template DNA 50-100 ng 
Primers 10 pmol each 
20mM mixed dNTPs 1 µl 
Phusion polymerase 0.5 µl 
ddH2O 35.5 µl 
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Polymerase	Chain	Reaction	cycling	parameters	were	varied	slightly	depending	upon	
the	precise	nature	of	the	reaction	being	performed:	the	annealing	temperature	was	
calculated	depending	upon	the	melting	temperature	(Tm)	of	the	primers	being	used,	
and	 the	 extension	 time	 was	 altered	 depending	 upon	 the	 length	 of	 the	 expected	
amplicon,	 according	 to	 the	 Fermentas	 Phusion	 polymerase	 instructions.	 As	 an	
example,	for	amplifying	the	entire	Cpl-1	gene	using	a	Techne	TCF3000X	thermocycler	
the	following	conditions	were	used:		
98°C  2 min  
98°C 10 s 
X 30 cycles 60°C 30 s 
72°C 30 s 
72°C 5 min  
10°C Hold  
2.3.4 PCR	DNA	Purification	
Following	 PCR,	 if	 the	 product	 was	 not	 to	 be	 loaded	 onto	 an	 agarose	 gel,	 it	 was	
“cleaned	up”	by	the	Qiagen	PCR	clean-up	kit,	as	per	the	manufacturer’s	instruction.	
The	clean-up	removed	unwanted	primers,	buffer	and	polymerase	from	the	reaction	
mixture.	 It	 was	 also	 used	 following	 restriction	 digests	 to	 remove	 small	 (<50	 bp)	
fragments	of	DNA.	
2.3.5 Agarose	gel	Electrophoresis	
1	%	agarose	gels	were	used	 for	 gel	 electrophoresis.	 10	μg	of	DNA	 sample	and	1x	
loading	dye	were	run	at	10	volts	per	centimetre	until	the	ladder	is	well	separated.	
Either	Thermo	Scientific	Generuler	1kb	ladder	or	Generuler	Mix	ladder	were	used	to	
confirm	DNA	length,	for	expected	large	or	small	bands	respectively.		
2.3.6 DNA	gel	extraction	
Following	agarose	gel	electrophoresis,	DNA	bands	of	interest	were	excised	from	the	
gel	using	a	sterile	scalpel	and	placed	into	a	microcentrifuge	tube	of	predetermined	
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mass.	The	excised	slice	of	agarose	was	the	weighed	and	extracted	using	the	QIAquick	
Gel	Extraction	Kit	from	Qiagen,	following	the	manufacturer’s	instructions.		
2.3.7 Site	directed	mutagenesis	by	PCR	
Primers	were	synthesised	by	Eurofins	and	used	in	conjunction	with	Polymerase	Chain	
Reaction	to	change	a	required	DNA	nucleotide.		
Figure	2.2	describes	the	process.	
	
Figure	2.2	Process	for	site	directed	mutagenesis.	Template	DNA	is	in	black	and	primers	are	in	
blue.	The	‘X’	indicates	a	point	mutation.	Primers	a	+	b	and	c	+	d	were	initially	use	in	separate	
reactions.	Then	the	two	reactions	were	combined	and	10	cycles	of	annealing	was	performed.	
Finally,	a	further	25	cycles	of	extension	with	primers	a	and	d	were	performed.	
a b
c d
a
d
Two	separate	
PCR	reactions	
(a+b,	c+d)
Anneal
PCR	extension	
and	
amplification
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2.3.8 Dephosphorylation	using	Antarctic	Phosphatase		
In	order	to	prevent	the	ligation	of	linearized	plasmid	DNA	after	restriction	digestion	
without	the	required	DNA	insertion,	the	5’	phosphate	was	removed.	For	1	pmol	of	
DNA	ends,	5	units	of	Antarctic	phosphatase	were	added	in	1X	Antarctic	phosphatase	
reaction	buffer.	After	incubation	at	37	°C	for	30	minutes,	the	reaction	was	stopped	
by	heat	inactivation	at	80	°C	for	2	minutes.	
2.3.9 Blunt-end	DNA	cloning	
Blunt-end	DNA	cloning	into	the	positive	selection	cloning	vector	pJET1.2/blunt	was	
carried	 out	 using	 a	 Thermo	 Scientific	 CloneJET	 PCR	 Cloning	 Kit	 according	 to	 the	
manufacturer’s	instructions.	
2.3.10 DNA	Restriction	endonuclease	digestion	
Linearization	of	the	pSRSapI	expression	vector,	and	excision	of	the	Gene	of	Interest	
(GoI)	 from	pJet	was	 carried	out	 as	 shown	 in	 the	 table	below,	 followed	by	1	hour	
incubation	at	37	°C.	
Tango Buffer 4 µl 
LguI (SapI) 1.2 µl 
PaeI (Sph1) 1 µl 
DNA 2 µl 
ddH2O 31.8 µl 
2.3.11 DNA	Ligation	
DNA	insert	and	vector	concentrations	were	adjusted	such	that	there	is	a	3:1	molar	
ratio	and	approximately	20	ng	of	vector.	Then	2	μl	of	10x	T4	DNA	ligase	buffer,	1	μl	
of	T4	ligase	(New	England	Biolabs)	and	ddH2O	up	to	20	μl	total	volume	was	added.	
This	mixture	was	then	incubated	at	room	temperature	for	1	hour.		
2.3.12 Competent	E.	coli	transformation	–	Heat	shock	
Competent	 E.	 coli	 (DH5α)	 stocks,	 stored	 at	 -80°C,	 were	 thawed	 on	 ice.	 For	
transformation	using	ligation	mixes,	the	whole	10	μl	ligation	reaction	mix	was	added	
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to	 100	 μl	 of	 E.	 coli	 stock	 in	 a	 1.5	 ml	 microcentrifuge	 tube.	 For	 intact	 plasmid	
transformations,	approximately	10	ng	of	DNA	was	sufficient.	An	additional	tube	of	
competent	 E.	 coli	 was	 also	 included	 as	 a	 negative	 control.	 The	 tubes	 were	 then	
incubated	on	ice	for	25	minutes,	followed	by	a	heat	shock	for	70	s	in	a	42	°C	water	
bath,	followed	by	an	additional	2	min	on	ice.	0.5	ml	of	liquid	LB	was	added	to	each	
tube	before	incubation	at	37	°C	for	1	hour	with	shaking.	100	μl	from	each	tube	was	
then	spread	onto	LB	amp100	or	LB	kan100	plates	(depending	on	antibiotic	resistance	
gene	in	the	plasmid)	and	incubated	at	37	°C	overnight.	
2.3.13 C.	reinhardtii	transformation	–	glass	bead	
TN72	is	a	photosynthesis-deficient,	cell	wall-deficient,	C.	reinhardtii	recipient	strain	
that	can	be	grown	heterotrophically	on	media	containing	a	carbon	source	e.g.	TAP	
medium.	It	is	also	photosensitive	so	cultures	grow	better	when	kept	in	the	dark.	TN72	
colonies	were	regularly	restreaked	on	fresh	TAP	agar	plates	over	three	weeks	until	
growing	healthily	before	starting	a	400	ml	liquid	TAP	culture.		
The	vector	pSRSapI	 (Young	and	Purton	2014)	contains	an	expression	cassette	 into	
which	 a	 gene	of	 interest	 can	 be	 inserted	 between	 SapI	 and	 SphI	 restriction	 sites.	
pSRSapI	can	then	rescue	photosynthetic	activity	 in	TN72	after	transformation	as	 it	
carries	 the	photosystem	 II	 gene	psbH,	which	 is	non-functional	 in	TN72.	Successful	
transformants	can	then	be	selected	for	on	minimal	media	under	bright	light,	by	their	
ability	to	grow	phototrophically.		
The	protocol	 followed	 for	glass	bead	transformation	was	based	upon	Kindle	et	al.	
(1991).	The	TN72	cells	were	harvested	by	centrifugation	at	3,800	x	g	for	15	minutes,	
once	the	culture	density	reached	1-2	x106	cells/ml.	The	pellet	was	then	resuspended	
in	liquid	HSM	to	give	a	final	concentration	of	2	x108	cells/ml.	300	μl	of	resuspended	
cells	were	transferred	to	an	autoclaved	glass	test	tube	containing	approximately	300	
mg	of	0.4	mm	diameter	pre-washed	glass	beads.	10	μg	of	DNA	were	added	per	tube	
to	11	tubes,	and	one	was	used	as	a	negative	control	-	with	no	DNA	added.	The	tubes	
were	vortexed	for	15	s,	and	then	3.5	ml	of	warm	soft	HSM	agar	were	added,	quickly	
swirled	and	poured	onto	HSM	plates.	After	20	minutes	the	plates	were	inverted	and	
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sealed	with	Parafilm,	making	two	small	piercings	in	the	film	with	a	sterile	pipette	tip.	
The	plates	were	then	placed	under	a	bright	light	for	21	days.	All	colonies	present	after	
this	time	were	twice	restreaked	onto	fresh	HSM	plates.		
2.3.14 E.	coli	colony	PCR	
E.	 coli	 colonies	 were	 picked	 using	 a	 sterile	 pipette	 tip	 and	 mixed	 well	 in	 a	 tube	
containing	Taq	Polymerase	PCR	mix	containing	relevant	primers.	PCR	was	carried	out	
as	described	previously,	but	with	an	extra	preliminary	2	minutes	of	cell	lysis	at	98°C.	
Confirmed	transformants	were	picked	again	from	the	plate	and	cultured	for	further	
work.	
2.3.15 E.	coli	plasmid	isolation	–	Crude	and	Kit		
For	plasmid	preparations	of	less	than	12	μg	a	Qiagen	Miniprep	kit	was	used	as	per	
the	 manufacturer’s	 instruction,	 while	 for	 larger	 preparations	 (<200	 μg)	 a	 Qiagen	
Midiprep	kit	was	used.		
2.3.16 E.	coli	test	digest	
Tango Buffer 1 µl 
LguI (SapI) 0.2 µl 
PaeI (SphI) 0.2 µl 
DNA sample 2 µl 
ddH2O 6.6 µl 
	
A	 digestion	 was	 performed	 on	 plasmid	 mini/midi	 preparations	 as	 above	 and	
incubated	at	37	°C	 for	1	hour.	Gel	electrophoresis	was	used	to	ensure	the	correct	
insertion	had	been	excised	by	digestion.	
2.3.17 C.	reinhardtii	genomic	DNA	isolation	
This	method	allows	checking	for	homoplasmicity,	that	is,	to	ensure	that	all	~80	copies	
of	the	chloroplast	plastome	have	been	successfully	transformed.	C.	reinhardtii	cells	
were	picked	using	a	sterile	pipette	tip	and	resuspended	in	20	μl	of	H2O.	Then	20	μl	of	
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100	%	ethanol	and	200	μl	of	5	%	CHELEX	were	added	and	mixed.	After	incubation	for	
10	minutes	in	a	98°C	heatblock	and	then	centrifugation	at	13,000	g	for	10	minutes,	
the	 supernatant	 was	 used	 in	 a	 PCR	 using	 the	 following	 primers	 (unless	 stated	
otherwise):	
Flank1:		 GTCATTGCGAAAATACTGGTGC	
rbcL.Fn:		 CGGATGTAACTCAATCGGTAG	
RY-psaR:		 CATGGATTTCTCCTTATAATAAC	 (For	pSRSapI	transformants)	
atpA.R:	 ACGTCCACAGGCGTCGT	 	 (For	pASapI	transformants)	
Successful	recombination:	primers	Flank1	and	RY-psaR	gave	a	1,135	bp	product,	and	
Flank1	and	atpa.R	gave	a	1,204	bp	product.	Parental	sequence	(e.g.	TN72):	primers	
Flank1	and	rbcL.Fn	gave	an	850	bp	product.		
2.3.18 DNA	Sequencing	
Source	Biosciences	 carried	out	DNA	 sequencing	upon	providing	DNA	 samples	and	
primers	according	to	their	instructions.		
2.4 Protein	analysis	
2.4.1 Preparation	of	total	protein	extracts	
The	OD740	of	C.	reinhardtii	culture	was	measured.	The	culture	was	then	centrifuged	
(3,795	g,	20	minutes)	and	the	pellet	resuspended	in	a	volume	corresponding	to	the	
obtained	OD.	For	example,	a	10	ml	C.	reinhardtii	culture,	with	an	OD	of	0.569,	would	
be	resuspended	in	0.569	ml	of	buffer	(20	mM	NaPi	buffer	+	Protease	inhibitor	unless	
otherwise	stated).	Then	10	μl	of	4x	protein	loading	dye	(200	mM	Tris-HCl	pH	6.8,	8	%	
(w/v)	SDS,	40	%	(v/v)	glycerol,	4	%	(v/v)	β-mercaptoethanol,	50	mM	EDTA,	0.08	%	
(w/v)	 bromophenol	 blue)	 was	 added	 to	 30	 μl	 of	 the	 sample	 to	 a	 final	 1x	
concentration.	The	mixture	was	 then	boiled	 for	3	min	at	98	°C	and	centrifuged	at	
11,000	g	for	2	min.	The	resulting	supernatant	was	used	as	the	prepared	sample.	
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2.4.2 Sodium	dodecyl	sulphate	polyacrylamide	gels	(SDS-PAGE)		
The	Bio-Rad	mini-PROTEAN	Tetra	System	was	used	to	cast	SDS-PAGE	gels.	The	gels	
consisted	 of	 a	 15	 %	 polyacrylamide	 resolving	 layer,	 topped	 with	 a	 3.75	 %	
polyacrylamide	stacking	layer,	as	detailed	below.	
RESOLVING GEL (FOR 2 GELS)  
Acrylamide/bisacrylamide (Sigma)40% 
stock, acrylamide:bisacrylamide = 37:1  
3.75 ml 
Resolving buffer (8x stock)0.25M Tris, 
1.92M glycine, 1% SDS, pH8.3 
1.25 ml 
10 % SDS 0.1 ml 
ddH2O 4 ml 
10 % ammonium persulphate 0.375 ml 
Tetramethylethlenediamine 3.75 μl 
	
STACKING GEL (FOR 2 GELS)  
Acrylamide/bisacrylamide (Sigma)40 % 
stock, acrylamide:bisacrylamide = 37:1  
0.47 ml 
Stacking buffer (4x stock) 0.5M Tris-HCl 
(pH 6.8) 
1.25 ml 
10 % SDS 0.05 ml 
ddH2O 3 ml 
10 % ammonium persulphate 0.25 ml 
Tetramethylethlenediamine 3.75 μl 
	
RESERVOIR BUFFER (10X STOCK)  
Tris     0.25 M 
Glycine 1.92 M 
SDS 1 % 
HCl To pH 8.3  
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The	prepared	sample	(20	μl	for	10-well	gel	or	12	μl	for	15-well	gel)	and	5	μl	of	protein	
ladder	(Color	Prestained	Protein	Standard,	Broad	Range	(11-245	kDa),	(New	England	
Biolabs))	were	loaded	onto	the	gel	and	run	in	reservoir	buffer	for	120	minutes	at	120	
V.	
2.4.3 Protein	preparation	for	dot	blot	
The	C.	 reinhardtii	 culture	was	 resuspended	 as	 for	 the	 SDS-PAGE	preparation.	 The	
freeze-thaw	method	was	then	used	to	mechanically	break	the	cells	(3	x	freezing	in	
liquid	nitrogen,	thawing	at	35	°C).	Then	the	samples	were	centrifuged	(16,200	g,	2	
min)	 and	 2	 μl	 of	 supernatant	 was	 pipetted	 directly	 onto	 the	 Hybond-ECL	
nitrocellulose	membranes	(GE	Healthcare).	The	membrane	was	allowed	to	dry	for	10	
min	and	then	immuno-detection	was	performed	as	below.	
2.4.4 Coomassie	Brilliant	Blue	R	staining	
The	SDS	gel	was	 incubated	 in	Coomassie	Brilliant	Blue	R	 solution	 for	1	hour,	with	
gentle	 agitation,	 followed	 by	washing	 in	 destaining	 solution	 overnight.	 Gels	were	
photographed	using	the	LiCor	Odyssey®	CLx	imaging	system.	
Coomassie	Blue	Solution:	
Coomassie Brilllant Blue R250 2.5 g/L 
Acetic acid 100 ml/L 
Methanol 450 ml/L 
ddH2O 450 ml/L 
	
Destaining	Solution:	
Acetic acid 100 ml/L 
Methanol 450 ml/L 
ddH2O 450 ml/L 
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2.4.5 Western	blot	analysis	
Semi-dry	 electrophoresis	was	 used	 to	 transfer	 separated	proteins	 from	SDS-PAGE	
onto	Hybond-ECL	nitrocellulose	membranes	(GE	Healthcare).	Initially	the	gel,	3MM	
Whatman	paper	and	nitrocellulose	were	soaked	in	Towbin	buffer	(25	mM	Tris,	192	
mM	glycine	and	20	%	(v/v)	methanol)	at	room	temperature	for	10	minutes.	A	transfer	
stack	was	built,	 consisting	 (in	order	 from	top	 to	bottom)	of	4	 sheets	of	Whatman	
paper,	SDS-PAGE	gel,	nitrocellulose	membrane,	4	more	sheets	of	Whatman	paper.	
This	was	then	placed	into	a	Bio-Rad	Trans-Blot	SD	semi-dry	electrophoretic	transfer	
system,	and	all	air	bubbles	were	rolled	out	and	excess	buffer	removed.	Transfer	was	
carried	out	according	to	the	manufacturer’s	instructions,	at	a	constant	voltage	of	20	
V	(Fisons	FEC	570	power	pack)	for	1	hour.		
2.4.6 Immuno-detection	
2.4.6.1.1 Antibodies	
ANTIBODY SOURCE DILUTION 
Primary antibodies   
Anti-HA (polyclonal, 
rabbit) 
Sigma Aldrich, #H6908 1:2,000 
Anti-rbcL (polyconal, 
rabbit) 
Gift from J. Gray, 
 University of 
 Cambridge 
1:20,000 
Anti-StrepII (polyclonal, 
rabbit) 
Abcam, #ab76949 1:2,000 
Secondary antibodies   
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, 
DyLight 488 
ThermoFisher Scientific, 
#35552 
1:20,000 
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2.4.6.1.2 Protocol	
After	transfer,	the	nitrocellulose	membrane	was	blocked	in	3%	(w/v)	skimmed	milk	
powder	in	TBS-T	(20	mM	Tris	base,	pH	adjusted	to	7.4	with	5	M	HCl,	137	mM	NaCl,	
0.1	%	(v/v)	Tween-20)	for	1	hour	at	room	temperature,	or	overnight	at	4°C.	This	was	
followed	by	primary	antibody	treatment	in	1.5	%	skimmed	milk	powder	in	TBS-T	for	
1	hour	at	room	temperature	while	shaking	at	60	rpm.	The	membrane	was	then	rinsed	
twice	in	TBS-T,	followed	by	a	10	min	wash	in	TBS-T	at	60	rpm.	The	secondary	antibody	
treatment	 was	 then	 applied	 1.5	 %	 milk	 solution,	 but	 diluted	 according	 to	 the	
manufacturer’s	 instructions.	Detection	was	performed	using	a	 LiCor	Odyssey®	CLx	
System	and	analysed	using	Odyssey®	Image	Studio	Lite	Version	5.5.	
2.4.7 Protein	quantification	assay	
In	order	to	determine	the	total	soluble	protein	concentration	of	samples,	a	Bradford	
assay	 was	 performed	 in	 a	 96	 well	 plate.	 This	 was	 performed	 according	 to	 the	
manufacturer’s	 instructions	 (Sigma	Aldrich).	Bovine	serum	albumin	 (BSA)	dilutions	
were	 used	 to	 generate	 a	 standard	 curve.	 Then	 various	 dilutions	 of	 the	 unknown	
sample	were	prepared	to	find	one	with	a	concentration	in	the	range	of	0.1-1.4	mg/ml.	
250	μl	of	Bradford	reagent	was	added	to	each	well	containing	the	BSA	or	unknown	
sample	and	the	plate	was	 incubated	at	room	temperature	for	10	minutes.	A	plate	
reader	was	 used	 to	measure	 absorbance	 at	 595	 nm.	 The	 net	 absorbance	 vs.	 the	
protein	concentration	of	each	standard	were	plotted,	and	then	by	comparing	the	net	
A595	values	of	the	sample	against	the	standard	curve	it	is	possible	to	determine	the	
concentration	of	protein	in	the	unknown	sample.	
2.5 C.	reinhardtii	protein	purification	
2.5.1 Crude	extract	preparation	
C.	 reinhardtii	 cell	 cultures	 were	 grown	 to	 an	 OD740nm	 of	 2	 –	 3	 and	 harvested	 by	
centrifugation	at	5,000	g	for	20	minutes.	The	pelleted	cells	were	then	resuspended	
in	20	mM	Na	Pi-buffer	(NaH2PO4,	the	pH	was	adjusted	to	6.9	with	NaOH),	or	Binding	
buffer	(20	mM	NaH2PO4,	280	mM	NaCl,	6	mM	potassium	chloride,	pH	7.4)	if	being	
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used	for	later	column	purification,	to	50x	concentration.	Roche	cOmplete,	EDTA-free	
protease	inhibitor	was	also	added.	The	cells	were	either	broken	through	free-thawing	
(3	cycles	of	freezing	in	liquid	nitrogen	and	thawing	in	a	37	°C	water	bath),	or	via	glass	
bead	 abrasion	 (1	 g	 of	 0.4	 mm	 diameter	 glass	 beads	 was	 added	 per	 10	 ml	 of	
concentrated	cells,	followed	by	vigorous	shaking	at	4°C	for	10	minutes).	Subsequently	
the	 broken	 cell	 suspension	 was	 centrifuged	 at	 21,000	 g	 for	 10	 minutes	 and	 the	
supernatant	collected.	The	supernatant	is	referred	to	as	crude	protein	extract.	
To	 further	 remove	 cell	 debris	 and	 insoluble	 proteins	 from	 the	 supernatant,	
ultracentrifugation	at	100,000	g	for	1	hour	was	performed,	producing	a	supernatant	
referred	to	as	ultracentrifuged	crude	protein	extract.	
2.5.2 Ammonium	sulphate	precipitation	
Ultracentrifuged	 crude	 protein	 extracts	 were	 stirred	 on	 ice	 and	 powdered	
ammonium	 sulphate	 was	 added	 until	 the	 desired	 percentage	 of	 saturation	 was	
reached.	After	30	minutes	of	stirring	the	solution	was	centrifuged	for	30	minutes	at	
3,000	g.	The	pellet	was	collected	for	further	analysis	and	the	process	was	repeated	
to	the	supernatant	to	collect	all	the	desired	protein	fractions.	
2.5.3 Anti-StrepII	purification	column	
Ultracentrifuged	crude	protein	extracts,	in	binding	buffer,	were	passed	through	a	1ml	
StrepTrap	HP	HiTrap™	column	(GE	Healthcare)	at	1	ml	per	minute	using	a	peristaltic	
pump	 and	 eluted	 using	 2.5	 mM	 desthiobiotin	 in	 binding	 buffer,	 as	 per	 the	
manufacturer’s	instructions.	
2.6 E.	coli	protein	preparation	
Three	 different	 methods	 of	 protein	 preparation	 were	 used	 for	 E.	 coli-produced	
recombinant	proteins:	
2.6.1 IPTG	induction	
For	E.	coli	transformed	with	the	pProEX	HTb	plasmid,	transgene	expression	must	be	
induced	using	Isopropyl	β-D-1-thiogalactopyranoside	(IPTG).	An	overnight	culture	of	
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E.	coli	was	diluted	1:100	and	grown	in	2	ml	LB	+	amp100	for	4	hours	at	37	°C.	After	4	
hours,	1	ml	was	snap	frozen	in	liquid	nitrogen	to	provide	the	“uninduced”	control.	1	
ml	of	LB	+	amp100	+	1	mM	IPTG	was	then	added	to	the	culture	and	incubated	at	20	°C	
overnight,	 to	 provide	 an	 induced	 culture	 which	 was	 then	 analysed	 by	 western	
blotting	or	used	for	further	investigation.	
2.6.2 BugBuster™	(Novagen)	
BugBuster	Protein	Extraction	Reagent	was	used	as	according	to	the	manufacturer’s	
instructions.	In	brief,	E.	coli	cells	were	harvested	by	centrifugation	(16,000	g	for	10	
minutes)	and	resuspended	in	BugBuster	reagent	(2.5	ml	of	BugBuster	for	every	50	ml	
of	 bacterial	 culture).	 The	 suspension	 was	 incubated	 for	 10	 minutes	 at	 room	
temperature	with	gentle	shaking.	Centrifugation	at	16,000	g	for	20	minutes	at	4	°C	
removed	the	insoluble	fraction	and	the	supernatant	was	used	for	SDS-PAGE	analysis	
or	purification.	
2.6.3 High	Pressure	Homogenizer	
E.	coli	were	harvested	by	centrifugation	(16,000	g	for	10	minutes)	and	resuspended	
in	1/5th	culture	volume	of	NaPi	buffer.	A	pre-equilibrated	high	pressure	homogenizer	
(Stansted	Fluid	Power)	was	used	to	lyse	the	cells	at	14	psi	and	washed	with	buffer	
between	runs.	The	resulting	cell	extract	was	centrifuged	(16,000	g	for	30	minutes	at	
4	°C)	to	remove	cell	debris	and	the	resulting	supernatant	was	filter	sterilised	(0.22	
μm)	before	being	used	for	colony	forming	unit	assays	or	SDS-PAGE	analysis.	
2.6.4 Sonication	
Overnight	 cultures	 of	 E.	 coli	 were	 harvested	 by	 centrifugation	 (16,000	 g	 for	 10	
minutes).	The	resulting	pellet	was	resuspended	in	1/5th	culture	volume	of	10mM	Tris-
HCl	buffer	(pH	8.0)	and	placed	in	a	polystyrene	microcentrifuge	tube.	Sonication	was	
performed	using	a	Q700	cup-horn	Sonicator	(QSonica).	The	bath	was	pre-cooled	to	4	
°C	 and	 sonication	 performed	 at	 100	%	 amplitude	 for	 a	 total	 of	 four	minutes	 (30	
seconds	on,	30	seconds	off).	The	lysed	cells	were	centrifuged	(16,000	g	for	30	minutes	
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at	4	°C)	and	the	pellet	and	supernatant	analysed	by	SDS-PAGE	or	used	for	 further	
analysis.	
2.6.5 Disulphide	bond	formation	in	vitro	
While	disulphide	bond	formation	in	vitro	was	unsuccessful	in	this	study,	the	following	
method	 was	 used,	 adapted	 from	 Hyvonen	 (2002).	 Sonication	 was	 used	 to	 lyse	
induced	E.	coli	cells	resuspended	 in	10mM	Tris-HCl	buffer	 (pH	8.0)	as	described	 in	
2.6.4,	and	the	resulting	supernatant	was	used	for	this	analysis.	To	create	an	oxidising	
environment	 conducive	 to	 disulphide	 bond	 formation,	 glutathione	was	 used	 as	 a	
redox	reagent,	both	in	its	oxidised	and	reduced	forms	(GSSG	and	GSH	respectively).	
Solutions	of	10mM	GSSG	and	GSH	were	made	fresh	from	powdered	stocks	(SIGMA).	
25	μl	of	E.	coli	cell	extract	was	combined	with	GSSG	and	GSH	in	order	to	achieve	a	
range	of	ratios	between	the	two.	In	general,	the	final	concentration	of	GSH	was	2-5	
mM,	with	10-fold	less	of	the	oxidised	form.	The	mixtures	were	incubated	overnight	
at	20	°C	before	being	separated	by	SDS-PAGE	and	analysed	by	western	blotting.	No	
β-mercaptoethanol	was	included	in	the	loading	dye	and	the	mixture	was	not	boiled	
before	running	on	the	gel.	
2.7 Antibacterial	activity	assays	
2.7.1 Colony	forming	unit	assay	
2.7.1.1 Streptococcus	pneumoniae		
S.	pneumoniae	cultures	were	grown	as	described	above.	100	μl	of	culture	was	mixed	
with	 endolysin	 samples	 and	 incubated	 at	 37	 °C	 for	 1	 hour.	 The	 mixture	 was	
subsequently	diluted	in	ten	10-fold	dilution	steps.	20μl	of	dilution	numbers	6-10	were	
spotted,	 in	 triplicate,	 onto	 Columbia	 blood	 agar	 plates	 and	 incubated	 at	 37	 °C	
overnight.	The	number	of	colonies	in	each	spot	were	counted	by	eye	and	the	number	
of	colony	forming	units	per	ml	was	calculated.	
2.7.1.2 Propionibacterium	acnes	
Cultures	of	P.	acnes	were	grown	anaerobically	as	described	above.	The	cultures	were	
centrifuged	at	5,000	g	for	20	minutes	and	resuspended	in	20	mM	NaPi	buffer.	50	μl	
		 84	
of	 bacterial	 suspension	 and	 50	 μl	 of	 filter	 sterilized	 cell	 lysate	 or	 buffer	 were	
incubated	at	37	°C	for	0,	30,	60,	90,	120	or	150	minutes.	10	μl	samples	were	taken	
after	 the	 incubation	 time	 from	 each	 combination	 and	 spotted	 in	 triplicate	 onto	
Columbia	 blood	 agar	 plates.	 After	 anaerobic	 incubation	 at	 37	 °C	 for	 one	 week	 a	
comparison	was	made	subjectively	between	growth	as	individual	colony	growth	was	
not	visible.		
2.7.2 Turbidity	reduction	assay	
2.7.2.1 Streptococcus	pneumoniae	
S.	pneumoniae	cultures	were	harvested	by	centrifugation	(15	min,	5,500	g)	and	the	
cells	were	resuspended	in	20	mM	NaPi-buffer	to	an	OD600nm	of	~0.8.	
The	 turbidity	 reduction	assays	were	performed	 in	96-well	microtitre	plates	with	a	
final	assay	volume	of	300	μl.	An	ELx	808	microplate	reader	(BIO-TEK	INSTRUMENTS	
INC.)	measured	the	OD595nm	every	minute	for	200	minutes,	including	2	s	of	shaking	
before	each	measurement,	at	37	°C.	
Unless	 otherwise	 stated,	 20	μl	 of	 antimicrobial	 sample,	with	 varying	 total	 soluble	
protein	quantities	were	added	to	280	μl	of	suspension	of	the	target	bacterium.	As	a	
positive	 lysis	 control	 for	 S.	 pneumoniae	 turbidity	 reduction	 assays,	 20	 μl	 of	
deoxycholate	 was	 added.	 As	 a	 negative	 control,	 samples	 were	 prepared	 from	
TN72_SR_Control.	
2.7.2.2 Escherichia	coli	
E.	coli	cultures	were	grown	in	LB	to	stationary	phase	and	pelleted	by	centrifugation	
(3,800	g,	5	min).	 The	 following	protocol	 to	disrupt	 E.	 coli	membranes	 is	based	on	
Nakimbugwe	et	al.	(2006):		
Chloroform	containing	Tris-HCl	buffer	was	prepared	by	adding	30	%	(v/v)	chloroform	
to	Tri-HCl	(50	mM,	pH	7.0)	and	shaking	for	30	min,	200	rpm,	at	25	°C.	The	top	phase	
of	this	mixture	was	then	used	to	resuspend	the	E.	coli	pellet	in	its	original	volume.	
This	was	then	shaken	for	45	min	at	25	°C	and	then	centrifuged	again	(8000	g,	20	min,	
4	°C).	The	pellet	was	then	washed	with	Tris-HCl	and	resuspended	in	Tris-HCl	buffer	to	
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an	OD600nm	between	0.7-0.8.	100	U	of	egg	white	 lysozyme	was	used	per	well	 as	a	
positive	lysis	control.	
The	assay	was	then	performed	as	described	for	S.	pneumoniae	above.	
2.7.2.3 Clostridium	difficile		
C.	difficile	cells	were	harvested	by	centrifugation	(2	min	at	5,000	g)	and	resuspended	
in	a	volume	of	20	mM	Na	Pi	buffer	equivalent	to	their	OD	(e.g.	1.2	ml	if	an	OD595nm	of	
1.2	was	measured).	10-50	μg	of	C.	reinhardtii	extract	in	30	μl	final	volume	was	added	
to	270	μl	of	prepared	C.	difficile	cells	in	buffer.	Positive	controls	were	100	U/well	of	
mutanolysin	 and	 30	 μl	 of	 CD27L	NiNTA-purified	 protein	 (unknown	 concentration)	
from	the	Mayer	lab.	A	Labsystems	Bioscreen	C	(Thermo	Fisher	Scientific)	measured	
the	OD	every	2	minutes	for	18	h,	at	37	°C,	in	a	Thermo	Fisher	100-well	honeycomb	
plate.	
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Chapter	3 Improving	accumulation	levels	of	Cpl-1	in	the	chloroplast	
of	Chlamydomonas	reinhardtii	
3.1 Introduction	
3.1.1 Introduction	to	bacteriophage	lysin	Cpl-1	
The	bacteriophage	Cp1	was	 first	 isolated	 in	1981,	 from	 throat	 samples	of	healthy	
children	(Ronda	et	al.	1981).	Cp1	infects	the	bacterium	Streptococcus	pneumoniae,	
which	causes	a	range	of	globally	significant	diseases.	S.	pneumoniae	 is	a	causative	
agent	of	pneumonia,	meningitis	and	febrile	bacteraemia,	causing	a	total	annual	death	
toll	 of	 1.6	 million	 people,	 mainly	 young	 children	 and	 the	 elderly	 in	 developing	
countries	(WHO	2007).	
In	1987	the	39	kDa	protein	of	Cp1	was	characterised	as	a	muramidase	and	named	
Cpl-1	 (García	et	al.	1987).	The	same	study	noted	 that	choline	was	 required	 in	 the	
pneumococcal	cell	wall	for	Cpl-1	to	be	active,	and	in	2003	the	crystal	structure	of	Cpl-
1	was	determined,	showing	two	active	choline	binding	sites	(Hermoso	et	al.	2003).	
Cpl-1,	displayed	in	Figure	3.1,	is	a	339-residue	polypeptide	chain	consisting	of	an	N-
terminal	catalytic	domain	and	a	C-terminal	cell	wall	binding	domain	(CBD),	joined	by	
a	10	residue	acid	linker.	
Cpl-1	belongs	to	the	glycosyl	hydrolase	(GH)	25	family,	based	upon	the	amino	acid	
sequence	similarity	of	 its	catalytic	domain,	and	 is	built	of	modules	homologous	to	
LytC,	a	major	S.	pneumoniae	autolysin	(Monterroso	et	al.	2008).	The	catalytic	domain	
displays	a	characteristic	peptidoglycan	binding	site	and	a	deep	hole	of	highly	negative	
electrostatic	 potential	 located	 at	 the	 C-terminal	 end	 of	 the	 catalytic	 barrel	 that	
constitutes	the	active	site.	
The	CBD	is	known	to	bind	the	choline	moiety	in	the	teichoic	and	lipoteichoic	acid	of	
the	S.	pneumoniae	cell	wall	(see	Figure	1.13),	with	two	identified	accessible	choline	
binding	domains	on	the	protein.	The	addition	of	free	choline,	or	the	substitution	of	
choline	for	ethanolamine	in	the	S.	pneumoniae	cell	wall,	inhibits	Cpl-1	activity.	The	
CBD	is	composed	of	two	well-defined	regions,	named	CI	and	CII,	containing	a	total	of	
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six	homologous	repeats	of	about	20	amino	acids.	CI	consists	of	four	repeats	in	a	left-
handed	 superhelical	 arrangement	 and	 includes	 both	 active	 choline	 binding	 sites,	
while	CII	has	two	repeats	arranged	as	an	antiparallel	six-stranded	β-sheet.		
	
Figure	3.1	Cpl-1	crystal	structure.	N-terminal	catalytic	domain	(green)	is	linked	via	a	flexible	
acidic	linker	(orange)	to	the	CI	domain	(blue)	and	the	CII	domain	(pink).	The	bound	choline	
molecules	are	displayed	in	situ,	in	ball-and-stick	representation.	Image	produced	using	Jmol	
(PDB	1oba).	
Production	of	Cpl-1	is	attractive	due	to	its	antimicrobial	potential.	Vincent	Fischetti	
was	the	first	to	propose	using	Cpl-1	as	a	novel	antibiotic	and	his	group	showed	its	
efficacy	in	bacteremic	mice	(Jado	et	al.	2003).	However,	as	previously	discussed	in	
1.1.2,	the	antibiotic	market	is	one	of	notoriously	low	margins,	and	producing	biologics	
is	currently	an	expensive	undertaking.	This	is	due	in	no	small	part	to	the	expensive	
purification	process	 involved	in	removing	antigens	and	endotoxins	associated	with	
traditional	protein	production	platforms,	such	as	E.	coli.	Given	the	GRAS	status	of	C.	
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reinhardtii,	we	 speculate	 that	 purifying	 recombinant	 Cpl-1	 from	 the	C.	 reinhardtii	
chloroplast	may	not	be	required	to	be	as	rigorous,	and	therefore	be	cheaper.		
3.1.2 Factors	to	consider	in	protein	accumulation	
The	 relatively	 low	 levels	 of	 recombinant	 protein	 accumulation	 achieved	 in	 the	C.	
reinhardtii	chloroplast,	when	compared	to	existing	platforms	such	as	E.	coli,	offer	an	
area	 for	 improvement.	 This	 chapter	 discusses	 two	 techniques	 investigated	 to	
improve	accumulation	of	the	Cpl-1	protein	in	the	C.	reinhardtii	chloroplast.		
When	protein	accumulation	is	considered,	one	must	break	the	issue	down	into	two	
key	 factors,	 protein	 synthesis	 and	 protein	 degradation,	 and	 investigate	 how	 the	
balance	of	the	two	is	leading	to	the	observed	accumulation.	
	
Figure	3.2	Protein	turnover	is	composed	of	protein	synthesis	(transcription	and	translation)	
and	protein	degradation.		
The	literature	has	described	that	an	increased	quantity	of	mRNA,	i.e.	by	increasing	
levels	 of	 transcription,	 does	 not	 appear	 to	 improve	 the	 final	 levels	 of	 protein	
accumulation	(Coragliotti	et	al.	2011).	Given	the	polyploid	nature	of	the	C.	reinhardtii	
chloroplast	 and	 the	 strength	 of	 promoters	 from	 chloroplast	 genes	 encoding	
photosynthetic	components,	one	can	imagine	that	the	rate	of	synthesis	of	transgene	
transcripts	is	likely	to	be	high	(Hosler	et	al.	1989;	Blowers	et	al.	1990).	The	same	study	
points	to	translation,	and	in	particular	ribosome	binding	and	translation	elongation,	
as	 likely	 limiting	 factors.	Work	by	Taunt	 (2013)	 indicates	 that	Cpl-1	degradation	 is	
minimal	in	the	C.	reinhardtii	chloroplast.	
This	chapter,	therefore,	investigates	two	potential	molecular	methods	for	improving	
protein	accumulation.	Firstly,	constructs	containing	two	similar	genes	under	different	
Transcription Translation Degradation
DNA mRNA Active	protein Amino	acids
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promoters	were	inserted	into	the	chloroplast	in	order	to	potentially	overcome	the	
process	 of	 Control	 by	 Epistasy	 of	 Synthesis	 (Choquet	 et	 al.	 1998).	 Secondly,	
continuing	 upon	 previous	 work	 by	 Taunt	 (2013),	 codon-pair	 optimization	 is	
investigated	in	order	to	improve	translation.		
Experiments	and	calculations	by	Taunt	(2013)	estimated	that	a	mid-log	culture	of	C.	
reinhardtii	can	accumulate	Cpl-1	to	approximately	8	mg	L	-1,	or	17	mg	g-1	dry	weight.	
A	 comparable	 endolysin,	 Pal,	 produced	 by	 Stoffels	 (2015)	 achieved	 slightly	 lower	
levels	of	accumulation:	5	mg	L-1	or	13	mg	g-1	dry	weight.	These	offer	a	bench	mark	
upon	which	we	should	aim	to	improve.	However,	in	this	thesis	dry	cell	weight	was	
not	 considered,	 as	 generally	we	were	 interested	 in	 relative	 improvements,	 rather	
than	actual	yields	of	protein.	However,	moving	forward	a	clear	understanding	of	dry	
cell	 weights	 achieved	 and	 their	 reliable	 quantification	 will	 be	 important	 in	
understanding	the	commercial	viability	of	the	platform.	
3.1.3 Epistasy	of	synthesis	in	the	C.	reinhardtii	chloroplast	
It	has	been	reported	that	in	the	C.	reinhardtii	chloroplast	the	5’	UTR	of	petA,	which	
encodes	the	apoprotein	of	cytochrome	f,	mediates	its	autoregulation	of	translation	
via	interaction	with	the	C-terminal	domain	of	the	unassembled	protein	(Choquet	et	
al.	1998).	This	process	is	called	Control	by	Epistasy	of	Synthesis	(CES)	and	effectively	
means	that	proteins	have	the	ability	to	control	the	rate	of	translation	of	their	own	
mRNA.	Therefore,	when	using	an	endogenous	5’	UTR	for	transgene	expression,	the	
native	associated	protein	levels	may	control	the	level	of	the	transgene	product.	
We	 hypothesize	 in	 this	 chapter	 that	 the	 CES	 process	 is	 limiting	 the	 level	 of	
recombinant	 protein	 synthesis,	 due	 to	 the	 presence	 of	 associated	 endogenous	
proteins.	By	introducing	two	copies	of	cpl1	and	expressing	them	under	the	control	of	
different	5’	promoter/UTRs	in	the	C.	reinhardtii	chloroplast	we	aim	to	increase	overall	
levels	of	Cpl-1	accumulation.	
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3.1.4 Codon	usage	in	the	C.	reinhardtii	chloroplast	genome	
Redundancy	in	the	genetic	code	results	in	multiple	codons	coding	for	the	same	amino	
acid.	It	is	well	established	that	there	is	a	difference	in	preference	amongst	organisms	
for	which	particular	codon	codes	for	which	amino	acid,	and	this	is	known	as	codon	
bias.	By	optimizing	nucleotide	sequences	such	that	preferred	codons	are	used,	it	is	
possible	to	improve	gene	expression	compared	to	un-optimized	versions	(Franklin	et	
al.	2002).		
Protein	 coding	 sequence	 analysis	 in	Escherichia	 coli	 by	Gutman	&	Hatfield	 (1989)	
revealed	that	there	is	also	a	strong	bias	in	codon	pairs,	in	that	they	do	not	appear	to	
be	randomly	distributed.	This	 is	believed	to	be	due	to	the	varying	compatibility	of	
adjacent	aminoacyl-tRNA	acceptors	at	the	A	and	P-sites	of	a	ribosome.	This,	in	turn,	
led	to	the	suggestion	that	codon	pairs	can	be	optimized	in	a	similar	way	to	codons,	
and	thus	further	improve	gene	expression	levels.	Indeed,	Irwin	et	al.	(1995)	produced	
evidence	to	suggest	that	the	influences	of	codon	pair	choice	are	more	important	than	
the	choice	of	individual	codons	in	E.	coli,	exemplified	by	the	fact	that	ACC	and	CUG	
are	 frequently	 used	 codons,	 but	 ACC:CUG	 and	 CUG:ACC	 are	 translated	 at	 very	
different	rates.		
Previous	 work	 by	 Taunt	 (2013)	 recognised	 a	 similar,	 non-random	 distribution	 of	
codon	pairs	 in	the	C.	reinhardtii	chloroplast	plastome.	One	pair	 in	particular	stood	
out	as	appearing	extremely	non-random,	the	phenylalanine:arginine	pair,	UUU:CGU.	
Under	 a	 random	 codon	 distribution,	 one	 would	 expect	 to	 observe	 this	 pair	
approximately	 28	 times	 in	 the	 chloroplast	 plastome,	 but	 in	 fact	 it	 never	 occurs.	
Interestingly,	 the	 UUU:CGU	 pair	 is	 present	 in	 the	 well	 expressed	 cpl1	 gene.	 This	
project	investigates	the	impact	of	this	codon	pair	upon	Cpl-1	expression.	
3.2 Aims	and	objectives	
1. To	identify	and	optimize	a	method	for	comparing	protein	accumulation	levels	
between	different	transgenic	C.	reinhardtii	lines.	
2. To	produce	transgenic	lines	of	C.	reinhardtii	in	which	two	copies	of	cpl1	are	
introduced	under	the	control	of	different	5’	UTR	sequences.	
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3. To	show	improved	levels	of	protein	accumulation	in	the	new	transgenic	lines	
compared	with	existing	lines.	
4. To	produce	 two	 transgenic	 lines	of	C.	 reinhardtii	with	different	 codon	pair	
optimization	strategies.	
5. To	 compare	 protein	 accumulation	 levels	 of	 the	 two	 codon	 pair	 optimized	
versions.	
	
3.3 Results	and	discussion	
3.3.1 Investigation	into	measuring	protein	accumulation	levels	
The	 first	 hurdle	 to	 overcome	 when	 attempting	 to	 improve	 protein	 accumulation	
levels	 in	 the	 C.	 reinhardtii	 chloroplast	 was	 to	 identify	 and	 optimize	 an	 accurate	
method	for	comparing	the	protein	accumulation	levels	between	two	cell	lines.	Given	
the	almost	impossible	task	of	starting	two	or	more	cultures	with	an	identical	number	
of	cells,	in	the	same	growth	phase,	and	growing	them	under	identical	physiological	
conditions,	it	was	apparent	that	a	suitable	normalisation	technique	was	required.	Of	
particular	concern	is	the	ability	to	estimate	the	error	introduced	at	each	stage	of	the	
protein	preparation	and	quantification	process.	
3.3.1.1 Quantifying	cells	per	millilitre	of	culture	
When	 comparing	 two	 or	more	 algal	 cultures,	 one	must	 be	 sure	 to	 inoculate	 the	
culture	with	the	same	number	of	cells.	This	immediately	introduces	an	opportunity	
for	error,	which	here	we	aim	to	quantify.	There	are	essentially	two	practised	methods	
to	 estimate	 the	 cell	 density	 of	 an	 algal	 culture	 –	 either	 direct	 counting	 using	 a	
haemocytometer	and	microscope,	or	by	using	optical	density	(OD)	as	a	proxy	for	cell	
number.	Both	of	these	methods	are	investigated	and	this	section	examines	the	error	
associated	with	each	method.		
The	following	set	of	experiments	were	carried	out	as	follows:	three	flasks	containing	
400ml	 TAP	medium	were	 inoculated	with	 equal	 starter	 volumes	 from	 a	 single	C.	
reinhardtii	 starter	 culture.	 These	 were	 incubated	 and	 measured	 in	 the	 Algem	
photobioreactor	for	96	hours.	After	this,	the	three	flasks	(labelled:	a,	b	and	c)	were	
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used	 to	 provide	 samples	 to	 test	 all	 of	 the	 subsequent	 techniques.	 Therefore,	 the	
following	set	of	experiments	were	performed	using	precisely	the	same	algal	cultures,	
enabling	them	to	be	compared.	
Two	errors	will	be	measured	with	each	technique.	Firstly,	the	error	between	identical	
samples	–	e.g.	measuring	the	same	cuvette	three	times.	This	gives	an	indication	of	
the	machine/technique	error.	Secondly,	the	error	between	flasks,	which	will	provide	
an	 understanding	 of	 the	 pipetting	 error,	 a	 combination	 of	 measuring	 out	 of	 the	
medium	and	in	adding	the	starter	culture.	
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3.3.1.1.1 Algem	Photobioreactor	
The	Algem	Photobioreactor	automatically	measures	Optical	Density	at	740	nm,	while	
maintaining	 near	 identical	 physiological	 conditions	 in	 three	 separate	 flasks.	 By	
starting	three	C.	reinhardtii	cultures,	and	comparing	their	OD740	over	96	hours,	it	is	
possible	to	see	the	error	introduced.	
	
Figure	3.3	Three	flasks	containing	the	same	volume	of	TAP	medium	and	the	same	volume	of	
starter	culture	(400	ml	TAP	medium	with	2	ml	of	starter	culture)	were	grown	in	the	Algem	
Photobioreactor	for	96	hours.	The	average	OD740	of	the	three	flasks	was	calculated	and	the	
error	bars	indicate	the	standard	deviation	between	the	flasks.	
In	order	to	estimate	the	error	introduced	by	the	Algem	photobioreactor,	the	standard	
deviation	 between	 every	 three	measurements	 in	 flask	 A	was	 calculated.	 As	 each	
measurement	was	taken	at	30-minute	intervals,	then	for	the	purposes	of	estimation,	
three	consecutive	measurements	will	be	considered	to	be	from	the	same	time	point.	
The	average	percentage	error	calculated	in	this	manner	was	1.99	%.		
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Meanwhile,	 the	average	error	between	the	three	separate	cultures,	shown	by	the	
error	bars	in	Figure	3.3,	was	4.17	%.	
3.3.1.1.2 Optical	density	error	
Three	biological	 replicates	of	C.	reinhardtii	cultures,	a,	b	and	c,	were	sampled	and	
measured	three	times	each	using	a	Unicam	UV/Vis	Spectrometer	(Thermo	Electron	
Corporation,	USA)	at	750	nm	(OD740):	
	
Three	 different	 samples	 were	 then	 taken	 from	 the	 same	 flasks	 and	 their	 OD740	
measured	in	the	same	manner:	
	
These	 results	 indicate	 that	 a	 Unicam	 UV/Vis	 Spectrometer	 (Thermo	 Electron	
Corporation,	USA)	has	an	average	error	margin	of	0.35	%	when	measuring	the	exact	
same	sample	three	times.	Taking	different	samples	from	the	same	flask,	at	the	same	
time-point,	raises	the	error	to	0.74	%	–	potentially	due	to	the	different	settling	of	cells	
and	 non-uniform	 distribution	 of	 cells	 through	 the	 culture.	 This	 is	 lower	 than	 the	
Algem	photobioreactor,	but	here	the	time	points	are	identical,	while	to	average	the	
Algem	they	were	90	minutes	apart.	It	 is	expected	that	the	true	error	of	the	Algem	
photobioreactor	is	similar	to	this,	as	it	uses	a	similar	technology.	
The	average	error	measured	between	the	cultures	is	4.15	%,	virtually	identical	to	that	
observed	in	the	Algem	photobioreactor.	
Count Calculations
1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4.28%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0025 0.17%
Av. 0.0052 0.35%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0024 0.17%
Av. 0.0093 0.60%
Count Calculations
1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4. 8
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 .0025 17
Av. .0052 35
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.509 0.499 0.522 0.0094 0.62%
c 0.503 0.521 0.499 0.0095 0.63%
Av. 0.0117 0.74%
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3.3.1.1.3 Haemocytometer	error	
A	haemocytometer	can	be	used	to	count	the	number	of	C.	reinhardtii	cells	in	a	certain	
volume	and	then	that	number	can	be	used	to	estimate	the	overall	concentration	of	
cells	in	the	culture,	as	explained	in	2.1.1.4.	
In	order	to	 investigate	the	error	 introduced	when	counting	C.	reinhardtii	cells,	the	
same	samples	as	above	were	diluted	in	a	ratio	of	1:4	with	sterile	TAP	media,	and	then	
iodine	tincture	was	added	to	immobilize	the	cells.		
	
To	calculate	the	total	cells/ml	of	culture,	the	counted	number	was	multiplied	by	the	
dilution	factor	and	then	by	10,000	as	according	to	the	manufacturer’s	instructions	–	
this	does	not	affect	the	percentage	error.	
The	average	standard	deviation	within	the	three	counts	of	the	same	samples	is	1.65	
x106	cells/ml,	representing	~4.3	%	error.	
Meanwhile,	the	average	error	calculated	between	the	cultures	is	8.16	%,	almost	twice	
that	of	the	Algem	photobioreactor	and	Unicam	Spectrometer.	
3.3.1.1.4 Cell	density	quantification	conclusions	
These	investigations	indicate	that	the	haemocytometer	introduces	the	largest	degree	
of	error	to	cell	density	estimations,	and	the	Unicam	UV/Vis	Spectrometer	introduces	
the	least.	This	is	most	likely	to	be	due	to	the	slightly	objective	nature	of	counting	cells	
on	a	grid,	to	decide	whether	the	cell	is	on	or	off	the	grid,	and	also	the	human	error	
when	counting	large	numbers.	It	could	also	be	due	to	the	uneven	dispersal	of	cells	
across	the	haemocytometer,	or	a	settling	of	cells	in	the	flask	before	the	sample	was	
Count Calculations
1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4.28%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0025 0.17%
Av. 0.0052 0.35%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0024 0.17%
Av. 0.0093 0.60%
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taken.	However,	the	Algem	photobioreactor	has	a	level	of	error	at	around	2	%,	but	
as	mentioned	earlier,	this	 is	certainly	an	overestimation	due	to	the	fact	that	three	
time	points	across	90	minutes	were	used,	and	with	a	C.	reinhardtii	doubling	rate	of	
approximately	5	hours,	 this	 is	a	significant	period	of	 time.	Additionally,	 the	Algem	
photobioreactor	is	able	to	automatically	measure	up	to	four	cultures	simultaneously	
across	an	extended	period	of	time.	
Therefore,	the	Unicam	UV/Vis	Spectrometer	will	be	used	for	cell	density	estimations	
and	comparisons	for	 infrequent	and	one-off	measurements.	Otherwise,	the	Algem	
photobioreactor	will	be	used	where	possible.		
The	manual	counting	method	of	the	haemocytometer	still	has	a	value	in	offering	a	
real	number	for	cell	density,	but	for	the	purposes	of	comparing	two	or	more	cultures,	
an	optical	density	reading	is	superior.		
3.3.1.2 Western	blot	quantification	
3.3.1.2.1 Anti-HA	primary	antibody	for	detection	and	quantification	
To	investigate	the	error	introduced	when	quantifying	western	blot	signals,	the	three	
separate	cultures	of	TN72_SR_cpl1-HA,	grown	in	the	Algem	Photobioreactor,	were	
prepared	for	western	blotting.	Equal	volumes	from	each	culture	were	loaded	in	three	
technical	 repeats	 onto	 an	 SDS	 gel	 and	 probed	 with	 anti-HA	 primary	 antibodies,	
followed	by	Goat	anti-Rabbit	IgG	(H+L)	Secondary	Antibody	IRDye®	800CW	(referred	
to	 henceforth	 as	 IRDye®).	 The	 resulting	 signal	 was	 quantified	 using	 the	 LiCor	
Odyssey®	CLx	System.		
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Figure	3.4	The	western	blot	was	quantified	using	Odyssey®	 Image	Studio	Lite	v5.	The	bar	
chart	 shows	 the	 raw	 data	 and	 percentage	 errors.	 The	 table	 shows	 the	 signal	 from	 each	
replicate	within	each	culture	and	the	corresponding	percentage	error.	
In	Figure	3.4	a	very	high	percentage	error	was	observed	between	technical	replicates,	
despite	an	equal	volume	of	sample	being	loaded	onto	the	SDS	gel.	It	is	possible	that	
different	quantities	of	protein	were	included	in	each	replicate,	due	to	pipetting	and	
loading	error.	
3.3.1.2.2 Anti-RbcL	primary	antibody	as	loading	control	
In	order	to	test	the	assertion	that	pipetting	and	loading	error	caused	the	high	level	of	
error	 in	 Figure	 3.4,	 the	 endogenous	 protein	 RbcL	 (which	 is	 the	 large	 subunit	 of	
Ribulose-1,5-bisphosphate	carboxylase/oxygenase	(RuBisCo),	the	product	of	the	rbcL	
gene),	 was	 probed	 with	 an	 anti-RbcL	 primary	 antibody	 on	 the	 same	 blot	 and	
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quantified	in	the	same	manner.	If	loading	error	is	indeed	to	blame,	then	one	would	
expect	to	see	correlating	variation	in	detection	of	this	control.		
	
Figure	3.5	The	western	blot	was	quantified	using	Odyssey®	 Image	Studio	Lite	v5.	The	bar	
chart	shows	the	raw	data.	The	table	shows	the	signal	from	each	replicate	within	each	culture	
and	the	corresponding	percentage	error.	
There	 appears	 to	 be	 little	 correlation	 between	 the	 RbcL	 and	HA	 detection	 levels,	
although	similar	levels	of	error	are	observed	between	replicates.	This	could	be	due	
to	a	number	of	factors.	Possibly	the	blotting	efficiency	varied	across	the	membrane,	
so	 proteins	 were	 unevenly	 blotted	 from	 the	 SDS	 gel	 onto	 the	 nitrocellulose	
membrane.	It	could	also	be	due	to	uneven	antibody	decoration	of	the	blot,	suggesting	
a	 longer	blotting	 time	 is	necessary.	 Finally,	 the	quantification	 technique	using	 the	
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Image	Studio	Lite	software	requires	the	drawing	of	a	discreet	box	around	the	band,	
which	requires	some	judgement	and	introduces	error.		
3.3.1.2.3 Anti-PsbO	antibody	as	loading	control	
To	further	confirm	the	result	above,	the	same	blot	was	additional	probed	with	a	PsbO	
primary	antibody,	which	is	expected	to	bind	to	another	photosynthesis	protein:	the	
33	 kDa	 subunit	 of	 the	 oxygen	 evolving	 system	 of	 photosystem	 II.	 As	 a	 highly	
conserved	protein,	the	aim	was	to	use	its	detection	as	a	loading	control.	However,	as	
seen	in	Figure	3.6,	no	33	kDa	protein	could	be	detected.	
	
Figure	3.6	Further	probing	with	an	anti-PsbO	antibody	failed	to	provide	a	useful	band	for	
normalization.	
Failure	 to	detect	PsbO	 left	 the	question	of	why	 such	high	 variation	was	observed	
between	western	blot	 technical	 repeats	unanswered,	but	the	RbcL	result	suggests	
that	using	a	single	protein	as	a	loading	control	is	unreliable.	
3.3.1.2.4 Total	Protein	Stain	as	loading	control	
REVERT™	Total	Protein	Stain	is	specifically	designed	for	western	blot	normalization	
and	 can	 be	 easily	 quantified	 using	 the	 LiCor	 Odyssey®	 CLx	 system,	 in	 a	 separate	
channel	to	the	protein	of	interest.		
To	investigate	the	usability	and	accuracy	of	this	system,	a	test	was	run	using	a	sample	
of	TN72_SR_cpl1-HA	in	various	dilutions,	as	shown	in	Figure	3.7.	
Sample	A
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Figure	3.7	REVERT	Total	Protein	Stain	analysis.	Three	dilutions	of	TN72_SR_cpl1-HA	extract	
were	separated	by	SDS-PAGE	and	 transferred	 to	nitrocellulose	membrane.	Whole	protein	
stained,	analysed	(A)	washed,	the	probed	for	HA	tagged	proteins	(B),	then	washed	again	and	
re-probed	using	anti-RbcL	(C).	Imaged	with	the	LiCor	Odyssey®	CLx	system.	(D)	Comparison	
of	the	signal	from	whole	protein	stain,	HA	detection	and	RbcL	detection.	Note:	Whole	protein	
stain	is	shown	as	1/20th	total	so	as	to	enable	comparison	to	other	bars.	
Figure	3.7	shows	that	the	REVERT®	Total	Protein	Stain	detects	similar	levels	of	total	
protein	within	the	three	replicates	of	each	dilution,	and	appears	to	be	well	correlated	
with	 Cpl-1	 detection	 at	 higher	 concentrations,	 but	 more	 variable	 at	 lower	
concentrations.	 RbcL	 detection	 on	 the	 other	 hand	 yet	 again	 displays	 a	 poor	
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correlation	 to	 anti-HA	 tagged	 protein	 detection.	 This	 is	 most	 likely	 due	 to	 the	
interaction	 of	 the	 RbcL	 protein	 and	 anti-RbcL	 antibody	 –	 for	 example,	 the	 RbcL	
protein	may	require	more	boiling	to	fully	denature	and	enable	the	anti-RbcL	antibody	
to	bind,	and	we	are	therefore	seeing	erratic	binding.		
Overall,	this	analysis	suggests	that	REVERT®	Total	Protein	Stain	is	a	good	method	of	
normalising	western	blot	signals	provided	the	signal	is	relatively	strong.	Therefore,	a	
ten	times	(10	x)	concentration	of	C.	reinhardtii	cultures,	at	a	growth	stage	with	an	
OD740	of	approximately	0.750	using	the	Unicam	UV/Vis	Spectrometer,	will	be	used	
for	protein	quantification	purposes	unless	otherwise	specified.	
3.3.1.2.5 Using	a	protein	standard	for	quantification	
A	protein	standard	enables	observed	protein	accumulation	levels	to	be	quantified	by	
comparing	them	to	a	standard	of	known	concentration.	Furthermore,	by	 including	
the	 same	 standard	 in	 all	 western	 blot	 analyses,	 one	 can	 normalize	 between	
membranes,	if	for	example	they	have	been	blotted	for	slightly	different	amounts	of	
time.	 A	 standard	 encoding	 two	 or	more	 epitopes	 will	 also	 enable	 comparison	 of	
differently	tagged	proteins.	
Previous	attempts	at	quantifying	accumulation	of	HA-tagged	recombinant	protein	in	
C.	reinhardtii	in	the	Purton	lab	have	used	a	MultiTag	protein	(AbCam)	that	includes	
an	HA	epitope,	or	a	commercially	available	HA-tagged	protein	 (Calcium	Regulated	
Heat	Stable	Protein	1	(CARHSP1))	as	protein	standards	against	which	the	HA-tagged	
proteins	 in	C.	 reinhardtii	 cell	 extracts	 have	 been	 compared.	 However,	 the	 results	
obtained	 in	 this	 manner	 have	 been	 unreliable	 due	 to	 several	 factors	 including	
degradation	 of	 the	 protein	 standards,	 the	 unknown	 efficiency	 of	 blotting	 to	
nitrocellulose	membrane	 and	 unknown	 accessibility	 of	 the	 HA	 tag	 to	 the	 anti-HA	
antibodies.	Furthermore,	estimated	 levels	of	a	protein	obtained	 in	this	way,	when	
expressed	as	‘percentage	of	total	soluble	protein	in	cell	extracts’	were	not	supported	
by	Coomassie	Brilliant	Blue	stained	SDS-PAGE	analysis	of	the	extracts	(Stoffels	2015)	
and	appeared	to	overestimate	the	quantity	of	accumulated	protein	in	C.	reinhardtii	
extracts.	
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3.3.1.2.6 Producing	a	bespoke	Cpl-1	protein	standard	
In	order	to	minimise	the	problems	stated	above	with	commercially	available	protein	
standards,	a	bespoke	Cpl-1	protein	standard	was	produced	in	E.	coli.	
A	 slightly	modified	 version	 of	 Cpl-1	was	 used	 (cpl1_dimer),	 for	 compatibility	with	
other	projects,	see	4.3.2,	and	both	HA	and	StrepII	epitope	tags	were	included	on	the	
C-terminus.	The	gene	was	codon	optimized	for	E.	coli	and	synthesized	by	Integrated	
DNA	Technologies.	NcoI	and	NotI	restriction	sites	were	used	to	clone	the	gene	 in-
frame	into	the	IPTG	inducible	expression	vector	pProEX-HTb.	The	resulting	plasmid	
was	 sequenced	 to	 confirm	 the	 correct	 insertion	 and	 used	 to	 transform	 DH5α	
competent	E.	coli	cells.	
The	resulting	E.	coli	strain	was	named	DH5α_ProEX_cpl1_dimer-HA-StrepII,	and	 its	
recombinant	 protein	 product,	 purified	 using	 StrepTactin	 affinity	 to	 the	 StrepII	
epitope	tag	and	quantified	using	a	Bradford	assay,	would,	therefore,	produce	a	more	
reliable	protein	standard	for	quantifying	Cpl-1	accumulation	in	C.	reinhardtii	than	the	
Multi-tag	or	CARHSP1	standards.	
IPTG	induction	was	performed	(2.6.1)	and	cpl1_dimer-HA-StrepII	accumulation	was	
confirmed	by	SDS-PAGE	and	Coomassie	Brilliant	Blue	R	staining	(Figure	3.8).	
	
Figure	3.8	Whole	cell	extracts	were	separated	by	SDS-PAGE	and	total	protein	staining	was	
performed	using	a	Coomassie	Brilliant	Blue	R	stain.	Note:	despite	the	name	Cpl1_dimer,	this	
is	a	standard	39	kDa	Cpl-1	monomer	(the	name	“dimer”	refers	to	 its	ability	to	dimerize	 in	
non-denaturing	conditions,	as	discussed	in	4.3.2).	
The	 IPTG-induced	 DH5α_ProEX_cpl1_dimer-HA-StrepII	 cells	 were	 lysed	 using	
BugBuster™	 (2.6.2).	 The	 StrepII	 epitope	 tag	 on	 the	 Cpl1_dimer-HA-StrepII	 protein	
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was	 then	 used	 for	 protein	 enrichment	 via	 a	 commercially	 available	 StrepTactin	
column	(Thermo	Fisher	Scientific).	The	purification	fractions	are	shown	in	Figure	3.9.		
	
Figure	 3.9	 The	 various	 fractions	 involved	 using	 the	 StrepTactin	 purification	 column	were	
separated	by	SDS-PAGE	and	stained	with	Coomassie	Brilliant	Blue	R	stain.		
Coomassie	Brilliant	Blue	staining	in	Figure	3.9	indicates	that	other	proteins	aside	from	
Cpl-1	are	still	present	in	the	eluted	fractions,	so	the	Cpl1-enriched	elution	was	then	
further	 purified	 and	 concentrated	 by	 ammonium	 sulphate	 precipitation	 –	 the	
fractions	of	which	are	shown	in	Figure	3.10.	
	
Figure	3.10	Coomassie	Brilliant	Blue	R	stained	SDS-PAGE.	The	20	–	40	%	ammonium	sulphate	
fraction	was	chosen	as	the	fraction	with	the	most	Cpl-1	compared	to	other	visible	proteins.	
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Three	dilutions	of	the	20	-	40	%	ammonium	sulphate	fraction	were	then	quantified	
using	a	Bradford	protein	assay.	Absorbance	at	595	nm	(A595)	was	measured	using	a	
Nanodrop	2000,	enabling	very	small	volumes	to	be	used.	These	measurements	were	
compared	to	a	standard	curve	measured	in	the	same	way,	shown	in	Figure	3.11.	The	
calculations	 using	 the	 standard	 curve	 to	 measure	 the	 protein	 concentration	 are	
shown	in	Figure	3.12.	
	
Figure	3.11	A	Bradford	assay	was	performed,	and	the	three	dilutions	compared	to	the	protein	
standards.	Each	coloured	point	shown	on	this	graph	is	the	average	of	4	measurements.	
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Figure	3.12	Bradford	Assay	calculations.	The	equation	was	derived	from	the	line	of	best	fit	
from	the	graph	in	Figure	3.11.		
It	was	inferred	from	Figure	3.12	that	the	stock	solution	of	purified	cpl1_dimer-HA-
StrepII	had	a	concentration	of	230	±	30	μg/ml.		
The	synthesis	of	this	protein	standard	will	enable	comparison	of	different	western	
blot	 analyses	 as	well	 as	 compare	 the	accumulation	 levels	 of	 proteins	 tagged	with	
different	epitopes,	in	this	case	HA	and	StrepII.	
3.3.2 Investigating	control	by	epistasy	of	synthesis	in	protein	accumulation	
The	low	yields	of	recombinant	protein	accumulation	in	the	C.	reinhardtii	chloroplast	
are	a	major	factor	impeding	it	as	a	production	platform.	Here	we	attempt	to	improve	
protein	accumulation	levels	of	Cpl-1	by	expressing	the	cpl1	gene	under	the	control	of	
two	different	promoter/5’UTRs.		
3.3.2.1 Existing	C.	reinhardtii	lines	
This	section	uses	two	C.	reinhardtii	lines	created	by	Taunt	(2013)	as	controls.	One	is	
a	negative	control	that	will	be	used	throughout	this	thesis,	named	TN72_SR_Control,	
as	shown	in	Figure	3.13	this	is	the	recipient	strain	of	C.	reinhardtii	transformed	with	
an	empty	pSRSapI	plasmid.	The	second	C.	reinhardtii	line	is	TN72_SR_cpl1-HA	which	
will	be	used	as	the	“benchmark”	for	this	chapter	-	i.e.	a	line	displaying	a	moderate	
level	of	Cpl-1	accumulation	upon	which	we	aim	to	improve.	
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3.3.2.1.1 C.	reinhardtii	line	TN72_	SR_Control	
	
Figure	 3.13	 TN72	 transformed	with	 an	 empty	 pSRSapI	 plasmid.	 Unlike	 the	 original	 TN72	
recipient,	the	control	is	wildtype	for	photosynthesis,	like	the	cpl1	transformants,	as	the	psbH	
deletion	has	been	rescued.	
3.3.2.1.2 C.	reinhardtii	line	TN72_	SR_cpl1-HA	
	
Figure	3.14	TN72	 transformed	with	 the	pSRSapI	expression	plasmid	containing	HA-tagged	
cpl1.		
3.3.2.1.3 Western	blot	confirmation	
To	show	that	Cpl-1	accumulation	occurs	in	TN72_SR_cpl1-HA	and	that	no	protein	of	
a	 similar	 size	 is	 detected	 in	 TN72_SR_Control,	 whole	 cell	 extracts	 of	 each	 were	
prepared	and	separated	by	SDS-PAGE.	A	blot	of	the	gel	was	then	probed	with	an	anti-
HA	 primary	 antibody	 and	 an	 anti-RbcL	 primary	 antibody,	 followed	 by	 IRDye®	
secondary	antibodies.	The	LiCor	Odyssey®	CLx	System	was	then	used	for	detection.	
The	55	kDa	RbcL	band	acts	as	an	approximate	loading	control	in	this	instance,	to	show	
that	cell	extract	was	present	in	the	negative	control	lane.	The	39	kDa	Cpl-1	protein	
can	only	be	seen	in	the	TN72_SR_cpl1-HA	transformed	line.	
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Figure	3.15	Western	blot	analysis	of	whole	cell	extracts.	A	Color	Prestained	Protein	Standard,	
Broad	Range	(New	England	Biolabs,	Inc.)	was	used	to	estimate	protein	size.	
3.3.2.2 The	production	of	C.	reinhardtii	lines	with	improved	Cpl-1	accumulation	
We	have	hypothesised	that	CES	limits	the	level	of	recombinant	protein	accumulation,	
due	to	the	use	of	endogenous	5’UTRs	for	recombinant	protein	expression	in	the	C.	
reinhardtii	chloroplast.	By	introducing	the	gene	of	interest	into	the	chloroplast	inside	
two	 different	 expression	 cassettes,	 we	 speculate	 that	 the	 level	 of	 protein	
accumulation	per	cell	can	be	improved.	In	this	case,	we	will	use	the	endogenous	psaA	
exon	1	5’UTR	and	the	atpA	5’UTR,	which	have	both	been	shown	to	achieve	moderate	
levels	of	recombinant	protein	accumulation	in	the	C.	reinhardtii	chloroplast	(Taunt	
2013).	
However,	given	that	we	wish	to	transform	C.	reinhardtii	using	the	convenient	TN72	
system	 for	 targeted	 insertion	 into	 the	 chloroplast,	 we	 have	 only	 one	 plastome	
insertion	site;	namely,	the	neutral	site	between	psbH	and	trnE2.	The	two	expression	
cassettes,	containing	the	same	gene	of	interest,	will,	therefore,	need	to	be	adjacent	
to	 one	 another	 in	 the	 transformation	 plasmid,	 and	 be	 integrated	 by	 a	 single	
transformation	event	into	the	plastome	by	homologous	recombination.		
The	gene	of	 interest	 in	 this	 instance	 is	cpl1	which	 is	~1	kb	 in	 length.	Homologous	
recombination	 between	 DNA	 direct	 repeats	 in	 the	 C.	 reinhardtii	 chloroplast	 is	
efficient	–	indeed,	it	is	this	propensity	to	recombine	which	we	exploit	for	the	targeted	
insertion	of	transgenes	when	performing	C.	reinhardtii	chloroplast	transformations.	
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However,	 two	 identical	 copies	 of	 cpl1	 in	 close	 proximity	 to	 one	 another	 are	
considered	 to	be	at	 very	high	 risk	of	undergoing	 recombination	between	 the	 two	
copies,	resulting	in	a	plastome	rearrangement	and	loss	of	one	copy	of	the	Gene	of	
Interest	(GOI)	(Figure	3.16).	Mudd	et	al.	(2014)	suggest	that	direct	repeats	of	~600	bp	
or	more	result	in	very	high	frequencies	of	homologous	recombination.	Additionally,	
such	a	recombination	event	would	still	produce	recombinant	protein,	so	may	go	un-
noticed	if	it	occurs	in	a	transformant	line	subsequent	to	molecular	analysis	confirming	
the	two-GOI	insertion.	
	
Figure	3.16	Two	expression	cassettes	in	parallel	orientation	might	homologously	recombine	
to	 leave	a	viable	expression	cassette	 in	 the	 chloroplast	plastome,	 thus	 still	 produce	Cpl-1	
protein.	
However,	 as	 illustrated	 in	 Figure	 3.17,	 by	 arranging	 the	 expression	 cassettes	 in	
antiparallel	directions,	recombination	events	will	merely	result	in	a	switching	of	the	
promoter	regions	and	no	loss	of	DNA	will	occur.	
5’psaA 1 cpl1-HA 3’rbcL5’atpA 3’rbcLcpl1-HA
cpl1-HA 3’rbcL5’atpA
cpl1-HA
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Figure	3.17	When	arranged	 in	 antiparallel	 directions,	 the	 recombination	event	would	not	
result	in	any	loss	of	DNA	from	the	transformed	plastome.	
Therefore,	the	antiparallel	configuration	was	used	when	transforming	C.	reinhardtii	
with	two	expression	cassettes	in	a	single	plasmid,	in	particular	when	the	two	genes	
are	 highly	 similar.	 Furthermore,	 Coragliotti	 et	 al.	 (2011)	 report	 no	 detectable	
difference	in	expression	as	a	result	of	transgene	orientation.	In	fact,	the	C.	reinhardtii	
chloroplast	contains	two	large	inverted	repeat	regions	which	allow	similar	“flip-flop”	
recombination	 of	 the	 entire	 plastome,	 and	 it	 is	 believed	 that	 the	 two	 possible	
orientations	exist	in	approximately	equal	proportion,	with	no	apparent	adverse	effect	
(Harris	2009).		
3.3.2.2.1 C.	reinhardtii	line	TN72_	A_cpl1_c-HA	
However,	to	reduce	the	chance	of	DNA	recombination	events	between	the	directly	
repeated	 cpl1	 genes,	 one	 gene	 was	 differently	 codon	 optimized	 to	 reduce	 the	
sequence	 similarity.	 The	different	 version	of	cpl1	was	named	cpl1_c,	with	 the	 “c”	
standing	for	codon	changed.	
3.3.2.2.1.1 Cpl-1_c	gene	design	
The	 original	 genetic	 sequence	 for	 cpl1	 as	 used	 by	 Taunt	 (2013),	 and	 present	 in	
TN72_SR_cpl1-HA,	was	uploaded	to	Codon	Usage	Optimizer	Beta	0.92	(Kong	2013)	
software	 and	 codons	were	manually	 edited	 to	 ones	 of	 similar	 “scores”	 for	 the	C.	
reinhardtii	 chloroplast.	 In	 total	 148	nucleotides	were	 changed	out	of	 1050	 (14	%)	
without	affecting	the	overall	score	for	codon	usage.	SapI	and	SphI	restriction	sites	
were	included	for	cloning.		
5’psaA 1 cpl1-HA 3’rbcL5’atpA3’rbcL cpl1-HA
cpl1-HA 3’rbcL5’psaA 1 5’atpA3’rbcL cpl1-HA
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3.3.2.2.1.2 Expression	cassette	production	and	E.	coli	transformation	
The	full-length	cpl1_c	gene	was	synthesized	by	 Integrated	DNA	Technologies.	SapI	
and	SphI	restriction	enzymes	were	used	to	clone	the	gene	into	the	pASapI	expression	
vector	in-frame,	producing	the	plasmid	pASapI_cpl1_c-HA.	DH5α	competent	E.	coli	
cells	 were	 transformed	 with	 the	 resulting	 plasmid	 and	 a	 plasmid	 midi-prep	 was	
performed	to	produce	suitable	quantities	of	plasmid	for	glass	bead	transformation.	
3.3.2.2.1.3 C.	reinhardtii	transformation	
The	pASapI_cpl1_c-HA	plasmid	was	used	to	transform	recipient	C.	reinhardtii	strain	
TN72	via	 the	glass	bead	method	as	described	 in	2.3.13.	Figure	3.18	 illustrates	 the	
resulting	C.	reinhardtii	cell	line,	TN72_A_cpl1_c-HA	
	
Figure	3.18	TN72	recipient	strain	successfully	transformed	to	carry	cpl1_c	under	the	atpA	5’	
UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	
The	plastomes	of	the	resulting	transformants	were	confirmed	to	be	homoplasmic	as	
described	in	2.3.17.	In	this	instance,	the	three	primers	used	were	Flank1,	atpa.R	and	
psbH.R.	 Figure	 3.19	 shows	 the	 resulting	 PCR	 products	 separated	 by	 gel	
electrophoresis.	TN72	was	used	as	a	negative	control.	As	a	final	step,	the	sequence	
integrity	 of	 the	 cassette	was	 confirmed	 by	 DNA	 sequencing	 of	 the	 PCR-amplified	
plastome	region,	as	in	2.3.18.	
trnE2 psbH
3’rbcL
TN72_A_cpl1_c-HA	
transformant MluI
5’atpA cpl1_c-HA
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Figure	3.19	PCR	screening	for	successful	transformation	of	TN72	and	reaching	a	homoplasmic	
state.	(A)	Schematic	showing	the	product	expected	with	each	primer	combination.	(B)	Gel	
electrophoresis	 of	 the	PCR	products	 confirms	 that	 the	 transformant	 is	 homoplasmic	 as	 it	
lacks	the	350	bp	band	of	the	recipient	strain.		
3.3.2.2.1.4 Western	blot	quantification	
A	whole	cell	extract	of	TN72_A_cpl1_c-HA	was	prepared	and	separated	by	SDS-PAGE.	
After	blotting	to	nitrocellulose	membrane	as	described	in	2.4.5,	the	membrane	was	
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probed	with	anti-HA	and	anti-RbcL	primary	antibodies,	followed	by	IRDye®	secondary	
antibodies	and	fluorescence	was	observed	using	the	LiCor	Odyssey®	CLx	system.		
	
Figure	3.20	Western	blot	analysis	shows	that	similar	levels	of	Cpl-1	protein	accumulation	are	
detected	in	the	two	C.	reinhardtii	lines.	RbcL	is	an	approximate	loading	control	to	show	that	
similar	 quantities	 of	 cell	 lysate	 were	 loaded	 onto	 the	 gel	 and	 a	 negative	 control,	
TN72_SR_Control	is	also	included.	
The	results	show	similar	levels	of	Cpl-1	protein	accumulation,	and	the	RbcL	loading	
control	confirms	that	similar	quantities	of	cell	lysate	were	used.		
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3.3.2.2.2 C.	reinhardtii	line	TN72_SR_cpl1-HA_A_cpl1_c-HA	
To	see	if	higher	levels	of	protein	accumulation	could	indeed	be	achieved	with	two	
different	cpl-1	expression	cassettes	inserted	into	the	C.	reinhardtii	chloroplast,	the	
SR_cpl1-HA	and	the	A_cpl1_c-HA	cassettes	were	combined	into	a	single	plasmid	and	
used	to	transform	C.	reinhardtii	recipient	strain	TN72.	
3.3.2.2.2.1 Expression	plasmid	production		
The	 final	assembly	of	pSRSapI_cpl1-HA_A_cpl1_c-HA	was	achieved	as	described	 in	
Figure	3.21.	The	existing	MluI	site	in	pSRSapI_cpl1-HA	was	used	to	open	the	vector,	
and	the	insert	was	created	by	site-directed	mutagenesis	PCR	to	 introduce	a	BssHII	
restriction	site	at	 the	3’	end	of	 the	A_cpl1-c-HA	cassette.	As	MluI	and	BssHII	 form	
compatible	 restriction	 sites,	 the	 cpl1-c	 containing	 expression	 cassette	was	 ligated	
into	the	open	vector,	producing	one	conserved	MluI	site.	The	resulting	plasmid	was	
called	 pSRSapI_cpl1-HA_A_cpl1_c-HA.	 It	 is	 believed	 that	 the	 alternative	
arrangement,	i.e.	opening	the	pASapI_cpl1-c-HA	plasmid	and	inserting	the	SR_cpl1-
HA	 cassette,	would	 have	 also	 been	 possible,	 but	when	 both	were	 attempted	 the	
cloning	succeeded	with	the	former	first	and	therefore	this	route	was	continued.	
The	 primers	 used	 for	 the	 PCR	 reaction	 are	 indicated	 below.	 The	 BssHII	 site	 is	
underlined,	and	the	mutated	nucleotide	is	shown	in	lowercase.	
Cpl1.F:	CAGGCAATTTGCTTACACCTTT	
Cpl1_BssHII.R:	TTAAGATAAgCGCGCTACATCC	
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Figure	3.21	Schematic	showing	the	stages	 in	 the	construction	of	pSRSapI_cpl1-HA_cpl1_c-
HA.	 (A)	Site-directed	mutagenesis	PCR	was	carried	out	upon	pASapI_cpl1_c-HA	to	amplify	
the	expression	cassette	and	to	introduce	a	point	mutation	to	create	a	BssHII	restriction	site.	
The	red	arrows	represent	the	primers	used	for	this	reaction.	(B)	The	PCR	product	resulting	
from	(A)	was	digested	with	MluI	and	BssHII	before	being	cleaned	up	using	a	PCR	purification	
kit.	 (C)	 pSRSapI_cpl1-HA	 was	 digested	 using	 MluI	 before	 being	 treated	 with	 Antarctic	
Phosphatase	to	prevent	re-circularization	of	the	plasmid.	(D)	The	resulting	insert	(A_cpl1_c-
HA)	and	vector	(pSRSapI_cpl1-HA)	were	then	ligated	using	T4	DNA	ligase.	
DH5α	E.	coli	were	transformed	with	the	resulting	plasmid.	Sequencing	confirmed	the	
successful	insertion	and	orientation	of	the	insert.	
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3.3.2.2.2.2 C.	reinhardtii	transformation	
The	pSRSapI_cpl1-HA_A_cpl1_c-HA	plasmid	was	used	to	transform	the	recipient	C.	
reinhardtii	 strain	TN72	via	 the	glass	bead	method	as	described	2.3.13.	Figure	3.22	
illustrates	the	resulting	C.	reinhardtii	cell	line,	TN72_SR_cpl1-HA_A_cpl1_c-HA.	
	
Figure	 3.22	 TN72	 recipient	 strain	 transformed	 with	 the	 pSRSapI_cpl1-HA_A_cpl1_c-HA	
plasmid,	thus	rescuing	psbH	activity.	Carrying	cpl1-HA	under	the	psaA	5’	UTR,	and	cpl1_c-HA	
under	the	atpA	5’	UTR	in	the	chloroplast.	
The	 resulting	 transformants	 were	 confirmed	 to	 be	 homoplasmic	 as	 described	 in	
2.3.17	and	represented	in	Figure	3.23.	Finally,	correct	insertion	into	the	plastome	was	
confirmed	 by	 PCR	 amplification	 from	 transformant	 genomic	 DNA	 and	 DNA	
sequencing,	as	in	2.3.18.	
trnE2 psbH
TN72_SR_cpl1-HA	
_A_cpl1_c-HA
transformant MluI
5’psaA 1 cpl1-HA 3’rbcL5’atpAcpl1_c-HA3’rbcL
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Figure	 3.23	 (A)	 Schematic	 describing	 the	 expected	 band	 when	 testing	 homoplasmic	
transformants.	The	combination	which	produces	 the	negative	band	can	be	seen	 in	Figure	
3.19.	 It	 is	the	absence	of	the	negative,	350	bp,	band	that	 indicates	homoplasmicity	 i.e.	no	
copies	 of	 the	 untransformed	 plastid	 remain	 (B)	 PCR	 products	 separated	 by	 gel	
electrophoresis	show	the	correct	expected	lengths	and	thus	show	that	the	new	transformant	
is	now	homoplasmic.	
3.3.2.2.2.3 Western	blot	quantification	
In	order	to	compare	the	relative	Cpl-1	accumulation	levels	between	TN72_SR_cpl1-
HA	and	TN72_SR_cpl1-HA_A_cpl1_c-HA,	and	investigate	whether	two	cassettes	with	
the	 same	gene	does	 indeed	 improve	overall	 protein	accumulation	 levels	 in	 the	C.	
reinhardtii	chloroplast,	western	blot	analysis	was	performed.	Whole	cell	extracts	of	
TN72_SR_cpl1-HA	 and	 TN72_SR_cpl1-HA_A_cpl1_c-HA	 were	 prepared,	 and	 five	
technical	 replicates	 of	 each	 were	 separated	 by	 SDS-PAGE.	 After	 blotting	 to	
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nitrocellulose	 membrane	 as	 described	 in	 2.4.5,	 the	 membrane	 was	 stained	 with	
REVERT™	Whole	Protein	Stain	which	confirmed	similar	quantities	of	cell	preparation	
were	 loaded	 onto	 the	 gel	 (Appendix	 A)	 and	was	 used	 to	 normalize	 small	 loading	
differences.	 After	 removal	 of	 the	 REVERT	 stain	 and	 blocking,	 the	membrane	was	
probed	with	the	anti-HA	primary	antibody,	followed	by	IRDye®	secondary	antibody	
and	fluorescence	was	observed	using	the	LiCor	Odyssey®	CLx	system.	The	western	
blot	image	and	analysis	are	shown	in	Figure	3.24.	
	
Figure	3.24	Western	blot	analysis	enabled	the	quantification	of	Cpl-1	accumulation	in	the	two	
C.	 reinhardtii	 lines.	 Cpl-1	 detection	 was	 normalised	 using	 the	 signal	 from	 REVERT	 Total	
Protein	Stain.		
A	two	sample	t-test	was	carried	out	to	compare	the	levels	of	protein	accumulation	in	
TN72_SR_cpl1-HA	 and	 TN72_SR_cpl1-HA_A_cpl1_c-HA,	 in	 order	 to	 identify	 any	
statistical	significance.	This	is	a	comparison	of	the	mean	protein	accumulation	levels,	
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and	it	is	a	two-tailed	test.	The	null	hypotheses	(H0)	is	that	the	means	are	the	same.	
The	alternative	hypothesis	(H1)	is	that	the	means	are	different.	
H0:	μ1	=	μ2	
H1:	μ1	≠	μ2	
The	 full	 results	 can	 be	 seen	 in	 Figure	 3.25,	 but	 in	 brief,	 there	 was	 a	 significant	
difference	 in	 accumulation	 for	 TN72_SR_cpl1-HA	 (M	 =	 0.247,	 Var	 =	 0.001)	 and	
TN72_SR_cpl1-HA_A_cpl1_c-HA	(M=	0.451,	Var	=	0.007);	t(8)	=	-5.14,	p	<	0.001.	
	
Figure	3.25	Statistical	report	generated	using	Microsoft	Excel	to	compare	the	levels	of	protein	
accumulation	in	the	two	lines	of	C.	reinhardtii.	
This	 result	 supports	 our	 original	 hypothesis	 -	 that	 protein	 accumulation	 can	 be	
improved	in	the	C.	reinhardtii	chloroplast	by	introducing	several	copies	of	the	GOI	as	
different	expression	cassettes.	It	suggests	that	CES	is	limiting	the	level	of	translation	
for	each	endogenous	5’	UTR	and	that	by	having	the	same	gene	under	the	control	of	
two	different	5’	UTRs,	this	can	be	improved.	
t-Test:	Two-Sample	Assuming	Equal	Variances
TN72_A_
cpl1-HA	
TN72_SR_cpl1-
HA_A_cpl1_c-HA	
Mean 0.2472 0.4512
Variance 0.0006 0.0073
Observations 5 5
Pooled	Variance 0.0039
Hypothesized	
Mean	Difference 0
df 8
t	Stat -5.1423
P(T<=t)	one-tail 0.0004
t	Critical	one-tail 1.8595
P(T<=t)	two-tail 0.0009
t	Critical	two-tail 2.3060
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3.3.2.2.3 C.	reinhardtii	line	TN72_	SR_cpl1-StrepII	
In	the	previous	experiment,	it	is	not	possible	to	determine	how	the	protein	synthesis	
load	is	being	shared	by	the	two	expression	cassettes,	as	the	proteins	are	both	tagged	
with	an	HA	epitope	and	are	therefore	indistinguishable	on	a	western	blot.	
We	therefore	produced	a	similar	C.	reinhardtii	cell	line	but	with	one	cpl1	encoding	a	
StrepII	epitope	tag	instead	of	an	HA	tag.	This	enables	the	Cpl-1	protein	from	the	two	
different	 promoters/5’UTRs	 to	 be	 distinguished	 on	 a	 western	 blot	 and	 the	
contribution	of	the	two	cassettes	compared.	
The	first	stage	in	this	process	was	to	produce	the	C.	reinhardtii	cell	line	TN72_SR_cpl1-
StrepII,	to	be	used	as	a	control	but	also	to	ensure	that	this	tag	can	be	detected	on	
western	blots	and	that	the	protein	accumulates	to	detectable	levels.	
3.3.2.2.3.1 Expression	cassette	production	
The	full-length	cpl1-StrepII	gene	was	synthesized	by	 Integrated	DNA	Technologies.	
SapI	 and	 SphI	 restriction	 enzymes	were	used	 to	 clone	 the	 gene	 in-frame	 into	 the	
pSRSapI	 expression	 vector,	 producing	 the	 plasmid	 pSRSapI_cpl1-StrepII.	 DH5α	
competent	E.	coli	cells	were	transformed	with	the	resulting	plasmid.	
3.3.2.2.3.2 C.	reinhardtii	transformation	
The	pSRSapI_cpl1-StrepII	plasmid	was	used	to	transform	the	recipient	C.	reinhardtii	
strain	TN72	via	the	glass	bead	method	as	described	in	2.3.13.	Figure	3.26	illustrates	
the	resulting	C.	reinhardtii	cell	line,	TN72_SR_cpl1-StrepII.	
	
Figure	3.26	TN72	 recipient	 strain	 successfully	 transformed	 to	 carry	cpl1-StrepII	 under	 the	
psaA	5’UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	
trnE2 psbH
5’psaA 1 3’rbcL
TN72_SR_cpl1-StrepII	
transformant MluI
cpl1-StrepII
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The	 resulting	 transformants	 were	 confirmed	 for	 homoplasmicity	 as	 described	 in	
2.3.17	 (Appendix	 B).	 Finally,	 the	 sequence	 integrity	 of	 the	 inserted	 cassette	 was	
confirmed	by	DNA	sequencing	as	in	2.3.18.	
3.3.2.2.3.3 Western	blot	detection	
Whole	cell	preparations	of	TN72_SR_cpl1-HA	(as	a	control)	and	TN72_SR_cpl1-StrepII	
were	 prepared	 and	 separated,	 in	 duplicate,	 by	 SDS-PAGE.	 After	 blotting	 to	
nitrocellulose	membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 one	membrane	was	
probed	with	an	anti-HA	primary	antibody,	while	the	second	membrane	was	probed	
with	anti-StrepII	primary	antibody.	Both	membranes	were	then	incubated	by	IRDye®	
secondary	 antibody	 and	 fluorescence	was	observed	using	 the	 LiCor	Odyssey®	CLx	
system.	The	resulting	images	are	shown	in	Figure	3.27.	
	
Figure	 3.27	 Two	 duplicate	membranes	 were	 probed	with	 anti-HA	 or	 anti-StrepII	 primary	
antibodies	and	Cpl-1	accumulation	was	detected	in	the	expected	cell	lines	i.e.	Cpl-1-HA	was	
detected	with	the	anti-HA	antibody	and	not	with	the	anti-StrepII	antibody	and	vice	versa.	The	
non-specific	band	seen	 in	 the	 lower	 image	confirms	that	a	similar	quantity	of	extract	was	
loaded	on	to	the	gel	for	both	strains.	
3.3.2.2.4 C.	reinhardtii	line	TN72_SR_cpl1-StrepII_A_cpl1_c-HA	
3.3.2.2.4.1 Transformation	plasmid	production	
The	 plasmid	 was	 produced	 in	 the	 same	 manner	 as	 in	 3.3.2.2.2.1,	 but	 using	
pSRSapI_cpl1-StrepII	instead	of	pSRSapI_cpl1-HA.	The	resulting	plasmid	was	named	
pSRSapI_SR_cpl1-StrepII_A_cpl1_c-HA.	
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3.3.2.2.4.2 C.	reinhardtii	transformation	
The	 pSRSapI_SR_cpl1-StrepII_A_cpl1_c-HA	 plasmid	 was	 used	 to	 transform	 the	
recipient	C.	reinhardtii	strain	TN72	via	the	glass	bead	method	as	described	in	2.3.13.	
Figure	3.28	illustrates	the	resulting	C.	reinhardtii	cell	line,	TN72_SR_cpl1-StrepII.	
	
Figure	3.28	TN72	 recipient	 strain	 successfully	 transformed	 to	 carry	cpl1-StrepII	 under	 the	
psaA	 5’	 UTR,	 and	 cpl1_c-HA	 under	 the	 atpA	 5’	 UTR	 in	 the	 chloroplast,	 and	 with	 psbH	
functionality	restored.	
Correct	 insertion	 of	 the	 two	 GOIs	 into	 the	 plastome	 and	 homoplasmy	 of	 the	
transformant	lines	were	confirmed	as	described	above.	
3.3.2.2.4.3 Western	blot	quantification	
In	order	to	compare	accumulation	of	proteins	tagged	with	different	epitope	tags,	and	
therefore	detected	via	different	antibodies,	a	protein	standard	tagged	with	both	HA	
and	 StrepII	 epitope	 tags	 was	 used	 to	 normalize	 the	 signal.	 This	 standard	 was	
produced	specifically	for	this	purpose,	as	described	in	3.3.1.2.6.	
C.	reinhardtii	whole	cell	extracts	from	the	various	cell	lines	constructed	in	this	chapter	
were	separated	by	SDS-PAGE	in	duplicate.	The	proteins	were	blotted	to	nitrocellulose	
membranes	 as	 described	 in	 2.4.5	 and	 REVERT™	 Total	 Protein	 stain	 was	 used	 to	
normalise	 loading	 error	 (Appendix	 C).	 One	 membrane	 was	 probed	 with	 anti-HA	
primary	antibody,	while	the	second	membrane	was	probed	with	anti-StrepII	primary	
antibody.	Both	membranes	were	 then	 incubated	with	 IRDye®	 secondary	antibody	
and	fluorescence	was	observed	using	the	LiCor	Odyssey®	CLx	system.	The	resulting	
images	are	shown	in	Figure	3.29.		
trnE2 psbH
TN72_SR_cpl1-StrepII
_A_cpl1_c-HA
transformant MluI
5’psaA 1 3’rbcL5’atpAcpl1_c-HA3’rbcL cpl1-StrepII
		 122	
The	protein	standard,	which	is	tagged	with	both	HA	and	StrepII	epitope	tags	was	then	
used	to	normalize	the	two	membranes,	as	was	the	REVERT™	total	protein	stain.	The	
relative	protein	accumulation	levels	of	each	C.	reinhardtii	strain	were	compared	in	
Figure	3.29	(B).	TN72_SR_cpl1-HA,	which	has	been	used	throughout	this	chapter	as	a	
benchmark	for	Cpl-1	protein	accumulation	level,	upon	which	to	improve,	was	set	to	
100%	and	other	levels	are	represented	as	percentages	of	this.		
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Figure	3.29	(A)	Western	blot	analysis	of	C.	reinhardtii	whole	cell	extracts	probed	with	anti-
HA	or	anti-StrepII	primary	antibodies.	IR	detection	was	performed	by	the	LiCor	Odyssey®	CLx.	
(B)	Protein	accumulation	levels	were	quantified	using	the	Odyssey®	Image	Studio	v	5.0	and	
the	signal	was	normalised	using	the	protein	standard	and	REVERT™	total	protein	staining.	
TN72_SR_cpl1-HA	is	the	benchmark	strain	in	this	investigation	and	was	therefore	set	to	100%	
accumulation.	Other	 strains	 are	 represented	 relative	 to	 this.	 Protein	 accumulation	 of	 the	
StrepII	tagged	Cpl-1	appears	to	be	considerably	lower	than	that	of	the	HA	tagged	protein.	
As	 observed	 in	 Figure	 3.24,	 the	 level	 of	 Cpl-1	 protein	 accumulation	 in	 the	
TN72_SR_cpl1-HA_A_cpl1_c-HA	is	approximately	equal	to	the	sum	of	TN72_SR_cpl1-
HA	and	TN72_A_cpl1_c-HA.	However,	it	is	interesting	to	note	that	accumulation	of	
StrepII-tagged	Cpl-1	is	considerably	lower	than	its	HA-tagged	equivalent.	This	could	
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be	due	to	either	the	StrepII	tag	destabilizing	the	protein,	or	it	could	possibly	be	an	
artefact	of	the	normalization	method.		
The	addition	of	any	peptide	to	a	protein	has	the	potential	to	destabilise	it	by	affecting	
the	ability	or	rate	of	folding	of	the	protein	into	a	stable	form,	and	this	may	be	the	
case	with	the	StrepII	tagged	Cpl-1.		
Alternatively,	it	is	possible	that	the	StrepII	tag	on	the	protein	standard	is	more	easily	
accessible	than	that	on	Cpl-1,	or	conversely	that	the	HA	tag	is	less	accessible	on	the	
standard	than	on	Cpl-1.	This	scenario	would	 lead	to	an	underestimation	of	StrepII	
tagged	proteins,	or	an	overestimation	of	HA	tagged	proteins,	respectively.	It	seems	
plausible	 that	 a	 little	 of	 both	 scenarios	may	 be	 occurring,	 given	 that	 the	 protein	
standard	is	tagged	with	an	HA	tag	at	the	C-terminal	end,	followed	by	the	StrepII	tag	
beyond	that.	Anti-HA	antibodies	could	therefore	be	slightly	hindered	by	the	presence	
of	 the	 StrepII	 tag,	 while	 anti-StrepII	 antibodies	may	 find	 the	 epitope	 to	 be	more	
accessible	due	to	its	slightly	increased	protuberance	from	the	Cpl-1	protein.		
To	 investigate	which	 of	 these	 theories	 is	 correct,	 two	 separate	 protein	 standards	
could	be	created	for	each	tagged	Cpl-1.	If	much	lower	levels	of	StrepII	tagged	Cpl-1	
are	still	observed,	then	it	could	be	concluded	that	the	StrepII	tag	is	destabilizing	Cpl-
1,	but	if	accumulation	levels	appear	to	be	similar	then	it	was	merely	an	artefact	of	
the	normalization	process.	
In	either	case,	it	appears	that	the	insertion	of	multiple	expression	cassettes	into	the	
C.	reinhardtii	chloroplast	results	in	a	simple	addition	of	the	protein	levels	observed	
when	cassettes	are	inserted	singly.		
3.3.3 Codon	pair	optimization	for	improvement	of	protein	accumulation	levels	
The	 second	 aspect	 of	 this	 chapter	 looks	 at	 using	 codon	 pair	 optimization	 as	 a	
technique	for	improving	recombinant	protein	accumulation	levels	in	the	C.	reinhardtii	
chloroplast.	Codon	optimization	is	a	well-known	approach	to	improve	recombinant	
protein	 yields,	 and	 has	 been	 shown	 to	 be	 particularly	 important	 for	 transgene	
expression	 in	 the	C.	 reinhardtii	 chloroplast	 –	 Franklin	 et	 al.	 (2002b)	 increased	gfp	
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expression	 by	 80-fold	 in	 a	 codon	 optimized	 version	 compared	 to	 a	 unoptimized	
version.	 The	 codon	 frequency	 chart	 for	 the	C.	 reinhardtii	 chloroplast	 is	 shown	 in	
Appendix	D.	Taunt	(2013)	 investigated	the	role	that	codon	pairs	play	and	whether	
these	 too	 could	be	optimized	 to	 improve	expression.	 The	 study	 identified	 several	
codon	pairs	which	had	high	predicted	occurrence	but	were	rarely	or	never	observed	
in	 the	 C.	 reinhardtii	 chloroplast	 plastome.	 These	 pairs	 were	 terms	 Unexpectedly	
Unseen	 Zero	 Scoring	 Codon	 Pairs	 (uuZSCP).	 Two	 such	 uuZSCP	 stood	 out	 as	 being	
particularly	significant,	a	Phenylalanine:Arginine	pair,	and	an	Aspartic	Acid:Leucine	
pair,	 shown	 in	 Figure	 3.30.	 The	 Phe:Arg	 pair	 was	 chosen	 for	 investigation	 in	 this	
project	as	it	happened	to	be	included	in	the	initial	codon	optimization	for	cpl1,	and	is	
therefore	present	in	TN72_SR_cpl1-HA.	
	
Figure	3.30	Two	uuZSCP	are	particularly	rare	in	the	C.	reinhardtii	chloroplast,	despite	their	
constitutive	codons	being	relatively	common.	The	relative	frequency	refers	to	the	frequency	
with	which	 this	 codon	would	be	chosen	 to	 represent	 this	amino	acid	 in	 the	C.	 reinhardtii	
chloroplast.	The	Predicted	Occurrence	is	how	often,	given	the	frequency	of	amino	acid	pairs,	
one	would	expect	to	see	this	codon	pair	in	the	total	2579	codon	pairs	in	the	C.	reinhardtii	
chloroplast.	
First	Codon Second	Codon Codon	 Pair
Amino
Acid	
Pair
Code Relative	Freq. Code
Relative
Freq.
Combined	
Relative
Freq.
Predicted
Occurrence
Actual
Occurrence
Phe:Arg UUU 0.67 CGU 0.73 0.49 28.29 0
Asp:Leu GAU 0.76 CUU 0.14 0.1 9.1 0
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Figure	3.31	The	amino	acid	sequence	of	Cpl-1.	The	Phe:Arg	pair	is	highlighted	in	yellow,	while	
the	purple	box	indicates	the	HA	tag.	
According	to	Maul	et	al	(2002),	the	C.	reinhardtii	chloroplast	plastome	contains	30	
identified	tRNA	genes,	providing	a	small	yet	sufficient	set	for	protein	synthesis.	After	
examination	 of	 the	 data	 and	 checking	 the	 chloroplast	 genome	 (GenBank:	
BK000554.2)	 for	 tRNA	 genes	 using	 tRNAscan-SE	 (http://lowelab.ucsc.edu/cgi-
bin/tRNAscan-SE),	a	couple	of	inaccuracies	in	the	tRNA	data	were	noticed.	Firstly,	the	
trnE	gene	is	counted	three	times,	when	in	fact	there	appear	to	be	only	two	copies	
identified	 on	 the	 plastome.	 There	 are	 therefore	 only	 29	 tRNA	 genes	 in	 the	 C.	
reinhardtii	chloroplast.	Secondly,	the	trnR2	is	labelled	with	the	incorrect	anti-codon	
–	it	should	read	trnR2(UCU),	not	trnR2(AGA)	–	likely	just	a	confusion	between	codon	
and	anticodon.	Thirdly,	while	not	a	mistake	per	se,	the	nomenclature	is	unclear	for	
tRNA	genes	and	 seems	 to	be	 inconsistent.	 For	example,	 there	are	 trnR	 and	 trnR2	
genes,	which	identify	tRNAs	with	different	anticodons,	but	no	trnR1	exists.	A	table	of	
all	the	tRNA	genes	in	the	C.	reinhardtii	chloroplast	has	been	compiled	in	Figure	3.33.	
The	C.	 reinhardtii	 chloroplast	 chromosome	map	by	Maul	et	al.	 (2002)	 is	 shown	 in	
MVKKNDLFVDVSSHNGYDITGILEQMGTTNTIIKISEST
TYLNPCLSAQVEQSNPIGFYHFARFGGDVAEAEREAQFF
LDNVPMQVKYLVLDYEDDPSGDAQANTNACLRFMQMIAD
AGYKPIYYSYKPFTHDNVDYQQILAQFPNSLWIAGYGLN
DGTANFEYFPSMDGIRWWQYSSNPFDKNIVLLDDEEDDK
PKTAGTWKQDSKGWWFRRNNGSFPYNKWEKIGGVWYYFD
SKGYCLTSEWLKDNEKWYYLKDNGAMATGWVLVGSEWYY
MDDSGAMVTGWVKYKNNWYYMTNERGNMVSNEFIKSGKG
WYFMNTNGELADNPSFTKEPDGLITVAYPYDVPDYA
		 127	
Figure	3.34.	It	shows	the	location	of	all	the	tRNA	genes	on	the	plastome	and	explains	
that	the	two	copies	of	trnA	and	trnI	are	due	to	their	location	on	the	inverted	repeat	
sequences.	
In	order	to	test	whether	the	presence	of	the	uuZSCP	Phe:Arg	codon	pair	is	affecting	
the	level	of	protein	accumulation	in	TN72_SR_cpl1-HA,	two	cpl1	gene	mutants	were	
created	by	site-directed	mutagenesis.	The	first,	CPOCv1	(Codon	Pair	Optimized	Cpl-1	
version	1),	was	a	mutation	of	the	phenylalanine	codon	from	UUU	to	UUC	–	there	is	
only	one	trnF	gene,	so	this	codon	would	be	served	by	the	same	tRNA	“wobbling”	as	
cpl1.	The	second	mutant,	CPOCv2,	 includes	a	mutation	of	the	arginine	codon	from	
CGU	to	AGG	–	this	was	designed	to	be	served	by	the	tRNA	encoded	by	trnR2,	rather	
than	that	encoded	by	trnR1	which	serves	cpl1.		
N.B.	AGA	is	a	slightly	more	frequently	seen	Arginine	codon	than	AGG,	as	shown	in	
Figure	7.4,	and	would	not	rely	on	tRNA	wobble.	However,	UUU:AGA	is	also	a	codon	
pair	that	is	never	observed	in	the	chloroplast,	so	for	this	reason,	UUU:AGG	which	is	
observed,	was	chosen.		
Phe	 Arg	 CPAI	 Present	in…	
UUU	 CGU	 0	 cpl1	
UUU	 CGC	 0	 	
UUU	 CGA	 0	 	
UUU	 CGG	 0	 	
UUU	 AGA	 0	 	
UUU	 AGG	 0.0625	 cpov2	
UUC	 CGU	 1	 cpov1	
UUC	 CGC	 0	 	
UUC	 CGA	 0.0625	 	
UUC	 CGG	 0	 	
UUC	 AGA	 0.0625	 	
UUC	 AGG	 0	 	
Figure	3.32	All	possible	codon	combinations	for	a	Phe:Arg	pair.	The	codon	pair	adaptation	
index	(CPAI)	is	the	ratio	of	codon	pair	frequency	to	the	frequency	of	the	most	observed	codon	
pair.	The	data	above	are	from	a	“hand-pick”	database	in	the	Codon	Usage	Optimizer	Beta	
0.92	 (Kong	 2013)	 software,	 whereby	 the	 codon	 pair	 usage	 in	 highly	 expressed	 genes	 is	
collected.	
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Given	the	theory	for	codon	pair	bias	laid	out	in	3.1.4,	it	was	hypothesised	that	CPOCv1	
would	be	unaffected	by	 the	codon	change,	while	CPOCv2	may	display	a	different,	
possibly	higher,	level	of	Cpl-1	protein	accumulation.	
	
Figure	3.33	A	 list	of	tRNA	genes	 identified	by	Maul	et	al.	 (2002).	The	yellow	rows	indicate	
duplicate	tRNA	genes,	i.e.	they	have	the	same	anticodon.	Green	rows	indicate	tRNA	genes	
with	different	anti-codons,	but	coding	for	the	same	amino	acid.		
No.	 Name Anticodon Codon Amino	Acid
1
trnA UGC
GCA Ala
trnA UGC
2 trnC GCA UGC Cys
3 trnD GUC GAC Asp
4
trnE UUC
GAA Glu
trnE UUC
5 trnF GAA UUC Phe
6 trnG1 UCC GGA Gly
7 trnG2 GCC GGC Gly
8 trnH GUG CAC His
9
trnI GAU
AUC Ile
trnI GAU
10 trnK UUU AAA Lys
11 trnL1 UAG CUA Leu
12 trnL2 UAA UUA Leu
13 trnM1 CAU AUG fMet
14 trnM2 CAU AUG Met
15 trnM3 LAU AUA Ile
16 trnN GUU AAC Asn
17 trnP UGG CCA Pro
18 trnQ UUG CAA Gln
19 trnR1 ACG CGU Arg
20 trnR2 UCU AGA Arg
21 trnS1 UGA UCA Ser
22 trnS2 GCU AGC Ser
23 trnT UGU ACA Thr
24 trnV UAC GUA Val
25 trnW CCA UGG Trp
26 trnY GUA UAC Tyr
Phenylalanine
Arginine
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Several	 naming	 changes	 have	 been	 made	 in	 Figure	 3.33	 to	 the	 original	 names	
published	in	Maul	et	al.	(2002).	The	new	names	fall	in	line	with	the	annotations	made	
to	 the	 chloroplast	 genome	 available	 at	 NCBI	
(https://www.ncbi.nlm.nih.gov/nuccore/BK000554).	The	names	mean	that	identical,	
duplicate	genes	 (trnA,	 trnI	and	 trnE)	have	 the	same	anticodon,	while	genes	which	
encode	 similarly	 charged	 tRNAs,	but	with	differing	anticodons,	 are	numbered	e.g.	
trnL1	and	trnL2.	The	only	change	made	from	the	NCBI	naming	is	to	name	both	trnE	
genes	the	same,	as	they	are	identical	duplicates.	It	should	also	be	noted	that	some	
discrepancy	exists	between	 the	defined	gene	 length	on	NCBI	and	 the	 tRNA	genes	
detected	using	 the	 tRNAscan	 software,	most	 likely	due	 to	 incorrect	 annotation	of	
NCBI.	
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Figure	Removed	
	
	
Figure	 3.34	 The	C.	 reinhardtii	 chloroplast	 chromosome.	 tRNA	 genes	 are	 identified	 on	 the	
outer	ring	in	black	and	labelled	with	a	single	letter.	e.g.	V,	which	indicates	trnV.	Two	tRNA	
genes	 (trnA	 and	 trnI)	 are	 located	 in	 the	 Inverted	 Repeat	 (IR)	 regions	 of	 the	 plastome,	
indicated	in	thick	black,	thus	explaining	their	duplication.	The	second	copy	of	trnL	(2	o’clock)	
should	be	black	to	indicate	tRNA,	as	should	trnI	and	trnA	on	the	right-hand	IR.	Reproduced	
from	 Maul	 et	 al.	 (2002).	 Note:	 As	 an	 aside,	 the	 neutral	 site	 used	 for	 chloroplast	
transformation	throughout	this	thesis	is	located	between	trnE	and	psbH,	5	o’clock.		
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3.3.3.1 Codon	Pair	Optimized	Cpl-1	version	1	and	2	(CPOCv1	and	CPOCv2)	
CPOCv1	was	designed	such	that	a	different	codon	coded	for	phenylalanine,	but	that	
codon	would	still	be	served	with	the	same	tRNA	as	was	used	in	the	original,	through	
the	 phenomenon	 known	 as	 tRNA	 wobble	 (Alkatib	 et	 al.	 2012).	 CPOCv1	 would	
therefore	act	as	a	control	 for	 this	 investigation,	as	 the	 theory	being	 tested	 is	 that	
tRNAs	interact	in	the	A	and	the	P	site	of	the	ribosome	in	a	manner	that	can	influence	
translation	efficiency.	Here,	 the	 same	 tRNAs	will	 be	used	 in	 this	mutant	 as	 in	 the	
original	version	and	thus	we	expect	to	see	no	change	in	translation	efficiency.		
CPOCv2	was	designed	such	that	a	different	codon	coded	for	arginine,	and	that	that	
codon	would	be	served	with	a	different	tRNA	to	the	original,	as	there	are	two	trnR	
genes	 in	 the	 C.	 reinhardtii	 chloroplast	 with	 different	 anti-codons.	 CPOCv2	 was	
produced	in	an	attempt	to	influence	accumulation	levels	of	Cpl-1,	as	different	tRNAs	
will	be	interacting	in	the	A	and	the	P	site	of	the	ribosome	compared	to	those	in	the	
original	version,	and	therefore	translation	may	progress	at	a	faster	rate.	
3.3.3.1.1 Codon	change	by	site-directed	mutagenesis	
To	create	CPOCv1,	primers	were	designed	to	mutate	U	→	C	in	the	third	position	of	
the	phenylalanine	codon	through	PCR,	and	for	CPOv2	to	mutate	C	→	A	in	the	first	
position	and	T	→	G	in	the	third	position	of	the	arginine	codon.	The	steps	taken	to	
perform	this	mutagenesis	are	shown	in	Figure	3.35	and	Figure	3.36	respectively.	The	
primers	used	are	indicated	below.	The	lower	case	letters	show	the	sites	for	mutation.	
cpl1.F:			 	 GCTCTTCAATGGTTAAAAAAAATGATTTATTC	
cpocv1_SDM.F:		 AGGTGGTGGTTcCGTCGTAA	
cpocv1_SDM.R:		 TTACGACGgAACCACCAACCT 
cpocv2_SDM.F:		 GTTGGTGGTTTaGgCGTAATAATG	
cpocv2_SDM.R:		 CATTATTACGcCtAAACCACCAAC	
cpl1.R:		 	 GCATGCTTATTAAGCATAATCTGGAAC 
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Figure	3.35	Site-directed	mutagenesis	was	performed	as	above	to	modify	the	phenylalanine	
codon	to	make	CPOCv1.	Primers	are	shown	in	blue	and	PCR	conditions	are	described	in	2.3.7.	
	
Figure	3.36	Site-directed	mutagenesis	was	performed	as	above	to	modify	the	arginine	codon	
to	make	CPOCv2.	Primers	are	shown	in	blue	and	PCR	conditions	are	described	in	2.3.7.	
3.3.3.1.2 Expression	cassette	production	
The	 expression	 cassette	 was	 assembled	 as	 with	 previous	 examples.	 The	 gene,	
including	the	HA	tag	at	the	C	terminus,	was	cloned	into	the	pSRSapI	vector	in	frame	
using	SapI	and	SphI	restriction	sites.	The	insertion	was	confirmed	by	DNA	sequencing	
TTT CGT
AAA GCA
AAG GCA
TTC CGT
TTC CGT
AAG GCA
TTC CGT
AAG GCA
1st PCR
2nd PCR
Final	product
Cpl-1
CPOCv1
cpl1.F
cpl1.R
cpocv1_SMD.F
cpocv1_SMD.R
TTT CGT
AAA GCA
AAA TCC
TTT AGG
TTT AGG
AAA TCC
TTT AGG
AAA TCC
1st PCR
2nd PCR
Final	product
Cpl-1
CPOCv2
cpl1.F
cpl1.R
cpocv2_SMD.F
cpocv2_SMD.R
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of	 the	 plasmid	 as	 described	 in	 2.3.18.	 The	 resulting	 plasmids	 were	 called	
pSRapI_CPOCv1-HA	and	pSRapI_CPOCv2-HA.	
3.3.3.1.3 C.	reinhardtii	transformation	
Two	 TN72	 transformations	 were	 performed,	 using	 pSRSapI_CPOCv1-HA	 and	
pSRSapI_CPOCv2-HA	 plasmids.	 Transformed	 C.	 reinhardtii	 lines	 were	 checked	 for	
homoplasmicity	by	PCR	and	finally	confirmed	by	sequencing.		
3.3.3.2 Western	 blot	 quantification	 of	 TN72_SR_CPOCv1-HA	 and	
TN72_SR_CPOCv2-HA	
It	is	hypothesised	that	the	codon	changes	made	above	will	result	in	different	levels	
of	protein	accumulation	between	 the	 two	 transformant	 lines.	To	 test	 this,	 four	C.	
reinhardtii	cultures,	TN72_SR_cpl1-HA,	TN72_SR_CPOCv1-HA,	TN72_SR_CPOCv2-HA	
and	 TN72_SR_Control,	 were	 grown	 in	 an	 Algem	 Photobioreactor	 simultaneously,	
with	the	same	starting	cell	density	and	with	the	same	physiological	conditions.	OD740	
was	measured	automatically	every	30	minutes	and	samples	were	taken	at	intervals	
for	analysis	by	western	blotting.	1	ml	samples	were	collected	from	the	culture	volume	
and	immediately	snap-frozen	in	liquid	nitrogen	and	stored	at	-80	°C.	The	culture	was	
grown	for	145	hours	in	total.	At	the	end	of	this	time	the	frozen	samples	were	analysed	
together	by	western	blotting.	Whole-cell	extracts	were	separated	by	SDS-PAGE,	with	
no	compensation	made	for	cell	density.	After	blotting	to	nitrocellulose	membrane	
and	blocking,	the	membranes	were	probed	with	anti-HA	primary	antibody,	followed	
by	 IRDye®	 secondary	 antibody	 and	 fluorescence	 was	 observed	 using	 the	 LiCor	
Odyssey®	CLx	system.	
Figure	3.37	shows	the	western	blot	analysis	–	a	rise	in	protein	accumulation	over	time	
as	cell	density	increases	is	to	be	expected.		
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Figure	3.37	Western	blot	analysis	of	four	C.	reinhardtii	strains	at	four	time	points.	The	known	
standard	was	used	to	normalise	any	difference	between	blotting	on	separate	membranes.	
The	 quantified	 and	 normalised	 data	 is	 displayed	 in	 Figure	 3.38,	 alongside	 optical	
density	 data	 collected	 by	 the	Algem	photobioreactor.	 The	whole	 experiment	was	
repeated	a	second	time,	and	the	final	results	can	be	seen	in	Figure	3.39,	with	western	
blot	analysis	in	Appendix	E.	
3.3.3.2.1 Statistical	analysis	of	western	blot	data	
A	 one-way	 ANOVA	 test	 was	 carried	 out	 on	 the	 recombinant	 protein	 yields	 of	
TN72_SR_cpl1-HA,	 TN72_SR_CPOCv1-HA	 and	 TN72_SR_CPOCv2-HA	 in	 order	 to	
identify	 any	 statistical	 difference	 between	 the	 levels	 of	 protein	 accumulation	 at	
different	time	points,	detailed	in	Appendix	F.	In	the	first	run	of	the	experiment,	it	was	
found	that	the	protein	accumulation	at	45	hours	and	58	hours	was	significantly	higher	
in	TN72_SR_CPOCv2-HA	than	in	the	other	cell	lines,	but	that	there	was	no	significant	
difference	 beyond	 this	 point.	On	 the	 other	 hand,	 the	 second	 performance	 of	 the	
experiment	was	run	for	longer	and	likewise,	suggests	that	protein	accumulation	of	
TN72_SR_CPOCv2	is	significantly	higher	the	45	and	56-hour	time	points.	However,	
CPOCv1	 and	 CPOCv2	 then	 continue	 to	 rise,	 while	 the	 protein	 accumulation	 in	
TN72_SR_cpl1-HA	rises	at	a	much	lower	rate,	being	significantly	lower	than	the	codon	
pair	 optimised	 versions	 at	 the	 112,	 139	 and	 194-hour	 time	 points.	 The	 statistical	
method	and	results	are	detailed	in	Appendix	G.	
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Figure	3.38	Algem	growth	data	(line	chart,	left	y-axis)	and	western	blot	quantification	(bar	chart,	right	y-axis).	The	Algem	photobioreactor	recorded	optical	
density	at	740	nm	every	90	seconds.	At	OD740	=	~2.5,	the	photobioreactor	is	unable	to	record	any	higher	OD	due	to	the	long	path-length	across	a	400	ml	
culture.	However,	as	indicated	by	the	protein	accumulation	levels,	the	cultures	are	reaching	their	stationary	phase	around	this	point	anyway.	The	relative	
detected	fluorescence	for	HA-tagged	protein	accumulation	is	taken	from	Figure	3.37,	and	normalised	using	the	protein	standard	and	the	OD740.	
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Figure	3.39	Algem	growth	data	(line	chart,	left	y-axis)	and	western	blot	quantification	(bar	chart,	right	y-axis).	The	starting	OD	was	lower	in	this	experiment,	
so	the	culture	takes	longer	to	reach	the	logarithmic	growth	stage.	The	original	western	blot	analysis	is	shown	in	Appendix	E,	in	this	instance	the	25	kDa	band	
of	the	protein	ladder	was	used	to	normalise	the	membranes,	this	enabled	more	samples	to	be	fitted	onto	a	single	gel	and	thus	measure	accumulation	over	a	
longer	time	period.
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Figure	3.38	indicates	that	CPOCv1	is	growing	slightly	slower	than	the	two	controls,	
and	CPOCv2	is	growing	slightly	faster.	This	 is	most	 likely	due	to	a	slightly	different	
number	of	cells	used	to	inoculate	the	cultures,	despite	efforts	to	ensure	they	were	
the	 same.	 However,	 to	 compensate	 for	 this	when	 comparing	 protein	 yields	 from	
western	blot	analysis,	the	detected	signal	was	divided	by	the	OD,	thus	normalising	
the	data	for	cell	density.	Each	of	the	four	membranes	used	for	western	blot	analysis	
also	showed	slightly	different	signals	for	the	protein	standard,	probably	due	to	non-
uniform	transfer	from	the	gel	to	the	membrane,	slightly	different	antibody	incubation	
times	 and	 slightly	 different	 dilutions	 of	 milk	 and	 antibody.	 Assuming	 that	 these	
variables	 are	 the	 same	 within	 membranes,	 but	 can	 vary	 from	 membrane	 to	
membrane,	 the	 data	were	 normalised	 by	 division	 of	 the	 average	 level	 of	 protein	
standard	detected.	The	same	is	true	for	Figure	3.39,	but	this	time	using	the	25	kDa	
band	of	the	protein	ladder	to	normalise	for	inter-membrane	differences,	as	there	was	
no	room	on	the	membrane	to	include	the	protein	standard	too.		
While	the	two	graphs	cannot	be	compared	directly,	due	to	the	longer	lag	time	in	the	
latter	 and	 different	 inter-membrane	 normalisation	 techniques,	 they	 do	 appear	 to	
display	two	trends.	Firstly,	that	CPOCv2	seems	to	accumulate	faster	than	the	other	
Cpl-1	variants	throughout	the	 logarithmic	growth	stage,	and	secondly	that	the	un-
optimised	version	of	Cpl-1	consistently	accumulates	to	a	lower	level	than	either	of	
the	CPO	versions.		
This	 is	 an	 interesting	 observation,	 as	 according	 to	 the	 theory	 of	 codon	 pair	
optimisation,	CPOCv1	accumulation	should	be	no	different	to	the	unchanged	Cpl-1,	
as	 the	 tRNAs	 serving	 the	 mRNA	 are	 identical.	 However,	 particularly	 in	 the	 later	
growth	 stages	 in	 Figure	 3.39,	 there	 is	 a	 consistently	 and	 significantly	 higher	
accumulation	of	CPOCv1	and	CPOCv2.		
Given	 the	 evidence	 from	 section	 3.3.1,	 in	 which	 data	was	 collected	 on	 the	 error	
introduced	at	various	points	of	measuring	protein	accumulation,	these	differences	
seem	 too	 large	 to	 be	 artefacts	 of	 variability	 in	 western	 blotting	 and	 cell	 density	
measuring	 techniques.	 Therefore,	 alternative	 explanations	 for	 this	 result	must	 be	
sought.	
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The	 first	 thing	 to	 consider	 is	 the	 fact	 that	 in	 CPOv2,	 another	 codon	 pair	 is	 being	
unintentionally	altered.	The	amino	acid	immediately	following	the	codon	optimized	
Arginine	is	another	Arginine,	as	can	be	seen	in	Figure	3.31.	This	Arg:Arg	codon	pair	is	
being	unintentionally	altered	when	the	preceding	Phe:Arg	codon	pair	is	optimized	in	
CPOv2.	This	presents	another	variable	that	has	not	been	accounted	for,	and	as	shown	
in	 Figure	 3.40,	 the	 new	 pair	 is	 never	 observed	 in	 the	 “hand-picked”	 database,	
consisting	of	highly	expressed	proteins	in	the	C.	reinhardtii	chloroplast,	generated	by	
Taunt	(2013).	This	presents	an	issue,	as	although	one	uuZSCP	(UUU:CGU)	has	been	
replaced,	another	unseen	pair	is	introduced	(AGG:CGU).	It	is,	therefore,	possible	that	
the	beneficial	effects	of	 the	 former	are	negated	by	 the	detrimental	effects	of	 the	
latter.	 There	 is	 no	 similar	 effect	made	 by	 CPOv1,	 as	 all	 Phenylalanine	 codons	 are	
served	by	a	single	tRNA.	
Arg	 Arg	 CAI	 Present	in…	
CGU	 CGU	 1	 cpl1	&	cpov1	
CGC	 CGU	 0	 	
CGA	 CGU	 0	 	
CGG	 CGU	 0	 	
AGG	 CGU	 0	 	
AGA	 CGU	 0	 cpov2	
Figure	3.40	Data	taken	from	the	“hand-pick”	database	of	Codon	Usage	Optimizer	Beta	0.92	
(Kong	 2013).	 This	 is	 a	 database	 of	 codon	 usage	 in	 highly	 expressed	 proteins,	 a	 common	
method	of	selecting	the	best	codon	usage.	
Another	possibility	is	that	while	gene	expression	appears	to	be	primarily	controlled	
at	the	level	of	translation	in	the	C.	reinhardtii	chloroplast,	the	transcriptional	level	still	
may	play	a	part	and	as	such	the	levels	of	mRNA	produced	for	CPOCv1	and	CPOCv2	
should	be	investigated.	If	these	are	found	to	remain	similar	then	it	can	be	discounted,	
but	should	be	investigated	nevertheless.		
Additionally,	 the	 unexpectedly	 unseen	 nature	 of	 UUU:CGU	 could	 be	 just	 a	
coincidence.	Although	this	seemed	unlikely,	given	the	convincing	statistical	analysis	
performed	by	 Taunt	 (2013),	 the	 assertion	 that	 this	 pair	 is	 purposefully	 avoided	 is	
slightly	undermined	by	the	frequent	presence	of	UUC:CGU.	UUC:CGU	accounts	for	33	
of	the	59	observed	instances	of	Phe:Arg	in	the	C.	reinhardtii	chloroplast,	but	given	
		 139	
the	fact	that	UUU	and	UUC	are	served	by	the	same	tRNA,	the	different	codon	should	
confer	 no	 difference	 in	 translational	 efficiency	 or	 codon	 selection.	 It	 could	 be	
therefore	that	some	neutral	mechanism	has	resulted	in	this	bias,	not	selection,	for	
example,	 preferential	mutation	bias	 during	DNA	 replication	or	 repair	 (Lucks	 et	 al.	
2008).	Another	alternative	is	that	the	single	base	change	in	the	cpl1	transgene	has	
created	 an	 unexpected	 local	 area	 of	 secondary	 structure	 within	 the	 mRNA,	 thus	
altering	 the	 translational	efficiency	 (Gaspar	et	al.	2013).	This	kind	of	 interaction	 is	
very	 difficult	 to	 predict,	 as	 the	 mRNA	 folding	 events	 may	 involve	 two	 distant	
sequences,	and	changing	one	base	might	strengthen/weaken	these	interactions.	
The	final	and	possibly	most	likely	explanation	is	one	which	is	little	understood.	This	is	
the	frequently	observed	and	reported	phenomenon	of	variable	transgene	expression	
between	“identical”	C.	 reinhardtii	chloroplast	 transformants	 (Mayfield	and	Schultz	
2004;	 Surzycki	 et	 al.	 2009;	 Michelet	 et	 al.	 2011).	 The	 differences	 can	 be	 quite	
remarkable:	 Surzycki	 et	 al.	 (2009)	 reported	 that	 recombinant	 protein	 expression	
levels	of	VP28,	a	White	Spot	Syndrome	virus	protein,	varied	between	transformants	
from	0.88	%	to	20.9	%	TCP.	When	only	a	low	number	of	transformants	are	generated,	
as	 is	 frequently	 the	case	with	the	glass	bead	method	regularly	used	 in	 the	Purton	
group,	 a	 significant	 difference	 in	 transgene	 expression	 could	 be	 incorrectly	
apportioned	 to	 a	 factor	 which	 really	 has	 little	 effect.	 The	 reason	 put	 forward	 by	
Surzycki	 et	 al.	 (2009)	 for	 this	 observation	 is	 transformation-associated	 genotypic	
modifications,	termed	the	“transformosome”.	The	paper	postulates	that	during	the	
process	 of	 genetic	 transformation,	 fragments	 of	 the	 transformation	 plasmid	 are	
unknowingly	 inserted	 into	 the	plastome	or	 nuclear	 genome,	 thus	 altering	nuclear	
genes	 that	 regulate	 chloroplast	 gene	 expression,	 protease	 expression,	 or	 sites	 of	
regulatory	 gene	 action	 in	 the	 chloroplast.	 Evidence	 is	 presented	 that	 the	 level	 of	
steady	state	transgene	mRNA	is	unaffected,	giving	further	weight	to	the	belief	that	
gene	regulation	occurs	primarily	at	the	translation	level	in	C.	reinhardtii.	
C.	 reinhardtii	 is	 extremely	 good	 at	 resource	management,	 and	 as	 such	 is	 able	 to	
prioritise	 the	production	of	key	proteins	over	others,	 for	example	when	Copper	 is	
limiting	the	cell	will	preferentially	produce	cytochrome	C	oxidase	over	plastocyanin	
for	use	in	the	electron	transfer	chain	of	PS1	(Merchant	and	Bogorad	1986).	However,	
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as	Cpl-1	is	a	recombinant	protein,	it	is	not	involved	in	this	hierarchy	and	is	therefore	
likely	to	be	the	first	protein	to	be	sacrificed	in	the	case	of	a	metabolic	limitation.	As	
the	 value	 for	 protein	 accumulation	 is	 relative	 (i.e.	 it	 has	 been	 normalised	 for	 the	
optical	density	of	the	culture),	Figures	3.38	and	3.39	both	show	increasing	levels	of	
protein	 accumulation	 as	 the	 culture	 progresses	 into	 stationary	 phase	 and	 then	 it	
plateaus.	 Therefore,	 metabolic	 limitation	 does	 not	 appear	 to	 be	 an	 issue	 in	 this	
instance.		
To	conclude,	it	appears	that	a	difference	in	Cpl-1	accumulation	has	been	observed,	
but	it	is	unclear	as	to	whether	this	difference	is	due	to	the	codon	pair	optimisation,	
as	the	results	do	not	support	the	theory	that	codon	pairs	can	be	optimised	due	to	the	
different	interactions	of	tRNAs	at	the	A	and	P-sites	of	the	ribosome,	and	the	observed	
differences	are	small	enough	to	be	accounted	for	by	other	factors.	
3.4 Conclusion	and	future	work	
This	 chapter	 has	 investigated	 two	 putative	 methods	 of	 improving	 recombinant	
protein	 expression	 in	 the	 C.	 reinhardtii	 chloroplast:	 the	 introduction	 of	 multiple	
expression	 cassettes;	 and	 the	 application	 of	 codon	 pair	 optimisation.	 The	 former	
appears	to	be	a	method	to	robustly	improve	protein	accumulation,	while	the	latter	
method	 remains	 unclear	 as	 the	 complex	 and	 incremental	 nature	 of	 the	 change	
appears	to	be	masked	by	other	factors	in	play.	Interestingly	the	concern	addressed	
at	the	start	of	the	chapter,	namely	how	to	accurately	compare	protein	accumulation	
between	 transformant	 lines,	 re-emerged	 as	 an	 issue	 towards	 the	 end	 of	 the	
investigation.	
3.4.1 Multiple	expression	cassette	strategy	
The	overall	conclusion	from	this	study	was	that	C.	reinhardtii	lines	transformed	with	
multiple	 expression	 cassettes	 produce	 a	 recombinant	 protein	 yield	 approximately	
equal	 to	 the	 sum	 of	 the	 yields	 observed	 in	 lines	 transformed	with	 each	 cassette	
individually.	This	finding	could	potentially	be	used	to	double	existing	yields	in	the	C.	
reinhardtii	chloroplast.	However,	some	further	work	into	what	the	limitations	of	this	
method	are	will	enable	us	to	better	understand	its	potential.	
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The	first	and	most	obvious	test	is	to	investigate	whether	this	result	can	be	repeated	
with	other	transgenes.	This	would	be	a	relatively	straightforward	test	to	perform,	but	
it	would	be	interesting	to	test	both	another	highly	expressed	gene,	as	well	as	a	gene	
which	is	currently	only	weakly	expressed	in	the	C.	reinhardtii	chloroplast.	The	cpl1	
gene	is	well	expressed,	and	therefore	it	is	possible	that	CES	mechanisms	are	limiting	
its	 accumulation	 under	 a	 single	 5’	 UTR,	 thus	making	 it	 a	 good	 candidate	 for	 this	
technique.	 On	 the	 other	 hand,	 proteins	 displaying	 poor	 accumulation	 might	 be	
limited	by	protease	activity	for	example,	and	will	therefore	remain	at	low	levels	of	
accumulation	despite	different	mRNA	transcripts.	
The	second	question	that	one	would	like	to	ask	is	to	what	point	can	this	theory	be	
extended.	Will	three	or	four	cassettes	triple	or	quadruple	the	protein	accumulation,	
for	 instance?	 Going	 beyond	 two	 copies	 of	 the	 gene	 raises	 the	 issue	 discussed	 in	
section	3.3.2.2	–	when	two	duplicate	genes	are	in	parallel	directions	to	each	other,	
there	is	a	potential	for	DNA	excision	to	occur	between	the	repeats.	Avoiding	this	by	
increasing	the	distance	between	the	copies	would	most	likely	require	another	neutral	
site	 to	 be	 used	 and	 targeted	 for	 transformation,	 requiring	 the	 use	 of	 a	 second	
selectable	marker,	 enabling	 sequential	 transformations.	 Two	 options	 exist	 in	 this	
case,	 either	 the	 addition	 of	 a	 positive	 selectable	 marker,	 such	 as	 aadA	 and	
maintaining	 the	 algae	 on	 spectinomycin	 containing	 media,	 or	 the	 addition	 of	 a	
negative	selectable	marker,	such	as	codA,	to	the	recipient	line	which	is	then	replaced	
in	the	second	transformation	event	(Young	and	Purton	2014).	The	latter	would	result	
in	 the	 formation	 of	 a	 marker-less	 mutant	 which	 is	 desirable	 for	 further	
transformations	but	requires	more	time	to	make	the	constructs.	As	an	initial	test	of	
how	 far	 the	multiple-cassette	 theory	 can	 be	 taken,	 it	 is	 suggested	 that	 using	 an	
antibiotic	 resistance	marker	 is	more	straightforward.	Furthermore,	 the	practice	of	
using	codon	manipulation	to	minimise	the	potential	for	DNA	excision,	as	performed	
in	3.3.2.2.1.1,	may	enable	more	cassettes	to	be	inserted	into	the	same	site.	However,	
given	 that	 codon	 optimisation	 has	 been	 shown	 to	 be	 very	 influential	 in	 protein	
accumulation	 the	C.	 reinhardtii	 chloroplast	 (Surzycki	 et	 al.	 2009),	 this	 can	only	be	
taken	so	far	without	a	considerable	reduction	in	translation.	
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As	discussed	in	3.3.2.2.4.3,	an	investigation	into	why	the	StrepII	epitope	appears	to	
be	affecting	protein	accumulation	so	profoundly	should	be	performed.	The	simplest	
explanation	 is	 that	 normalising	 to	 the	 protein	 standard	 is	 skewing	 the	 results	 by	
having	a	different	epitope	accessibility	than	that	of	the	singly	tagged	proteins.	This	
was	an	issue	encountered	previously	in	the	Purton	group	(Taunt	2013;	Stoffels	2015),	
whereby	the	commercial	multi-tagged	protein	standard	suggested	levels	of	protein	
accumulation	that	could	not	be	confirmed	by	SDS-PAGE	and	Coomassie	Blue	staining.	
Furthermore,	a	similar	result	in	5.3.2.4.3	suggests	that	this	is	the	case,	where	another	
endolysin,	CD27L,	also	appears	 to	accumulate	 to	a	much	 lower	 level	when	StrepII	
tagged.	However,	it	may	be	that	the	endolysin	is	extremely	sensitive	to	C-terminal	
epitope	tags	in	terms	of	stability,	in	which	case	an	investigation	into	the	accumulation	
using	different	epitope	tags	could	be	carried	out	and	one	should	also	consider	tagging	
the	N-terminus	instead.	
Finally,	a	calculation	of	recombinant	protein	yield	as	a	percentage	of	Total	Soluble	
Protein	(TSP)	or	Total	Cell	Protein	(TCP)	would	be	possible	once	the	issue	surrounding	
the	protein	standard	has	been	resolved.	This	would	allow	comparison	to	other	yields	
achieved	 in	 the	 literature.	 Alternatively,	 an	 ELISA	 assay	 could	 be	 performed	 but	
antibodies	 would	 have	 to	 be	 raised	 against	 Cpl-1,	 which	 is	 expensive.	 A	 robust	
method	of	estimating	protein	yield	using	an	epitope	tag	and	western	blot	analysis	
would	be	cheaper	and	more	flexible,	enabling	quantification	of	other	proteins	in	the	
future.		
3.4.2 Identical	transformant	transgene	variability	
The	issue	of	large	variability	in	transgene	expression	between	supposedly	identical	
transformants,	 also	 known	 as	 “clonal	 variation”,	 has	 the	 potential	 to	 mask	 or	
exaggerate	 investigations	 into	 other	methods	 of	 improving	 protein	 accumulation.	
Until	this	issue	has	been	addressed,	“fine-tuning”	techniques	will	remain	difficult	to	
assay	and	are	unlikely	to	be	as	effective	as	simply	screening	many	transformants	and	
selecting	 the	 best,	 as	 many	 protein	 production	 companies	 working	 with	 Pichia	
pastoris	currently	do	(Aw	et	al.	2017).	
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The	 most	 useful	 tool	 to	 aid	 investigation	 into	 this	 phenomenon	 would	 be	 the	
development	 of	 a	 sensitive	 and	 robust	 reporter	 gene	 for	 C.	 reinhardtii.	 Reporter	
genes	 such	 as	GFP	 have	 been	used	 for	 this	 purpose	 in	many	 other	 organisms,	 as	
fluorescence	 is	 graded	 and	 easily	 measured	 in	 vivo,	 enabling	 rapid	 quantitative	
screening	 of	 many	 transformants.	 However,	 while	 some	 studies	 have	 produced	
reasonable	levels	of	GFP	in	the	C.	reinhardtii	chloroplast	(Franklin	et	al.	2002),	due	to	
the	high	levels	of	auto-fluorescence	in	C.	reinhardtii,	GFP	is	unsuitable	as	it	must	be	
produced	at	high	levels	to	be	detectable	(Mayfield	and	Schultz	2004).	Luciferase	has	
been	developed	as	a	viable	alternative,	with	fluorescence	shown	to	be	proportional	
to	protein	accumulation,	and	no	interference	by	cell	auto-fluorescence	(Mayfield	and	
Schultz	 2004).	 Surzycki	 et	 al.	 (2009)	 demonstrated	 that	 co-introduced	 selectable	
marker	genes	are	expressed	in	a	manner	proportional	to	the	GOI.	Therefore,	the	co-
introduction	of	luciferase	with	a	GOI	should	enable	its	fluorescence	to	be	used	as	a	
reliable	 proxy	 for	 recombinant	 protein	 accumulation.	 This	 in	 turn	will	 enable	 the	
rapid	screening	of	many	different	transformants,	and	the	production	of	a	bell-curve	
for	transgene	expression.	Once	this	method	can	be	used	to	create	a	reproducible	bell-
curve	of	luciferase	detection,	then	statistical	analysis	can	reliably	deduce	how	smaller	
changes	are	influencing	protein	accumulation	levels.		
	
Figure	 3.41	 A	 comparison	 of	 means.	 By	 producing	 two	 bell	 curves	 with	 the	 luciferase	
expression	level	measured	from	many	transformants,	 it	will	be	possible	to	identify	subtler	
improvements	in	protein	accumulation.	Here	!	is	the	difference	between	two	transformant	
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lines,	with	the	blue	line	representing	all	the	transformants	of	one	treatment,	and	the	red	line	
all	the	transformants	of	another.	
Development	 of	 the	 above	 will	 enable	 more	 precise	 testing	 of	 other	 strategies	
including	 codon	 and	 codon	 pair	 optimization.	 The	 above	 also	 depends	 upon	 the	
development	of	a	more	efficient	system	of	transforming	C.	reinhardtii	chloroplast,	as	
many	 transformants	need	 to	be	 rapidly	produced	 for	 this	method	 to	be	effective.	
Current	 work	 in	 the	 Purton	 lab	 by	 Saowalak	 Changko	 aims	 to	 improve	 current	
transformation	methods.	Another	future	advantage	of	such	a	system	is	that	it	would	
allow	the	identification	of	outliers,	cells	which	produce	very	high	or	very	low	levels	of	
recombinant	protein.	With	the	cost	of	whole	genome	sequencing	(WGS)	falling	all	
the	time,	these	outliers	could	be	subjected	to	WGS	in	an	attempt	to	understand	what	
factors	are	influencing	protein	expression	so	heavily,	and	then	attempt	to	specifically	
introduce	those	changes.	WGS	has	already	been	used	to	successfully	identify	point	
mutations	in	C.	reinhardtii	(Dutcher	et	al.	2012).	This	will	improve	our	understanding	
of	the	subtleties	of	current	transformation	methods	and	the	complex	role	of	nuclear	
factors	in	chloroplast	gene	expression.		
3.4.3 Codon	pair	optimisation	
As	 discussed	 in	 the	 previous	 section,	 attempting	 to	 manipulate	 and	 detect	
differences	in	codon	pair	optimisation	strategies	may	be	premature	at	this	stage	of	
developing	the	C.	reinhardtii	chloroplast	as	a	protein	production	platform.	However,	
given	the	importance	of	codon	optimization	often	reported	in	the	literature	(Franklin	
et	al.	2002;	Surzycki	et	al.	2009;	Coragliotti	et	al.	2011),	and	the	clear	existence	of	a	
codon	pair	bias	in	the	C.	reinhardtii	chloroplast	(Taunt	2013),	it	is	possible	that	codon	
pair	optimisation	will	become	an	important	tool	in	the	future.		
Codon	and	codon	pair	optimisation	are	currently	just	a	‘best	guess’	at	how	to	express	
a	recombinant	protein	to	a	high	level.	It	appears	that	codon	optimisation	by	the	host	
in	its	own	endogenous	genes	enables	controlled,	delicate	adjustments	of	expression.	
The	discovery	of	codon	pair	optimisation	further	muddies	the	waters	around	deriving	
which	 codons	 to	 use	 in	 a	 transgene.	 It	 seems	 intuitive	 that	 just	 using	 the	 most	
common	codons	with	 the	 largest	pool	of	 available	 tRNAs	will	 result	 in	 the	 fastest	
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translation	and	therefore	the	greatest	level	of	protein	production.	However,	there	is	
evidence	to	suggest	that	more	subtle	mechanisms	are	in	play,	such	as	the	use	of	rare	
codons	to	slow	down	translation	in	sections	of	the	protein	that	require	complex	co-
translational	folding	for	example	(Sherman	and	Qian	2013).		
When	one	 is	 trying	to	express	proteins	 for	commercial	uses,	generally	 the	highest	
possible	level	of	protein	accumulation	is	desired,	something	that	the	host	cell	rarely	
attempts	to	do	in	natura.	On	the	other	hand,	bacteriophage,	which	infect	host	cells	
and	 whose	 genomes	 follow	 similar	 codon	 usage	 patterns	 to	 their	 host,	 often	 do	
attempt	to	produce	as	much	protein	as	possible,	to	make	as	many	phage	progenies	
as	possible	(Lucks	et	al.	2008).	In	the	case	of	endolysins,	as	they	are	designed	to	be	
highly	expressed	in	natura,	it	can	be	assumed	that	they	are	already	coded	in	a	near-
optimal	manner	for	the	host	bacterium.	This	raises	the	possibility	of	generating	an	
inter-species	 codon	 map,	 by	 which	 one	 can	 map	 a	 rare	 codon	 in	 Streptococcus	
pneumoniae	to	a	rare	codon	in	C.	reinhardtii	for	example,	thus	conserving	the	pattern	
of	“fast”	and	“slow”	codons	that	has	been	optimised	over	millennia.		
Overall,	 this	 study	 demonstrates	 that	 there	 is	 huge	 potential	 to	 improve	 protein	
accumulation	 yields	 in	 the	 C.	 reinhardtii	 chloroplast,	 and	 the	 technique	 of	 using	
multiple	expression	cassette	insertions	appears	to	be	a	robust	method	of	improving	
protein	yields.	However,	other	methods	of	improving	protein	accumulation	such	as	
codon	 pair	 optimisation	 firstly	 require	 improvements	 in	 understanding	 of	 clonal	
variation	 and	 transformosome	 effects	 before	 they	 can	 be	 properly	 assayed	 and	
implemented.		
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Chapter	4 Improving	the	activity	of	Cpl-1	against	Streptococcus	
pneumoniae	
4.1 Introduction	
This	chapter	aims	to	improve	the	activity	of	the	Streptococcus	pneumoniae	targeting	
endolysin,	 Cpl-1,	 in	 its	 ability	 to	 lyse	S.	 pneumoniae	 cells.	 Several	 strategies	were	
tested	with	this	aim	in	mind,	namely:	manipulating	the	cell	wall	binding	site	of	Cpl-1;	
attempting	to	form	pre-dimerised	Cpl-1	endolysins	in	the	C.	reinhardtii	chloroplast;	
and	 investigating	 holin	 production	 in	 the	C.	 reinhardtii	 chloroplast.	While	 Cpl-1	 is	
already	a	highly	active	endolysin,	with	proven	efficacy	 in	vivo	using	mouse	and	rat	
models	(Loeffler	et	al.	2003;	Entenza	et	al.	2005;	McCullers	et	al.	2007;	Grandgirard	
et	al.	2008),	an	increase	in	activity	would	enable	a	reduction	in	dose,	thus	minimising	
some	 of	 the	 potential	 limitations	 discussed	 in	 1.2.2.4	 involving	 immunogenic	
reactions.	
4.1.1 Manipulating	Cpl-1	binding	activity	
The	function	of	an	endolysin,	when	produced	by	a	bacteriophage,	is	to	lyse	the	host	
bacterium,	 thus	 allowing	 the	 release	 of	 phage	 progeny	 into	 the	 environment	 in	
search	 of	 another	 bacterial	 host.	 The	 endolysin,	 therefore,	 should	 lyse	 only	 the	
current	 host	 cell,	 and	 not	 neighbouring	 bacterial	 cells,	 which	 could	 be	 potential	
future	hosts	 for	 the	progeny.	One	characteristic	of	endolysins	 is	 that	 they	tend	to	
bind	strongly,	often	in	the	pico-	to	nanomolar	range	(Loessner	et	al.	2002),	to	their	
substrate	 -	 it	 has	 been	 postulated	 that	 this	 is	 a	 tethering	 mechanism	 to	 reduce	
unintentional	damage	to	nearby	bacteria	(Chapot-Chartier	2014).		
This	feature,	while	beneficial	to	bacteriophage,	often	reduces	the	activity	level	of	the	
endolysin	 as	 an	 enzyme	 as	 it	 restricts	 its	 lytic	 activity	 to	 a	 localised	 area	 of	 the	
peptidoglycan	 cell	 wall	 (Nelson	 et	 al.	 2001).	 For	 some	 endolysins,	 such	 as	 Cpl-1,	
removal	 of	 the	 C-terminal	 cell	 wall	 binding	 domain	 (CBD)	 results	 in	 an	 almost	
complete	loss	of	function	(Sanz	et	al.	1992),	but	for	others	such	as	CD27L	(a	clostridial	
endolysin)	removing	the	CBD	can	improve	lytic	activity	and	broaden	the	spectrum	of	
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bacteria	 against	 which	 it	 is	 active	 (in	 this	 case,	 to	 include	 two	 more	 species,	 in	
addition	to	the	six	species	susceptible	to	the	full-length	CD27L	protein)	(Mayer	et	al.	
2011).	
While	it	is	clear	from	the	literature	(Sanz	et	al.	1992;	García	et	al.	1999;	Monterroso	
et	al.	2008)	that	a	complete	removal	of	the	Cpl-1	CBD	results	in	a	reduction	in	activity,	
we	 propose	 that	 if	 binding	 could	 be	 weakened,	 activity	 may	 be	 improved.	 With	
weaker	binding,	the	endolysin	may	be	able	to	release	after	lysis	and	repeat	its	lytic	
actions	elsewhere,	thus	making	the	endolysin	more	suited	to	a	therapeutic	role.	This	
project	 involved	 mutating	 the	 cell	 wall	 binding	 site	 of	 Cpl-1	 via	 site-directed	
mutagenesis,	and	comparing	the	activity	of	 the	resulting	proteins	with	that	of	 the	
original.		
It	is	worth	noting	that	in	this	case	of	manipulating	the	cell	wall	binding	site,	we	are	
using	a	slightly	different	definition	of	“activity”.	The	SI	unit	for	enzyme	activity	is	the	
katal,	1	katal	=	1	mol	s-1,	i.e.	the	number	of	moles	of	substrate	converted	per	second.	
However,	in	this	instance,	we	are	more	interested	in	the	number	of	moles	converted	
per	endolysin	molecule,	which	is	what	is	termed	“activity”	in	this	chapter.		
From	 a	 protein	 engineering	 perspective,	 Gram-positive-targeting	 endolysins	 are	
particularly	 attractive	 due	 to	 their	 modular	 structure,	 and	 the	 decoupling	 of	 the	
binding	and	catalytic	domains.	In	many	globular	enzymes,	the	binding	and	catalytic	
sites	are	the	same,	such	that	changes	to	binding	sites	often	reduce	the	ability	of	the	
enzyme	to	catalyse	the	reaction.	While	the	endolysin	catalytic	domain	must	still	bind	
its	 substrate,	 the	 majority	 of	 binding	 specificity	 and	 affinity	 is	 conferred	 by	 the	
binding	domain	(Mayer	et	al.	2011).	
4.1.2 Dimerisation	as	a	method	to	improve	protein	stability	
Cpl-1	exhibits	extensive	similarities	with	both	major	pneumococcal	autolysins,	LytA	
and	LytC.	In	the	presence	of	choline,	LytA	dimerises	–	becoming	stable	and	active,	
while	LytC	is	active	as	a	monomer	but	is	stabilized	in	the	presence	of	choline.	Cpl-1	is	
believed	to	dimerise	through	its	C-terminal	(cell	wall	binding)	domain	when	choline	
is	present.	The	additional	activity	of	the	dimers	is	likely	to	be	due	to	the	doubling	of	
		 148	
Figure	Removed	
active	sites	spatially	orientated	next	to	the	pneumococcal	cell	wall	(Monterroso	et	al.	
2008).	
	
Figure	4.1	The	stable	and	active	LytA	dimer.	Cell	binding	domains	are	shown	in	orange,	the	
catalytic	domain	in	blue	and	the	10	choline	ligands	shown	in	CPK	colour	scheme.	Resch	et	al.	
(2011)	postulate	that	Cpl-1	could	dimerise	 in	a	similar	manner	given	the	homology	of	 the	
final	13	amino	acids	at	the	C-terminus.	Image	reproduced	from	Maestro	&	Sanz	(2016).	
Cpl-1	 is	 known	 to	be	 cleared	 from	 the	blood	plasma	of	mice	 in	 approximately	20	
minutes	(Witzenrath	et	al.	2009),	presenting	a	possible	issue	for	systemic	use.	Resch	
et	al.	(2011)	hypothesised	that	a	“pre-dimerised”	Cpl-1	homodimer	would	be	a	more	
stable	 and	 active	 therapeutic	 than	 the	native	monomer.	 LytA	dimerisation	occurs	
through	the	13	amino	acids	at	the	C-terminus	(Fernández-Tornero	et	al.	2002),	and	
10	of	these	13	amino	acids	were	found	to	be	identical	to	the	C-terminus	of	Cpl-1.	By	
the	mutation	of	each	of	the	13	amino	acids	in	turn,	Resch	et	al.	(2011)	produced	a	
series	of	mutated	Cpl-1	proteins,	in	an	attempt	to	find	one	which	forms	a	disulphide	
bridge	between	two	monomers	to	produce	a	homodimer.	The	successful	mutated	
Cpl-1	dimer	was	shown	to	have	a	10-fold	reduction	in	plasma	clearance	and	a	two-
fold	increase	in	activity,	compared	to	the	monomeric	version	(Resch	et	al.	2011a).	
Cpl-1	naturally	dimerises	on	binding	choline,	the	crystal	structure	of	which	has	been	
reported	by	Buey	et	al.	(2007)	and	is	displayed	in	Figure	4.2.	This	dimerisation	occurs	
not	at	the	C-terminus,	as	the	pre-dimerising	mutant	created	by	Resch	et	al.	(2011)	
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does,	but	between	the	final	choline	binding	repeats	at	the	N-terminus	of	the	cell	wall	
binding	 domain	 –	 i.e.	 the	 choline	 binding	 repeat	 closest	 to	 the	 acidic	 linker	 and	
catalytic	domain.		
	
Figure	4.2	The	C-terminus	of	the	CBD	is	circled	in	red	in	each	monomer.	The	box	shows	the	
side-chain	of	 the	aromatic	 residue	 involved	 in	dimerisation.	Reproduced	 from	Buey	et	 al.	
(2007).	
Figure	4.2	does	not	show	the	acidic	linker	joining	the	two	domains	of	each	monomer	
as	 this	 could	 not	 be	 accurately	modelled.	 This	 observed	mode	 of	 dimerisation	 is	
similar	to	that	of	the	dimer-dimer	interactions	of	LytA	to	form	a	tetramer	(Buey	et	al.	
2007).	
The	quaternary	structure	of	LytA	and	LytC	is	crucial	to	their	hydrolytic	activity,	and	
given	 the	 homology	 each	 displays	 to	 Cpl-1,	 it	 is	 reasonable	 to	 believe	 that	 the	
quaternary	structure	of	Cpl-1	is	also	important.	However,	given	the	stability	of	Cpl-1	
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both	as	a	monomer	and	without	the	presence	of	choline,	it	may	not	be	as	important	
as	with	the	pneumococcal	autolysins.	
4.1.3 The	role	of	holins	in	the	bacteriophage	lytic	cycle	
In	the	canonical	two-gene	model	of	bacteriophage-mediated	cell	lysis,	the	holin	plays	
an	essential	role	in	enabling	the	endolysin	to	access	the	peptidoglycan	cell	wall,	by	
creating	a	hole	 in	 the	cytoplasmic	membrane	of	 the	bacterium	(Young	1992).	The	
timing	of	 this	 event	 is	 critically	 important	 to	 the	 success	 of	 the	bacteriophage	by	
controlling	 the	 length	 of	 the	 cycle,	 and	 thus	 the	 holin	 gene	 is	 under	 enormous	
selective	pressure	(Wang	et	al.	2000).	It	is	perhaps	due	to	this	selective	pressure	that	
holins	 are	 such	 a	 diverse	 functional	 group,	 comprising	 seven	 superfamilies	
encompassing	52	recognised	families	with	no	clear	conserved	sequence	motif	(Reddy	
and	 Saier	 2013).	 However,	 all	 holins	 have	 certain	 characteristics	 including	 the	
possession	of	at	least	one	transmembrane	α-helical	sequence	and	a	highly	charged	
hydrophilic	C-terminal	domain	(Gu	et	al.	2014).	
The	 release	 of	 endolysins	 beyond	 the	 cytoplasmic	 membrane	 is	 a	 carefully	
orchestrated	event,	and	one	which	is	not	wholly	understood.	Several	theories	exist	
on	how	this	timing	is	controlled,	but	the	most	well-established	theory	is	that	there	is	
a	late	expression	of	holins,	which	accumulate	in	the	cytoplasmic	membrane.	When	
the	concentration	of	these	holins	reaches	a	critical	threshold,	a	raft	 is	formed	and	
then	a	conformational	change	causes	the	formation	of	a	hole	(White	et	al.	2011).	This	
sequence	of	events	is	illustrated	in	Figure	4.3.	
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Figure	 4.3	 An	 illustration	 of	 the	 holin	 triggering	 mechanism,	 and	 the	 consequential	
depolarisation	of	the	membrane.	pmf	=	proton	motive	force.	
A	further	method	of	holin	control	exists	in	some	bacteriophage	systems,	involving	an	
antiholin.	An	antiholin	is	almost	identical	to	the	holin,	but	with	one	or	two	additional	
N-terminal	amino	acids,	one	of	which	is	a	positively	charged	residue	(usually	lysine)	
and	is	translated	from	a	dual	start	motif	encoding:	Met-Lys-(x)-Met-….	The	antiholin	
then	binds	to	the	holin	resulting	in	heterodimers	unable	to	form	the	raft	displayed	in	
Figure	4.3.	However,	 this	binding	 is	PMF	 (proton	motive	 force)-dependent:	as	 the	
antiholin	 is	produced	at	a	slightly	 lower	rate	 than	the	holin,	a	hole	will	eventually	
form,	resulting	in	a	lowering	of	the	PMF	and	the	unbinding	of	the	anti-holin	and	a	
positive-feedback	resulting	in	the	collapse	of	the	PMF	and	the	‘all	or	nothing’	release	
of	endolysins	beyond	the	cell	(Pang	et	al.	2013;	Lella	et	al.	2016).	
The	gene	cph1,	encoding	a	holin,	is	located	immediately	upstream	of	cpl1	in	the	Cp-
1	 bacteriophage	 genome.	 The	 two	 genes	 are	 transcribed	 from	 two	 tandem	
promoters	upstream	of	cph1	and	are	expressed	from	late	phage	transcripts	(Martín	
et	al.	1998).	The	cph1	gene	does	not	display	the	classical	dual-start	motif,	although	it	
does	encode	another	methionine	residue	at	position	six,	but	no	 lysine	residue	 lies	
between	them.	Cph-1	belongs	to	the	Holin	IV	superfamily	and	has	three	predicted	
transmembrane	α-helical	segments	(Reddy	and	Saier	2013).	
Recent	 literature	 has	 suggested	 that	 holins	 can	 be	 applied	 exogenously	 to	
Streptococcus	suis	(Shi	et	al.	2012)	and	Staphylococcus	aureus	(Song	et	al.	2016)	in	
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conjunction	with	endolysins	to	produce	an	enhanced	antibacterial	effect,	improving	
the	killing	efficacy	and	also	broadening	the	spectrum	of	susceptible	pathogens	(Song	
et	al.	2016).	The	studies	by	Shi	et	al.	(2012)	demonstrate	that	the	transmembrane	
domains	of	the	holin	are	essential	for	its	antimicrobial	activity,	and	it	is	assumed	that	
the	formation	of	large	holes	in	the	membrane	causes	cell	death.	However,	it	is	not	
understood	how	the	holin	gains	access	to	the	cell	membrane	given	the	presence	of	
the	 peptidoglycan	 layer,	 nor	 how	 capsules	 and	 slime-layers	 affect	 holin	 access.	
Further	investigation	of	holin	structure	and	its	potential	as	a	novel	antibacterial	has	
been	 hindered	 by	 the	 difficulties	 involved	 in	 successfully	 expressing	 holins	 in	
prokaryotic	systems,	given	the	cytotoxicity	of	holins	(Garrett	et	al.	1990).	Therefore	
we	aim	to	produce	holins	in	the	C.	reinhardtii	chloroplast	to	enable	further	research.	
4.2 Aims	and	objectives	
1. To	 identify	 and	 optimize	 a	 method	 for	 comparing	 activity	 levels	 between	
different	mutant	Cpl-1	endolysins	against	S.	pneumoniae.	
2. To	produce	seven	transgenic	C.	reinhardtii	lines	expressing	cpl-1	genes	with	
different	mutations	in	their	choline	binding	sites	(CBS).	
3. To	confirm	accumulation	of	the	CBS	mutant	Cpl-1	proteins	in	the	C.	reinhardtii	
chloroplast	by	western	blotting.	
4. To	 compare	 the	 activity	 of	 the	 CBS	 mutant	 Cpl-1	 proteins	 against	 S.	
pneumoniae.	
5. To	 produce	 a	 transgenic	C.	 reinhardtii	 line	 expressing	 a	 variant	 cpl-1	 gene	
encoding	a	dimerising	mutant.	
6. To	confirm	accumulation	of	a	Cpl-1	dimer	in	the	C.	reinhardtii	chloroplast	by	
western	blotting.	
7. To	 produce	 the	 holin	 Cph-1	 in	 the	 C.	 reinhardtii	 chloroplast	 and	 confirm	
accumulation	by	western	blotting.	
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4.3 Results	and	discussion	
4.3.1 Manipulation	of	the	Cpl-1	choline	binding	sites	to	improve	activity	
The	 two	 choline	 binding	 sites	 on	 the	 C-terminus	 of	 the	 Cpl-1	 protein	 recruit	 the	
endolysin	to	the	cell	wall	by	binding	to	the	integral	(lipo)teichoic	acids.	Here	the	key	
residues	involved	in	Cpl-1	choline	binding	are	identified	and	mutated	by	site	directed	
mutagenesis.	The	resulting	Cpl-1	mutants	are	assayed	for	lytic	activity.	
4.3.1.1.1 Identification	of	potentially	important	residues	in	choline	binding	
The	binding	affinity	of	the	Cpl-1	cell	binding	domain	to	choline	is	relatively	weak	for	
an	endolysin,	Kd	≈	3.6	mM	 (Monterroso	et	al.	 2008),	however	 the	 requirement	of	
bacteriophages	to	tether	their	endolysins	to	only	the	host’s	cell	wall	suggests	that	it	
is	 unlikely	 to	 completely	 dissociate,	 and	 Cpl-1	 possibly	 transits	 across	 the	
glycopeptide	network	to	reach	new	cleavable	bonds	(Jervis	et	al.	1997;	Monterroso	
et	al.	2008).	In	order	to	test	whether	there	is	an	optimal	binding	affinity	that	improves	
activity,	and	lies	between	the	two	extremes	of	complete	CBD	removal	and	the	native	
tethering	CBD,	a	graded	weakening	of	the	CBD	was	tested.		
The	crystal	structure	of	Cpl-1	binding	choline,	shown	in	Figure	3.1,	was	analysed	using	
Jmol1.	Interactions	of	less	than	5	angstroms	from	the	choline	moiety	were	considered	
to	 be	 of	 importance	 for	 hydrogen	 bonding	 during	 endolysin	 binding	 and	 two	
tryptophan	residues	and	one	tyrosine	were	identified	in	each	binding	site	to	fit	these	
criteria.	 This	 confirmed	 the	 original	 analysis	 by	 Hermoso	 et	 al.	 (2003)	which	 also	
identified	these	three	residues	as	important,	forming	a	hydrophobic	cavity	into	which	
the	choline	methyl	group	sits.	Hydrogen	bonds	form	between	the	three	residues	and	
the	choline	and	these	interactions	are	shown	in	Figure	4.4.	For	the	purposes	of	this	
investigation,	 the	 two	 tryptophan	 residues	 in	 each	 binding	 site	were	 selected	 for	
mutation.	
																																																						
1	 Jmol	 is	 an	 open-source	 Java	 viewer	 for	 chemical	 structures	 in	 3D.	
http://www.jmol.org/	
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The	cell	wall	binding	domain	of	Cpl-1	has	six	choline	binding	repeats	(p1-6,	see	Figure	
4.5),	at	 the	 interface	of	which	a	putative	choline	binding	site	exists.	However,	 the	
crystal	structure	of	Cpl-1	suggests	that	only	the	first	two	choline	binding	sites	are	in	
fact	active,	namely:	p1/p2	and	p2/p3	(Hermoso	et	al.	2003).	At	the	p1/p2	site,	there	
are	two	key	interactions:	the	nitrogen	atoms	on	Trp202	and	Trp209	interacting	with	
the	choline	moiety.	At	the	second	choline	binding	site,	the	p2/p3	site,	it	is	Trp223	and	
Trp230	that	interact	with	the	choline.	When	the	fact	that	an	O-H	bond	and	N-H	bond	
are	 approximately	 one	 Angstrom	 in	 length	 is	 accounted	 for,	 the	 hydrogen	 bonds	
formed	 in	 these	 interactions	 cover	 approximately	 3-4	 Angstroms.	 According	 to	
Jeffrey	 (1997),	 hydrogen	 bonds	 over	 this	 distance	 range	 from	 “moderate,	mostly	
electrostatic”	to	“weak,	electrostatic”.	
	
Figure	 4.4	 The	 two	 active	 choline	 binding	 sites	 in	 the	 CBD	 of	 Cpl-1.	 Distances	 are	 in	
Angstroms.	It	should	be	noted	that	the	distances	are	between	the	nitrogen	(blue)	and	oxygen	
(red)	atoms,	so	are	not	a	direct	representation	of	a	hydrogen	bond	length	as	the	hydrogen	
must	 be	 accounted	 for	 too	 in	 each	 case.	 However,	 these	 remain	 “moderate/weak	 and	
electrostatic”	hydrogen	bonds.	
Given	 that	 tryptophan	 is	 a	 polar	 amino	 acid,	 and	 it	 is	 this	 polarity	which	 creates	
hydrogen	bonds,	it	was	decided	to	mutate	these	to	the	amino	acid	alanine,	which	is	
non-polar.	This	method	of	systematically	substituting	residues	for	alanine	is	known	
as	 ‘alanine	scanning’	and	is	a	widely	used	mutagenesis	approach	(Kristensen	et	al.	
p2/p3	binding	sitep1/p2	binding	site
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1997).	The	disruption	of	these	hydrogen	bonds	was	designed	to	weaken	the	affinity	
of	Cpl-1	to	choline,	and	potentially	improve	the	lytic	activity	of	the	endolysin.	
4.3.1.2 Production	of	C.	reinhardtii	lines	expressing	cpl1	CBS	mutants	
4.3.1.2.1 Site-directed	mutagenesis	of	cpl1		
Of	the	four	identified	tryptophan	residues,	shown	as	part	of	the	whole	Cpl-1	amino	
acid	sequence	in	Figure	4.6,	none	offered	a	more	or	less	obvious	target	for	mutation	
and	 therefore	 seven	C.	 reinhardtii	 cell	 lines	 expressing	 cpl1	with	 either	 individual	
tryptophan	mutations	or	combinations	of	tryptophan	mutations	were	generated.		
	
Figure	 4.5	 The	 six	 putative	 choline	 binding	 repeats	 of	 Cpl-1.	 Asterisks	 indicate	 strictly	
conserved	residues,	while	a	colon	indicates	conservative	substitutions.	Red	circles	highlight	
the	mutated	residues.	Reproduced	and	annotated	from	Monterroso	et	al.	(2008).	
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Figure	4.6	identifies	the	four	mutated	tryptophan	residues	in	the	cpl1	gene.	The	seven	
gene	mutants	which	were	intended	to	be	created	are	displayed	in	Figure	4.7,	with	
each	 tryptophan	 codon	 (TGG)	 being	mutated	 by	 site	 directed	mutagenesis	 to	 an	
alanine	codon	(GCT).	
	
	
Figure	4.6	The	four	tryptophan	residues	identified	to	be	of	importance	in	choline	binding	are	
highlighted	in	yellow	in	the	context	of	the	entire	protein	sequence.	W202	and	W209	form	
part	of	the	p1/p2	choline	binding	site,	and	W223	and	W230	form	part	of	the	p2/p3	site.	The	
HA	tag	used	for	western	blot	detection	is	highlighted	in	purple.	
MVKKNDLFVDVSSHNGYDITGILEQMGTTNTIIKISEST
TYLNPCLSAQVEQSNPIGFYHFARFGGDVAEAEREAQFF
LDNVPMQVKYLVLDYEDDPSGDAQANTNACLRFMQMIAD
AGYKPIYYSYKPFTHDNVDYQQILAQFPNSLWIAGYGLN
DGTANFEYFPSMDGIRWWQYSSNPFDKNIVLLDDEEDDK
PKTAGTWKQDSKGWWFRRNNGSFPYNKWEKIGGVWYYFD
SKGYCLTSEWLKDNEKWYYLKDNGAMATGWVLVGSEWYY
MDDSGAMVTGWVKYKNNWYYMTNERGNMVSNEFIKSGKG
WYFMNTNGELADNPSFTKEPDGLITVAYPYDVPDYA
202 209 223 230
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Figure	4.7	The	gene	cpl1	was	subjected	to	site	directed	mutagenesis	to	create	seven	unique	
mutants.	 The	 naming	 of	 each	 construct	 indicates	 the	mutation	 location	 and	 nature,	 e.g.	
cpl1_W202A-HA	is	the	cpl1	gene	with	tryptophan-202	mutated	to	an	alanine	residue,	and	
tagged	with	an	HA	tag.	Multiple	mutations	are	separated	by	an	underscore.	
A	 pair	 of	 primers	 was	 designed	 for	 each	mutation,	 as	 displayed	 below,	 with	 the	
mutation	site	in	lowercase,	and	start	and	stop	codons	underlined.	cpl1.F	and	cpl1.R	
are	the	primers	at	the	start	and	end	of	the	gene.	
cpl1.F:			 	 GCTCTTCAATGGTTAAAAAAAATGATTTATTC 
cpl1.R:		 	 GCATGCTTATTAAGCATAATCTGGAAC	
W202A_SDM.F:		 GTACAgctAAACAAGATTCAAAAG 
W202A_SDM.R:	 CTTTTGAATCTTGTTTagcTGTAC	
W209A_SDM.F:		 CAAAAGGTgctTGGTTTC 
W209A_SDM.R:		 GAAACCAagcACCTTTTG	
W223A_SDM.F:		 CCATATAATAAAgctGAAAAAATTG	
Trp202 Trp209 Trp223 Trp230
TGG TGG TGG TGG
GCT TGG TGG TGG
TGG GCT TGG TGG
TGG TGG GCT TGG
TGG TGG TGG GCT
GCT GCT TGG TGG
TGG TGG GCT GCT
GCT GCT GCT GCT
cpl1_W202A-HA
cpl1_W209A-HA
cpl1_W223A-HA
cpl1_W230A-HA
cpl1_W202A_W209A-HA
cpl1_W223A_W230A-HA
cpl1_W202A_W209A_-
W223A_W230A-HA
cpl1-HA
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W223A_SDM.R:		 CAATTTTTTCagcTTTATTATATGG	
W230A_SDM.F:		 GTGGTGTTgctTATTATTTCG	
W230A_SDM.R:		 CGAAATAATAagcAACACCAC 
The	first	four	mutant	genes,	which	have	only	one	W→A	change,	were	produced	using	
site	 directed	 mutagenesis	 (SDM)	 as	 shown	 in	 Figure	 4.8.	 These	 mutated	 DNA	
sequences	were	then	used	as	template	DNA	in	subsequent	rounds	of	SMD	PCR	to	
produce	the	final	three	genes,	which	have	more	than	one	mutated	codon.		
	
Figure	 4.8	 Site	 directed	mutagenesis	was	 performed	 as	 above	 to	mutate	 the	 tryptophan	
encoding	codon,	TGG,	to	the	alanine	encoding	one,	GCT.	Primers	are	shown	in	blue	and	PCR	
conditions	are	described	in	2.3.7.	
Of	 the	seven	mutants,	 six	were	successfully	 created.	The	 transformation	of	E.	 coli	
with	cpl1_W223A-HA	in	an	intermediate	vector,	pJet,	was	repeatedly	unsuccessful.	It	
is	not	clear	why	this	particular	mutant	was	so	problematic,	and	it	is	discussed	further	
in	4.4.1,	but	due	to	time	constraints	it	was	not	possible	to	investigate	this	further.		
	
TGG
ACC
GCT
CGA
GCT
CGA
GCT
CGA
1st PCR
2nd PCR
Final	product
Cpl-1
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4.3.1.2.2 Expression	cassette	production	
The	resulting	PCR	products	were	digested	with	SapI	and	SphI	and	 ligated	 in-frame	
into	the	pSRSapI	vector.	The	insertion	was	confirmed	by	DNA	sequencing.	
4.3.1.2.3 C.	reinhardtii	transformation	
The	C.	 reinhardtii	 recipient	 line	TN72	was	 transformed	by	 the	glass	bead	method,	
using	 the	 pSRSapI_cpl1	 plasmids	 (2.3.13).	 The	 resulting	 transformed	 lines	 are	
represented	in	Figure	4.9.	Photosystem	II	functionality	is	restored	by	psbH	and	the	
resulting	 transformants	 were	 capable	 of	 growing	 phototrophically	 on	 minimal	
medium.	Each	of	the	six	transformed	lines	was	shown	to	reach	a	homoplasmic	state	
by	 PCR	 as	 described	 in	 2.3.17.	 As	 a	 final	 step,	 the	 integrity	 of	 the	 cassette	 was	
confirmed	by	DNA	sequencing	of	the	PCR-amplified	plastome	region,	as	in	2.3.18.	
	
Figure	 4.9	 The	 resulting	 C.	 reinhardtii	 lines	 express	 the	 mutated	 cpl1	 gene	 under	 the	
endogenous	 psaA	 exon	 1	 5’UTR/promoter.	 The	 successfully	 transformed	 colonies	 are	
selected	by	their	ability	to	grow	phototrophically	on	minimal	medium.	
4.3.1.2.4 Western	blot	confirmation	
Whole	cell	extract	from	each	of	the	six	C.	reinhardtii	cell	lines	was	separated	by	SDS-
PAGE	 and	 blotted	 to	 nitrocellulose	 membrane	 for	 western	 blot	 analysis.	 The	
membrane	 was	 probed	 with	 anti-HA	 primary	 antibodies	 followed	 by	 IRDye®	
secondary	 antibody	 to	 enable	detection	using	 the	 LiCor	Odyssey®	CLx	 system.	An	
image	of	the	western	blot	analysis	is	shown	in	Figure	4.10	and	relative	quantification	
of	Cpl-1	accumulation	is	shown	in	Figure	4.11.	The	error	bars	in	Figure	4.11	represent	
the	standard	deviation	in	signal	detection	when	this	blot	was	repeated.	
trnE2 psbH
5’psaA 1 3’rbcL
TN72_SR_cpl1_WxxxA-HA	
transformant
MluI
cpl1_WxxxA-HA
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Figure	4.10	Western	blot	analysis	of	each	of	the	six	C.	reinhardtii	 lines	expressing	mutated	
cpl1.	 Visible	 levels	 of	 accumulation	 are	 seen	 in	 all	 cases.	 TN72_SR_cpl1-HA	 and	
TN72_SR_Control	are	included	as	positive	and	negative	controls,	respectively.	
	
Figure	4.11	Quantification	of	two	western	blot	analyses.	In	general,	the	first	four	cell	 lines	
produce	 levels	 of	 protein	 accumulation	 comparable	 to	 the	 unmodified	 version,	 while	
TN72_SR_cpl1_W223A_W230A-HA	 and	 TN72_SR_cpl1_W202A_W209A_W223A_W230A-
HA	accumulate	to	lower	levels,	approximately	30%	of	that	observed	for	the	others.	
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As	 discussed	 at	 length	 in	 3.3.2.2.4.3,	 the	 reason	 for	 the	 difference	 in	 protein	
accumulation	 levels	 is	disputable.	However,	 for	 the	purposes	of	 this	 investigation,	
only	the	relative	accumulation	levels	are	necessary	to	ensure	that	equal	quantities	of	
protein	were	used	in	future	assays.		
4.3.1.3 Activity	of	Cpl-1	CBS	mutants	against	S.	pneumoniae	
The	six	C.	reinhardtii	lines	described	above	were	created	with	the	intention	of	altering	
Cpl-1	 activity.	 To	 measure	 this	 activity	 several	 approaches	 were	 taken,	 namely:	
turbidity	 reduction	 assays	 and	 colony	 forming	 unit	 assays,	 using	 both	 crude	 cell	
extracts,	 and	 extracts	 enriched	 and	 concentrated	 by	 ammonium	 sulphate	
precipitation	or	epitope	tag	enrichment.	
4.3.1.3.1 Activity	of	crude	extracts	–	turbidity	reduction	assay	
One	of	the	proposed	advantages	of	using	C.	reinhardtii	as	a	recombinant	endolysin	
production	platform	is	that,	due	to	its	GRAS	status,	simple	crude	extracts	could	be	
used	 therapeutically,	 particularly	 for	 topical	 applications,	 thus	 removing	 the	
expensive	requirement	to	purify	the	final	protein.		
It	was	 therefore	 investigated	whether	crude	extracts	of	 the	six	Cpl-1	CBS	mutants	
described	 in	 this	 section	 display	 different	 levels	 of	 lytic	 activity	 towards	 S.	
pneumoniae,	when	compared	to	the	activity	of	the	un-mutated	Cpl-1	protein.		
Crude	extracts	were	prepared	as	described	in	2.4.1.	In	brief,	the	six	C.	reinhardtii	cell	
lines	 were	 grown	 simultaneously	 and	 their	 OD740	 measured	 after	 72	 hours.	 The	
cultures	were	centrifuged	and	the	pellet	resuspended	in	20	mM	NaPi	buffer	to	give	
suspensions	of	equivalent	cell	density	measured	at	OD740.	The	cells	were	 lysed	by	
freeze-thaw	 and	 ultracentrifuged	 to	 remove	 the	 cell	 debris.	 The	 supernatant	was	
stored	 at	 4	 °C	 and	 this	was	 considered	 the	 “crude	 extract”.	 Fresh	 S.	 pneumoniae	
cultures	 were	 prepared	 as	 described	 in	 2.7.1.1	 and	 resuspended	 in	 20	mM	NaPi	
buffer	to	an	OD595	=	~0.8.		
In	a	96-well	plate,	S.	pneumoniae	cells	and	C.	reinhardtii	crude	extract	were	combined	
and	the	change	in	OD595	measured	with	a	plate	reader	over	a	period	of	150	minutes	
at	37	°C.	200	μl	of	resuspended	S.	pneumoniae	cells	were	incubated	with	~50	μl	of	
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crude	extract.	The	precise	volume	was	adjusted	according	to	data	shown	in	Figure	
4.11,	to	ensure	an	equal	quantity	of	Cpl-1	protein	was	included	in	each	well.	Crude	
TN72_SR_Control	was	used	as	a	negative	control.	
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Figure	4.12	Turbidity	reduction	assay	of	S.	pneumoniae	when	challenged	with	crude	C.	reinhardtii	extracts	containing	different	Cpl-1	CBS	mutants.	Change	in	
OD595	is	shown	rather	than	measured	OD595	due	to	the	different	volumes	of	crude	extract	in	each	well.	Each	combination	was	performed	in	triplicate	and	the	
average	is	shown.
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From	 Figure	 4.12,	 it	 appears	 that	 the	 un-modified	 TN72_SR_cpl1-HA	 is	 the	most	
active	 endolysin,	 while	 all	 the	 mutated	 endolysins	 showed	 activity	 intermediate	
between	 this	 and	 the	 negative	 control,	 TN72_SR_Control.	 The	 high	 level	 of	 lysis	
observed	by	the	buffer	alone	is	surprising.	However,	it	has	been	noted	in	previous	
endolysin	activity	assays	using	crude	extracts	that	an	 increase	 in	osmotic	pressure	
due	to	the	presence	of	large	quantities	of	protein	in	the	suspension	can	lead	to	an	
inhibition	of	cell	lysis	(Mayer	et	al.	2010)	-	this	is	exemplified	here	by	the	high	level	of	
autolysis	observed	when	NaPi	buffer	(20mM)	is	added,	compared	to	that	seen	in	the	
negative	control.	
First	inspection	of	the	data	shown	in	Figure	4.12	suggests	that	altering	the	CBD	of	Cpl-
1	has	a	detrimental	effect	upon	enzymatic	activity.	While	this	result	 is	not	entirely	
unexpected,	 given	 the	 issue	 of	 osmotic	 pressure	 affecting	 bacterial	 cell	 lysis,	
combined	with	the	different	levels	of	protein	accumulation	observed	in	Figure	4.11,	
it	was	decided	that	turbidity	reduction	assays	with	crude	extracts	are	insufficiently	
precise	to	enable	a	comparison	of	the	various	Cpl-1	CBS	mutant	activities.		
4.3.1.3.2 Enrichment	of	CBS	mutant	Cpl-1	by	ammonium	sulphate	precipitation	
In	order	to	address	the	above	concerns,	ammonium	sulphate	precipitation	was	used	
to	 partially	 purify	 and	 concentrate	 the	 Cpl-1	 CBS	mutants,	 providing	 an	 enriched	
crude	 extract.	 The	 enriched	 extracts	 were	 separated	 by	 SDS-PAGE,	 blotted	 to	
nitrocellulose	 membrane	 and	 probed	 with	 antibodies	 for	 western	 analysis.	 The	
resulting	analysis	and	relative	quantification	are	displayed	in	Figure	4.13.	
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Figure	4.13	The	western	blot	analysis	of	six	Cpl-1	CBS	mutants	concentrated	and	enriched	by	
ammonium	sulphate	precipitation,	alongside	positive	and	negative	controls	(TN72_SR_cpl1-
HA	and	TN72_SR_Control,	respectively).	Image	Studio	Lite	5.0	software	and	LiCor	Odyssey®	
CLx	system	enabled	the	quantification	of	each	band,	shown	below	each	lane	as	a	bar	chart.		
4.3.1.3.3 Activity	of	extracts	enriched	by	ammonium	sulphate	precipitation	-	Colony	
forming	unit	assay	
The	 turbidity	 reduction	 assay	 shown	 in	 Figure	 4.12	 required	 fresh	 S.	 pneumoniae	
cultures	to	be	grown	on	the	morning	of	each	assay,	which	often	leads	to	difficulties	
in	the	reproducibility	of	the	assay.	On	the	other	hand,	colony	forming	unit	assays,	as	
described	 in	2.7.1.1,	were	performed	using	snap-frozen	aliquots	of	S.	pneumoniae	
suspensions,	thus	enabling	a	much	more	reproducible	and	robust	assay.	The	number	
of	 colony	 forming	 units	 was	 counted	 by	 eye	 and	 when	 an	 uncountable	 lawn	 of	
indistinguishable	colonies	was	present,	this	was	counted	as	“100”.	Serial	dilutions	of	
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bacterial	 suspension	 containing	 endolysin	 were	 performed	 after	 one	 hour	 of	
incubation	at	37	°C,	and	three	10	μl	drops	of	each	dilution	were	spotted	onto	blood	
agar	plates.	The	mean	count	across	the	three	spots	was	calculated.	The	data	from	
Figure	 4.13	 enabled	 similar	 quantities	 of	 HA-tagged	 protein	 to	 be	 added	 to	 the	
bacterial	suspension.
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Figure	4.14	Colony	forming	unit	assay	of	S.	pneumoniae	cells	treated	with	Cpl-1	CBS	mutant	ammonium	sulphate-enriched	crude	extracts.		
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The	colony	forming	unit	assay	in	Figure	4.14	confirms	that	TN72_SR_cpl1-HA	is	more	
active	than	any	of	the	Cpl-1	CBS	mutants,	however	there	still	exists	the	problem	of	
varying	osmotic	pressure	due	to	the	varying	concentrations	of	protein	present.	While	
equal	 quantities	of	 endolysin	have	been	achieved,	 this	 has	probably	 resulted	 in	 a	
different	 level	of	 total	protein,	because	ammonium	sulphate	precipitation	enables	
the	 enrichment	 of	 all	 proteins	 within	 a	 range	 of	 solubility,	 which	 undoubtedly	
includes	many	other	proteins.	In	order	to	include	similar	quantities	of	the	HA-tagged	
Cpl-1	CBS	mutant	 protein,	 differing	 volumes	of	 the	 ammonium	 sulphate	 enriched	
extract	were	used,	 thus	altering	 the	osmotic	pressure	on	the	bacterial	cells	 in	 the	
suspension.	In	this	case	too,	it	is	worth	noting	that	the	20	mM	NaPi	buffer	is	causing	
lysis	 to	 a	 greater	 extent	 than	 all	 of	 the	 extracts	 except	 for	 the	 unmodified	
TN72_SR_cpl1-HA.	
4.3.1.3.4 Protein	enrichment	via	epitope	tags	–	HA	tags	
All	Cpl-1	CBS	mutants	were	tagged	with	an	HA	epitope	tag	for	detection	in	western	
blot	analysis,	but	it	is	also	possible	to	use	this	epitope	to	purify	the	protein.	Each	of	
the	six	Cpl-1	CBS	mutants	was	purified	using	an	anti-HA	resin,	and	the	fractions	were	
spotted	onto	a	nitrocellulose	membrane	for	a	dot	blot,	as	described	in	2.4.3.	After	
probing	 with	 anti-HA	 antibodies	 and	 IR	 secondary	 antibody,	 the	 membrane	 was	
analysed	using	the	LiCor	Odyssey®	CLx	system,	shown	in	Figure	4.15	
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Figure	4.15	Dot	blot	analysis	of	HA-resin	purification	fractions.	The	C.	reinhardtii	lines	were	
abbreviated	to	just	the	mutation	for	clarity	e.g.	‘TN72_SR_cpl1_W202A-HA’	is	just	labelled	
‘W202A’.	 Mixed	 results	 were	 achieved,	 with	 W202A,	 W202A_W209A,	
W202A_W209A_W223A_W230A,	and	the	un-mutated	Cpl-1	being	the	only	strains	where	the	
elution	had	visible	quantities	of	HA-tagged	protein.	
It	is	noteworthy	that	TN72_SR_Control	gives	a	strong	signal	for	the	crude	extract	and	
flow-through,	which	 suggests	 that	 there	 are	 background	 proteins	 fluorescing	 and	
disguising	 the	 HA-tagged	 proteins	 in	 these	 fractions.	 However,	 these	 background	
proteins	 are	 not	 present	 in	 the	 elution	 fractions.	 To	 confirm	 that	 the	 fluorescing	
protein	is	indeed	the	endolysin,	the	most	promising	examples	from	the	dot	blot	were	
separated	by	SDS-PAGE.	Western	blot	analysis	allows	relative	quantification	of	the	
yield	achieved	with	this	purification	method,	shown	in	Figure	4.16.	
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Figure	4.16	Western	blot	analysis	of	both	crude	C.	 reinhardtii	extracts	and	then	the	same	
extract	 enriched	 using	 the	 HA	 tag.	 Only	 mutants	 which	 have	 visible	 enriched	 bands	 are	
shown.	The	bands	were	quantified	used	the	LiCor	Odyssey®	CLx	system	and	the	results	are	
shown	 in	 the	 bar	 chart.	 The	 percentage	 of	 recovered	 protein	 ranged	 from	 33%	 for	 the	
unmodified	 Cpl-1	 to	 only	 6%	 recovery	 for	 the	 Cpl1-W202A_W209A_W223A_W230A-HA	
protein.		
Only	 three	 of	 the	 Cpl-1	 CBS	 mutants	 achieved	 sufficient	 levels	 of	 protein	
accumulation	to	enable	a	colony	forming	unit	assay	to	be	performed.	
The	 colony	 forming	 unit	 assay	was	 performed	 using	 the	 same	 batch	 of	 frozen	 S.	
pneumoniae	 cells	 as	 in	 Figure	 4.14.	 The	C.	 reinhardtii	 crude	 extracts	 and	 the	HA-
purified	elutions	were	diluted	such	that	they	contained	equal	concentrations	of	HA-
tagged	protein	before	being	used.	The	method	can	be	found	in	2.7.1.1.	The	number	
of	 colony	 forming	 units	 was	 counted	 by	 eye	 and	 when	 an	 uncountable	 lawn	 of	
indistinguishable	colonies	was	present,	this	was	counted	as	100.	Serial	dilutions	of	
bacterial	suspension	and	endolysin	were	performed	after	one	hour	of	incubation	at	
37	°C	and	three	10	μl	drops	of	each	dilution	were	spotted	onto	blood	agar	plates.	The	
count	was	then	averaged	across	the	three	spots.		
(kDa)	
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Figure	4.17	Colony	forming	unit	assay	of	S.	pneumoniae	cells	treated	with	Cpl-1	CBS	mutant	
crude	extracts	(dotted	line)	and	the	HA-resin	purified	elution	(solid	line).		
Generally,	the	crude	extracts	are	less	active	than	the	purified	extracts	–	although	the	
purified	 TN72_SR_Control	 appears	 to	 achieve	 the	 second	 highest	 level	 of	
antibacterial	activity.	The	buffer	control	sits	nearly	in	the	middle	of	the	crude	extract	
and	 purified	 extract	 activities,	 which	 lends	 weight	 to	 the	 argument	 that	 osmotic	
pressure	is	reducing	cell	lysis	in	the	crude	extracts.	The	un-mutated	Cpl-1	protein	has	
the	greatest	antibacterial	effect,	while	the	Cpl-1	CBS	mutants	are	no	more	effective	
than	 the	 purified	 TN72_SR_Control,	 which	 expresses	 no	 recombinant	 protein,	
suggesting	a	complete	loss	of	activity	in	the	mutant	proteins.	Given	the	poor	results	
achieved	using	anti-HA	purification	resin,	enabling	us	to	only	test	three	of	the	six	CBS	
mutants,	a	different	system	is	required.	
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4.3.1.3.5 Protein	enrichment	via	epitope	tags	–	StrepII	tags	
The	HA	epitope	has	been	widely	used	 in	 the	Purton	 group,	 as	well	 as	 other	 algal	
research	 groups.	 The	 original	 expression	 of	 cpl1	 in	 C.	 reinhardtii	 encoded	 an	 HA	
epitope	 tag	 on	 its	 C-terminus	 (Taunt	 2013),	 and	 this	 was	 continued	 into	 this	
investigation.	However,	while	convenient	for	western	blot	detection,	using	the	HA-
tag	 for	 protein	 purification	 is	 expensive	 compared	 to	 some	 other	 epitopes,	 as	 it	
involves	affinity	purification	using	an	anti-HA	monoclonal	antibody.	The	StrepII	tag	
was	chosen	as	an	alternative	as	 it	has	been	used	 in	the	algal	 field	to	purify	native	
chloroplast	 proteins	 from	 C.	 reinhardtii	 (Derrien	 et	 al.	 2012;	 Derrien	 2013).	
Furthermore,	 as	 the	 system	 is	 based	 on	 the	 affinity	 of	 biotin	 and	 streptavidin,	
purification	columns	are	relatively	cheap.	3.3.2.2.3	describes	the	production	of	the	C.	
reinhardtii	 line	 TN72_SR_cpl1-StrepII,	 which	 is	 used	 again	 here	 to	 investigate	 the	
StrepII-tag	for	protein	purification	and	enrichment.	Polyhistidine	tags	(His-tags)	are	
the	most	common	epitope	tag	used	for	this	purpose	but	a	StrepII	tag	was	chosen	in	
this	instance	due	to	its	previous	success	in	the	C.	reinhardtii	chloroplast,	as	well	as	
the	fact	that	it	can	be	readily	used	for	detection	in	western	blotting,	while	antibodies	
to	His	tags	are	more	problematic.		
4.3.1.3.6 Enrichment	of	Cpl1-StrepII	using	HiTrap	StrepII	Column	
C.	reinhardtii	cell	extracts	were	prepared	as	described	in	2.5.1,	and	ultracentrifuged	
at	100,000	g	for	1	hour	to	remove	cell	debris.	This	ultracentrifuged	(UC)	extract	was	
then	 enriched	 for	 StrepII-tagged	proteins	 using	 the	 commercially	 available	HiTrap	
StrepII	Column	(GE	Lifesciences)	and	eluted	with	desthiobiotin,	as	described	in	2.5.3.	
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Figure	4.18	Samples	from	extract	preparation	and	the	HiTrap	StrepII	column	were	collected	
and	separated	by	SDS-PAGE.	Western	blot	analysis	and	relative	quantification	using	the	LiCor	
Odyssey®	 CLx	 system	 enabled	 the	 StrepII-tagged	 protein	 recovery	 to	 be	 estimated	 as	 a	
percentage	of	the	ultracentrifuged	(UC)	extract	passed	through	the	column.		
Approximately	 one-third	 of	 the	 total	 protein	 remains	 in	 the	 supernatant	 on	
ultracentrifugation,	but	virtually	100%	of	this	was	recovered	using	the	HiTrap	StrepII	
column.	 Further	 optimisation	 of	 ultracentrifugation	 speeds	 and	 durations	 could	
increase	 the	 proportion	 remaining	 in	 the	 supernatant	 further,	 but	 for	 this	
investigation	maximising	total	protein	yield	is	not	the	aim.	
As	a	negative	control,	HiTrap	StrepII	purification	was	also	performed	with	an	extract	
of	TN72_SR_Control.	This	controls	 for	any	C.	reinhardtii	cell	components	that	may	
have	non-specifically	bound	to	the	column	and	be	present	in	the	eluted	fraction.	
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4.3.1.3.7 Activity	of	purified	Cpl1-StrepII	
A	S.	pneumoniae	colony	forming	unit	assay	was	performed	as	described	previously	
(4.3.1.3.4),	using	the	eluted	fraction,	described	here	as	an	“enriched	extract”,	from	
both	TN72_SR_cpl1-StrepII	and	TN72_SR_Control.	Bacterial	suspension	and	extract	
were	 combined	 in	 a	 1:1	 ratio	 and	 serial	 dilutions	 of	 bacterial	 suspension	 and	
endolysin	were	performed	after	one	hour	of	incubation	at	37	°C,	whereupon	three	
10	μl	drops	of	each	dilution	were	spotted	onto	blood	agar	plates.		
	
Figure	 4.19	 Colony	 forming	 unit	 assay	 of	 S.	 pneumoniae	 cells	 treated	 with	 Cpl1-StrepII	
enriched	extracts.	“Control”	refers	to	a	purified	extract	from	TN72_SR_Control.	The	number	
of	 colony	 forming	 units	 was	 counted	 by	 eye	 and	 when	 an	 uncountable	 lawn	 of	
indistinguishable	 colonies	 was	 present,	 this	 was	 counted	 as	 100.	 The	 count	 was	 then	
averaged	across	the	three	spots.	Three	dilutions	of	the	enriched	extract	were	tested	(100	%,	
75	 %	 and	 25	 %),	 and	 the	 percentage	 indicates	 the	 initial	 concentration,	 not	 the	 final	
concentration	(i.e.	prior	to	mixing	with	the	bacterial	suspension).	
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The	 colony	 forming	 unit	 assay	 in	 Figure	 4.19	 indicates	 a	 measurable	 difference	
between	the	three	Cpl-1	dilutions,	and	they	are	clearly	more	active	than	the	extract	
from	TN72_SR_Control	at	the	two	higher	concentrations.	These	data	suggest	that	this	
method	 of	 enrichment	 removes	 both	 the	 mild	 antibacterial	 activity	 of	 the	 C.	
reinhardtii	crude	extract	and	the	osmotic	pressure	effect	that	seemed	to	be	masking	
results	in	previous	trials.	
Unfortunately,	time	limitations	prevented	the	application	of	this	more	robust	assay	
to	the	investigation	of	binding	site	mutation.	By	reproducing	each	of	the	C.	reinhardtii	
lines	expressing	CBS	mutants,	this	time	encoding	a	StrepII	epitope	instead	of	an	HA	
epitope,	 it	would	be	possible	to	more	accurately	compare	the	relative	activities	of	
the	 mutants.	 However,	 given	 the	 problems	 encountered	 above	 and	 the	 longer	
transformation	time	of	C.	reinhardtii	lines,	in	this	particular	case	investigations	could	
be	more	easily	carried	out	using	recombinant	proteins	produced	in	E.	coli.	E.	coli	is	an	
excellent	platform	for	rapidly	producing	recombinant	proteins	to	a	high	level	and	in	
this	 case	 would	 allow	 easy	 comparison	 of	 different	 mutants.	 The	 best	 of	 these	
mutants,	if	indeed	cell	wall	binding	site	mutagenesis	can	improve	endolysin	activity,	
could	then	be	expressed	in	C.	reinhardtii	for	the	final	therapeutic	drug	production.	In	
addition,	 proteins	 toxic	 to	 E.	 coli,	 such	 as	 the	 endolysin	 SPN9CC,	 which	 can	 be	
expressed	in	C.	reinhardtii	(Young	and	Purton	2015)	could	be	investigated	using	this	
method.	
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4.3.2 Improving	Cpl-1	stability	through	dimerisation		
The	C.	 reinhardtii	 chloroplast	 is	 known	 to	 produce	 and	 regulate	 the	 formation	 of	
disulphide	bonds	(Kim	1997),	and	research	suggests	that	yields	of	proteins	containing	
disulphide	bonds	can	be	improved	in	the	C.	reinhardtii	chloroplast	by	the	addition	of	
selenocystamine	to	the	culture	medium	(Ferreira-Camargo	et	al.	2015).	Furthermore,	
Resch	 et	 al.	 (2011)	 showed	 that	 Cpl-1	 can	 be	 modified	 to	 “pre-dimerise”,	 thus	
decreasing	plasma	clearance	and	improving	its	clinical	potential.		
Cpl-1	 is	 stable	 as	 a	monomer,	 but	 Cpl-1	 dimerisation	 occurs	 naturally	 on	 choline	
binding	 (Buey	 et	 al.	 2007).	 We	 expect	 that	 the	 addition	 of	 a	 disulphide	 bridge	
between	 two	 Cpl-1	 monomers	 will	 reduce	 the	 rate	 of	 degradation	 in	 storage	 by	
limiting	both	protease	access	and	the	denaturing	of	the	protein,	as	well	as	achieving	
the	decreased	plasma	clearance	reported	by	Resch	et	al.	(2011).	The	aim	is	also	to	
show	 that	 the	 C.	 reinhardtii	 chloroplast	 is	 a	 suitable	 platform	 for	 producing	
disulphide-bonded	endolysins	as	therapeutics.	
4.3.2.1.1 Stability	of	Cpl-1	under	varying	conditions	
An	initial	investigation	into	the	stability	of	Cpl-1	in	storage	was	conducted.	An	extract	
from	the	C.	reinhardtii	line	TN72_SR_cpl1-HA	was	prepared	as	described	in	2.5.1.	The	
cells	were	 either	 resuspended	 and	 lysed	 in	 20	mM	NaPi	 buffer	 or	 20	mM	NaPi	 +	
Protease	Inhibitor	buffer,	then	both	were	ultracentrifuged	for	one	hour	at	100,000	g.	
Each	supernatant	was	then	split	into	two	tubes	and	stored	at	25	°C	or	4	°C	for	seven	
days.	The	four	tubes	were	sampled	at	24-hour	intervals	and	the	samples	were	snap-
frozen	in	liquid	nitrogen	and	stored	at	-80	°C.	At	the	end	of	the	seven-day	period,	all	
samples	 were	 thawed	 and	 separated	 by	 SDS-PAGE	 before	 being	 blotted	 to	
nitrocellulose	membrane	and	analysed	by	western	blotting.	Relative	quantification	
using	the	LiCor	Odyssey®	CLx	system	produced	the	data	displayed	in	Figure	4.20.		
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Figure	4.20	Cpl-1	protein	degradation	over	a	seven-day	period	when	stored	at	4	°C	or	25	°C	
with	and	without	protease	inhibitor.		
The	data	displayed	 in	Figure	4.20	appears	very	erratic	as	 this	was	only	performed	
once,	but	in	general	 it	appears	that	the	protein	is	best	conserved	at	4	°C	and	with	
protease	inhibitor,	which	was	to	be	expected.	This	has	established	a	benchmark	for	
the	 stability	 of	 monomeric	 Cpl-1	 when	 stored	 under	 lab	 conditions.	 If	 Cpl-1	
dimerisation	can	be	achieved,	then	this	stability	may	be	improved,	thus	enabling	the	
addition	 of	 less	 protease	 inhibitor	 which	 would	 reduce	 costs	 and	 simplify	 the	
therapeutic	regulatory	procedure.		
4.3.2.2 Production	of	a	C.	reinhardtii	line	expressing	cpl-1	dimer		
The	 pre-dimerised	 Cpl-1	 protein	 produced	 by	 Resch	 et	 al.	 (2011)	 was	 achieved	
through	 site-directed	mutagenesis,	 and	 their	 experiments	 are	 briefly	 summarised	
here:	 site-directed	 mutagenesis	 firstly	 changed	 a	 cysteine	 residue	 near	 the	 N-
terminus	(C45)	to	a	serine	(see	Figure	4.21).	This	first	step	removed	the	possibility	of	
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interactions	 with	 this	 solvent-accessible	 cysteine.	 Then	 an	 aspartic	 acid	 residue	
(D324),	 in	a	position	13	amino	acids	away	from	the	C-terminus,	was	mutated	to	a	
cysteine.	 The	 13	 final	 amino	 acids	 are	 highly	 conserved	 and,	 in	 the	 case	 of	 the	
homologous	lysin	LytA,	responsible	for	LytA	dimerisation,	so	were	not	modified.	
4.3.2.2.1 Site-directed	mutagenesis	of	cpl1		
Site	directed	mutagenesis	was	performed	as	described	in	2.3.7.	The	primers	used	in	
this	instance	are	below,	and	mutation	sites	are	in	lowercase:	
cpl1.F:			 	 GCTCTTCAATGGTTAAAAAAAATGATTTATTC	
cpl1_C45S.F	 	 ACATATTTAAATCCATcaTTATCAGCTC	
cpl1_C45S.R	 	 GAGCTGATAAtgATGGATTTAAATATGT	
cpl1_D324C.F	 	 GTGAATTAGCAtgtAATCCTTCATTT	
cpl1_D324C.R	 	 AAATGAAGGATTacaTGCTAATTCAC	
cpl1.R:		 	 GCATGCTTATTAAGCATAATCTGGAAC	
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Figure	4.21	The	two	amino	acids	selected	for	mutation	are	highlighted	 in	yellow.	C45	was	
mutated	 to	 a	 serine	 to	 prevent	 unwanted	 interactions,	 as	 this	 cysteine	 is	 believed	 to	 be	
solvent-accessible.	 D324	 was	 mutated	 to	 a	 cysteine	 to	 form	 a	 disulphide	 bridge	 in	 a	
homodimer.	The	HA	tag	is	highlighted	in	purple.	
4.3.2.2.2 Expression	cassette	production	
The	final	PCR	product,	named	cpl1_dimer-HA,	was	inserted	into	the	pSRSapI	vector	
using	SapI	and	SphI	as	previously	described	(4.3.1.2.2).	Competent	DH5α	E.	coli	were	
then	 transformed	with	 the	 resultant	 plasmid	 and	 DNA	 sequencing	 confirmed	 the	
correct	insertion	and	that	the	intended	mutations	had	been	successfully	introduced.	
4.3.2.2.3 C.	reinhardtii	transformation	
The	 TN72	 recipient	 line	 was	 transformed	 with	 the	 pSRSapI_cpl1_dimer-HA	
transformation	 plasmid.	 Transformed	 C.	 reinhardtii	 lines,	 named	
TN72_SR_cpl1_dimer-HA	were	checked	for	homoplasmicity	by	PCR	(Appendix	I)	and	
finally	confirmed	by	sequencing.		
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4.3.2.2.4 Western	blot	confirmation	
Whole	 cell	 extracts	 of	 TN72_SR_cpl1-HA	 and	 TN72_SR_Control	 (as	 controls)	 and	
TN72_SR_cpl1_dimer-HA	were	prepared,	both	with	and	without	β-mercaptoethanol	
(BME),	 and	 separated	 by	 SDS-PAGE.	 The	 BME	 reduces	 disulphide	 bonds	 so	 was	
included	to	test	if	the	dimerised	Cpl-1	could	be	detected	when	BME	was	absent	but	
not	 when	 present	 –	 this	 would	 confirm	 disulphide	 presence.	 After	 blotting	 to	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	 with	 anti-HA	 primary	 antibody,	 then	 incubated	 with	 IRDye®	 secondary	
antibody.	 Fluorescence	 was	 observed	 using	 the	 LiCor	 Odyssey®	 CLx	 system.	 The	
resulting	analysis	is	shown	in	Figure	4.22.	
	
Figure	4.22	Western	blot	 analysis	of	 TN72_SR_cpl1_dimer-HA.	 The	 loading	mixture	either	
contained	β-mercaptoethanol	or	did	not,	indicated	by	+/-	BME.	The	predicted	band	location	
for	Cpl-1_dimer	is	indicated	but	no	bands	were	observed.		
No	 spontaneously	 forming	 Cpl-1	 dimers	were	 observed	 in	 the	whole	 cell	 extract.	
However,	 monomeric	 Cpl-1	 still	 accumulates	 to	 similar	 levels	 as	 seen	 in	
TN72_SR_cpl1-HA.	The	presence	of	the	monomer	suggests	that	there	is	no	issue	with	
synthesis,	but	for	some	reason	dimerisation	is	not	occurring,	perhaps	due	to	steric	
issues	involving	the	C-terminal	HA	tag,	or	simply	that,	at	the	concentrations	observed,	
the	equilibrium	is	shifted	towards	monomers	and	dimers	are	not	formed.	
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4.3.2.2.5 Addition	of	selenocystamine	
The	 addition	 of	 the	 small	molecule	 selenocystamine	 to	 the	 growth	medium	of	C.	
reinhardtii	 was	 reported	 to	 catalyse	 disulphide	 bond	 formation	 in	 recombinant	
proteins	(Ferreira-Camargo	et	al.	2015).		
Selenocystamine	was	added	to	C.	 reinhardtii	 cultures	 to	a	 final	concentration	of	2	
μM,	the	optimal	concentration	observed	by	Ferreira-Camargo	et	al.	 (2015).	Whole	
cell	 extracts	 of	 TN72_SR_cpl1-HA	 and	 TN72_SR_Control	 (as	 controls)	 and	
TN72_SR_cpl1_dimer-HA,	 all	 grown	both	with	and	without	2	μM	selenocystamine	
were	prepared,	without	β-mercaptoethanol	(BME),	and	separated	by	SDS-PAGE.	The	
western	blot	analysis,	carried	out	as	previously,	is	displayed	in	Figure	4.23.	
	
Figure	 4.23	 Western	 blot	 analysis	 of	 whole	 cell	 C.	 reinhardtii	 extracts,	 grown	 with	
selenocystamine	 (+	 Sel.)	 and	 without.	 All	 were	 prepared	 in	 the	 absence	 of	 β-
mercaptoethanol	and	the	predicted	Cpl-1	dimer	band	location	indicated.		
The	addition	of	selenocystamine	to	the	growth	medium	of	TN72_SR_cpl1_dimer-HA	
failed	to	catalyse	spontaneous	Cpl-1	dimerisation,	nor	did	it	significantly	affect	levels	
of	monomeric	Cpl-1	accumulation.	
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4.3.2.2.6 Addition	of	choline	
The	 investigation	 by	 Resch	 et	 al.	 (2011)	 used	 DEAE-Sepharose™	 affinity	
chromatography	to	purify	Cpl-1	from	E.	coli	extracts.	DEAE	acts	as	a	choline	analogue	
and	therefore	this	method	exploits	the	choline	binding	ability	of	Cpl-1.	Cpl-1	was	then	
eluted	from	the	column	using	a	buffer	containing	10	%	choline.	However,	no	crude	
lysate	analysis	was	performed	by	Resch	et	al.	(2011)	and	only	the	purified	Cpl-1	was	
shown	on	SDS-PAGE.	While	it	is	most	likely	that	in	the	experiments	by	Resch	et	al.	
(2011)	Cpl-1	dimerisation	occurred	in	vivo	in	the	E.	coli	periplasm,	it	is	possible	that	
the	dimerisation	occurred	in	vitro	when	the	addition	of	free	choline	recruited	Cpl-1	
monomers	together,	enabling	spontaneous	in	vitro	dimerisation.		
To	test	this	hypothesis,	free	choline	was	added	to	cell	extract	containing	Cpl-1_dimer,	
at	varying	concentrations,	and	incubated	for	one	hour.	The	samples	were	separated	
by	 non-reducing	 SDS-PAGE	 and	 analysed	 by	western	 blotting,	 displayed	 in	 Figure	
4.24.	
	
Figure	4.24	Western	blot	analysis	of	whole	cell	C.	reinhardtii	extracts,	incubated	with	choline.	
The	first	band	has	no	choline	added.	All	were	prepared	in	the	absence	of	β-mercaptoethanol	
and	the	predicted	Cpl-1	dimer	band	location	indicated.		
Incubation	with	choline	failed	to	induce	Cpl-1	dimerisation.	The	presence	of	choline	
was	expected	to	recruit	Cpl-1	towards	the	free	choline	and	enable	the	formation	of	
a	disulphide	bond	between	the	two	monomers.	The	native	dimerisation	of	Cpl-1	upon	
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the	addition	of	choline	reported	by	Monterroso	et	al.	(2005)	was	not	expected	to	be	
observed,	given	the	denaturing	conditions	of	SDS-PAGE.	
4.3.2.2.7 Production	of	Cpl-1_dimer	in	E.	coli	and	enrichment		
As	 shown	 in	 Figure	 3.8,	 the	 E.	 coli	 line	 DH5α_pProEX_cpl1_dimer-HA-StrepII	 was	
shown	 to	 express	 Cpl-1	 to	 a	 high	 level,	 and	 the	 application	 of	HiTrap	 StrepTactin	
purification	 columns	 enabled	 the	 production	 of	 an	 enriched	 extract.	 This	 was	
performed	to	reproduce	the	work	of	Resch	et	al.	(2011),	as	well	as	to	act	as	a	protein	
standard	as	described	in	3.3.1.2.6.	When	separated	by	SDS-PAGE	under	non-reducing	
conditions,	no	dimerisation	could	be	observed,	however	this	was	to	be	expected	as	
disulphide	bond	formation	requires	an	oxidising	environment	 in	order	to	oxidise	a	
pair	of	 cysteines.	 In	Gram-negative	prokaryotes,	 such	as	E.	 coli,	 this	occurs	 in	 the	
periplasmic	 space,	 where	 enzymes	 catalyse	 the	 reaction.	 Recombinant	 proteins	
therefore	require	an	N-terminal	signal	peptide	to	target	them	to	the	periplasm	for	
disulphide	bond	 formation,	which	was	not	 included	on	our	cpl1_dimer	 transgene.	
Resch	 et	 al.	 (2011)	 expressed	 cpl1	 using	 a	 plasmid	 based	 upon	 pIN-IIIA,	 which	
attaches	an	outer	membrane	protein	A	(OmpA)	signal	peptide	to	the	N-terminus	of	
cloned	proteins	to	promote	secretion	of	the	recombinant	protein	into	the	periplasm.	
Given	that	the	plasmid	used	here,	pProEX_HTb,	does	not	attach	an	N-terminal	signal	
peptide,	it	was	necessary	to	perform	dimerisation	in	vitro.	
4.3.2.2.8 Dimerisation	of	E.	coli-produced	Cpl-1	using	oxidised	glutathione	in	vitro	
Disulphide	bond	formation	can	occur	spontaneously	if	the	environment	is	oxidising,	
and	can	 therefore	be	 formed	 in	vitro	 (Berkmen	2012).	Glutathione	 is	a	commonly	
used	 reagent	 in	 its	 reduced	 (GSH)	 and	 oxidised	 (GSSH)	 form	 to	 produce	 a	 redox	
environment	beneficial	to	disulphide	bond	formation.	The	protocol	is	described	fully	
in	2.6.5,	adapted	from	Hidaka	et	al.	(1998)	and	Hyvonen	(2002).	
A	 crude	 cell	 lysate	of	E.	 coli	 cells	 induced	 to	express	cpl1_dimer	was	obtained	by	
sonication,	and	ultracentrifugation	removed	the	insoluble	fraction.	An	existing	Cpl-
1_StrepII	enriched	extract	from	C.	reinhardtii	was	used	as	a	control	(from	4.3.1.3.6).	
The	 soluble	 fraction	and	 the	control	were	 then	 incubated	overnight	at	20	 °C	with	
varying	GSH:GSSG	ratios.	SDS-PAGE	was	used	to	separate	the	fractions,	with	no	β-
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mercaptoethanol	and	no	heat	denaturation	prior	 to	running	the	gel.	The	resulting	
western	blot	analysis	is	shown	in	Figure	4.25.	
	
Figure	4.25	Western	blot	analysis	attempting	to	detect	in	vitro	dimerisation	of	Cpl-1_dimer,	
with	Cpl-1_StrepII	being	used	as	a	negative	control.	The	Cpl-1_dimer	runs	slightly	larger	than	
the	Cpl-1_StrepII	due	to	the	additional	epitope	tags	and	slightly	different	charge.	The	sample	
in	the	first	lane	of	each	blot	was	boiled	for	3	minutes	in	the	presence	of	β-mercaptoethanol,	
which	should	reduce	any	disulphide	bonds.	The	subsequent	 lanes	all	contain	2.5	mM	GHS	
and	increasing	quantities	of	GSSG,	from	0	mM	to	5	mM.	The	‘?’	marks	the	expected	location	
of	the	78	kDa	Cpl-1	dimer	band,	but	as	discussed	below,	the	observed	band	is	not	believed	
to	be	the	dimer.		
Despite	the	presence	of	a	78	kDa	band,	which	is	the	predicted	size	of	a	Cpl-1	dimer	
(Resch	et	al.	2011a),	this	is	not	believed	to	be	a	Cpl-1	dimer.	The	presence	of	the	78	
kDa	band	in	the	first	lane,	where	the	sample	has	been	boiled	in	the	presence	of	β-
mercaptoethanol,	suggests	that	this	is	an	artefact	of	non-specific	binding	of	the	anti-
StrepII	antibody	rather	than	dimerised	Cpl-1.	It	is	possible	that	this	band	is	masking	
Cpl-1	 dimer	 formation	 in	 subsequent	 lanes,	 however	 this	 seems	 unlikely,	 as	 one	
would	expect	to	be	able	to	see	two	bands	even	if	they	were	located	close	together	
or	 the	 single	 band	 would	 become	 brighter.	 No	 non-specific	 band	 is	 seen	 in	 the	
negative	control,	but	this	is	an	extract	from	C.	reinhardtii	that	has	been	purified	using	
a	StrepTrap	column	as	previously	described,	so	has	a	different	background	protein	
make-up	to	the	E.	coli-derived	crude	extract.	It	serves	its	purpose	of	showing	that	no	
dimerisation	occurs	with	the	un-mutated	Cpl-1,	while	the	β-mercaptoethanol	lane	is	
a	negative	control	for	the	mutated	Cpl-1.	
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There	are	a	couple	of	factors	that	could	be	preventing	dimerisation	of	Cpl-1_dimer,	
even	in	vitro.	The	first	and	most	likely	issue	is	the	presence	of	C-terminal	epitope	tags	
causing	steric	hindrance.	The	HA	tag	in	the	C.	reinhardtii	version	of	the	protein	and	
the	HA	and	StrepII	tags	in	the	E.	coli	version	are	both	on	the	C-terminus	of	the	protein.	
In	hindsight,	locating	these	on	the	N-terminus	may	have	been	a	better	approach	as	
the	Cpl-1	protein	has	been	engineered	to	form	a	disulphide	bridge	close	to	the	C-
terminus.	Resch	et	al.	(2011)	note	that	the	positioning	of	the	new	cysteine	residue	
near	the	C-terminus	is	of	crucial	importance	to	dimerisation.	Given	all	of	this,	it	is	not	
surprising	that	the	inclusion	of	an	8-9	amino	acid	epitope	tag	at	the	C-terminus	would	
interfere	with	dimerisation.	
The	same	Cpl-1_dimer	protein	was	expressed	as	a	recombinant	 in	E.	coli	after	the	
failure	 to	 achieve	 dimerisation	 in	C.	 reinhardtii	 to	 test	whether	 this	 failure	was	 a	
property	of	the	protein	per	se	or	a	result	of	the	expression	platform.	In	essence,	if	
dimerisation	of	Cpl-1_dimer	could	be	achieved	in	E.	coli	but	not	in	C.	reinhardtii	then	
we	would	conclude	that	the	C.	reinhardtii	chloroplast	is	unsuitable	for	pre-dimerised	
Cpl-1	production.	However,	 if	dimerisation	could	not	be	achieved	 in	E.	coli	either,	
then	the	conclusion	would	be	that	the	protein	design	was	in	some	way	preventing	
dimerisation.	
In	 this	 study,	 the	 lack	of	 targeting	 to	 the	E.	coli	periplasm	 likely	prevented	 in	vivo	
dimerisation	from	occurring.	Future	studies	should	use	vector	such	as	pIN-III,	which	
includes	an	N-terminal	OmpA	target	peptide	and	may	rectify	this,	or	consider	using	
an	engineered	strain	of	competent	E.	coli	such	as	Rosetta-gami™	(Novagen)	which	
displays	enhanced	disulphide	bond	formation	in	the	cytoplasm.	The	failure	of	in	vitro	
dimerisation	 could	 be	 due	 to	 a	 lack	 of	 condition-optimisation	 of	 the	 dimerisation	
protocol,	as	only	a	relatively	narrow	range	of	conditions	were	tested.	For	example,	
different	reagents	could	be	used,	such	as	cysteine	and	cystine,	and	in	different	ratios	
to	create	the	redox	environment,	as	well	as	different	temperatures	and	incubation	
times.	Optimisation	of	this	protocol	for	Cpl-1_dimer	may	have	enabled	dimerisation.		
		 186	
4.3.3 Expression	of	the	Cpl-1	associated	holin,	Cph-1	
4.3.3.1 Production	of	C.	reinhardtii	lines	expressing	cph-1		
The	C.	reinhardtii	derived	psaA	5’	UTR/promoter	is	functional	in	E.	coli,	as	are	several	
chloroplast	promoters	probably	due	to	the	chloroplast’s	prokaryotic	origins	(Young	
and	 Purton	 2015).	 Given	 the	 ability	 of	 holins	 to	 form	 holes	 in	 the	 cytoplasmic	
membrane	of	E.	coli,	and	thus	inhibit	cell	growth	(Catalão	et	al.	2011),	the	use	of	the	
pSRSapI	plasmid	to	clone	these	in	E.	coli	is	unlikely	to	be	possible.	
	A	strategy	developed	by	Young	&	Purton	 (2015)	makes	use	of	a	 ‘spare’	opal	 stop	
codon,	UGA,	that	is	unused	in	the	C.	reinhardtii	chloroplast.	The	codon	is	reassigned	
to	code	for	a	tryptophan	by	the	co-introduction	of	a	modified	tryptophan	tRNA	gene	
(trnW)	into	the	C.	reinhardtii	chloroplast,	along	with	the	gene	of	interest.	The	gene	
of	 interest	 is	 modified	 to	 contain	 several	 UGA	 codons	 in	 the	 place	 of	 UGG	
(Tryptophan)	–	these	are	read	as	“Stop”	codons	by	the	E.	coli	translational	machinery,	
but	 as	 tryptophan	 codons	 in	 the	 chloroplast.	 A	 plasmid,	 named	 pWUCA2	 was	
developed	to	perform	this	cloning	strategy.	The	plasmid	 is	very	similar	 to	pSRSapI	
(2.2)	but	with	the	addition	of	a	trnWUCA	gene	upstream	of	the	gene	of	interest	(GOI)	
expression	cassette,	illustrated	in	Figure	4.26.	
	
Figure	4.26	The	pWUCA2	 transformation	vector	 is	based	upon	pSRSapI	and	has	 the	same	
cloning	 sites	 for	 the	 GOI	 and	 the	 same	 flanking	 regions	 for	 homologous	 recombination.	
However,	 an	 additional	 synthetic	 gene,	 trnWUCA,	 has	 been	 inserted	 upstream	 of	 the	 GOI	
expression	cassette.	
This	 strategy	 enables	 the	 cloning	 in	E.	 coli	 of	 genes	 under	 functional/constitutive	
promoters,	which	would	otherwise	produce	proteins	that	are	toxic	or	detrimental	to	
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E.	 coli	 growth.	 In	 this	 case,	 the	 E.	 coli	 translational	 machinery	 will	 stop	 short	 of	
producing	the	whole	length	protein	due	to	the	presence	of	stop	codons	in	the	middle	
of	the	GOI.	
Producing	holins	in	the	C.	reinhardtii	chloroplast	may	avoid	the	problem	of	E.	coli	lysis	
that	occurs	when	holins	are	expressed	as	recombinant	proteins	in	bacterial	platforms	
(Smith	et	al.	1998;	Shi	et	al.	2012;	Song	et	al.	2016).	This	problem	has	been	largely	
overcome	 by	 the	 use	 of	 induction	 systems,	 but	 allows	 only	 10	 –	 15	 minutes	 of	
accumulation	before	the	metabolic	activity	fails	(Smith	et	al.	1998).	Furthermore,	the	
nature	of	the	protein	means	that	it	must	be	purified	from	the	bacterial	membrane	to	
which	 it	 localises,	 which	 further	 reduces	 yields	 and	 increases	 costs.	 While	 C.	
reinhardtii	achieves	only	low	levels	of	recombinant	protein	expression	compared	to	
E.	coli	for	many	proteins,	given	these	two	issues	it	may	be	that	it	can	compete	as	an	
expression	platform	when	producing	holins.		
4.3.3.1.1 Gene	design	and	codon	optimization		
Codon	Usage	Optimizer	Beta	0.92	(Kong	2013)	was	used	to	optimize	the	cph1	gene	
for	C.	reinhardtii	chloroplast	expression.	Two	tryptophan	codons	early	 in	the	gene	
were	changed	from	UGG	to	UGA.	SapI	and	SphI	 restriction	sites	were	 included	for	
cloning	 into	 the	 pWUCA	 expression	 vector.	 The	 full-length	 cph1-HA	 gene	 was	
synthesized	by	Integrated	DNA	technologies	(Appendix	H).	
4.3.3.1.2 Expression	cassette	production		
SapI	and	SphI	restriction	enzymes	were	used	to	digest	and	ligate	the	cph1	gene	into	
pWUCA2	 in-frame,	producing	 the	plasmid	pWUCA2_cph1-HA.	DH5α	competent	E.	
coli	cells	were	transformed	with	the	resulting	plasmid	and	sequencing	confirmed	the	
correct	plasmid	assembly.	
4.3.3.1.3 C.	reinhardtii	transformation	
The	pWUCA2_cph1-HA	plasmid	was	used	 to	 transform	 the	 recipient	C.	 reinhardtii	
strain	TN72	via	the	glass	bead	method	as	described	in	2.3.13.	Figure	4.27	illustrates	
the	resulting	C.	reinhardtii	cell	line,	pWUCA2_cph1-HA.	
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Figure	4.27	TN72	recipient	strain	successfully	transformed	to	carry	cph1-HA	under	the	psaA	
exon	1	promoter/5’UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	A	modified	
trnW	gene	has	been	co-introduced	to	correctly	code	for	the	introduced	UGA	codons	in	the	
cph1	gene.	The	approximate	positions	of	the	UGA	codons	are	indicated	in	red.	
The	 resulting	 transformants	 were	 confirmed	 for	 homoplasmicity	 as	 described	 in	
2.3.17.	In	this	instance,	due	to	the	addition	of	the	trnWUCA	gene,	the	expected	band	
size	for	homoplasmicity	will	be	291	bp	larger,	giving	a	total	expected	size	of	1421	bp	
(Primers:	Flank1	&	psa.R	 (Appendix	O:	List	of	Primers)).	Gel	electrophoresis	of	 the	
resulting	PCR	product	from	three	transformants	is	shown	in	Figure	4.28.	
	
Figure	4.28	The	resulting	PCR	products	are	approximately	1.4	kb	in	size	as	expected.	The	lack	
of	an	850	bp	product	confirms	that	all	three	of	these	transformants	are	homoplasmic.	
Finally,	the	integrity	of	the	inserted	cassette	was	confirmed	by	DNA	sequencing	as	in	
2.3.18.	
4.3.3.1.4 Western	blot	confirmation	
Whole	cell	extracts	of	TN72_WUCA2_cph1-HA	and	TN72_SR_Control	(as	a	negative	
control)	were	prepared	and	separated	by	SDS-PAGE.	After	blotting	to	nitrocellulose	
membrane	and	blocking	as	described	in	2.4.5,	the	membrane	was	probed	with	anti-
HA	primary	antibody,	then	incubated	with	IRDye®	secondary	antibody.	Fluorescence	
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was	observed	using	the	LiCor	Odyssey®	CLx	system.	The	resulting	image	is	shown	in	
Figure	4.29.	
	
Figure	4.29	Western	blot	analysis	 indicates	 that	a	~15	kDa	protein	 is	detected	by	anti-HA	
antibodies	 in	 the	 TN72_WUCA2_cph1-HA	extract,	 and	not	 in	 the	negative	 control.	 This	 is	
likely	to	be	Cph-1	protein.		
Cph-1	 appeared	 to	 be	 present	 in	 TN72_WUCA2_cph1-HA	 whole	 cell	 extract.	
However,	it	was	noted	that	the	transformed	C.	reinhardtii	lines	did	not	appear	to	be	
as	 healthy	 as	 other	 lines,	 in	 that	 they	 took	 a	 longer	 time	 to	 reach	 a	 bright	 green	
culture,	taking	approximately	six	days	rather	than	the	usual	three	or	four.	This	was	
merely	 an	 observation,	 and	 no	 data	 was	 collected	 at	 the	 time	 to	 objectively	
investigate	a	change	in	growth	rate.		
4.3.3.1.5 Investigation	into	holin	localisation	
Given	the	non-specific	 insertion	of	holins	 into	bacterial	cell	membranes,	 it	 is	 likely	
that	 the	 holin	 would	 insert	 into	 chloroplast	 membranes	 when	 produced	 as	 a	
recombinant.	 In	 order	 to	 investigate	 whether	 the	 holin	 was	 integrating	 into	 the	
thylakoid	membrane	or	chloroplast	envelope,	TN72_WUCA2_cph1-HA	was	lysed	by	
sustained	glass	bead	agitation	at	4	°C	and	subjected	to	ultracentrifugation	at	100,000	
g	for	1	hour	at	4	°C.	This	was	designed	to	separate	the	membrane	fraction	(pellet)	
(kDa)	
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and	 cytoplasmic	 fraction	 (supernatant).	 However,	 when	 the	 two	 fractions	 were	
separated	 by	 SDS-PAGE	 and	 analysed	 by	 western	 blotting	 as	 before,	 no	 15	 kDa	
protein	could	be	detected.		
In	an	attempt	to	detect	Cph-1	accumulation	again,	very	high	concentrations	of	cell	
extract	were	separated	on	SDS-PAGE	and	analysed	by	western	blotting,	as	well	as	
using	ammonium	sulphate	precipitation	to	concentrate	large	volumes	of	cell	extract,	
but	no	Cph-1	was	detected.	Again,	only	observationally,	it	was	noted	that	at	the	time	
of	these	further	experiments,	the	TN72_WUCA2_cph1-HA	cell	line	seemed	to	grow	
at	a	normal	 rate	and	 it	had	recovered	 from	 its	earlier	unhealthy	appearance.	This	
observation	and	the	lack	of	detectable	Cph-1	accumulation	suggested	that	the	gene	
had	been	silenced	 in	some	way,	either	 through	point	mutations	or	 recombination	
events	between	similar	sequences.	
4.3.3.1.6 Investigating	cph1	silencing	
Figure	 4.28	 demonstrates	 that	 the	 three	 TN72_WUCA2_cph1-HA	 lines	 were	
homoplasmic,	meaning	that	all	of	the	~70	chloroplast	genome	copies	contained	the	
desired	expression	cassette.	This	was	achieved	by	several	rounds	of	selection	upon	
minimal	 medium,	 thus	 selecting	 for	 photosynthetically-competent	 cells	 and	
promoting	 the	 presence	 of	 the	 transformed	 plastome	 copies.	 However,	 once	
homoplasmicity	had	been	achieved	and	confirmed,	cells	were	grown	mixotrophically	
upon	 acetate	 and	 under	 light	 which	 promotes	 faster	 growth.	 Had	 the	 cell	 been	
heteroplasmic	 at	 this	 stage	 and	 the	 GOI	 was	 sufficiently	 toxic,	 it	 is	 possible	 that	
selection	 could	 be	 driven	 the	 other	way,	 back	 to	 the	 photosynthetically	 deficient	
recipient	line.	However,	the	selection	for	photosynthesis	is	so	strong	that	this	seems	
quite	unlikely	and	the	loss	of	psbH	functionality	also	confers	photosensitivity,	further	
increasing	the	pressure	on	the	plastome	to	gain	psbH	function.	However,	given	that	
the	lines	were	homoplasmic,	this	cannot	be	the	case.	The	sensitivity	of	PCR	means	
that	even	if	one	plastome	copy	were	without	the	expression	cassette,	this	is	likely	to	
be	visible	in	Figure	4.28.	
There	are	several	sites	in	the	inserted	expression	cassette	that	could	be	subject	to	
recombination	 events	 within	 the	 chloroplast	 as	 they	 are	 of	 endogenous	 origin,	
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namely	the	psaA	exon	1	promoter	and	5’UTR,	rbcL	3’UTR	and	trnW.	However,	the	
native	rbcL	gene	and	the	psaA	exon	1	are	respectively	46	and	47	kbp	away	from	the	
insertion	site,	and	the	trnW	gene	is	61	kbp	away,	which	would	be	expected	to	reduce	
recombination	rates,	although	this	relationship	has	not	been	confirmed	(Mudd	et	al.	
2014).	 Furthermore,	each	of	 these	 repeated	 sequences	 is	 relatively	 small:	 trnW	 is	
73bp;	psaA	 exon	1	promoter	 and	5’UTR	 is	 294	bp;	 and	 rbcL	 3’UTR	 is	 407	bp.	 For	
context,	Mudd	et	al.	(2014)	suggest	that	repeats	of	650	bp	separated	by	5	kbp	results	
in	efficient	recombination,	but	no	strict	rule	has	been	suggested.	Another	alternative	
is	that	point	mutations	in	either	the	modified	trnW	gene	or	cph1	gene	have	resulted	
in	failed	translation	or	instability	of	the	protein.	
To	test	the	above	theories,	the	cassette	region	was	amplified	by	PCR	from	genomic	
DNA	and	sequenced	(regions	b	and	c	in	Figure	4.30),	as	performed	after	the	initial	
confirmation	 of	 homoplasmicity.	 Sequencing	 confirmed	 the	 presence	 of	 both	 the	
holin	 and	 trnWUCA	 genes,	 with	 no	mutations.	 The	 psbH.R	 primer	 binds	 inside	 the	
downstream	flanking	region	of	the	transformation	plasmid,	and	123a	binds	upstream	
of	 the	 trnWUCA	 gene,	which	 therefore	 suggests	 that	 the	whole	 cassette	 is	 present.	
However,	the	Flank1	primer	lies	outside	the	transformation	plasmid,	upstream	of	the	
cassette,	and	no	product	could	be	seen	when	this	primer	was	used.		
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Figure	4.30	Reactions	a-c	produced	the	expected	amplified	PCR	product,	while	d	and	e	failed	
to	produce	any	product.	The	successful	amplification	of	a-c	shows	that	the	cassette	is	present	
somewhere	in	the	genome.	The	success	of	amplification	in	Figure	4.28	(the	same	primers	as	
e	above)	suggests	that	the	cassette	was	originally	in	the	correct	locus.	However,	the	failure	
of	d	&	e	here	suggests	 that	 the	cassette	 is	no	 longer	present	 in	 the	 intended	neutral	 site	
between	 trnE2	 and	 psbH	 in	 the	 chloroplast.	 The	 two	 lanes	 show	 two	 different	
TN72_WUCA_cph1-HA	transformants.	Primer	sequences	can	be	found	in	Appendix	O:	List	of	
Primers.	
It	 is	possible	that	a	very	small	number	of	plastome	copies	remain	with	the	correct	
cassette	insertion,	but	that	the	majority	of	copies	have	recombined	in	a	manner	so	
as	to	silence	gene	expression.	However,	as	mentioned	previously,	the	sensitivity	of	
PCR	would	normally	enable	even	a	single	copy	to	be	detected.	Mudd	et	al.	 (2014)	
does	 note	 that	 recombination	 has	 been	 observed	with	 relatively	 small	 repeats	 in	
Chlamydomonas,	 for	 example,	 216	 bp	 direct	 repeats	 in	 the	 chlL	gene	 are	 able	 to	
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recombine.	 The	 most	 likely	 explanation	 is	 therefore	 that	 some	 combination	 of	
recombination	events	has	led	to	the	relocation	of	the	expression	cassette	to	a	silent	
site	in	the	plastome,	which	was	then	highly	selected	for,	given	the	apparent	toxicity	
of	Cph-1.		
4.4 Conclusion	and	future	work	
This	 chapter	 has	 examined	 three	 strategies	 to	 improve	 Cpl-1	 activity	 against	 S.	
pneumoniae,	the	first	two	of	which	deal	with	direct	protein	engineering	and	the	third	
attempts	to	exploit	synergy	with	another	protein,	a	holin.		
4.4.1 Cell	wall	binding	site	mutagenesis	
Six	binding	site	mutated	Cpl-1	proteins	were	expressed	in	C.	reinhardtii	to	detectable,	
albeit	varying,	 levels.	However,	difficulties	arose	when	attempting	to	compare	the	
activity	of	these	proteins	as	lytic	enzymes	against	S.	pneumoniae.	Firstly,	the	potential	
for	improvements	around	the	mutations	themselves	will	be	discussed,	followed	by	a	
discussion	of	how	the	activity	assays	might	be	adapted	and	suggestions	of	possible	
alternative	assays.	
It	 is	 noted	 in	 4.3.1.1.1	 and	 illustrated	 in	 Figure	 4.4	 that	 there	 are	 three	 residues	
believed	 to	 be	 of	 key	 importance	 in	 each	 choline	 binding	 site,	 two	 tryptophan	
residues	and	a	tyrosine	residue.	Hermoso	et	al.	(2003)	also	suggest	that	a	lysine	is	
involved	 in	 capping	 the	 site	 and	 stabilising	 the	 phosphate	 group	 of	 phosphoryl-
choline.	This	investigation	only	considered	the	two	tryptophan	residues	of	each	site,	
simply	 due	 to	 time	 constraints	 and	 the	 fact	 that	 they	 appear	 to	 be	 closer	 to	 the	
choline	 residue.	 It	 appears	 that	 mutating	 the	 tryptophan	 residues	 did	 indeed	
negatively	affect	 choline	binding,	but	 that	 this	 resulted	 in	 reduced	 lytic	activity.	 It	
would,	therefore,	be	interesting	to	consider	the	tyrosine	and	lysine	in	each	binding	
site	as	 they	may	enable	a	 subtler	mutation	 to	be	produced.	Alanine	 scanning	 is	a	
common	approach	to	mutating	residues	of	interest,	as	it	eliminates	the	role	of	the	
polar	side	chain,	however,	in	this	instance,	this	may	result	in	too	drastic	a	change	in	
polarity.	Therefore,	a	more	conservative	mutation	might	be	considered,	for	example,	
the	 mutation	 of	 tryptophan	 to	 tyrosine.	 The	 binding	 site	 is	 clearly	 sensitive	 to	
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mutations	and	highly	conserved,	and	the	alanine	changes	appear	to	have	been	too	
severe	and	resulted	in	reduced	activity.		
Furthermore,	the	Cpl1_W223A-HA	construct	was	never	successfully	synthesised,	for	
reasons	 unknown.	 It	 is	 interesting	 to	 note	 that	 the	 Cpl1_W223A_W230A-HA	 and	
Cpl1_W202A_W209A_W223A_W230A-HA,	which	both	contain	the	W223A	mutation	
in	addition	to	others,	produce	consistently	detectable	levels	of	protein	accumulation.	
This	is	somewhat	unexpected,	as	W223	is	not	a	strictly	conserved	residue	in	choline	
binding	repeats	(Figure	4.5)	while	W209	and	W230	are,	though	no	problems	were	
observed	when	these	were	mutated.	The	issues	arose	after	PCR	when	attempting	to	
insert	 the	 gene	 into	 pJet,	 a	 vector	 from	 a	 commercially	 available	 PCR	 cloning	 kit	
(ThermoFischer),	enabling	blunt	end	cloning	and	transformation	of	E.	coli.	No	E.	coli	
colonies	 were	 observed	 in	 any	 of	 the	 attempts	 to	 produce	 cpl1_W223A-HA,	
suggesting	this	mutated	gene	is	either	highly	toxic	to	E.	coli	or	for	some	reason	unable	
to	ligate	into	the	pJet	vector.	In	future	either	a	different	intermediate	vector,	such	as	
pGemTEasy	could	be	used	or	the	intermediate	step	could	be	skipped	and	attempt	to	
clone	directly	into	pSRSapI	using	a	digested	PCR	product.		
An	 interesting	 and	 related	 point	 of	 discussion	 is	why	 the	 inactive	 choline	 binding	
repeats	(p4-p6)	remain	so	highly	conserved.	As	these	repeats	appear	to	be	sterically	
unable	 to	 bind	 choline,	 it	 would	 be	 reasonable	 to	 assume	 that	 there	 was	 little	
evolutionary	pressure	 for	 them	to	remain	unaltered.	The	 fact	 that	 they	remain	so	
highly	conserved	indicates	that	they	also	have	some	other	important	function.	This	
may	suggest	that	the	three-dimensional	shape	of	the	protein	is	highly	dependent	on	
the	interaction	of	these	repeats	and	that	mutations	to	them	have	effects	more	wide-
ranging	that	merely	altering	choline	binding.	
Given	that	initial	attempts	to	disrupt	the	choline	binding	sites	appeared	to	result	in	a	
reduction	of	activity,	and	that	the	p4-p6	repeats	are	highly	conserved	despite	their	
purported	 inactivity,	 an	 alternative	 protein	 engineering	 focus	 could	 be	 taken.	 For	
example,	the	flexible	acidic	linker	that	joins	the	cell	wall	binding	domain	and	catalytic	
domain	would	be	an	interesting	site	for	improvement.	If	it	is	indeed	the	case	that	the	
binding	 domain	 remains	 bound	 to	 choline	 in	 the	 cell	 wall,	 then	 the	 number	 of	
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Figure	Removed	
peptidoglycan	cleavages	that	can	be	performed	by	the	catalytic	domain	is	limited	by	
the	length	and	nature	of	this	linker.	When	producing	Artilysins®,	Briers	et	al.	(2014)	
investigated	the	effect	of	increasing	linker	length	between	the	peptide	and	endolysin.	
It	was	found	that	antibacterial	activity	increased	in	a	stepwise	fashion	as	the	linker	
was	 extended,	 then	 began	 to	 plateau	 at	 around	 18	 amino	 acids	 in	 length	 (Figure	
4.31).		
	
Figure	4.31	L0,	L1,	L2,	L3,	and	L4	correspond	to	 linker	amino	acid	sequences	of	AGAS	 (4),	
AGAGAS	 (6),	AGAGAGAGAS	 (10),	AGAGAGAGAGAGAS	 (14),	 and	AGAGAGAGAGAGAGAGAS	
(18).	Reproduced	from	Briers	et	al.	(2014).	
The	acidic	 linker	 for	Cpl-1	 comprises	 residues	189-199,	with	amino	acid	 sequence	
DDEEDDKPKTA.	While	not	directly	analogous	to	the	linker	investigated	by	Briers	et	al.	
(2014),	 it	would	be	 interesting	 to	attempt	 to	extend	 the	Cpl-1	 linker	 to	 see	 if	any	
improvement	 in	 activity	 can	 be	 achieved.	 However,	 it	 is	 unlikely	 that	 much	
improvement	to	activity	can	be	gleaned	by	extending	the	acidic	linker,	as	this	would	
have	probably	been	highly	selected	for	throughout	evolution.	This	is	in	contrast	to	
choline	 binding	 which,	 as	 discussed	 previously,	 appears	 to	 act	 as	 a	 tethering	
mechanism	to	prevent	accidental	lysis	of	potential	future	host	bacterial	cells.		
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DEAE	cellulose	acts	as	a	choline	analogue	and	has	therefore	been	exploited	for	ion	
exchange	chromatography	to	purify	Cpl-1,	using	a	protocol	first	described	by	Loeffler	
et	al.	(2001).	Cpl-1	binds	to	DEAE	and	can	then	be	eluted	using	a	free	choline.	This	
method	 was	 not	 used	 in	 this	 investigation,	 as	 choline	 binding	 was	 the	 object	 of	
investigation.	 However,	 the	 method	 could	 be	 adapted	 into	 an	 assay	 for	 choline	
binding	ability.	For	example,	a	mutated	Cpl-1	protein	displaying	weakened	choline	
binding	would	be	eluted	from	the	DEAE	column	more	easily	 than	strongly	binding	
Cpl-1.	This	assay	could	be	used	to	confirm	that	any	change	in	activity	was	indeed	due	
to	choline	binding	alteration,	and	not	due	to	some	other	unknown	factor	or	three-
dimensional	shape	change.		
The	protein	engineering	steps	taken	in	this	section	were	highly	speculative	and	would	
have	 benefitted	 from	 testing	 a	 larger	 number	 of	 mutants	 more	 quickly.	 For	 this	
reason,	the	choice	of	C.	reinhardtii	as	a	platform	limited	these	initial	investigations,	
as	 transformations	 take	 more	 time,	 recombinant	 protein	 yields	 are	 lower,	 and	
background	 antimicrobial	 effects	 disrupted	 activity	 assays	 compared	 to	 other	
platforms	such	as	E.	coli.	This	work	would	have	been	better	suited	to	E.	coli,	which	
enables	rapid	prototyping	and	testing	of	recombinant	proteins.	C.	reinhardtii	should	
then	be	used	further	down	the	production	line,	once	the	protein	sequence	has	been	
optimised.	At	that	point,	the	many	benefits	of	using	C.	reinhardtii	as	a	platform	for	
the	production	of	therapeutic	recombinant	proteins	can	still	be	harnessed.		
4.4.2 Cpl-1	dimerisation	
Cpl-1	dimerisation	was	attempted	for	two	reasons.	Firstly,	a	report	by	Resch	et	al.	
(2011)	 demonstrated	 that	 pre-dimerised	 Cpl-1	 had	 a	 10-fold	 reduction	 in	 plasma	
clearance	and	a	two-fold	increase	in	activity.	Secondly,	the	C.	reinhardtii	chloroplast	
is	known	to	control	redox	reactions	and	is	capable	of	catalysing	disulphide	bonds	in	
recombinant	 proteins	 (Tran	 et	 al.	 2009),	 which	 can	 be	 further	 increased	 by	 the	
addition	of	selenocystamine	to	the	growth	medium	(Ferreira-Camargo	et	al.	2015).	
However,	our	attempt	to	produce	a	Cpl-1	dimer	in	the	C.	reinhardtii	chloroplast	was	
unsuccessful,	as	was	in	vitro	formation	of	disulphide	bonds	using	an	E.	coli	produced	
Cpl-1.		
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The	most	likely	reason	for	this	failure	is	the	presence	of	epitope	tags	on	the	protein	
C-terminus,	as	previously	discussed.	The	first	step	towards	testing	this	theory	is	to	
redesign	 the	 cpl1_dimer	 gene	 such	 that	 it	 encodes	 an	 N-terminal	 tag,	 with	 no	
additional	amino	acids	on	the	C-terminus.	The	gene	should	also	be	transformed	into	
E.	coli	using	a	plasmid	such	as	pIN-III	which	will	target	the	protein	to	the	periplasm	
for	disulphide	bond	catalysis,	or	into	an	engineered	strain	of	competent	E.	coli	such	
as	Rosetta-gami™.	If	this	successfully	produces	a	Cpl-1	dimer,	which	it	should	as	it	is	
a	simple	replication	of	the	work	by	Resch	et	al.	(2011),	then	the	same	gene	should	be	
transformed	into	the	C.	reinhardtii	chloroplast.	At	this	point,	it	will	be	clear	that	if	no	
dimer	can	be	seen	 in	 the	C.	 reinhardtii	 transformants,	 then	 it	 is	an	 issue	with	 the	
platform,	rather	than	the	protein.		
If	Cpl-1	dimers	can	accumulate	in	the	C.	reinhardtii	chloroplast,	then	investigations	
into	the	use	of	selenocystamine	can	be	untaken.	It	may	be	that	this	strategy	can	be	
used	to	increase	accumulation	levels	of	Cpl-1	in	total,	particularly	if	the	dimer	is	more	
stable	 than	 the	monomer.	 An	 investigation	 can	 also	 be	 carried	 out	 into	whether	
dimerised	 Cpl-1	 is	 less	 susceptible	 to	 degradation	 whilst	 in	 storage,	 as	 it	 would	
potentially	be	less	accessible	to	proteases	and	less	prone	to	denaturation.	This	would	
be	an	important	property	for	the	future	commercialisation	and	distribution	of	Cpl-1	
as	a	therapeutic.		
4.4.3 Holin	production	
Holins	enable	endolysins	to	cross	the	cell	membrane	during	the	bacteriophage	lytic	
cycle.	 The	 treatment	 of	 some	 bacteria	with	 both	 endolysins	 and	 holins	 has	 been	
shown	to	have	a	synergistic	effect	upon	cell	lysis	(Shi	et	al.	2012;	Song	et	al.	2016).	
However,	the	production	of	holins	in	bacterial	systems	is	problematic	as	they	insert	
into	cell	membranes	and	depolarise	the	cell.	Here	we	have	reported	the	successful	
accumulation	 of	 the	 holin	 Cph-1	 in	 the	 C.	 reinhardtii	 chloroplast	 but	 found	 that	
accumulation	quickly	ceased.	
The	‘silencing’	of	Cph-1	is	worthy	of	investigation,	as	chloroplast	transformations	are	
not	 usually	 susceptible	 to	 gene	 silencing,	 although	 it	 is	 common	 in	 nuclear	
transformations.	The	most	 likely	explanation	 is	 that	 in	 fact	homoplasmicity	of	 the	
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plastome	was	never	achieved	and	that	some	non-specific	PCR	amplification	occured,	
which	led	to	Figure	4.28	appearing	to	confirm	homoplasmicity.	Sequencing	of	the	PCR	
product	could	have	confirmed	this	and	a	TN72	negative	control	should	have	been	
included	to	demonstrate	that	heteroplasmicity	would	have	been	detected.	However,	
as	discussed	previously,	even	 if	 this	was	 the	case	 it	 seems	unlikely	 that	 the	strain	
would	 revert	 to	 the	 parental	 sequence,	 as	 loss	 of	 psbH	 function	 results	 in	
photosensitivity,	so	growth	under	bright	light	would	also	encourage	homoplasmicity.	
Furthermore,	an	investigation	by	PCR	of	the	genomic	DNA	is	displayed	in	Figure	4.30,	
and	clearly	demonstrates	that	the	cassette	is	present	somewhere	in	the	C.	reinhardtii	
genome.	 However,	 the	 same	 investigation	 failed	 to	 confirm,	 or	 refute,	 that	 the	
cassette	was	 located	 in	 the	 targeted	 location,	namely	between	the	 trnE	and	psbH	
genes	in	the	chloroplast.	A	primer	located	beyond	the	psbH	gene	is	required	so	that	
the	 entire	 region	 can	 be	 amplified	 to	 confirm	 that	 the	 cassette	 is	 not	 present	 or	
otherwise	-	this	would	be	very	straightforward.		
We	 know	 that	 over	 the	 millennia	 since	 the	 first	 photosynthetic	 prokaryote	 was	
engulfed	into	a	eukaryote	to	become	a	chloroplast,	the	vast	majority	of	the	genetic	
information	 from	the	chloroplast	genome	has	been	eliminated	or	migrated	 to	 the	
nucleus,	leaving	only	genes	essential	for	photosynthesis	in	the	chloroplast	(Howe	and	
Purton	2007).	It	is	possible	that	the	highly	undesirable	cph1-containing	cassette	has	
been	 translocated	 to	 the	 nucleus	 under	 a	 similar	 mechanism,	 and	 once	 there,	
silencing	mechanisms	are	prolific.	The	potential	mechanism	for	such	a	DNA	relocation	
is	 not	 understood,	 but	 such	 a	 mechanism	 is	 known	 to	 exist	 (Cullis	 et	 al.	 2009).	
Furthermore,	 such	 transfers	 have	 been	 shown	 to	 occur	 at	 high	 frequencies	 in	
tobacco:	more	than	1	in	5	million	cells	were	able	to	successfully	transfer	a	marker	
from	the	chloroplast	to	the	nucleus	(Stegemann	et	al.	2003).	Such	an	event	would	
explain	the	presence	of	the	cassette,	yet	lack	of	expression.	A	method	such	as	inverse	
PCR	could	then	be	used	to	discover	the	location	of	the	cassette.	
Regardless	 of	 the	 mechanism	 used	 by	 the	 C.	 reinhardtii	 cells	 to	 prevent	 Cph-1	
accumulation,	 it	 clearly	 is	 not	 tolerated	 by	 the	 cell.	 It	 is	 likely	 that	 the	 holin	was	
inserting	 into	 the	 thylakoid	 membranes,	 given	 their	 similarity	 to	 bacterial	 cell	
membranes.	As	shown	in	Figure	4.3,	a	large	number	of	holin	monomers	are	required	
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to	form	a	raft	and	then	oligomerise	into	a	hole	before	any	depolarisation	will	occur.	
It	may	be	that	the	holin	was	only	weakly	expressed	and	therefore	not	lethal	to	the	
cell,	but	caused	enough	selective	pressure	that	it	was	highly	undesirable.	This	would	
explain	why	transformants	were	obtained	but	quickly	lost	their	Cph-1	expression.		
It	is	likely	that	any	repeated	attempt	to	express	Cph-1	in	the	C.	reinhardtii	chloroplast	
will	 result	 in	 the	 activation	 of	 a	 mechanism	 to	 prevent	 its	 expression.	 However,	
holins,	unlike	endolysins,	are	not	species	specific	in	nature	and	are	generally	able	to	
insert	into	the	membranes	of	a	wide	range	of	bacterial	species	(Savva	et	al.	2008).	It	
would	be	interesting	to	express	a	holin	and	anti-holin	pair,	such	as	S105	and	S107	
from	the	lambda	bacteriophage,	as	well	as	the	holin	alone,	to	see	whether	expressing	
the	pair	prevents	silencing	of	the	holin	gene.	This	would	enable	a	continuation	of	the	
investigation	into	whether	the	addition	of	a	holin	alongside	Cpl-1	can	improve	its	lytic	
activity.	
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Chapter	5 Extending	the	Chlamydomonas	reinhardtii	chloroplast	
platform	to	other	endolysins	
5.1 Introduction	
5.1.1 Previous	endolysin	expression	in	the	C.	reinhardtii	chloroplast	
Dr	Henry	Taunt,	working	in	the	Purton	Lab,	was	the	first	to	successfully	express	an	
active	endolysin	in	the	C.	reinhardtii	chloroplast	(Taunt	2013).	The	work	showed	that	
Cpl-1	 accumulated	 to	 a	 relatively	 high	 level,	 approximately	 1%	 of	 total	 soluble	
protein,	 in	 the	 chloroplast	 and	 that	 it	 was	 active	 against	 S.	 pneumoniae	 in	 vitro.	
However,	Dr	Taunt	was	unable	to	show	expression	of	two	other	endolysins,	Gp20	and	
Lys16	that	target	Propionibacterium	acnes	and	Staphylococcus	aureus,	respectively.	
The	work	by	Taunt	 (2013)	also	attempted	to	 identify	elements	of	endolysin	genes	
that	resulted	in	successful	or	unsuccessful	expression	in	the	C.	reinhardtii	chloroplast.	
However,	while	 several	 fusion	 proteins	were	 created	 to	 test	 this	 theory,	 no	 clear	
conclusions	 could	 be	 drawn.	 Additionally,	 work	 by	 Dr	 Laura	 Stoffels,	 also	 of	 the	
Purton	group,	achieved	expression	and	activity	of	the	S.	pneumoniae	endolysin	Pal,	
but	 failed	 to	 show	 activity	 of	 the	Staphylococcus	 aureus	 targeting	 endolysin	φ11,	
despite	detecting	expression	 (Stoffels	2015).	Another	endolysin	SPN9CC,	 targeting	
Salmonella	typhimurium,	was	expressed	by	Dr	Rosie	Young	as	a	proof	of	concept	that	
recombinant	proteins	highly	toxic	to	E.	coli	can	be	synthesised	in	the	C.	reinhardtii	
chloroplast	 using	 a	 synthetic	 tRNA	 system,	 but	 the	 activity	 of	 SPN9CC	 was	 not	
investigated	(Young	and	Purton	2015).	As	a	Gram-negative	targeting	endolysin,	it	is	
unlikely	to	be	active	against	the	target	bacterium	without	modification	owing	to	the	
presence	of	the	outer	membrane.		
Current	 work	 in	 the	 Purton	 Group	 by	 Juliana	 de	 Costa	 Ramos	 (unpublished)	 is	
focussed	 upon	 producing	 endolysins	 targeting	 Gram-negative	 bacteria.	 Two	 such	
endolysins	 (LysAB2	 and	 LoGT-023)	 have	 been	 successfully	 expressed	 in	 the	 C.	
reinhardtii	 chloroplast,	 and	 although	 the	 ‘target	 bacteria’	 for	 both	 endolysins	 is	
Acinetobacter	baumannii,	Gram-negative	endolysins	 tend	 to	be	much	 less	 specific	
than	 those	 targeting	 Gram-positive	 bacteria	 and	 therefore	 have	 a	 much	 broader	
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spectrum	of	lytic	activity.	For	example,	the	endolysin	LysAB2	has	been	reported	to	
effectively	 lyse	 Staphylococcus	 aureus,	 Bacillus	 subtilis,	 Streptococcus	 sanguis,	
Escherichia	 coli,	 Citrobacter	 freundii	 and	 Salmonella	 enterica,	 all	 in	 addition	 to	
Acinetobacter	 baumannii,	 which	 the	 bacteriophage	 producing	 LysAB2	 specifically	
infects	(Lai	et	al.	2011).	Table	5.1	lists	all	known	attempts	at	expressing	endolysins	in	
the	C.	reinhardtii	chloroplast	to	date.		
Endolysin	 Target	pathogen	 Successfully	
expressed	in	
C.	reinhardtii	
chloroplast	
Active	
against	
target	
pathogen	
Reference	
Cpl-1	 Streptococcus	
pneumoniae	
Yes	 Yes	 (Taunt	2013)	
Gp20	 Propionibacterium	
acnes	
No	 N/A	 (Taunt	2013)	
Lys16	 Staphylococcus	
aureus	
No	 N/A	 (Taunt	2013)	
Pal	 Streptococcus	
pneumoniae	
Yes	 Yes	 (Stoffels	2015)	
φ11	 Staphylococcus	
aureus	
Yes	 No	 (Stoffels	2015)	
SPN9CC	 Salmonella	
typhimurium	
Yes	 Not	tested	 (Young	and	
Purton	2015)	
LoGT-023	
(Artilysin®)	
Acinetobacter	
baumannii	
Yes	 Yes	 Juliana	de	
Costa	Ramos	
(unpublished)	
LysAB2	 Acinetobacter	
baumannii	
Yes	 Yes	 Juliana	de	
Costa	Ramos	
(unpublished)	
CD27L1-179	 Clostridium	difficile	 Yes	 Yes	 This	study	
Table	5.1	The	full	list	of	endolysin	expression	attempts	by	the	Purton	Group.	SPN9CC,	LoGT-
023	 and	 LysAB2	 target	 Gram-negative	 bacteria,	while	 the	 others	 all	 target	 Gram-positive	
bacteria.	
5.1.2 The	need	for	more	endolysins	
As	discussed	in	1.2.2.4,	Gram-positive	endolysins	have	a	very	narrow	spectrum	of	lytic	
activity.	 This	 property	 is	 highly	 advantageous	 in	 some	 respects,	 yet	 highly	
problematic	in	others.	The	advantage	of	a	narrow	spectrum	antibiotic	is	that	only	the	
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target	 pathogenic	 bacteria	 are	 killed,	 while	 the	 commensal	 bacteria	 remain	
unharmed.	This	property	limits	the	development	of	resistance	and	the	opportunity	
for	pathogenic	re-colonisation.	The	disadvantage	is	that	a	precise	identification	of	the	
pathogen	 causing	 the	disease	must	 be	made	before	 the	 correct	 endolysin	 can	be	
prescribed	by	a	clinician,	and	a	distinct	endolysin	therapeutic	must	be	produced	for	
every	common	bacterial	infection.	
Unlike	 conventional	 antibiotics,	 where	 a	 single	 new	 drug	 discovery	 (such	 as	
teixobactin	 1.1.2.2)	 has	 the	 potential	 to	 treat	 hundreds	 of	 different	 bacterial	
infections,	 endolysin	 therapy	 requires	 the	development	 of	 a	 large	 arsenal	 of	 very	
specific	protein	pharmaceuticals.	As	shown	in	Table	5.1,	the	ability	to	produce	active	
endolysins	in	C.	reinhardtii	is	far	from	routine,	with	only	a	~56%	success	rate	so	far.	It	
is	important,	therefore,	to	continue	to	attempt	to	express	new	endolysins	as	well	as	
to	try	to	understand	the	factors	affecting	expression.	This	chapter	demonstrates	the	
successful	 expression	 of	 CD27L	 in	 the	 C.	 reinhardtii	 chloroplast,	 as	 well	 as	
documenting	an	attempt	to	achieve	expression	of	Gp20,	which	has	failed	to	express	
in	previous	efforts.		
5.2 Aims	and	objectives	
1. To	produce	a	transgenic	 line	of	C.	reinhardtii	 in	which	the	endolysin	CD27L	
accumulates.	
2. To	demonstrate	the	activity	of	CD27L	on	C.	difficile	in	vitro.	
3. To	produce	a	transgenic	line	of	C.	reinhardtii	in	which	Gp20	accumulates.	
4. To	demonstrate	the	activity	of	Gp20	on	P.	acnes	in	vitro.	
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5.3 Results	and	discussion	
5.3.1 Clostridium	difficile,	ΦCD27	and	CD27L1-179	
Clostridium	difficile	is	a	Gram-positive	bacterium	of	particular	importance	due	to	its	
prevalence	as	a	common	hospital-acquired	infection.	C.	difficile	 infection	(CDI)	 is	a	
toxin-mediated	infection,	and	is	the	major	cause	of	pseudomembranous	colitis	(Best	
et	 al.	 2012).	 The	 ability	 of	 C.	 difficile	 to	 form	 spores,	 which	 can	withstand	 harsh	
conditions	and	antibiotics,	means	that	 it	 is	often	the	first	bacterium	to	re-colonise	
the	human	gut	after	treatment	with	broad-spectrum	antibiotics.	While	resistance	to	
antibiotics	 has	 been	 reported	 in	 C.	 difficile,	 vancomycin	 remains	 the	 first	 line	 of	
treatment	and	until	2014	resistance	to	vancomycin	was	rarely	observed	(Hargreaves	
and	Clokie	2014).	However,	recently	there	have	been	reports	of	reduced	vancomycin	
susceptibility	(Spigaglia	2016),	emphasizing	the	need	for	new	treatments.		
5.3.2 C.	difficile	endolysin	CD27L	
The	 bacteriophage	 ΦCD27	 infects	 C.	 difficile,	 and	 its	 endolysin,	 CD27L,	 has	 been	
identified	and	demonstrated	to	cause	C.	difficile	 lysis	 in	vitro	when	expressed	as	a	
recombinant	protein	in	E.	coli	(Mayer	et	al.	2008).	CD27L	has	a	similar	conformation	
to	many	endolysins	–	a	C-terminal	cell	binding	domain,	and	an	N-terminal	catalytic	
domain.	 Removal	 of	 the	 C-terminal	 domain,	 to	 create	 CD27L1-179	 was	 found	 to	
improve	enzyme	activity	 and	marginally	 extend	 the	 lytic	 range	of	 the	endolysin	 –	
enabling	it	to	lyse	more	bacterial	species	(Mayer	et	al.	2008).		
The	 C.	 reinhardtii	 chloroplast	 has	 been	 successfully	 used	 to	 express	 two	 active	
endolysins	to	date,	Cpl-1	and	Pal,	both	of	which	are	specific	to	S.	pneumoniae.	To	
develop	the	C.	reinhardtii	chloroplast	as	a	platform	to	produce	endolysins,	and	given	
the	specific	nature	of	endolysins,	 it	 is	 important	to	show	production	of	endolysins	
that	 are	 active	 against	 a	 range	 of	 bacteria.	 To	 this	 end,	 the	 truncated	 endolysin	
CD27L1-179,	which	has	a	partially	resolved	crystal	structure	(PDB	code	4CU5	and	3QAY)	
and	has	been	shown	to	be	active	against	a	small	range	of	bacteria	when	produced	in	
E.	coli,	was	chosen	as	a	novel	candidate	for	C.	reinhardtii	chloroplast	expression.	
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5.3.2.1 Production	of	a	C.	reinhardtii	line	expressing	CD27L	
From	 hence	 forth,	 CD27L	 will	 refer	 to	 the	 truncated	 version	 of	 the	 endolysin,	
previously	referred	to	as	CD27L1-179.		
5.3.2.1.1 Gene	design	and	codon	optimization	
The	CD27L	protein	is	accessible	by	PDB	codes	3QAY	(catalytic	domain)	and	4CU5	(Cell	
binding	domain).	The	179-amino	acid	sequence	(catalytic	domain)	was	obtained	from	
RCSB	PDB	(a	histidine	amino	acid	was	removed	from	the	N-terminus,	which	remained	
from	the	His-tag)	and	the	gene	sequence	was	codon	optimized	for	the	C.	reinhardtii	
chloroplast	 as	 described	 in	 2.3.2.	 An	HA	 tag	was	 added	 to	 the	 C-terminus	 of	 the	
protein	coding	sequence	 for	western	blot	detection,	and	SapI	and	SphI	 restriction	
sites	were	 included	 for	 cloning	purposes.	The	 full-length	gene	was	 synthesized	by	
Integrated	DNA	Technologies	as	a	gBlock®	Gene	Fragment	(Appendix	J).	
5.3.2.1.2 Expression	cassette	production	
Given	that	CD27L	has	previously	been	expressed	in	E.	coli	without	detrimental	effects	
to	E.	 coli	 growth,	 there	were	no	concerns	about	 its	 toxicity	during	cloning,	 so	 the	
pSRSapI	 transformation	 vector	 could	 be	 safely	 used	 instead	 of	 the	 variant	 vector	
pWUCA2	that	allows	UGA	stop	codons	to	be	introduced	into	the	coding	region	(Young	
and	Purton	2015).	The	synthesized	DNA	was	digested	with	SapI	and	SphI	restriction	
enzymes	and	ligated	into	the	pSRSapI	vector	and	the	insertion	was	confirmed	by	DNA	
sequencing.	
5.3.2.1.3 C.	reinhardtii	transformation	
The	 recipient	 line	 TN72	 was	 transformed	 by	 the	 glass	 bead	 method	 using	 the	
pSRSapI_cd27l-HA	plasmid.	The	resulting	transformed	line	 is	represented	 in	Figure	
5.1.	Photosystem	II	functionality	is	restored	by	psbH	and	the	resulting	transformants	
were	capable	of	growing	phototrophically	on	minimal	media.	Transformants	were	
shown	to	reach	a	homoplasmic	state	by	PCR	(Appendix	K)	as	described	in	2.3.17.	
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Figure	5.1	TN72	recipient	strain	successfully	transformed	to	carry	cd27l-HA	under	the	psaA	
exon	1	promoter/5’UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	
5.3.2.1.4 Western	blot	confirmation	
Whole	cell	preparations	of	three	TN72_SR_cd27l-HA	transformants	(T1-3),	as	well	as	
TN72_SR_cpl1-HA	 and	 TN72_SR_Control	 (as	 positive	 and	 negative	 controls,	
respectively)	 were	 prepared	 and	 separated	 by	 SDS-PAGE.	 After	 blotting	 to	 a	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	with	 anti-HA	primary	 antibody,	 then	 incubated	with	 an	 IRDye®	 secondary	
antibody.	 Fluorescence	 was	 observed	 using	 the	 LiCor	 Odyssey®	 CLx	 system.	 The	
resulting	image	is	shown	in	Figure	5.2.	
	
Figure	 5.2	 Western	 blot	 analysis	 shows	 that	 a	 ~21	 kDa	 protein	 is	 detected	 by	 anti-HA	
antibodies	in	the	three	TN72_SR_cd27l-HA	extracts,	and	not	in	the	negative	control.	This	is	
likely	to	be	CD27L	protein.		
(kDa)	
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CD27L	 protein	 accumulates	 to	 easily	 detectable	 levels	 in	 all	 three	 transformant	
clones,	and	is	of	the	expected	size.		
5.3.2.2 Activity	of	CD27L	crude	extract	against	‘stripped’	E.	coli		
Since	it	was	not	feasible	to	set	up	C.	difficile	cultivation	facilities	in	our	lab,	an	assay	
using	‘stripped’	E.	coli	was	used	since	CD27L	had	been	shown	to	be	active	against	this	
bacterium	(Mayer	et	al.	2011).	The	E.	coli	had	to	be	stripped	of	their	outer-membrane	
to	enable	access	to	the	cell	wall	by	the	endolysin	as	described	in	2.7.2.2	(Nakimbugwe	
et	al.	2006).	
Crude	 extracts	 of	 TN72_SR_cd27l-HA	 and	 TN72_SR_Control	 were	 prepared	 as	
described	in	2.5.1,	and	a	Bradford	assay	was	performed	to	measure	the	total	protein	
in	each	sample.	5	μg	of	each	crude	extract,	as	well	as	5	μg	of	BSA	to	act	as	an	osmotic	
pressure	control,	were	added	to	a	96-well	plate,	containing	200	μl	of	stripped	E.	coli	
in	each	well.	The	change	in	OD595	was	measured	by	a	FLUOstar	Omega	plate	reader	
(BMG	Labtech)	over	a	period	of	200	minutes	at	37	°C.	The	resulting	change	in	OD595	
is	displayed	in	Figure	5.3.	
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Figure	 5.3	 A	 turbidity	 reduction	 assay,	measuring	 the	 reduction	 in	 OD	 (595	 nm)	 in	wells	
containing	E.	coli	stripped	of	their	outer-membrane	and	challenged	with	crude	C.	reinhardtii	
extracts.	The	BSA	is	used	as	an	osmotic	pressure	control,	while	the	NaPi	buffer	shows	the	
rate	of	cell	autolysis	when	added	to	the	cells	in	the	absence	of	osmotic	pressure.	
The	crude	extract	containing	CD27L	appears	to	show	activity	against	the	stripped	E.	
coli	cells,	as	there	is	a	much	greater	drop	in	OD	than	in	the	BSA	control.	However,	
there	does	appear	to	be	some	activity	from	the	crude	extract	of	the	control	strain	
also.	The	shape	of	the	curve	for	the	two	C.	reinhardtii	crude	extracts	looks	more	like	
the	characteristic	kill	curve	expected,	than	the	linear	rate	observed	for	the	addition	
of	NaPi	Buffer.	
5.3.2.3 Activity	of	CD27L	crude	extract	against	C.	difficile	
In	order	to	test	the	endolysin	against	C.	difficile,	a	category	two	biohazard	for	which	
our	lab	was	not	equipped,	a	collaboration	was	established	with	Dr	Melinda	Mayer,	
whose	group	at	the	Quadram	Institute	Bioscience	(formerly	the	Norwich	Institute	of	
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Food	Research)	were	the	first	to	identify	CD27L	(Mayer	et	al.	2008).	This	enabled	the	
testing	 of	 the	 CD27L-containing	 crude	C.	 reinhardtii	 extract	 directly	 on	C.	 difficile	
using	the	Mayer	group’s	established	protocol.	
A	 turbidity	 reduction	 assay	 was	 performed	 as	 described	 in	 2.7.2.3.	 Two	
concentrations	of	 crude	extract,	 in	NaPi	buffer,	were	used:	 10	μg	and	50	μg.	 The	
purified	CD27L	was	provided	by	Dr	Mayer	and	used	as	a	positive	control.	It	was	an	
old	(2008)	NiNTA-purified	CD27L	sample	produced	in	E.	coli,	so	the	concentration	was	
deemed	 irrelevant	 due	 to	 its	 age	 as	 much	 of	 it	 was	 thought	 to	 have	 degraded,	
however,	it	still	serves	as	a	useful	positive	control.		
	
Figure	5.4	Clostridium	difficile	turbidity	reduction	assay.	The	purified	CD27L	was	provided	by	
Dr	Mayer	as	a	positive	control	and	TN72_SR_Control	as	a	negative	control.	Performed	by	Dr	
Melinda	Mayer	at	Quadram	Institute	Bioscience,	Norwich,	UK.	
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Figure	5.4	shows	that	the	TN72_SR_Control,	which	was	used	as	a	negative	control,	
appears	to	have	an	inhibitory	effect	upon	cell	lysis	when	compared	to	the	NaPi	buffer	
control.	This	is	believed	to	be	due	to	the	effect	of	a	higher	osmotic	pressure	on	the	
C.	difficile	cells	due	to	the	presence	of	other	proteins	in	the	crude	extract,	and	has	
been	reported	previously	(Mayer	et	al.	2010).	
5.3.2.4 Enriched	CD27L	crude	extract		
The	osmotic	pressure	effects	seen	in	the	C.	difficile	turbidity	reduction	assay	(Figure	
5.4),	and	the	apparent	activity	of	the	control	extract	observed	in	Figure	5.3	against	
stripped	E.	coli	cells,	hindered	our	ability	to	satisfactorily	measure	the	activity	of	the	
C.	 reinhardtii	produced	endolysin.	Consequently,	 it	was	decided	to	change	the	HA	
epitope	tag	on	the	C-terminus	of	the	CD27L	protein	to	a	StrepII	tag	to	better	enable	
enrichment	or	 purification.	 This	was	performed	 to	 enable	 a	better	 comparison	of	
endolysin	activities	without	the	effects	of	the	C.	reinhardtii	crude	extract.		
5.3.2.4.1 Expression	of	CD27L-StrepII	in	C.	reinhardtii	
PCR	was	used	to	change	the	epitope	tag	on	the	cd27l	gene.	The	reverse	primer	was	
designed	to	have	an	overhang	with	the	StrepII	tag	sequence	attached,	thus	removing	
the	HA	tag	and	adding	the	StrepII	tag.	The	StrepII	tag	is	shown	in	lower	case,	and	the	
start	and	stop	codons	are	underlined	on	the	primers	below:	
cd27l.F:		 	 TGGTATTGCTCTTCAATGAAAATTTGTATTACT 
cd27l_StrepII.R:		 ACTGACGCATGCTTATTAtttttcgaattgtgggtgagacca 
GTTAATGTTTTTGTTTAAAACACCTTCAAC 
 
The	PCR	product	was	digested	with	SphI	and	SapI	restriction	enzymes	and	ligated	into	
pSRSapI	as	described	in	2.3.10	and	2.3.11.	Sequencing	confirmed	the	addition	of	the	
correct	encoding	sequence	for	the	StrepII	tag.	
The	 recipient	 line	 TN72	 was	 transformed	 by	 the	 glass	 bead	 method	 using	 the	
pSRSapI_cd27l-StrepII	 plasmid.	 The	 resulting	 transformed	 line	 is	 represented	 in	
Figure	 5.5.	 Photosystem	 II	 functionality	 was	 restored	 by	 psbH	 and	 the	 resulting	
transformants	 were	 capable	 of	 growing	 phototrophically	 on	 minimal	 media.	
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Transformants	were	 shown	 to	 reach	a	homoplasmic	 state	 (Appendix	 L)	by	PCR	as	
described	in	2.3.17.	
	
Figure	5.5	 TN72	 recipient	 strain	 successfully	 transformed	 to	 carry	cd27l-StrepII	 under	 the	
psaA	exon	1	promoter/5’UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	
5.3.2.4.2 Confirmation	by	Western	blotting	
Whole	cell	preparations	of	TN72_SR_cd27l-StrepII,	as	well	as	TN72_SR_cd27l-HA,	and	
TN72_SR_Control	(as	positive	and	negative	controls	respectively)	were	prepared	and	
separated	by	SDS-PAGE.	After	blotting	to	nitrocellulose	membrane	and	blocking	as	
described	 in	2.4.5,	 the	membrane	was	probed	with	 anti-StrepII	 primary	 antibody,	
then	incubated	with	IRDye®	secondary	antibody.	Fluorescence	was	observed	using	
the	 LiCor	Odyssey®	 CLx	 system.	 The	membrane	was	 then	 re-probed	with	 anti-HA	
primary	 antibody	 and	 IRDye®	 secondary	 antibody.	 The	 two	 images	 are	 shown	 in	
Figure	5.6.		
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Figure	5.6	Western	blot	analysis	of	 the	membrane	probed	firstly	with	anti-StrepII	primary	
antibodies	(left),	then	additionally	with	anti-HA	antibodies	(right).	CD27L	accumulation	was	
detected	 in	 the	 expected	 cell	 lines	 i.e.	 CD27L-StrepII	 was	 detected	 with	 the	 anti-StrepII	
antibody	and	the	use	of	the	anti-HA	antibody	also	revealed	the	presence	of	CD27L-HA.	The	
non-specific	band	confirms	that	a	similar	quantity	of	extract	was	loaded	on	to	the	gel	for	all	
three	strains.		
5.3.2.4.3 Relative	protein	accumulation	levels	
The	 use	 of	 the	 protein	 standard,	 described	 in	 3.3.1.2.5,	 enabled	 the	 relative	
quantification	of	CD27L	protein	accumulation	in	the	two	C.	reinhardtii	 lines.	Figure	
5.7	shows	comparisons	of	the	two	whole	protein	cell	preparations	used	in	5.3.2.4.2	
and	a	10	μg	protein	standard	is	included.	The	standard	is	tagged	with	HA	and	StrepII	
epitopes,	enabling	an	approximate	comparison	of	the	protein	accumulation	seen	in	
each	sample.		
(kDa)	
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Figure	5.7	Western	blot	analysis	of	whole	cell	extracts,	first	normalised	by	culture	OD740	and	
compared	 to	 a	 10	 μg	 protein	 standard.	 Quantification	 was	 performed	 using	 the	 LiCor	
Odyssey®	CLx	system,	after	which	the	standard	was	used	to	normalise	the	two	blots	and	the	
signal	from	the	21	kDa	bands	compared	in	a	bar	chart.		
The	 protein	 accumulation	 level	 of	 the	 HA-tagged	 protein	 appears	 to	 be	
approximately	 six	 times	 greater	 than	 the	 StrepII-tagged	 protein.	 However,	 as	
discussed	 in	 3.3.2.2.4.3,	 the	 difference	 observed	 is	 possibly	 due	 to	 the	 different	
accessibility	 of	 the	 epitope	 tags	 on	 the	 Cpl_1-HA-StrepII	 protein	 standard.	 This	 is	
supported	by	that	fact	that	this	pattern	also	appears	between	the	Cpl1-HA	and	Cpl1-
StrepII	accumulation	levels	and	it	seems	unlikely	that	the	StrepII	tag	is	having	such	a	
consistently	detrimental	effect	upon	accumulation	levels.		
(kDa)	
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5.3.2.4.4 Enrichment	of	CD27L-StrepII	using	HiTrap	StrepII	Column	
The	inclusion	of	a	StrepII	tag	on	CD27L	enables	enrichment	of	the	protein	and	will	
thus	allow	a	clearer	investigation	into	its	antibacterial	properties.	C.	reinhardtii	cell	
extracts	were	prepared	as	described	in	2.5.1,	and	ultracentrifuged	at	100,000	g	for	1	
hour	to	remove	cell	debris.	The	resulting	ultracentrifuged	(UC)	supernatant	was	then	
enriched	for	StrepII-tagged	proteins	using	the	commercially	available	HiTrap	StrepII	
Column,	 as	 described	 in	 2.5.3.	Western	 blot	 analysis	 of	 the	 resulting	 fractions	 is	
shown	in	Figure	5.8.	
	
Figure	5.8	Western	blot	analysis	using	anti-StrepII	primary	antibody	and	IRDye®	secondary	
antibody.	Fractions	from	sample	preparation	and	the	HiTrap	StrepII	column	were	collected	
and	separated	by	SDS-PAGE.	The	eluted	fraction	has	no	non-specific	band,	and	 ‘Elution	2’	
was	used	for	further	experiments.	
It	is	clear	from	Figure	5.8	that	enrichment	has	been	successful,	and	that	the	eluted	
fractions	contain	high	quantities	of	CD27L	and	low	quantities	of	the	non-specifically	
recognised	protein.	It	is	also	noticeable	that	a	large	proportion	of	the	CD27L	protein	
is	lost	in	the	ultracentrifuged	pellet,	but	for	the	purposes	of	this	investigation,	this	is	
not	 important.	 In	 the	 future,	optimisation	of	 this	protocol	may	 result	 in	a	greater	
yield.		
5.3.2.4.5 Activity	of	enriched	CD27L	crude	extract	against	stripped	E.	coli		
The	enriched	CD27L	extract	was	prepared	as	above	(5.3.2.4.4)	and	an	enriched	Cpl-1	
extract	was	used	as	a	negative	control.	A	Bradford	assay	was	performed	to	measure	
the	total	protein	in	each	sample.	
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The	enriched	extract	was	initially	tested	for	activity	using	the	stripped	E.	coli	assay.	
0.4	μg	of	each	enriched	extract,	as	well	as	5	units	of	egg	white	lysozyme	to	act	as	a	
positive	control,	were	added	to	a	96-well	plate	with	stripped	E.	coli.	The	change	in	
OD595	was	measured	over	a	period	of	90	minutes	at	37	°C.	The	resulting	change	in	
OD595	is	displayed	in	Figure	5.3.	
	
	
Figure	5.9	A	turbidity	reduction	assay,	measuring	the	reduction	in	OD595	in	wells	containing	
E.	coli	stripped	of	their	outer-membrane	and	treated	with	enriched	C.	reinhardtii	extracts.	
The	Cpl-1	extract	acts	as	a	negative	control.	Only	the	first	25	minutes	are	shown,	as	the	OD	
remains	stable	beyond	this.	
The	enriched	CD27L	appears	to	be	highly	active,	with	the	OD595	drop	plateauing	after	
approximately	15	minutes.	The	Cpl-1	enriched	extract	demonstrates	the	specificity	
of	endolysins,	and	acts	as	a	negative	control	in	this	instance.	The	20mM	NaPi	buffer	
does	not	appear	 to	produce	 the	same	 level	of	 cell	 lysis	as	observed	 in	Figure	5.3,	
		 215	
probably	because	smaller	sample	volumes	were	used	in	this	instance	–	around	5	μl	
as	opposed	to	~30	μl.	There	is	little	difference	observed	between	the	Cpl-1	and	NaPi	
buffer,	 suggesting	 that	 this	 enrichment	 has	 removed	many	 of	 the	 other	 proteins	
contributing	 to	 the	 osmotic	 pressure	 effect	 described	 previously.	 The	 lysozyme,	
which	was	included	to	act	as	a	positive	control,	does	cause	some	level	of	cell	lysis	but	
plateaus	with	an	OD595	drop	of	approximately	0.1.	
5.3.2.5 Activity	of	enriched	CD27L	crude	extract	against	C.	difficile		
Given	the	success	of	enriched	CD27L	against	E.	coli	shown	in	Figure	5.9,	similar	fresh	
samples	 were	 sent	 to	 Norwich	 for	 in	 vitro	 testing	 upon	 C.	 difficile.	 The	 turbidity	
reduction	assay	was	performed	as	described	in	2.7.2.3.	
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Figure	5.10	A	turbidity	reduction	assay,	measuring	the	reduction	in	OD600	in	wells	containing	
C.	difficile	challenged	with	enriched	C.	reinhardtii	extracts.	The	Cpl-1	extract	acts	as	a	negative	
control.	The	buffer	used	 is	the	Strep-Tactin®	elution	buffer	provided	by	the	HiTrap	StrepII	
column	kit,	containing	desthiobiotin	(a	biotin	analogue).	0.3	μg	of	each	enriched	extract	were	
used.	 The	CD27L	 (E.	 coli)	 refers	 to	 a	purified	CD27L	 recombinant	protein	produced	by	Dr	
Mayer	 in	 E.	 coli,	 to	 act	 here	 as	 a	 positive	 control.	 This	 turbidity	 reduction	 assay	 was	
performed	by	Dr	Melinda	Mayer	at	Quadram	Institute	Bioscience,	Norwich,	UK.	
The	 data	 show	 convincing	 lysis	 of	 C.	 difficile	 cells	 in	 vitro,	 despite	 the	 fact	 that	
autolysis	 appears	 to	 be	 relatively	 high,	 as	 is	 characteristic	 of	 C.	 difficile	 when	
incubated	for	extended	periods	of	time	in	oxygenated	conditions,	as	C.	difficile	is	an	
obligate	anaerobe	(Mayer	et	al.	2011).	The	samples	were,	unfortunately,	much	more	
dilute	than	Dr	Mayer	commonly	uses	for	turbidity	reduction	assays,	and	in	the	future	
a	technique	such	as	ammonium	sulphate	precipitation	may	enable	more	endolysin	
(~10	μg	rather	than	0.3	µg)	to	be	added	to	each	well.		
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The	conclusions	of	all	of	these	CD27L	experiments	is	that	another	biologically	active	
and	stable	endolysin	can	be	produced	in	the	C.	reinhardtii	chloroplast.	The	addition	
of	 a	 StrepII	 tag	 to	 the	 recombinant	 protein	 enables	 the	 fast	 and	 relatively	 cheap	
enrichment	of	crude	extracts,	which	in	turn	has	allowed	us	to	observe	more	clearly	
the	activity	of	the	endolysin.		
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5.3.3 Propionibacterium	acnes,	bacteriophage	PA6	and	its	endolysin	Gp20	
Propionibacterium	acnes	is	a	prevalent,	Gram-positive,	commensal	bacterium	known	
best	for	its	role	in	the	common	skin	condition	acne	vulgaris.	Acne	vulgaris	is	believed	
to	affect	over	80	%	of	adolescents	and	as	such,	antibiotics	to	treat	it	have	been	over-
used	and	resistance	has	become	commonplace	(Leyden	et	al.	1983;	Bojar	and	Holland	
2004;	Taylor	et	al.	2014).	Some	broad-spectrum	antimicrobial	agents,	such	as	benzoyl	
peroxide,	 while	 still	 effective,	 have	 side	 effects	 that	 make	 their	 prolonged	 use	
unadvisable	(Fulton	et	al.	1974;	Bojar	et	al.	1995).	
The	treatment	of	acne	vulgaris	offers	a	large	market	and	unmet	need,	which	could	
possibly	be	served	by	endolysin	treatment.	As	acne	vulgaris	is	a	topical	affliction,	it	
also	presents	a	plausible	target	for	treatment	with	a	C.	reinhardtii	crude	extract.	
The	 bacteriophage	 PA6	 is	 known	 to	 infect	 P.	 acnes	 and	 in	 2007	 its	 genome	was	
sequenced	(Farrar	et	al.	2007).	The	same	study	showed	that	PA6	was	able	to	infect	
32	different	P.	acnes	isolates	including	antibiotic	resistant	strains.	PA6	belongs	to	the	
Siphoviridae,	 the	 same	 virus	 family	 as	 Dp-1	 (from	 which	 the	 endolysin	 Pal	 was	
isolated)	and	Φ11	(from	which	a	Staphylococcal	endolysin	was	isolated).	The	resulting	
genome	analysis	 identified	a	gene	encoding	a	putative	amidase,	named	gp20.	The	
identification	of	gp20	as	encoding	an	endolysin	is	further	supported	by	the	fact	that	
the	gene	immediately	downstream	of	it,	gp21,	appears	to	encode	a	holin:	a	classic	
endolysin-holin	gene	arrangement.	
To	date,	there	are	no	reports	in	the	literature	describing	the	successful	expression	of	
Gp20	as	a	recombinant	protein,	or	a	demonstration	of	peptidoglycan	cleavage	of	P.	
acnes	or	cell	lysis.	However,	a	US	patent	(US_2012_0195872_A1)	was	filed	in	2010	by	
Lysando	(an	aforementioned	endolysin	company)	describing	the	fusion	of	Gp20	to	an	
18	amino	acid	peptide	sequence,	which	was	shown	to	be	active	against	two	P.	acnes	
strains,	 presumably	working	 in	 a	 similar	manner	 to	 the	Artilysins®,	 also	discussed	
earlier	(1.2.2.1).	 
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5.3.3.1 Previous	attempts	to	express	Gp20	in	the	C.	reinhardtii	chloroplast	
Several	previous	attempts	to	express	Gp20	in	the	C.	reinhardtii	chloroplast	have	been	
made	in	the	Purton	lab.	These	have	included	insertion	into	the	chloroplast	in	different	
expression	cassettes,	with	different	promoter/5’UTRs,	and	even	as	chimeric	genes,	
but	detection	has	not	been	achieved	(Taunt	2013).	
5.3.3.2 New	attempt	to	produce	a	C.	reinhardtii	line	expressing	gp20		
One	variable	that	has	not	been	altered	however	 is	 the	C-terminal	HA	tag.	Epitope	
tags,	such	as	the	HA	tag,	are	an	extremely	useful	tool	for	detecting	proteins	for	which	
no	antibody	is	available,	such	as	new	proteins.	Traditionally	epitope	tags	are	added	
to	a	protein	terminus	in	the	hope	that	they	will	not	interfere	with	protein	function.	
However,	 as	 seen	 in	 this	 thesis	 and	 elsewhere	 in	 the	 literature	 (e.g.	 Brault	 et	 al.	
(1999)),	 epitope	 choice	 and	 position	 can	 alter	 protein	 accumulation	 levels	 and	
function.	A	terminal	tag	remained	a	sensible	choice,	given	that	the	structure	of	the	
Gp20	protein	is	unknown,	so	a	simple	switch	from	the	C-terminus	to	the	N-terminus	
of	the	protein	was	proposed.	
5.3.3.2.1 Gene	design	and	codon	optimization	of	gp20N	
The	 success	 of	 the	 pWUCA2	 expression	 vector	 (which	 allows	 stop	 codons	 to	 be	
inserted	into	a	gene-of-interest,	thereby	circumventing	toxicity	issues	when	cloning	
in	E.	coli	(Young	and	Purton	2015))	in	achieving	similar	levels	of	protein	accumulation	
in	the	C.	reinhardtii	chloroplast,	and	the	unknown	toxicity	of	the	Gp20	endolysin	in	E.	
coli	led	us	to	use	the	pWUCA2	plasmid	as	a	precaution.	Codon	Usage	Optimizer	Beta	
0.92	(Kong	2013)	was	used	to	optimize	the	gp20	gene	for	C.	reinhardtii	chloroplast	
expression.	 Three	 tryptophan	 codons	 spaced	 throughout	 the	 gene	were	 changed	
from	UGG	to	UGA.	The	HA	tag	coding	sequence	was	included	at	the	N	terminus.	SapI	
and	SphI	restriction	sites	were	included	for	cloning	into	the	pWUCA2	vector.	The	full-
length	gp20N-HA	(the	‘N’	indicates	that	the	HA	tag	is	placed	on	the	N	terminus)	gene	
was	synthesized	by	Integrated	DNA	Technologies	(Appendix	M).	
5.3.3.2.2 Expression	cassette	production	
SapI	 and	 SphI	 restriction	 enzymes	 were	 used	 to	 digest	 and	 ligate	 the	 gene	 into	
pWUCA2	in	frame,	producing	the	plasmid	pWUCA2_gp20N-HA.	DH5α	competent	E.	
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coli	cells	were	transformed	with	the	resulting	plasmid	and	sequencing	confirmed	the	
correct	insertion.	
5.3.3.2.3 C.	reinhardtii	transformation	
The	pWUCA2_gp20N-HA	plasmid	was	used	to	transform	recipient	C.	reinhardtii	strain	
TN72	 via	 the	 glass	 bead	 method	 as	 described	 2.3.13.	 Figure	 5.11	 illustrates	 the	
resulting	C.	reinhardtii	cell	line,	pWUCA2_gp20N-HA.	
	
Figure	5.11	TN72	recipient	strain	successfully	transformed	to	carry	gp20N-HA	under	the	psaA	
exon	1	promoter/5’UTR	in	the	chloroplast,	and	with	psbH	functionality	restored.	A	modified	
trnW	gene	has	been	co-introduced	to	translate	the	introduced	UGA	codons	(indicated	as	red	
bars)	in	the	gp20N	gene	as	tryptophans.	
The	resulting	transformants	were	confirmed	for	homoplasmicity	by	PCR	as	described	
in	 2.3.17	 (Appendix	 N).	 Finally,	 the	 correct	 insertion	 was	 confirmed	 by	 DNA	
sequencing	as	in	2.3.18.	
5.3.3.2.4 Western	blotting	unable	to	confirm	accumulation	
To	 test	 for	 the	 accumulation	 of	Gp20	 in	C.	 reinhardtii,	whole	 cell	 preparations	 of	
TN72_WUCA2_gp20N-HA,	TN72_A_gp20-HA	(Taunt	2013),	and	TN72_SR_Control	(as	
two	negative	controls)	were	prepared	and	separated	by	SDS-PAGE.	After	blotting	to	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	 with	 anti-HA	 primary	 antibody,	 then	 incubated	 with	 IRDye®	 secondary	
antibody.	 Fluorescence	 was	 observed	 using	 the	 LiCor	 Odyssey®	 CLx	 system.	 The	
resulting	image	is	shown	in	Figure	5.12.	
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Figure	5.12	Western	blot	analysis	of	whole	cell	extracts.	TN72_SR_Control	acts	as	a	negative	
control,	and	TN72_A_gp20-HA	demonstrates	the	previous	attempt	made	by	Taunt	(2013)	to	
express	gp20	in	the	C.	reinhardtii	chloroplast.	
No	protein	can	be	seen	 in	Figure	5.12	at	35	kDa,	 the	expected	size	 for	Gp20.	The	
possible	reasons	for	which	are	discussed	in	the	following	section.	
5.3.3.3 Possible	causes	for	gp20	expression	failure	
As	alluded	to	earlier	in	this	thesis,	failure	of	recombinant	protein	expression	is	quite	
commonplace	in	the	C.	reinhardtii	chloroplast	as	the	platform	is	still	in	the	relatively	
early	 stages	of	development.	 Two	possible	 reasons	 for	 failure	 to	detect	Gp20	are	
either	the	failure	of	translation	or	instability	of	the	protein.	This	same	conclusion	was	
drawn	by	Taunt	(2013),	when	gp20	failed	to	express	in	C.	reinhardtii	on	a	previous	
occasion,	 with	 transcription	 issues	 and	 protein	 degradation	 being	 considered	 as	
unlikely	due	to	previous	literature	suggesting	that	transcripts	are	usually	present	in	
failed	 recombinant	 protein	 expression	 attempts	 (Rochaix	 2001),	 and	 endolysins	
having	 evolved	 to	 remain	 stable	 in	 a	 prokaryotic	 environment	 (Oey	 et	 al.	 2009).	
Significant	efforts	were	made	by	Taunt	(2013)	to	investigate	and	ameliorate	failures	
of	 translation.	These	efforts	were	 focussed	upon	the	ribosome	binding	site.	Given	
that	the	upstream	atpA	promoter/5’	UTR	used	by	the	pASapI	expression	cassette	are	
known	 to	 be	 functional	 (See	 Cpl-1	 work	 3.3.2.2.1.4),	 it	 was	 supposed	 that	 the	
downstream	box	was	 playing	 an	 important	 role	 and	 in	 the	 instance	of	gp20,	was	
hindering	ribosome	binding.	This	was	investigated	by	including	the	first	34	codons	of	
(kDa)	
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the	endogenous	atpA	gene	followed	by	the	GOI,	to	create	a	fusion	(separated	by	a	
stromal	processing	peptidase).	The	plasmid	used	to	perform	this	was	named	pASap2	
and	was	created	by	Dr	Chloe	Economou	(Taunt	2013).	However,	 this	strategy	also	
failed	to	produce	any	visible	level	of	protein	accumulation.	
5.3.3.4 Production	of	an	E.	coli	line	expressing	Gp20	
The	 failure	 to	 detect	 Gp20	 accumulation	 in	 the	 C.	 reinhardtii	 chloroplast	 after	
attempting	 several	 strategies	 led	 us	 to	 investigate	whether	 Gp20	was	 stable	 and	
active	when	expressed	as	a	recombinant	protein	in	E.	coli.	A	previous	investigation	
by	Taunt	(2013)	failed	to	observe	expression	of	Gp20	in	E.	coli	lines	transformed	with	
pASapI	 containing	 the	 gp20	 gene,	 believing	 a	 lack	 of	 optimisation	 of	 the	 atpA	
promoter/5’UTR	for	E.	coli	expression	to	be	responsible	(Wannathong	et	al.	2016).	
We	investigate	this	further	here,	as	if	protein	accumulation	can	be	achieved	in	E.	coli,	
then	 it	 suggests	 that	 the	 protein	 is	 likely	 to	 be	 stable	 in	 C.	 reinhardtii	 and	 that	
translation	 is	 likely	 to	 be	 the	 key	 issue	 in	 the	 failure	 to	 detect	 the	 recombinant	
protein.	
5.3.3.4.1 Expression	cassette	production	
The	gp20N-HA	gene	used	previously	 could	not	be	 reused	 for	 expression	 in	E.	 coli	
owing	to	the	presence	of	stop	codons	in	the	gene,	as	it	was	originally	designed	for	
use	 with	 the	 pWUCA2	 plasmid.	 A	 gp20	 gene	 with	 a	 C-terminal	 HA	 tag,	 codon	
optimized	 for	 Synechocystis	 expression	 in	 another	 project	 and	 synthesized	 by	
Integrated	 DNA	 technologies,	 was	 used	 as	 a	 template.	 Primers	were	 designed	 to	
introduce	a	NcoI	restriction	site	upstream	of	the	ATG.	A	BamHI	site	already	existed	
below	 the	 stop	 codons	 so	 did	 not	 need	modifying.	 The	 introduced	mutations	 are	
shown	in	lowercase,	while	the	start	and	stop	codons	are	underlined.	
	 gp20_NcoI.F:		 CGTATACccATGGTGCGTTA	
gp20.R:		 GATTGCGGATCCTTATTAGGC	
The	PCR	product	was	digested	and	ligated	into	the	high	expression,	IPTG	inducible,	
plasmid	pProEX	HTb	(Figure	5.13)	and	transformed	into	E.	coli	strain	DH5a.	
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Figure	Removed	
	
Figure	 5.13	 Structural	 plasmid	 map	 of	 pProEX	 HTb	 and	 details	 of	 the	 multiple	 cloning	 site.	 Reproduced	 from	
http://www.biofeng.com/zaiti/dachang/pProEXHTb.html.		
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5.3.3.4.2 Coomassie	stain	confirmation	of	expression	
Synthesis	of	the	recombinant	protein	was	induced	using	IPTG	as	described	in	2.6.1.	
E.	 coli	 lysates	were	 then	 created	using	BugBuster™	as	described	 in	2.6.2	 for	both	
induced	and	uninduced	cultures	and	prepared	for	protein	analysis.	The	preparations	
were	separated	by	SDS-PAGE	and	stained	with	Coomassie	Brilliant	Blue	as	described	
in	2.4.4.	The	stained	gel	was	analysed	using	the	LiCor	Odyssey®	CLx	system	and	the	
resulting	image	is	displayed	in	Figure	5.14.	
	
Figure	5.14	Whole	cell	preparations	of	induced	and	uninduced	E.	coli	transformed	with	
pProEX_gp20-HA	were	separated	by	SDS-PAGE	and	total	protein	staining	was	performed	
using	a	Coomassie	stain.		
High	accumulation	is	observed	in	the	induced	E.	coli	at	the	expected	size	for	Gp20,	
which	is	~35	kDa.	There	is	no	protein	seen	in	the	uninduced	samples	which	gives	us	
confidence	that	the	observed	protein	is	indeed	Gp20.	
5.3.3.5 Activity	of	Gp20	
A	crude	lysate	of	the	induced	E.	coli	expressing	gp20	was	produced	using	a	Stansted	
‘Pressure	 cell’	 homogeniser	 (2.6.3),	 and	 centrifuged	 at	 5,000	 g	 for	 20	minutes	 to	
remove	 cell	 debris.	 The	 lysate	 was	 then	 filter	 sterilized	 using	 a	 0.22	 μm	 filter	 to	
remove	 any	 remaining	 viable	 E.	 coli	 cells.	 The	 same	 procedure	 was	 applied	 to	 a	
culture	 of	 untransformed	DH5α	 cells	 as	 a	 negative	 control.	 Untransformed	DH5α	
were	used	instead	of	uninduced	DH5α_ProEX_gp20-HA	to	avoid	issues	around	leaky	
expression	of	gp20	in	the	uninduced	control.	
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5.3.3.5.1 Crude	lysate	for	activity	assay	
The	pellet,	 lysate	and	 filter	 sterilized	 lysate	were	prepared	and	separated	by	SDS-
PAGE.	After	blotting	to	nitrocellulose	membrane	and	blocking	as	described	in	2.4.5,	
the	 membrane	 was	 probed	 with	 anti-HA	 primary	 antibody,	 then	 incubated	 with	
IRDye®	secondary	antibody.	Fluorescence	was	observed	using	the	LiCor	Odyssey®	CLx	
system.	The	resulting	image	is	shown	in	Figure	5.15.	
	
Figure	5.15	Western	blot	analysis	shows	HA-tagged	Gp20	in	all	three	lanes	of	the	induced	
DH5α_ProEX_gp20-HA	lysate,	and	not	in	the	negative	control	lanes.		
Although	it	appears	that	a	large	proportion	of	Gp20	protein	is	lost	in	the	pellet,	there	
is	still	a	detectable	quantity	in	the	filter	sterilised	lysate.	This	is	an	encouraging	result,	
as	it	suggests	that	recombinant	Gp20	can	exist	in	a	stable	form.	This	finding	reduces	
the	likelihood	that	Gp20	instability	is	the	major	cause	of	the	lack	of	detectable	protein	
the	 C.	 reinhardtii	 chloroplast,	 and	 requires	 us	 to	 look	 once	 again	 at	 translation	
elongation	as	the	most	likely	issue	preventing	accumulation.		
5.3.3.5.2 Colony	forming	unit	assay	against	P.	acnes	
In	order	to	test	whether	the	recombinant	Gp20	is	active,	a	colony	forming	unit	assay	
against	P.	acnes	was	performed	using	the	filter	sterilized	lysates	as	shown	in	Figure	
5.15.	
(kDa)	
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Cultures	of	P.	acnes	were	grown	anaerobically	as	described	in	2.1.5.3.	The	cultures	
were	centrifuged	at	5,000	g	for	20	minutes	and	resuspended	in	20	mM	NaPi	buffer.	
50	 μl	 of	 bacterial	 suspension	 and	 50	 μl	 of	 filter	 sterilized	 lysate	 or	 buffer	 were	
incubated	at	37	°C	for	0,	30,	60,	90,	120	or	150	minutes.	Three	10	μl	samples	were	
taken	 after	 the	 stated	 incubation	 time	 from	 each	 combination	 and	 spotted	 onto	
blood	 agar	 plates.	 After	 anaerobic	 incubation	 at	 37	 °C	 for	 one	week,	 growth	was	
visible	and	the	plates	were	photographed,	shown	in	Figure	5.16.	
	
Figure	5.16	P.	acnes	growth	on	blood	agar	plates	after	incubation	with	crude	E.	coli	lysates	
with	and	without	Gp20,	or	just	with	20	mM	NaPi	buffer.	As	is	often	the	case	with	P.	acnes,	
individual	colonies	tend	not	to	be	visible	and	a	small	lawn	of	cells	appears	instead	(Stoffels	
2015).	
The	presence	of	a	lawn,	rather	than	distinct	colonies	of	P.	acnes	makes	quantification	
of	 the	 antimicrobial	 effect	 of	 Gp20	 difficult	 to	 measure.	 However,	 visually	 there	
appeared	 to	 be	 no	 difference	 in	 growth	 between	 any	 of	 the	 spots	 regardless	 of	
substrate	and	incubation	time.	In	fact,	the	buffer	alone	appeared	to	reduce	the	lawn	
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the	most,	perhaps	due	to	the	osmotic	pressure	effects	described	previously	in	this	
thesis.	 Unfortunately,	 this	 experiment	 lacks	 a	 positive	 control,	 without	 which	we	
cannot	be	sure	that	Gp20	is	not	working	as,	for	example,	the	visible	bacteria	may	be	
something	other	than	P.	acnes	or	the	dosage	might	not	be	high	enough.		
This	result	tentatively	suggests	that	Gp20,	when	produced	as	a	recombinant	protein	
in	E.	coli,	does	not	display	strong	antibacterial	properties	towards	P.	acnes,	however,	
as	 mentioned,	 the	 assay	 requires	 improvements	 for	 this	 conclusion	 to	 be	 more	
convincing.	Since	Taunt	(2013)	initially	investigated	gp20	expression	in	C.	reinhardtii,	
13	 other	 P.	 acnes	 targeting	 endolysins	 have	 been	 identified	 from	 other	
bacteriophages	(Marinelli	et	al.	2012).	These	putative	endolysins	display	remarkable	
sequence	 similarity,	 as	 do	 the	 whole	 bacteriophage	 genomes	 themselves.	 This	 is	
unusual	for	bacteriophage	and	unexpected,	as	usually	a	high	level	of	genetic	diversity	
exists	 amongst	 bacteriophage	 (Pride	 et	 al.	 2012).	 The	 differences	 that	 do	 occur	
between	endolysin	sequences	are	mostly	in	the	flexible	linker	region	separating	the	
two	domains.	This	significant	level	of	similarity	led	Marinelli	et	al.	(2012)	to	suggest	
that	 any	 of	 the	 14	 endolysins	 chosen	 for	 recombinant	 production	 and	 endolysin	
therapy	would	be	successful.		
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5.4 Conclusion	and	future	work	
This	 chapter	 has	 attempted	 to	 express	 two	 endolysins	 in	 the	 C.	 reinhardtii	
chloroplast.	 The	 first,	 CD27L,	 has	 been	 shown	 in	 the	 literature	 to	be	 active	when	
produced	in	E.	coli	and	tested	in	vitro	against	C.	difficile	(Mayer	et	al.	2008).	Here	we	
have	shown	that	CD27L	can	be	expressed	in	C.	reinhardtii	to	a	relatively	high	level	
and	 is	 active	 in	 vitro	 against	 both	 stripped	E.	 coli	 and	C.	 difficile.	 In	 contrast,	 the	
second	endolysin,	Gp20,	has	no	literature	demonstrating	its	recombinant	synthesis	
or	activity	in	vitro	or	otherwise,	and	previous	attempts	to	express	gp20	in	E.	coli	and	
C.	reinhardtii	have	failed,	for	unknown	reasons	(Taunt	2013).	After	failing	to	achieve	
expression	in	C.	reinhardtii	with	a	different	epitope	tag	position,	the	focus	shifted	to	
achieving	expression	in	E.	coli	and	assaying	for	activity	against	P.	acnes.	Expression	in	
E.	coli	was	successful	but	activity	was	not	satisfactorily	assayed,	as	will	be	discussed	
further	below.		
5.4.1 CD27L	endolysin	
The	investigation	into	expressing	CD27L	in	C.	reinhardtii	has	been	relatively	successful	
to	date.	Expression	has	been	achieved	and	 the	use	of	 the	StrepII	 tag	has	enabled	
enrichment	of	CD27L	from	crude	extracts,	allowing	more	precise	activity	assays	to	be	
performed.	Activity	has	been	confirmed	 in	vitro	against	both	C.	difficile,	 its	natural	
target,	and	E.	coli	cells	when	stripped	of	their	outer-membrane,	which	acts	as	a	useful	
assay	when	C.	difficile	facilities	are	unavailable.		
As	with	Cpl-1	in	Chapter	3,	attempts	to	quantify	CD27L	accumulation	have	produced	
varied	 results.	 The	 StrepII-tagged	 CD27L	 protein	 appears	 to	 accumulate	 to	
significantly	lower	levels	than	the	HA-tagged	version	–	a	pattern	also	seen	with	Cpl-
1.	The	 finding	 that	StrepII-tagged	proteins	consistently	appear	 to	accumulate	 to	a	
lower	level	than	their	HA-tagged	counterparts	has	led	us	to	question	the	validity	of	
the	double-tagged	protein	standard	produced	in	3.3.1.2.6,	as	has	been	discussed	in	
more	 detail	 in	 3.3.2.2.4.3.	 For	 both	 this	 CD27L	 work	 and	 the	 Cpl-1	 work,	 it	 is	
important	 to	address	 this	 issue	and	 find	a	 suitable	method	of	quantifying	protein	
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accumulation,	such	as	raising	antibodies	to	CD27L	itself	and	using	the	purified	protein	
as	a	standard.	
While	the	results	shown	in	Figure	5.10	appear	credible,	demonstrating	the	activity	of	
C.	reinhardtii-produced	CD27L	against	C.	difficile	requires	a	few	minor	modifications	
to	the	assay	to	make	it	more	convincing.	The	first	is	to	perform	the	assay	with	higher	
concentrations	of	endolysin.	Dr	Mayer	usually	includes	10	μg	of	endolysin	per	well,	
while	we	were	 only	 able	 to	 use	 0.3	 μg	 per	well	 due	 to	 the	 diluted	 nature	 of	 the	
extract.	 This	 can	 be	 easily	 remedied	 by	 performing	 an	 ammonium	 sulphate	
precipitation	upon	 the	extract	 to	 concentrate	 the	protein.	 It	 is	 expected	 that	 this	
improvement	will	widen	the	gap	between	the	positive	and	negative	controls,	thus	
making	the	assay	more	convincing.	Secondly,	a	distinction	must	be	made	between	
cell	lysis	and	cell	viability.	While	it	is	reasonable	to	assume	that	the	two	are	related,	
a	minor	reduction	in	turbidity	does	not	necessarily	mean	that	cell	viability	is	equally	
unaffected.	For	example,	an	endolysin	may	cleave	the	peptidoglycan	in	only	a	few	
locations,	enough	to	lyse	the	cell,	but	leaving	the	wall	otherwise	mostly	intact.	This	
will	register	as	a	low	level	of	turbidity	reduction,	but	has	reduced	cell	viability	to	the	
same	level	as	an	endolysin	that	breaks	the	wall	into	many	pieces.	In	order	to	confirm	
the	efficacy	of	an	endolysin,	it	is	therefore	important	to	include	a	direct	measurement	
of	cell	viability,	such	as	a	CFU	assay.	By	plating	the	contents	of	the	wells	from	the	
turbidity	 reduction	 assay	 onto	 nutrient	 agar	 it	 would	 be	 possible	 to	 quantify	 the	
remaining	number	of	viable	bacteria.		
A	recently	discovered	property	of	some	endolysins,	such	as	CD27L	and	CTP1L	(Dunne	
et	al.	2016)	and	Lys170	(Proença	et	al.	2015),	is	their	encoding	of	a	second,	internal,	
translation	 start	 site.	 This	 second	 translation	 start	 site	 results	 in	 the	 additional	
synthesis	of	the	C-terminal	domain	i.e.	a	free	cell	wall	binding	domain.	This	free	CBD	
forms	a	multimeric	endolysin	with	the	full-length	endolysin	to	enable	it	to	become	
fully	active.	It	was	noted	by	Dunne	et	al.	(2016)	that	the	recombinant	endolysin	CTP1L	
produced	 from	a	 codon-optimised	 gene	displayed	 significantly	 lower	 activity	 than	
that	produced	from	the	wild-type	nucleotide	sequence.	The	codon	optimised	version	
produced	 much	 lower	 levels	 of	 free	 CBD,	 and	 the	 addition	 of	 recombinantly	
synthesised	free	CBD	rescued	activity	levels.		
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The	cd27l	gene	expressed	here	in	C.	reinhardtii	is	the	truncated	version	of	the	full-
length	gene,	as	discussed	 in	5.3.2.1,	and	as	such	does	not	contain	 the	CBD	or	 the	
putative	internal	ribosome	binding	site	identified	by	Dunne	et	al.	(2016).	Dunne	et	al.	
(2016)	 noted	 that	 the	 free	 CBD	 of	 CD27L	 was	 not	 necessary	 for	 activity,	 but	
postulated	 that	 it	 may	 play	 a	 role	 when	 the	 endolysin	 is	 under	 physiological	
conditions	which	have	yet	to	be	investigated.		
It	would	be	interesting	to	express	the	full-length	CD27L	endolysin	 in	C.	reinhardtii,	
using	a	codon	optimised	version	but	ensuring	that	the	Shine	Dalgarno	(SD)	and	RBS	
of	the	putative	 internal	 translation	site	remain	unchanged.	This	would	answer	the	
question	of	whether	the	C.	reinhardtii	chloroplast	machinery	is	able	to	recognise	this	
internal	translation	site.	It	seems	unlikely	that	the	internal	site	will	be	recognised	by	
the	 chloroplast	 machinery,	 as	 although	 the	 chloroplast	 system	 does	 share	 many	
features	with	its	prokaryotic	ancestors,	translation	initiation	is	less	well	understood	
in	 the	 C.	 reinhardtii	 chloroplast.	 For	 example,	 although	 chloroplast	 16S	 rRNA	
molecules	 display	 a	 highly	 conserved	 anti-SD	 sequence	 near	 their	 3’	 end,	 the	
complementary	 SD	 sequences	 on	 chloroplast	 mRNA	 UTRs	 are	 hypervariable,	 if	
present	at	all	(Rochaix	et	al.	1998).	A	C-terminal	StrepII	tag	on	the	full-length	CD27L	
protein	will	enable	enrichment	and	detection	of	both	the	full-length	protein	and	any	
product	synthesised	from	the	internal	translation	site.	If	the	internal	translation	site	
fails	 to	 produce	 a	 free	CBD,	 then	 it	would	 also	be	of	 interest	 to	 express	 the	CBD	
independently,	under	an	alternative	promoter/5’UTR.		
The	investigation	by	Dunne	et	al.	(2016)	concluded	that	the	free	CBD	oligomerised	
with	the	full-length	CD27L,	but	for	this	endolysin	it	did	not	appear	to	greatly	affect	
activity.	 Therefore,	 it	 may	 be	 more	 relevant	 to	 look	 at	 CTP1L,	 an	 endolysin	 that	
targets	Clostridium	tyrobutyricum,	and	was	shown	to	require	the	free	CBD	for	activity.	
The	potential	 for	CTP1L	as	 a	 future	 candidate	 for	C.	 reinhardtii	 expression	will	 be	
discussed	later	in	this	chapter.	
Usually,	at	this	stage	of	an	endolysin	project,	most	further	work	would	involve	the	
use	of	an	animal	model	for	in	vivo	testing.	However,	in	the	case	of	C.	difficile	models,	
the	most	helpful	next	 stage	 is	probably	more	advanced	 in	 vitro	 testing,	using,	 for	
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example,	a	triple-stage	chemostat	model	of	the	human	gut.	The	reason	for	this	is	that	
the	 most	 well-used	 animal	 model	 for	 CDI,	 the	 Syrian	 Hamster,	 is	 not	 fully	
standardised	 and	 presents	 several	 important	 and	 problematic	 differences	 in	
pathophysiology	to	human	infection	(Best	et	al.	2012).	The	triple-stage	human	gut	
model	was	designed	by	Macfarlane	et	al.	(1998)	and	has	since	been	improved	and	
updated,	but	essentially	consists	of	three	connected,	pH	controlled,	anaerobically-
maintained	vessels,	with	growth	media	fed	into	the	top	at	a	specific	flow	rate.	The	
model	 emulates	 the	 characteristics	 (spatial,	 temporal,	 nutritional	 and	
physicochemical)	of	the	proximal	to	the	distal	bowel	 (Best	et	al.	2012).	The	triple-
stage	chemostat	human	gut	model	has	been	used	extensively	for	testing	C.	difficile	
treatment	efficacy	(Freeman	et	al.	2007;	Baines	et	al.	2008)	and	will	enable	various	
questions	 around	 the	 CD27L	 endolysin	 to	 be	 asked	 and	 answered,	 such	 as:	 how	
quickly	does	the	endolysin	degrade/denature	in	the	human	gut	environment?	How	
much	endolysin	is	required	to	achieve	a	reduction	in	C.	difficile	bacterial	load	and	how	
often	must	doses	be	given?	What	delivery	mechanism	is	likely	to	enable	the	delivery	
of	 CD27L	 to	 the	 key	 C.	 difficile	 infection	 sites?	 How	 does	 CD27L	 compare	 to	
vancomycin	treatment?	Can	CD27L	act	synergistically	with	vancomycin	treatment?	
However,	major	issues	with	even	an	advanced	in	vitro	model	still	exist,	such	as	the	
absence	of	immunological	influence.	To	address	this,	eventually	some	form	of	in	vivo	
model	will	 doubtless	be	 required,	but	 the	use	of	 advanced	 in	 vitro	 testing	 should	
reduce	the	reliance	upon	these	and	 inform	more	precisely	which	tests	need	to	be	
carried	out.	
An	 interesting	 final	 consideration	of	C.	 reinhardtii-produced	CD27L	 is	 the	delivery	
mechanism.	 To	 date,	 C.	 reinhardtii-produced	 therapeutics	 have	 been	 considered	
most	viable	for	topical	applications	due	to	the	potential	cost	savings	made	by	using	a	
crude	 extract,	 on	 the	 assumption	 that	 a	 crude	 extract	 would	 not	 achieve	 FDA	
approval	 for	 systemic	 use.	 However,	 C.	 difficile	 has	 recently	 emerged	 as	 an	
increasingly	prevalent	pathogen	in	food	animals	(Songer	2004;	Keel	et	al.	2007),	such	
as	pigs,	calves	and	ostriches	as	well	as	pets	such	as	cats,	dogs	and	horses	(Gould	and	
Limbago	2010).	These	offer	a	potential	market	that	may	be	less	tightly	regulated	and	
enable	C.	reinhardtii	produced	therapeutics	to	show	a	proof-of-concept.	Work	by	Dr	
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Priscilla	Rajakumar	in	the	Purton	Lab	investigated	the	administration	of	oral	vaccines	
produced	 in	 C.	 reinhardtii	 to	 chickens	 and	 fish,	 and	 discussed	 the	 use	 of	 the	 C.	
reinhardtii	cell	as	a	delivery	capsule	(Rajakumar	2016).	While	this	concept	has	not	
been	 practically	 tested,	 Rajakumar	 (2016)	 suggests	 that	 the	 cell	 wall	 and	 the	
chloroplast	 of	 C.	 reinhardtii	 protect	 the	 therapeutic	 recombinant	 proteins	 from	
degradation	through	the	upper	levels	of	the	digestive	system,	enabling	them	to	reach	
the	 gut.	 This	 will,	 of	 course,	 depend	 upon	 which	 animal	 is	 being	 treated,	 as	 for	
example	the	chickens	studied	by	Rajakumar	(2016)	have	a	very	short	intestinal	tract,	
while	the	same	strategy	may	not	work	in	cattle.		
5.4.2 Gp20	endolysin	
The	Gp20	endolysin	has	been	problematic	 since	 recombinant	expression	was	 first	
attempted	 by	 Taunt	 (2013).	 As	 an	 endolysin	 targeting	 a	 topical	 and	 prevalent	
bacterial	species,	it	would	be	an	ideal	candidate	for	production	in	C.	reinhardtii	as	a	
treatment	for	acne	vulgaris.	However,	previous	attempts	to	achieve	gp20	expression	
in	the	C.	reinhardtii	chloroplast,	as	well	as	new	attempts	described	in	this	chapter,	
have	all	failed	to	produce	detectable	levels	of	expression.	To	test	whether	the	Gp20	
protein	 is	 stable	 and	 active	 outside	 the	 P.	 acnes	 intracellular	 environment,	 the	
endolysin	was	expressed	 in	E.	coli.	 In	E.	coli	Gp20	accumulated	 to	high	 levels,	but	
colony	forming	unit	assays	using	a	crude	lysate	against	P.	acnes	failed	to	show	any	
activity.	Given	high	levels	of	interest	in	P.	acnes,	and	the	identification	of	at	least	14	
relevant	 putative	 endolysins,	 it	 does	 seem	 remarkable	 that	 no	 reports	 of	 a	
recombinantly	 produced	 endolysin	 targeting	 P.	 acnes	 exist,	 other	 than	 the	
aforementioned	patent	application	by	Lysando.	Here	we	will	discuss	in	more	detail	
the	possible	reasons	for	issues	faced	in	expression	and	activity,	and	potential	future	
lines	of	investigation.		
After	failed	initial	attempts	to	express	gp20	 in	the	C.	reinhardtii	chloroplast,	Taunt	
(2013)	 investigated	 whether	 translation	 initiation	 was	 the	 issue	 by	 creating	 a	
cpl1:gp20	 fusion,	 but	 again	 expression	 failed,	 while	 a	 positive	 control	 cpl1:pal	
succeeded.	This	suggested	that	the	ribosome	was	stalling	at	some	point	within	the	
gp20	gene,	an	issue	most	commonly	associated	with	codon	usage.	However,	further	
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codon	 optimisation	 failed	 to	 solve	 the	 problem.	 Taunt	 (2013)	was	 also	 unable	 to	
detect	gp20	expression	in	E.	coli,	leading	to	a	suggestion	that	rapid	protein	turnover	
may	be	to	blame.	However,	strong	gp20	expression	in	E.	coli	was	described	earlier	in	
this	 chapter,	making	 this	 a	 less	 likely	 suspect,	 although	admittedly	 the	E.	 coli	 and	
chloroplast	environments	are	not	identical.		
As	mentioned	earlier,	the	remarkable	similarity	between	the	14	P.	acnes	 targeting	
endolysins	described	so	far	means	that	testing	the	expression	of	a	different	endolysin	
is	unlikely	to	make	any	difference.	The	potential	demand	for	solutions	to	P.	acnes	
infection	 from	 both	 the	 cosmetic	 and	 pharmaceutical	 industries	 means	 that	 this	
endolysin	remains	worthy	of	investigation.	
The	alignment	performed	by	Marinelli	et	al.	 (2012)	 (Figure	5.17)	provides	a	useful	
indication	of	the	two	endolysin	domains,	as	the	area	of	least	homology	is	likely	to	be	
the	 glycine	 rich	 linker	 domain	 (circa	 position	 200).	 This	 is	 further	 supported	 by	
database	comparisons	predicting	that	the	N-terminal	domain	is	associated	with	N-
acetylmuramoyl-1-alanine	amidase	activity	(Farrar	et	al.	2007).	Given	that	endolysin	
modules	generally	remain	stable	when	separated	(Mayer	et	al.	2008;	Dunne	et	al.	
2016),	it	would	be	interesting	to	attempt	to	express	the	two	separate	domains	in	the	
C.	 reinhardtii	 chloroplast.	 This	 would	 give	 an	 insight	 into	 where	 the	 ribosome	 is	
stalling,	and	could	potentially	be	subjected	to	further	codon	optimisation	to	minimise	
this.	Furthermore,	as	demonstrated	with	CD27L,	occasionally	the	endolysin	catalytic	
domain	alone	is	sufficient	for	cell	lysis	which	could	be	tested	here	if	expression	can	
be	achieved.		
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Figure	Removed	
	
Figure	5.17	Protein	sequence	alignment	of	14	putative	endolysins	from	P.	acnes	bacteriophages.	The	alignment	shows	that	the	sequence	is	highly	conserved,	
with	the	majority	of	differences	located	in	the	glycine-rich	linker	at	around	position	200.	The	C-terminus	cell	wall	binding	module	is	less	highly	conserved	
than	the	catalytic	N-terminus	module.	Gp20	from	the	PA6	bacteriophage	is	the	4th	from	the	bottom,	labelled	PA6_rev_gp20,	as	it	is	a	revised	annotation	of	
the	PA6	genome.	Reproduced	from	Marinelli	et	al.	(2012).
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The	next	issue	to	resolve	is	the	apparent	lack	of	activity	of	the	E.	coli-produced	Gp20	
protein	against	P.	acnes.	The	first	question	to	address	in	this	case	is	the	CFU	assay	
itself,	which	was	not	fully	satisfying	and	was	not	repeated	due	to	time	constraints.	
The	 investigation	 requires	a	 suitable	positive	control,	 the	obvious	choice	being	an	
antibiotic	 such	 as	 erythromycin,	 the	 first	 line	 of	 treatment	 in	 a	 clinical	 setting	
(Zaenglein	 et	 al.	 2016).	 However,	 it	 would	 be	 preferable	 to	 have	 a	more	 specific	
antibacterial,	which	will	partially	confirm	that	the	bacteria	seen	are	indeed	P.	acnes	
and	not	a	contaminating	species.	The	peptide	adrenomedullin	is	secreted	by	human	
epithelial	 cells	 and	 has	 been	 demonstrated	 to	 have	 an	 antimicrobial	 effect	 upon	
several	microorganisms	 found	on	the	skin	and	respiratory	 tract,	but	 is	particularly	
effective	against	P.	acnes,	M.	luteus,	P.	gingivalis	and	H.	pylori	(Allaker	et	al.	1999).	It	
therefore	represents	a	narrower-spectrum	antimicrobial,	when	used	at	an	optimal	
concentration,	 than	 erythromycin	 and	 may	 provide	 a	 useful	 positive	 control.	 To	
further	confirm	that	the	bacterium	in	question	is	P.	acnes,	Gram	stain	(+),	catalase	(+)	
and	indole	(+)	tests,	followed	by	sequencing	of	the	16S	rRNA	gene	for	species-level	
identification	can	be	performed	(Butler-Wu	et	al.	2011).	
Assuming	that	the	above	assay	is	improved	to	an	acceptable	standard	but	activity	is	
still	not	observed,	several	issues	could	be	at	play.	The	first	is	that	P.	acnes	is	known	
to	secrete	many	protective	enzymes	which	allow	it	to	survive	in	the	harsh	human	skin	
environment,	 including	hydrolases	 and	proteases	 (Holland	 et	 al.	 2010),	 as	well	 as	
propionic	 and	 acetic	 acid	 which	 inhibit	 the	 growth	 of	 competing	 species	 (Wilson	
2005).	It	is	plausible	that	some	combination	of	these	factors	is	causing	the	endolysin	
to	denature	or	be	degraded	before	it	can	bind	and	lyse	the	cell	wall.	As	the	endolysins	
have	 evolved	 to	 be	 active	 from	 within	 the	 bacterial	 cell,	 it	 is	 possible	 that	 such	
extrinsic	barriers	are	blocking	its	action.	Another	possibility	is	that	the	holin,	which	is	
normally	expressed	alongside	the	endolysin,	 is	required	for	cell	 lysis,	although	this	
seems	unlikely	and	has	not	been	reported	before,	to	the	author’s	knowledge.		
As	seen	earlier	 in	 this	chapter,	while	most	endolysins	consist	of	a	 simple	modular	
monomer,	others	such	as	PlyC	are	multimeric,	and	still	others	such	as	CTP1L	require	
oligomerisation	with	their	own	truncated	C-terminal	domain.	It	is	possible	that	the	
lack	of	 activity	 observed	with	Gp20	 is	 due	 to	 the	 requirement	 to	oligomerise	 like	
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CTP1L	 for	 full	 activity.	 Figure	 5.17	 shows	 a	 conserved	 methionine	 residue	 at	
approximately	position	193	which	could	be	an	internal	start	codon.	Also	at	position	
210	in	Figure	5.17	the	alternative	start	codon,	GTG,	codes	for	a	valine.	This	residue	is	
conserved	 as	 either	 a	 methionine	 or	 a	 valine	 in	 the	 other	 putative	 endolysins,	
however	an	analysis	of	the	nucleotide	sequence	is	required	to	identify	whether	this	
is	a	potential	internal	start	codon.	This	location	is	similar	to	that	observed	in	CTP1L	
and	CD27L	and	would	similarly	 result	 in	 the	synthesis	of	a	 free	CBD.	However,	no	
Shine	Dalgarno	consensus	can	be	seen	upstream	of	either	the	methionine-encoding	
ATG	or	valine-encoding	GTG	when	the	nucleotide	sequence	of	gp20	is	examined,	and	
analysis	 using	 the	 NCBI	 Open	 Reading	 Frame	 Finder	
(https://www.ncbi.nlm.nih.gov/orffinder/)	 software	 did	 not	 identify	 either	 as	 a	
potential	ORF	(Figure	5.18).	
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Figure	5.18	Results	from	https://www.ncbi.nlm.nih.gov/orffinder/	with	the	putative	endolysin	sequence	gene	ID	5247034.	Only	ORF1	is	in	frame	and	in	the	
same	direction	as	the	full-length	endolysin.	ORF1	is	654	nucleotides	in	length,	producing	a	217	amino	acid	protein.	
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The	internal	ribosome	binding	site	and	ORF	identified	in	Figure	5.18	would	result	in	
the	synthesis	of	a	 free	CBD,	 like	CTP1L,	but	 includes	a	much	 larger	portion	of	 the	
catalytic	domain	than	would	be	expected.	Nevertheless,	 it	would	be	 interesting	to	
attempt	to	express	gp20	 in	E.	coli	using	the	wild-type	nucleotide	sequence,	which	
may	identify	whether	an	internal	ribosome	binding	site	is	active.	Such	a	finding	may	
result	in	the	improvement	of	activity	against	P.	acnes.		
5.4.3 Future	endolysins	
As	discussed	earlier	in	this	chapter,	the	problems	surrounding	Gp20	cannot	be	solved	
by	merely	attempting	to	express	an	alternative	P.	acnes	targeting	endolysin,	as	the	
level	of	homology	between	the	proteins	is	so	high	that	it	is	extremely	unlikely	that	
this	 will	 make	 any	 difference.	 In	 this	 case	 the	 strategy	 needs	 to	 be	 to	 better	
understand	 why	 the	 endolysin	 is	 failing	 to	 express	 and	 attempting	 to	 solve	 any	
problems	with	activity.		
There	are	several	other	endolysins	which	would	be	interesting	to	express	in	the	C.	
reinhardtii	 chloroplast	 in	 the	 future.	 CTP1L	 is	 an	 interesting	 endolysin	 due	 to	 its	
requirement	 to	oligomerise	with	 its	 free	CBD,	but	 is	 also	 a	 commercially	 relevant	
endolysin,	 as	 it	 targets	 Clostridium	 tyrobutyricum.	 Clostridium	 tyrobutyricum	
contamination	can	lead	to	extensive	costs	in	the	cheese	production	industry	through	
‘late-blowing’,	 a	 phenomenon	 affecting	 high-pH	 cheeses	 such	 as	 Edammer	 and	
Gouda,	and	resulting	in	excess	bubbles	and	an	abnormal	flavour.	An	application	of	
CTP1L	 is	therefore	 in	food	safety	and	production,	and	given	that	C.	reinhardtii	has	
GRAS	status,	this	may	well	be	a	very	well	suited	market	for	C.	reinhardtii-produced	
endolysins.		
Work	by	Jado	et	al.	(2003)	demonstrated	that	two	S.	pneumoniae	endolysins,	Pal	and	
Cpl-1,	are	able	to	act	synergistically.	There	are	numerous	advantages	to	exploiting	
drug	 synergies	 therapeutically,	 such	 as	 lower	 dosages,	 greater	 efficacy,	 and	
minimising	 the	 opportunity	 for	 resistance	 to	 occur.	 It	 would	 be	 interesting	 to	
investigate	 whether	 a	 similar	 synergy	 can	 be	 observed	 with	 endolysins	 targeting	
other	bacteria,	such	as	C.	difficile.	Wang	et	al.	 (2015)	 identified	another	C.	difficile	
endolysin,	named	PlyCD,	which	was	demonstrated	to	be	active	against	C.	difficile	in	
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vitro	and,	similarly	to	CD27L,	more	active	in	its	truncated	form,	PlyCD1-174.	Successful	
expression	of	PlyCD	in	the	C.	reinhardtii	chloroplast	would	allow	testing	of	both	PlyCD	
as	 a	 stand-alone	 endolysin,	 as	 well	 as	 enabling	 an	 investigation	 into	 whether	 a	
synergistic	effect	can	be	observed	between	PlyCD	and	CD27L.		
As	 a	 final	 note	 on	 selecting	 future	 endolysins,	 one	 method	 might	 be	 termed	 a	
‘disease-orientated’	 approach.	 This	 approach	 looks	 at	 the	 bacterial	 species	
associated	with	certain	identifiable	diseases	and	designing	‘endolysin	cocktails’	to	kill	
all	of	those	species.	For	example,	the	skin	disease	impetigo	is	typically	treated	with	a	
broad-spectrum	antibiotic	cream	(George	and	Rubin	2003),	despite	the	fact	that	it	is	
known	to	be	caused	by	one	of	only	two	bacterial	species:	Staphylococcus	aureus	or	
Streptococcus	pyogenes.	 It	 is	 therefore	conceivable	that	a	cocktail	of	 two	or	more	
endolysins	 targeting	S.	 aureus	 and	S.	 pyogenes	would	be	 a	 viable	 treatment.	 This	
particular	 example,	 as	 a	 topical	 application,	 would	 again	 be	 well	 suited	 to	 C.	
reinhardtii	 production.	 Two	 potential	 endolysins,	 in	 this	 case,	 could	 be	 LysH5	
(targeting	S.	aureus)	(Gutiérrez	et	al.	2014)	and	PlyC	(targeting	S.	pyogenes)	(Shen	et	
al.	2013).		
Overall,	this	chapter	has	demonstrated	that	while	the	C.	reinhardtii	chloroplast	can	
be	a	very	well	suited	platform	for	endolysin	production,	there	remain	several	issues	
and	 unexplored	 areas	 which	 leave	 recombinant	 endolysin	 expression	 far	 from	
routine.	However,	non-expressing	endolysin	genes	such	as	gp20	offer	an	opportunity	
to	understand	more	about	 factors	affecting	chloroplast	expression,	 such	as	codon	
optimisation	and	translation	elongation.	The	suggested	future	work	laid	out	in	this	
section	 may	 help	 us	 to	 progress	 the	 C.	 reinhardtii	 chloroplast	 platform	 towards	
achieving	more	reliable	protein	production.	
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Chapter	6 Final	discussion	and	future	prospects	
6.1 Summary		
6.1.1 Summary	of	results	
The	research	described	in	this	thesis	sought	to	address	two	overarching	issues.	The	
first	 is	 the	 improvement	 of	 the	 genetic	 engineering	 technology	 underpinning	 the	
development	of	 the	C.	 reinhardtii	chloroplast	as	a	novel	platform	for	recombinant	
protein	production.	The	second	is	the	advancement	of	endolysins	as	an	alternative	
to	conventional	antibiotics.	
Chapter	3	investigates	the	issue	of	relatively	low	levels	of	transgene	expression	seen	
in	C.	reinhardtii	and	demonstrates	techniques	available	to	improve	this.	As	demand	
grows	 for	 protein	 therapeutics,	 such	 as	 monoclonal	 antibodies,	 hormones	 (e.g.	
human	insulin),	and	vaccines,	so	does	the	requirement	for	suitable	platforms	for	their	
recombinant	production.	As	discussed	in	1.3.1,	there	are	various	platforms	currently	
used	 for	 therapeutic	 protein	 production,	 each	 with	 different	 advantages	 and	
limitations.	The	green	alga	C.	reinhardtii	offers	a	novel	alternative	cell	factory,	with	
important	advantages	over	 several	more	widely	used	platforms.	However,	 several	
limitations	of	C.	reinhardtii,	including	low	levels	of	expression,	need	to	be	addressed	
before	it	can	realistically	compete	with	the	established	platforms.	Initially,	methods	
used	 to	 compare	 protein	 accumulation	 levels	 between	 different	 transgenic	 C.	
reinhardtii	 lines	 were	 investigated.	 The	 chapter	 highlights	 the	 limitations	 of	
comparing	protein	accumulation	levels	whilst	clonal	variation	appears	to	be	having	
such	 a	 large	 effect,	 as	 well	 as	 proposing	 and	 testing	 improved	 methods	 of	
comparison.	As	such,	attempts	to	investigate	the	effects	of	codon	pair	optimisation	
remain	inconclusive.	However,	the	chapter	does	demonstrate	that	the	introduction	
of	two	expression	cassettes	into	the	C.	reinhardtii	chloroplast	plastome	results	in	a	
robust	two-fold	increase	in	protein	accumulation	compared	with	a	single	expression	
cassette.		
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The	growing	threat	of	antibiotic	resistance	has	encouraged	research	into	developing	
alternatives	to	conventional	antibiotics.	Endolysins	are	of	increasing	interest	and	the	
first	 endolysin	 based	 therapies	 are	now	available	 (1.3.3.3).	 Chapter	 4	 investigates	
whether	 the	 activity	 of	 these	 endolysins	 can	 be	 improved	 against	 their	 target	
bacterium,	 S.	 pneumoniae,	 either	 by	 direct	 mutation	 of	 the	 protein	 or	 through	
synergistic	effects	with	holins.	Site	directed	mutagenesis	was	used	to	disrupt	the	cell	
wall	binding	domain	of	Cpl-1	and	expression	was	achieved	for	all	six	mutants	 in	C.	
reinhardtii.	However,	such	modifications	appeared	only	to	decrease	the	activity	of	
the	endolysin,	demonstrating	that	the	functionality	of	the	two	active	choline	binding	
sites	is	essential	for	the	activity	of	the	endolysin	in	this	instance.	Dimerisation	of	Cpl-
1	via	a	disulphide	bridge	was	also	investigated,	but	could	not	be	achieved	in	the	C.	
reinhardtii	 chloroplast.	 Several	 reasons	 for	 the	 failure	 of	 Cpl-1	 to	 dimerise	 were	
suggested,	 along	 with	 possible	 solutions,	 mostly	 revolving	 around	 the	 steric	
hindrance	 of	 the	 C-terminal	 epitope	 tag.	 Finally,	 the	 holin	 protein	 Cph-1	 was	
expressed	in	the	C.	reinhardtii	chloroplast.	However,	expression	quickly	ceased	and	
the	possible	reasons	for	this	were	discussed.	
Chapter	 5	 describes	 attempts	 at	 increasing	 the	 suite	 of	 endolysins	 that	 can	 be	
produced	in	the	C.	reinhardtii	chloroplast.	The	C.	difficile	targeting	endolysin,	CD27L,	
was	successfully	expressed	in	the	C.	reinhardtii	chloroplast	and	its	activity	against	C.	
difficile	 was	 demonstrated	 in	 vitro.	 Meanwhile,	 the	 P.	 acnes	 targeting	 endolysin,	
Gp20,	 failed	 to	 express	 in	 transformed	 C.	 reinhardtii	 lines.	 However,	 it	 was	
successfully	expressed	in	E.	coli	under	an	inducible	promoter,	but	activity	could	not	
be	observed	against	P.	acnes.		
	
6.1.2 Summary	of	short-term	future	work	
Future	work	has	been	roughly	divided	into	two	categories	in	this	thesis:	‘short-term’	
future	work	and	‘long-term’	future	work.	While	both	of	these	terms	are	relative,	the	
goal	of	this	system	is	to	distinguish	between	work	that	will	enable	the	progression	or	
conclusion	of	current	projects	(short-term),	and	work	that	looks	further	to	the	future	
and	would	serve	as	a	stand-alone	project	in	its	own	right	(long-term).	Relevant	short-
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term	future	work	has	been	suggested	at	the	end	of	each	results	chapter,	much	of	
which	is	very	specific.	However,	the	most	interesting	area	that	each	results	chapter	
highlighted	for	further	investigation	is	summarised	briefly	below.	Potential	paths	for	
long-term	future	projects	are	discussed	in	6.2	below.	
The	issue	of	clonal	variation	highlighted	in	Chapter	3	limits	our	ability	to	accurately	
investigate	 strategies	 for	 improving	 recombinant	 protein	 accumulation	 in	 the	 C.	
reinhardtii	chloroplast,	but	also	offers	an	opportunity	to	understand	what	leads	to	a	
very	high	or	 very	 low	expressing	 ‘clone’.	 In	order	 to	enable	 the	 investigation	 into	
subtler	methods	of	improving	recombinant	protein	accumulation,	in	3.4.2	we	suggest	
that	the	use	of	a	reporter	gene,	such	as	luciferase,	and	the	use	of	high-throughput	
techniques	 will	 enable	 ‘comparison-of-means’	 analysis.	 Advancements	 in	 whole	
genome	 sequencing,	 and	 importantly	 its	 falling	 cost,	 may	 eventually	 enable	 a	
methodical	whole	genome	analysis	of	high-expressing	clones	to	identify	mutations	or	
insertions	that	are	resulting	in	high	levels	of	protein	accumulation.	These	mutations	
might	 be	 affecting	 nuclear	 genes	 for	 chloroplast	 regulatory	 factors,	 proteases,	 or	
chaperones.	 These	 changes	 can	 then	be	 purposefully	 introduced	 alongside	 future	
transgenes,	thus	improving	C.	reinhardtii	as	a	protein	production	platform.	
The	endolysin	Cpl-1	was	the	main	focus	of	 investigation	 in	Chapter	4,	and	as	such	
much	 of	 the	 proposed	 future	 work	 was	 specific	 to	 this	 endolysin.	 However,	 the	
unexpected	 and	unexplained	 result	 that	Cph-1	 expression	was	 achieved	 and	 then	
ceased	 is	worthy	of	 further	 investigation.	Silencing	mechanisms,	while	common	 in	
nuclear	 transformations,	 have	 not	 previously	 been	 described	 in	 the	 chloroplast	
(Daniell	et	al.	2005).	It	is	therefore	important	to	understand	how	the	termination	of	
expression	 has	 occurred,	 the	 findings	 of	 which	 may	 help	 prevent	 this	 from	
reoccurring,	but	also	could	become	a	useful	molecular	switch.		
Chapter	5	demonstrated	the	successful	expression	and	activity	of	a	synthetic	gene	
encoding	CD27L,	and	also	documented	the	unsuccessful	attempts	to	express	gp20	in	
C.	 reinhardtii.	 However,	 it	 is	 the	gp20	 result	 that	 remains	 interesting	 in	 terms	 of	
gaining	a	greater	understanding	of	C.	 reinhardtii	expression	and	 its	suitability	as	a	
platform	for	producing	endolysins.	Despite	repeated	attempts	and	failures	to	achieve	
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gp20	expression	in	the	C.	reinhardtii	chloroplast,	there	is	still	some	way	to	go	before	
we	 can	 deduce	 the	 precise	 reason	 for	 this	 and	 attempt	 to	 ameliorate	 it.	 Codon	
optimisation,	 translation	 initiation,	 and	 epitope	 tag	 location	 have	 all	 been	
investigated	and	do	not	appear	 to	be	causing	 failure	of	expression.	Attempting	 to	
express	the	two	domains	of	the	endolysin	separately	may	shed	some	light	on	to	the	
problem,	 and	 aid	 us	 in	 a	 broader	 understanding	 of	 expression	 failure	 in	 the	 C.	
reinhardtii	chloroplast.		
	
6.2 Discussion	and	long-term	future	prospects	
6.2.1 Alternative	strategies	to	improving	expression	levels	in	C.	reinhardtii	
chloroplast	
6.2.1.1 Synthetic	promoters	and	5’UTRs	
Synthetic	promoters	and	5’UTRs	are	becoming	widely	used	in	synthetic	biology	and	
in	 recombinant	 protein	 production,	 due	 to	 their	 frequent	 ability	 to	 provide	more	
consistent	 and	 higher	 final	 protein	 yields	 than	 endogenous	 regulatory	 elements	
(Gilman	 and	 Love	 2016).	 As	 discussed	previously	 in	 this	 thesis	 (3.1.2),	 chloroplast	
gene	 expression	 appears	 to	 be	mostly	 controlled	 at	 the	 level	 of	 translation	 in	 C.	
reinhardtii,	rather	than	transcription,	and	as	such	the	improvement	of	5’UTRs	is	of	
greater	 interest	than	that	of	promoters	at	this	stage.	To	date,	the	most	consistent	
levels	of	gene	expression	in	the	C.	reinhardtii	chloroplast	have	been	achieved	using	
endogenous	promoter/5’UTR	sequences	from	highly	expressed	proteins,	and	in	some	
cases	higher	levels	have	been	achieved	through	combinations	with	nuclear	mutants	
(Michelet	et	al.	2011)	and	altered	CES	mechanisms	(Manuell	et	al.	2007)	which	will	
be	discussed	is	the	next	section	(6.2.1.2).		
Research	by	Specht	&	Mayfield	(2013)	used	a	 luciferase	reporter	gene	(Figure	6.1)	
and	high-throughput	analysis	to	compile	an	unbiased	dataset	of	mutated	psaA	and	
psbD	5’UTRs,	from	which	the	first	successful	synthetic	C.	reinhardtii	chloroplast	5’UTR	
was	 designed.	 The	 resulting	 synthetic	 5’UTR	 improved	 protein	 accumulation	 by	
approximately	66	%,	compared	to	endogenous	5’UTRs.	
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Figure	6.1	C.	reinhardtii	transformed	with	expression	cassettes	containing	mutated	5’UTRs	
controlling	 luciferase	 expression	 in	 the	 chloroplast.	 This	 false	 colour	 image	 illustrates	 the	
differences	in	luciferase	expression	under	different	5’UTRs.	Techniques	such	as	this	enable	
the	processing	and	expression	quantification	of	hundreds	of	C.	reinhardtii	colonies	in	a	very	
small	 amount	 of	 time.	 The	 positive	 control	 (wild	 type	 UTR)	 and	 negative	 control	 (no-
luciferase)	are	indicated	on	the	bottom	left	of	the	plate.	Reproduced	from	Specht	&	Mayfield	
(2013).	
As	high-throughput	techniques	become	more	accessible	and	defined	in	C.	reinhardtii,	
the	potential	for	producing	large	unbiased	datasets	improves.	The	availability	of	such	
datasets	may	enable	the	identification	of	consensus	motifs	in	both	the	promoter	and	
5’UTRs	 of	 endogenous	 genes	 and	 pave	 the	 way	 towards	 producing	 synthetic	
promoters	and	5’UTRs	that	dramatically	improve	protein	yields	as	well	as	providing	
consistent	levels	of	gene	expression.	The	work	by	Specht	&	Mayfield	(2013)	is	the	first	
step	 in	 achieving	 this,	 but	 their	 use	 of	 particle	 bombardment	 to	 transform	 C.	
reinhardtii	recipient	lines	remains	subject	to	the	issue	of	clonal	variation,	and	as	such	
very	precise	deductions	about	5’UTR	consensus	sequences	are	difficult	to	draw	and	
an	even	larger	dataset	is	likely	to	be	required.	Recent	advancements	in	precision	gene	
editing	may	provide	the	solution	to	this	issue,	as	will	be	discussed	in	the	following	
section.		
6.2.1.2 The	potential	of	CRISPR/Cas9	gene	editing	
As	an	alternative	to	modifying	the	5’UTR	which	is	regulated	by	various	elements	in	
the	 C.	 reinhardtii	 chloroplast	 (a	 cis-acting	 element),	 one	 could	 also	 modify	 the	
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regulatory	 elements	 themselves	 (trans-acting	 factors).	 Such	 an	 experiment	 was	
performed	by	Michelet	et	al.	(2011),	where	chloroplast	transgenes	were	shown	to	be	
upregulated	 when	 expressed	 in	 a	 cellular	 background	 that	 included	 a	 nuclear	
mutation.	The	mutation	in	this	instance	was	within	a	trans-splicing	factor	that	was	
imported	to	the	chloroplast	from	the	nucleus,	thus	preventing	trans-splicing	in	the	
chloroplast.	However,	this	mutation	also	led	to	a	loss	of	photoautotrophy	meaning	
that	the	C.	reinhardtii	cells	must	be	grown	in	the	dark	and	require	acetate	as	a	carbon	
source.	The	discovery	of	CRISPR/Cas9	gene	editing,	and	the	recent	application	of	this	
technology	to	the	C.	reinhardtii	nucleus	(Baek	et	al.	2016;	Shin	et	al.	2016),	will	result	
in	experiments	such	as	that	described	by	Michelet	et	al.	(2011)	becoming	far	easier	
to	 perform	 since	 targeted	 knock-outs	 of	 nuclear	 genes	would	be	possible.	 Rather	
than	knocking	out	trans-acting	elements	such	as	splicing	factors	which,	as	described,	
result	 in	 other	 undesirable	 phenotypes,	 CRISPR/Cas9	 could	 be	 used	 to	 knock-out	
other	 factors	 that	 indirectly	 control	 protein	 accumulation,	 such	 as	 chloroplast-
targeted	proteases.	The	ease	with	which	such	mutations	could	be	introduced	should	
quickly	enable	researchers	to	manipulate	the	chloroplast	environment	into	one	that	
is	 more	 amenable	 to	 recombinant	 protein	 accumulation	 without	 having	 large	
detrimental	effects	on	cell	physiology.		
6.2.1.3 Expression	of	novel	chaperones	
As	 discussed	 earlier,	 the	 primary	 suspect	 for	 causing	 low	 rates	 of	 successful	
recombinant	protein	expression	in	the	C.	reinhardtii	chloroplast	has	been	translation	
initiation	and	elongation.	However,	poor	protein	stability	or	high	proteolysis	could	
also	be	playing	a	role	 in	this.	Misfolded	proteins	and	those	that	have	not	reached	
their	native	state	are	targets	of	proteases.	While	knocking	out	proteases	may	be	part	
of	 the	 solution	 to	 improving	 protein	 accumulation,	 the	 quality	 of	 protein	 being	
produced	 is	 equally	 important,	 and	 disruption	 of	 proteases	 may	 have	 other	
detrimental	effects	upon	the	cell	(Ramundo	and	Rochaix	2014).		
While	recombinant	protein	yields	in	E.	coli	have	been	steadily	improved	over	the	past	
four	 decades,	 through	 a	 process	 of	 largely	 trial	 and	 error,	 we	 must	 attempt	 to	
reproduce	 these	 advances	 in	C.	 reinhardtii	by	 analysing	 those	 improvements	 and	
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specifically	introducing.	Many	of	the	successful	improvements	in	E.	coli	were	due	to	
the	co-expression	of	chaperones	(Makino	et	al.	2011),	and	therefore	this	is	worthy	of	
investigation.	 Many	 chaperones	 are	 known	 to	 be	 expressed	 in	 the	 C.	 reinhardtii	
nucleus	 and	 targeted	 to	 the	 chloroplast	 to	 aid	 protein	 folding	 (Schroda	 2004).	
However,	some	novel	chaperones	may	have	specific	abilities	to	aid	in	the	folding	of	
certain	 recombinant	 proteins,	 and	 studies	 in	 E.	 coli	 have	 found	 that	 co-
overproduction	of	certain	chaperones	in	the	E.	coli	cytoplasm	have	aided	in	protein	
solubility	 and	 yields	 (de	Marco	 et	 al.	 2007).	 It	would,	 therefore,	 be	 of	 interest	 to	
identify	relevant	chaperones,	such	as	Heat	Shock	Protein	70	(Willmund	et	al.	2008),	
and	attempt	to	express	them	alongside	endolysins	 in	the	C.	reinhardtii	chloroplast	
with	the	goal	of	improving	protein	accumulation	and	expression	success	rates.	
6.2.2 Other	microalgal	hosts	for	scale-up	
C.	reinhardtii	has	been	an	important	model	organism	for	the	study	of	photosynthesis,	
chloroplast	biogenesis,	and	flagellar	function	for	decades	(Rochaix	1995).	Given	the	
years	 of	 research	 behind	 it	 and	 its	 well-defined	 genetics,	 C.	 reinhardtii	 was	 the	
obvious	 initial	 candidate	 for	 proving	 the	 concept	 of	microalgae	 as	 a	 recombinant	
protein	 production	 platform.	 However,	 when	 it	 comes	 to	 scaling	 up	 microalgae	
production	 for	 commercial	 exploitation,	 other	 species	may	be	more	 suitable,	 and	
research	performed	on	C.	reinhardtii	should	be	readily	transferable	to	these	species.	
For	example,	some	species	such	as	those	of	Spirulina,	Chlorella,	Haematococcus,	and	
Dunaliella	have	all	been	grown	on	commercial	scales	for	some	time	(Figure	6.2)	and	
are	well	suited	to	cultivation	(Rosenberg	et	al.	2008).		
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Figure	Removed	
	
Figure	 6.2	 Spirulina	 growing	 in	 open	 ponds	 (raceways)	 for	 commercial	 production	 at	
Cyanotech’s	facilities	in	Hawaii2.	
The	advantage	to	using	one	of	the	above	microalgae	is	that	the	technology	already	
exists	 for	their	 large	scale	production,	as	well	as	data	on	growth	optimisation	and	
commercial	viability.	While	yields	of	therapeutic	proteins	from	C.	reinhardtii	are	very	
low,	 hovering	 around	 5-8	mg	 L-1	culture	 volume	 (1.3.3.3),	 the	 potential	 for	 cheap	
cultivation	and	high	volumes	goes	some	way	towards	negating	this	issue.	In	contrast	
CHO	 cells,	 as	 an	 example,	 must	 be	 grown	 in	 highly	 controlled	 environments	 in	
extremely	expensive	media,	it	is	understandable	their	yield	per	litre	must	be	very	high	
to	make	this	economically	viable.	It	is	therefore	plausible	to	expect	that	moving	to	a	
new	algal	platform	could	be	economically	feasible	without	requiring	vast	increases	in	
protein	yield.		
Other	microalgae	of	interest	include	extremophiles,	because	their	culture	conditions	
generally	minimise	contamination,	which	is	a	big	issue	when	growing	microalgae	at	
the	 commercial	 scales	 and	 open	 raceways	 shown	 in	 Figure	 6.2.	 For	 example,	
Cyanidioschyzon	merolae	is	a	microalga	that	inhabits	hot	(40	–	56	°C)	and	acidic	(pH	
0.2-4)	environments,	and	its	chloroplast	has	recently	been	transformed	for	the	first	
time	(Zienkiewicz	et	al.	2017).	Attempting	to	express	recombinant	proteins,	such	as	
Cpl-1,	in	C.	merolae	and	similar	organisms	will	be	an	important	step	in	determining	
																																																						
2	https://www.cyanotech.com/company/facility.html	
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the	best	 option	 for	 commercial	 scale-up.	However,	 use	of	 high	 temperatures	 and	
extremophiles	 will	 require	 investigation	 into	 the	 thermostability	 of	 the	 proteins	
looking	to	be	produced,	and	will	not	be	suitable	for	all	products.	Furthermore,	the	
cost	 of	 maintaining	 cultures	 at	 such	 temperatures	 may	 negate	 or	 minimize	 the	
savings	made	by	adopting	such	a	system.			
6.3 Concluding	remarks	
6.3.1 Views	on	the	future	of	antibiotics	
As	 with	 many	 emerging	 technologies,	 the	 adoption	 of	 endolysins	 as	 antibiotics	
depends	heavily	upon	the	status	of	the	existing	technology:	conventional	antibiotics.	
The	recent	discovery	of	a	new	antibiotic,	teixobactin,	and	the	novel	manner	in	which	
it	 was	 discovered	 (see	 1.1.2.2)	 may	 yet	 extend	 the	 ruling	 era	 of	 small	 molecule	
antibiotics.	While	the	discovery	of	new	antibiotics	is	clearly	a	good	thing,	it	is	vitally	
important	that	complacency	does	not	 limit	the	research	 into	endolysins	and	other	
antibiotic	 alternatives.	 Conventional	 antibiotics	 have	 clear	 disadvantages	 when	
compared	 to	endolysins	–	namely	 the	huge	selective	pressure	 they	exert	upon	all	
bacteria	 to	 form	 resistance,	 thus	 making	 us	 increasingly	 dependent	 upon	 new	
discoveries.	 It	 is	 of	 great	 importance,	 therefore,	 that	 research	 continues	 into	 the	
development	of	more	advanced	antibiotics	so	that	we	can	spread	our	reliance	across	
several	 strategies	 rather	 than	 continuing	 to	 depend	 upon	 the	 discovery	 of	 new	
conventional	antibiotics.	With	approximately	1031	bacteriophage	in	existence	on	the	
planet,	there	is	a	vast,	and	constantly	evolving,	supply	of	potential	antibiotics	in	the	
form	of	phage-therapy	and	endolysins,	offering	a	much	more	stable	and	sustainable	
source	of	future	therapies.		
For	 full	 adoption	 of	 endolysins	 and	 replacement	 of	 conventional	 antibiotics,	 both	
much	 improved	 point-of-care	 diagnostics,	 and	 much	 more	 research	 into	 tackling	
Gram-negative	bacteria	are	 required.	Both	of	 these	are	 stumbling	blocks	 that	will	
take	 time	 and	 resources	 to	 overcome,	 but	 the	 final	 result	 will	 be	 a	 far	 superior	
solution	 to	 tackling	 bacterial	 infections.	 Furthermore,	 if	 endolysins,	 or	 any	 other	
technology,	 do	 become	 the	 first-line	 treatment	 for	 bacterial	 infections,	 research	
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should	constantly	strive	to	find	alternatives,	as	the	‘arms-race’	with	bacteria	is	never-
ending,	and	resistance	to	any	new	technologies	will	eventually	emerge.		
6.3.2 Views	on	the	future	of	microalgae-produced	therapeutics	
Hypothetical	 conversations	with	 drug	 regulatory	 bodies	 and	 thought-experiments	
around	 the	 advantages	 of	 algae-based	 therapeutics	 are	 clearly	 important	 initial	
stages	 of	 developing	 a	 new	 recombinant	 protein	 platform,	 and	 currently	 more	
immediate	 issues	 such	 as	 low	 recombinant	 protein	 yields	 are	 preventing	
advancement	of	the	platform.	However,	to	perform	a	cost	comparison	of	microalgae	
and	 other	 platforms,	 and	 to	 establish	 the	 viability	 of	 the	 platform,	 it	 is	 vitally	
important	 to	 understand	 the	 extent	 to	 which	 drug	 regulatory	 bodies	 will	 look	
favourably	upon	proteins	produced	in	GRAS	organisms	such	as	C.	reinhardtii.	If	it	is	
the	 case	 that	 crude	 or	 enriched	 algal	 extracts	 can	 be	 approved,	 then	 this	will	 be	
enormously	encouraging	for	the	future	of	the	platform.	However,	 if	this	 is	not	the	
case,	 then	the	use	of	established	platforms	will	almost	always	be	more	 financially	
favourable.	 In	 this	 situation,	 the	 future	 of	 microalgae	 as	 recombinant	 protein	
production	 platforms	 must	 shift	 towards	 alternative	 markets,	 such	 as	 cosmetics,	
veterinary	medicine,	 and	 food	 safety,	 and	 look	 to	 other	 proteins	 that	 cannot	 be	
expressed	in	other	systems	or	have	marked	synergies	with	algal	crude	extracts.	Other	
protein	production	platforms	with	GRAS	status,	such	as	spinach	(Schulz	et	al.	2015),	
and	possibly	even	the	bacterial	system	Lactococcus	lactis	(Cano-Garrido	et	al.	2014),	
are	likely	to	reach	the	point	of	commercial	viability	sooner	than	microalgae	and	this	
will	offer	valuable	insights	into	how	these	proteins	are	received	and	regulated	by	the	
relevant	regulatory	bodies.		
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Chapter	7 Appendices		
7.1 Results	Chapter	3	Appendices		
7.1.1 Appendix	A	
	
Figure	 7.1	 Total	 protein	 staining	 of	 five	 technical	 repeats	 of	 TN72_SR_cpl1-HA	 and	
TN72_SR_cpl1-HA_A_cpl1_c-HA.	 These	 data	 were	 used	 for	 normalisation	 of	 the	 anti-HA	
signal	to	account	for	loading	error.		
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		 275	
7.1.2 Appendix	B	
	
Figure	7.2	Demonstration	of	homoplasmicity	of	TN72_SR_cpl1-StrepII.	Primers	used	in	this	
instance	were	Flank1,	psa.R,	RbcL.F	which	provide	an	850	bp	band	for	the	recipient	strain	
and	a	1135	bp	band	for	a	homoplasmic	strain.		
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7.1.3 Appendix	C	
	
Figure	7.3	Total	protein	staining	used	to	normalise	for	loading	errors	when	comparing	total	
protein	accumulation	between	the	above	C.	reinhardtii	lines.		
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Figure	Removed	
7.1.4 Appendix	D	
	
Figure	7.4	Codon	frequency	chart	generated	for	C.	reinhardtii	chloroplast	transgene	codon	
optimization,	from	Codon	Usage	Optimizer	Beta	0.92	(Kong	2013).	
7.1.5 Appendix	E	
	
Figure	 7.5	 Western	 blot	 analysis	 demonstrating	 the	 varying	 levels	 of	 HA-tagged	 protein	
accumulation	over	a	194	hour	culture	period.	
0 unidentified codons.
Nucleotide frequency:   A=29   U=45   G=15   C=10  X=0 
GC Content: 25.25%    1st letter GC: 36.36%    2nd letter GC: 27.27%    3rd letter GC: 12.12% 
 
Summary table:
Sequence length: 21279      Number of protein genes: 32      Total codons: 7093
0 unidentified codons.
Nucleotide frequency:   A=5880   U=7318   G=4106   C=3975  X=0 
GC Content: 37.98%    1st letter GC: 50.53%    2nd letter GC: 41.41%    3rd letter GC: 21.99% 
 
Weight table from reference set:
 
Codon
Usage
Optimizer
Beta 0.6
Amino acid | Codon | Number | Frequency per thousand
Phe UUU 1 30.3 Ser UCU 0 0.0 Tyr UAU 1 30.3 Cys UGU 0 0.0
UUC 0 0.0 UCC 0 0.0 UAC 1 30.3 UGC 0 0.0
Leu UUA 6 181.8 UCA 0 0.0 STOP UAA 1 30.3 STOP UGA 0 0.0
UUG 0 0.0 UCG 0 0.0 UAG 0 0.0 Trp UGG 0 0.0
Leu CUU 3 90.9 Pro CCU 0 0.0 His CAU 0 0.0 Arg CGU 0 0.0
CUC 0 0.0 CCC 0 0.0 CAC 0 0.0 CGC 0 0.0
CUA 0 0.0 CCA 0 0.0 Gln CAA 0 0.0 CGA 0 0.0
CUG 0 0.0 CCG 0 0.0 CAG 0 0.0 CGG 0 0.0
ile AUU 2 60.6 Thr ACU 1 30.3 Asn AAU 0 0.0 Ser AGU 1 30.3
AUC 2 60.6 ACC 0 0.0 AAC 0 0.0 AGC 0 0.0
AUA 0 0.0 ACA 2 60.6 Lys AAA 2 60.6 Arg AGA 0 0.0
Met AUG 1 30.3 ACG 0 0.0 AAG 0 0.0 AGG 0 0.0
Val GUU 2 60.6 Ala GCU 1 30.3 Asp GAU 0 0.0 Gly GGU 4 121.2
GUC 0 0.0 GCC 0 0.0 GAC 0 0.0 GGC 0 0.0
GUA 2 60.6 GCA 0 0.0 Glu GAA 0 0.0 GGA 0 0.0
GUG 0 0.0 GCG 0 0.0 GAG 0 0.0 GGG 0 0.0
Amino acid | Codon | Number | Frequency per thousand
Phe UUU 171 24.1 Ser UCU 147 20.7 Tyr UAU 87 12.3 Cys UGU 61 8.6
UUC 285 40.2 UCC 0 0.0 UAC 152 21.4 UGC 3 0.4
Leu UUA 544 76.7 UCA 144 20.3 STOP UAA 30 4.2 STOP UGA 0 0.0
UUG 5 0.7 UCG 9 1.3 UAG 2 0.3 Trp UGG 170 24.0
Leu CUU 152 21.4 Pro CCU 119 16.8 His CAU 23 3.2 Arg CGU 245 34.5
CUC 0 0.0 CCC 2 0.3 CAC 148 20.9 CGC 10 1.4
CUA 53 7.5 CCA 200 28.2 Gln CAA 218 30.7 CGA 2 0.3
CUG 9 1.3 CCG 13 1.8 CAG 10 1.4 CGG 0 0.0
ile AUU 343 48.4 Thr ACU 210 29.6 Asn AAU 83 11.7 Ser AGU 80 11.3
AUC 102 14.4 ACC 3 0.4 AAC 198 27.9 AGC 30 4.2
AUA 4 0.6 ACA 193 27.2 Lys AAA 240 33.8 Arg AGA 8 1.1
Met AUG 182 25.7 ACG 12 1.7 AAG 9 1.3 AGG 2 0.3
Val GUU 258 36.4 Ala GCU 433 61.0 Asp GAU 135 19.0 Gly GGU 586 82.6
GUC 0 0.0 GCC 9 1.3 GAC 115 16.2 GGC 24 3.4
GUA 261 36.8 GCA 173 24.4 Glu GAA 311 43.8 GGA 19 2.7
GUG 6 0.8 GCG 23 3.2 GAG 20 2.8 GGG 7 1.0
TN72_SR_cpl1-HA
45
	h
TN72_SR_CPOCv1-HA
TN72_SR_Control
TN72_SR_CPOCv2-HA
53
.5
	h
66
.5
	h
97
	h
12
2	
h
13
9	
h
19
4	
h
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7.1.6 Appendix	F	
A	one-way	ANOVA	test	was	carried	out	at	each	time	point	e.g.	 t	=	45	 for	samples	
taken	 at	 45	 hours	 into	 the	 experiment.	 In	 this	 experiment,	 four	 time	 times	were	
analysed,	with	3	replicates	of	each	on	the	western	blot	(Figure	3.37).	
Results	at	t=	45
Summary of 
Data
Treatments
CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.115 0.4351 0.1253 0.6754
Mean 0.0383 0.145 0.0418 0.075
∑X2 0.0044 0.0632 0.0054 0.073
Std.Dev. 0.0035 0.0066 0.0075 0.0528
Result Details
Source SS df MS
Between-
treatments 0.0221 2 0.011
F = 
293.575
58
Within-treatments 0.0002 6 0
Total 0.0223 8
The f-ratio value is 293.57558. The p-value is < 
.00001. The result is significant at p < .05.
Results at t= 58
Summary of 
Data
Treatments
CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.3091 1.5043 0.2813 2.0948
Mean 0.103 0.5014 0.0938 0.2328
∑X2 0.0319 0.7607 0.0274 0.82
Std.Dev. 0.0038 0.0565 0.0221 0.2038
Result Details
Source SS df MS
Between-
treatments 0.325 2 0.1625
F = 
131.778
38
Within-treatments 0.0074 6 0.0012
Total 0.3324 8
The f-ratio value is 131.77838. The p-value is 
.000011. The result is significant at p < .05.
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Results at t= 77
Summary of 
Data
Treatments
1 CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.9648 1.4821 0.663 3.1099
Mean 0.3216 0.494 0.221 0.3455
∑X2 0.3137 0.8476 0.1472 1.3085
Std.Dev. 0.0411 0.2403 0.0178 0.171
Result Details
Source SS df MS
Between-
treatments 0.1144 2 0.0572
F = 
2.87208
Within-treatments 0.1195 6 0.0199
Total 0.2339 8
The f-ratio value is 2.87208. The p-value is .133348. 
The result is not significant at p < .05.
Results	at	t=	119
Summary of 
Data
Treatments
1 CPOCv1 CPOCv2 cpl1-HA Total
N 2 2 2 6
∑X 0.894 0.9605 0.8009 2.6554
Mean 0.447 0.4803 0.4004 0.4426
∑X2 0.4022 0.4775 0.3281 1.2078
Std.Dev. 0.0505 0.1271 0.086 0.0807
Result Details
Source SS df MS
Between-
treatments 0.0064 2 0.0032
F = 
0.36948
Within-treatments 0.0261 3 0.0087
Total 0.0325 5
The f-ratio value is 0.36948. The p-value is .718715. 
The result is not significant at p < .05.
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7.1.7 Appendix	G	
A	one-way	ANOVA	test	was	carried	out	at	each	time	point	e.g.	 t	=	45	 for	samples	
taken	at	45	hours	 into	 the	experiment.	 In	 this	 second	 running	of	 the	experiment,	
seven	time	points	were	analysed	but	with	only	two	replicates	of	each	(Figure	7.5).	
Results	at	t	=	45
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.0837 0.2317 0.0405 0.3559
Mean 0.0418 0.1158 0.0202 0.0593
∑X2 0.0039 0.0268 0.0009 0.0316
Std.Dev. 0.02 0.0006 0.0059 0.0458
Result Details
Source SS df MS
Between-
treatments 0.0101 2 0.005
F = 
34.67033
Within-treatments 0.0004 3 0.0001
Total 0.0105 5
The f-ratio value is 34.67033. The p-value is 
.008445. The result is significant at p < .05.
Results	at	t	=	53.5
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.0713 0.1784 0.1145 0.3642
Mean 0.0357 0.0892 0.0573 0.0607
∑X2 0.0026 0.0159 0.0066 0.0251
Std.Dev. 0.0062 0.0057 0.0008 0.0244
Result Details
Source SS df MS
Between-
treatments 0.0029 2 0.0015
F = 
61.0499
Within-treatments 0.0001 3 0
Total 0.003 5
The f-ratio value is 61.0499. The p-value is .003714. 
The result is significant at p < .05.
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Results	at	t	=	66.5
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.1001 0.2606 0.1458 0.5065
Mean 0.05 0.1303 0.0729 0.0844
∑X2 0.005 0.0356 0.011 0.0516
Std.Dev. 0.0003 0.0405 0.0193 0.0421
Result Details
Source SS df MS
Between-
treatments 0.0068 2 0.0034
F = 
5.09397
Within-treatments 0.002 3 0.0007
Total 0.0089 5
The f-ratio value is 5.09397. The p-value is .108497. 
The result is not significant at p < .05.
Results	at	t	=	97
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.1803 0.2498 0.1553 0.5854
Mean 0.0901 0.1249 0.0776 0.0976
∑X2 0.0168 0.0313 0.0121 0.0603
Std.Dev. 0.0235 0.0102 0.0095 0.0251
Result Details
Source SS df MS
Between-
treatments 0.0024 2 0.0012
F = 
4.82318
Within-treatments 0.0007 3 0.0002
Total 0.0031 5
The f-ratio value is 4.82318. The p-value is .11554. 
The result is not significant at p < .05.
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Results	at	t	=	122
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.9233 0.8594 0.3558 2.1385
Mean 0.4617 0.4297 0.1779 0.3564
∑X2 0.4288 0.3714 0.0634 0.8636
Std.Dev. 0.0505 0.0458 0.0095 0.1424
Result Details
Source SS df MS
Between-
treatments 0.0966 2 0.0483
F = 
30.59972
Within-treatments 0.0047 3 0.0016
Total 0.1014 5
The f-ratio value is 30.59972. The p-value is 
.010101. The result is significant at p < .05.
Results	at	t	=	139
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 1.1899 1.1952 0.3528 2.7379
Mean 0.595 0.5976 0.1764 0.4563
∑X2 0.7086 0.7301 0.0634 1.5021
Std.Dev. 0.0245 0.126 0.0342 0.2248
Result Details
Source SS df MS
Between-
treatments 0.2351 2 0.1175
F = 
20.00184
Within-treatments 0.0176 3 0.0059
Total 0.2527 5
The f-ratio value is 20.00184. The p-value is 
.018426. The result is significant at p < .05.
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Results	at	t	=	194
Summary of 
Data
Treatments
CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 1.4863 1.4019 0.6651 3.5533
Mean 0.7431 0.7009 0.3326 0.5922
∑X2 1.1065 0.9986 0.222 2.327
Std.Dev. 0.0445 0.1261 0.0284 0.211
Result Details
Source SS df MS
Between-
treatments 0.204 2 0.102
F = 
16.38062
Within-treatments 0.0187 3 0.0062
Total 0.2227 5
The f-ratio value is 16.38062. The p-value is 
.024298. The result is significant at p < .05.
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7.2 Results	Chapter	4	Appendices		
7.2.1 Appendix	H	
	
Figure	7.6	cph1	sequence	as	ordered	from	Integrated	DNA	Technologies.	The	start	codon	is	
highlighted	in	green.	The	introduced	TGA	codons	for	tryptophan	are	highlighted	in	orange.	
The	stop	codons	are	highlighted	 in	red.	The	HA	tag	 is	highlighted	 in	purple.	SapI	and	SphI	
restriction	sites	are	indicated	by	blue	arrows.	
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7.2.2 Appendix	I	
	
Figure	7.7	Demonstration	of	homoplasmicity	of	TN72_SR_cpl1_dimer-HA.	Primers	used	 in	
this	 instance	were	 Flank1,	 psa.R,	 RbcL.F	which	produce	 an	850	bp	band	 for	 the	 recipient	
strain	and	an	1135	bp	band	for	a	homoplasmic	strain.	
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7.3 Results	Chapter	5	Appendices		
7.3.1 Appendix	J	
	
Figure	7.8	cd27l	sequence	as	ordered	from	Integrated	DNA	Technologies.	The	start	codon	is	
highlighted	 in	green.	The	 stop	codons	are	highlighted	 in	 red.	The	HA	 tag	 is	highlighted	 in	
purple.	SapI	and	SphI	restriction	sites	are	indicated	by	blue	arrows.	
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7.3.2 Appendix	K	
	
Figure	 7.9	 Demonstration	 of	 homoplasmicity	 of	 TN72_SR_cd27l-HA.	 Primers	 used	 in	 this	
instance	were	Flank1,	psa.R,	RbcL.F	which	produce	an	850	bp	band	for	the	recipient	strain	
and	an	1135	bp	band	for	a	homoplasmic	strain.	Six	transformants	were	tested.	
7.3.3 Appendix	L	
	
Figure	7.10	Demonstration	of	homoplasmicity	of	TN72_SR_cd27l-StrepII.	Primers	used	in	this	
instance	were	Flank1,	psa.R,	RbcL.F	which	produce	an	850	bp	band	for	the	recipient	strain	
and	an	1135	bp	band	for	a	homoplasmic	strain.	Two	transformants	were	tested.	
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7.3.4 Appendix	M	
	
Figure	7.11	gp20N	sequence	as	ordered	from	Integrated	DNA	Technologies.	The	start	codon	
is	highlighted	in	green.	The	introduced	TGA	codons	for	tryptophan	are	highlighted	in	orange.	
The	stop	codons	are	highlighted	 in	red.	The	HA	tag	 is	highlighted	 in	purple.	SapI	and	SphI	
restriction	sites	are	indicated	by	blue	arrows.	
TG GTA TGC TCT TCA ATG GCA TAC CCA TAT GAT
GTA CCT GAC TAT GCT GTT CGT TAT ATT CCA GCT
GCT CAT CAC TCA GCA GGT TCT AAC AAT CCT GTT
AAT CGT GTA GTA ATT CAT GCA ACA TGT CCA GAT
GTA GGA TTT CCT AGT GCT AGC CGT AAA GGT CGT
GCT GTT TCA ACT GCT AAT TAC TTC GCA TCA CCA
TCT AGT GGT GGT AGC GCT CAC TAT GTG TGT GAC
ATT GGA GAA ACA GTA CAA TGT TTA TCT GAA AGT
ACT ATT GGA TGG CAC GCA CCA CCA AAC CCT CAT
TCA TTA GGT ATT GAA ATT TGT GCT GAT GGT GGT
TCT CAT GCT AGC TTT CGT GTG CCT GGT CAC GCA
TAT ACA CGT GAA CAA TGA TTA GAT CCA CAA GTT
TGG CCA GCT GTT GAA CGT GCT GCA GTA TTA TGT
CGT CGT TTA TGT GAC AAA TAC AAT GTA CCT AAA
CGT AAA TTA TCA GCT GCT GAC TTA AAA GCA GGT
CGT CGT GGT GTT TGT GGT CAT GTT GAT GTA ACT
GAC GCT TGA CAC CAA AGC GAT CAT GAT GAT CCA
GGA CCA TGG TTT CCT TGG GAC AAA TTC ATG GCT
GTT GTA AAC GGT GGT AGC GGT GAC AGC GGA GAA
TTA ACA GTT GCA GAT GTA AAA GCT TTA CAC GAT
CAA ATT AAA CAA TTA TCA GCA CAA TTA ACT GGT
AGC GTG AAC AAA TTA CAT CAC GAT GTT GGT GTT
GTA CAA GTG CAA AAC GGT GAC TTA GGA AAA CGT
GTA GAC GCT TTA AGC TGG GTG AAA AAT CCA GTG
ACT GGA AAA TTA TGA CGT ACA AAA GAT GCT TTA
TGG TCT GTT TGG TAT TAT GTA TTA GAA TGT CGT
AGC CGT TTA GAT CGT TTA GAA AGC GCT GTA AAT
GAC TTA AAA AAA TAA TAA GCA TGC GTC AGT ttt
t
SapI
SphI
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7.3.5 Appendix	N	
	
Figure	7.12	Demonstration	of	homoplasmicity	of	TN72_SR_gp20N-HA.	Primers	used	in	this	
instance	were	Flank1,	psa.R,	RbcL.F	which	produce	an	850	bp	band	for	the	recipient	strain	
and	an	1135	bp	band	for	a	homoplasmic	strain.	Two	transformants	were	tested.	
7.3.6 Appendix	O:	List	of	Primers	
Primers	in	order	of	appearance	in	this	thesis.	
NAME SEQUENCE NOTES 
Flank1 GTCATTGCGAAAATACTGGTGC 
Primers for general 
sequencing, PCR and 
homoplasmicity testing 
RbcL.F CGGATGTAACTCAATCGGTAG 
Rbcl.R CAAACTTCACATGCAGCAGC 
Psa.R CATGGATTTCTCCTTATAATAAC 
atpA.R ACGTCCACAGGCGTCGT 
123a GGAGGGAAGTAGGCAGTAGC 
psbH.R GCAACAGGAACTTCTAAAGC 
psaSEQ AACTATTTGTCTAATTTAATAACC 
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cpl1.F GCTCTTCAATGGTTAAAAAAAATGATTTATTC 
Primers for the site-
directed mutageneis of 
the cell wall binding 
domain 
cpl1.R GCATGCTTATTAAGCATAATCTGGAAC 
W202A_SDM.F GTACAGCTAAACAAGATTCAAAAG 
W202A_SDM.R CTTTTGAATCTTGTTTAGCTGTAC 
W209A_SDM.F CAAAAGGTGCTTGGTTTC 
W209A_SDM.R GAAACCAAGCACCTTTTG 
W223A_SDM.F CCATATAATAAAGCTGAAAAAATTG 
W223A_SDM.R CAATTTTTTCAGCTTTATTATATGG 
W230A_SDM.F GTGGTGTTGCTTATTATTTCG 
W230A_SDM.R CGAAATAATAAGCAACACCAC 
Cpl1_BssHII.F CAGGCAATTTGCTTACACCTTT Primers to introduce a 
BssHII restriction site 
into Cpl-1 Cpl1_BssHII.R TTAAGATAAGCGCGCTACATCC 
cpl1_C45S.F ACATATTTAAATCCATCATTATCAGCTC 
Primers to remove and 
introduce cysteine 
residues to create 
Cpl1_dimer 
cpl1_C45S.R GAGCTGATAATGATGGATTTAAATATGT 
cpl1_D324C.F GTGAATTAGCATGTAATCCTTCATTT 
cpl1_D324C.R AAATGAAGGATTACATGCTAATTCAC 
cd27l.F TGGTATTGCTCTTCAATGAAAATTTGTATTACT Primers for the 
replacement of the HA 
tag with a StrepII tag on 
cd27l 
cd27l_StrepII.R ACTGACGCATGCTTATTATTTTTCGAATTGTGGGTGAGACCAGTTAATGTTTTTGTTTAA
AACACCTTCAAC 
gp20_NcoI.F CGTATACCCATGGTGCGTTA Primers to introduce an 
NcoI restriction site to 
gp20 gp20.R GATTGCGGATCCTTATTAGGC 
	
